Note: Descriptions are shown in the official language in which they were submitted.
CA 02504160 2011-02-03
25771-1022
1
NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT
AND MEDICAMENTS CONTAINING THESE COMPOUNDS
The present invention relates to new alkyne compounds, the physiologically
acceptable salts thereof as well as their use as MCH antagonists and their
use in preparing a pharmaceutical preparation which is suitable for the
prevention and/or treatment of symptoms and/or diseases caused by MCH or
causally connected with MCH in some other way. The invention also relates
to the use of a compound according to the invention for influencing eating
behaviour and for reducing body weight and/or for preventing any increase in
body weight in a mammal. It further relates to compositions and medicaments
containing a compound according to the invention and processes for
preparing them.
Background to the Invention
The intake of food and its conversion in the body is an essential part of life
for
all living creatures. Therefore, deviations in the intake and conversion of
food
generally lead to problems and also illness. The changes in the lifestyle and
nutrition of humans, particularly in industrialised countries, have promoted
obesity in recent decades. In affected people, obesity leads directly to
restricted mobility and a reduction in the quality of life. There is the
additional
factor that obesity often leads to other diseases such as, for example,
diabetes, dyslipidaemia, high blood pressure, arteriosclerosis and coronary
heart disease. Moreover, high body weight alone puts an increased strain on
the support and mobility apparatus, which can lead to chronic pain and
diseases such as arthritis or osteoarthritis. Thus, obesity is a serious
health
problem for society.
The term obesity means an excess of adipose tissue. In this connection,
obesity is fundamentally to be seen as the increased level of fatness which
leads to a health risk. In the last analysis it is not precisely possible to
draw a
distinction between normal individuals and those suffering from obesity, but
Boehringer Ingelheim 2 Case 1-1406 if
the health risk accompanying obesity is presumed to rise continuously as the
level of fatness increases. For simplicity's sake, in the present invention,
individuals with a Body Mass Index (BMI), which is defined as the body weight
measured in kilograms divided by the height (in metres) squared, above a
value of 25 and more particularly above 30 are preferably regarded as
suffering from obesity.
Apart from physical activity and a change in nutrition, there is currently no
convincing treatment option for effectively reducing body weight. However, as
obesity is a major risk factor in the development of serious and even life-
threatening diseases, it is all the more important to have access to
pharmaceutical active substances for the prevention and/or treatment of
obesity. One approach which has been proposed very recently is the
therapeutic use of MCH antagonists (cf. inter alia WO 01/21577, WO
01/82925).
Melanin-concentrating hormone (MCH) is a cyclic neuropeptide consisting of
19 amino acids. It is synthesised predominantly in the hypothalamus in
mammals and from there travels to other parts of the brain by the projections
of hypothalamic neurones. Its biological activity is mediated in humans
through two different G-protein-coupled receptors (GPCRs) from the family of
rhodopsin-related GPCRs, namely the MCH receptors 1 and 2 (MCH-1 R,
MCH-2R).
Investigations into the function of MCH in animal models have provided good
indications for a role of the peptide in regulating the energy balance, i.e.
changing metabolic activity and food intake [1,2]. For example, after
intraventricular administration of MCH in rats, food intake was increased
compared with control animals. Additionally, transgenic rats which produce
more MCH than control animals, when given a high-fat diet, responded by
gaining significantly more weight than animals without an experimentally
altered MCH level. It was also found that there is a positive correlation
between phases of increased desire for food and the quantity of MCH mRNA
in the hypothalamus of rats. However, experiments with MCH knock-out mice
CA 02504160 2005-04-28
Boehringer Ingelheim 3 Case 1-1406 ff
are particularly important in showing the function of MCH. Loss of the
neuropeptide results in lean animals with a reduced fat mass, which take in
significantly less food than control animals.
The anorectic effects of MCH are mediated in rodents through the Gvs-
coupled MCH-1 R [3-6]. Unlike primates, ferrets and dogs, no second receptor
has hitherto been found in rodents. After losing the MCH-1 R, knock-out mice
have a lower fat mass, an increased energy conversion and, when fed on a
high fat diet, do not put on weight, compared with control animals. Another
indication of the importance of the MCH-MCH-1 R system in regulating the
energy balance results from experiments with a receptor antagonist (SNAP-
7941) [3]. In long term trials the animals treated with the antagonist lose
significant amounts of weight.
In addition to its anorectic effect, the MCH-1 R antagonist SNAP-7941 also
achieves additional anxiolytic and antidepressant effects in behavioural
experiments on rats [3]. Thus, there are clear indications that the MCH-MCH-
1 R system is involved not only in regulating the energy balance but also in
affectivity.
Literature:
1. Qu, D., et al., A role for melanin-concentrating hormone in the central
regulation of feeding behaviour. Nature, 1996. 380(6571): p. 243-7.
2. Shimada, M., et al., Mice lacking melanin-concentrating hormone are
hypophagic and lean. Nature, 1998. 396(6712): p. 670-4.
3. Borowsky, B., et al., Antidepressant, anxiolytic and anorectic effects of a
melanin-concentrating hormone-1 receptor antagonist. Nat Med, 2002.
8(8): p. 825-30.
4. Chen, Y., et al., Targeted disruption of the melanin-concentrating
hormone receptor-1 results in hyperphagia and resistance to diet-
induced obesity. Endocrinology, 2002. 143(7): p. 2469-77.
CA 02504160 2005-04-28
Boehringer Ingelheim 4 Case 1-1406 if
CA 02504160 2005-04-28
5. Marsh, D.J., et al., Melanin-concentrating hormone I receptor-deficient
mice are lean, hyperactive, and hyperphagic and have altered
metabolism. Proc Natl Acad Sci U S A, 2002. 99(5): p. 3240-5.
6. Takekawa, S., et al., T-226296: A novel, orally active and selective
melanin-concentrating hormone receptor antagonist. Eur J Pharmacol,
2002. 438(3): p. 129-35.
In the patent literature certain amine compounds are proposed as MCH
antagonists. Thus, WO 01/21577 (Takeda) describes compounds of formula
R
Ar'-X-Ar-Y-N"
R 2
wherein Ar' denotes a cyclic group , X denotes a spacer, Y denotes a bond or
a spacer, Ar denotes an aromatic ring which may be fused with a non-
aromatic ring, R1 and R2 independently of one another denote H or a
hydrocarbon group, while R1 and R2 together with the adjacent N atom may
form an N-containing hetero ring and R2 with Ar may also form a spirocyclic
ring, R together with the adjacent N atom and Y may form an N-containing
hetero ring, as MCH antagonists for the treatment of obesity.
Moreover WO 01/82925 (Takeda) also describes compounds of formula
R
Ar'-X-Ar-Y- N
R 2
wherein Ar' denotes a cyclic group , X and Y represent spacer groups, Ar
denotes an optionally substituted fused polycyclic aromatic ring, R' and R2
independently of one another represent H or a hydrocarbon group, while R1
and R2 together with the adjacent N atom may form an N-containing
heterocyclic ring and R2 together with the adjacent N atom and Y may form an
N-containing hetero ring, as MCH antagonists for the treatment of obesity,
inter alia.
Aim of the invention
The aim of the present invention is to discover new alkyne compounds,
particularly those which have an activity as MCH antagonists.
Boehringer Ingelheim 5 Case 1-1406 if
A further aim of the invention is to provide new alkyne compounds which
make it possible to influence the eating behaviour of mammals and in
particular achieve a reduction in body weight and/or prevent an increase in
body weight in mammals.
The present invention further sets out to provide new pharmaceutical
compositions which are suitable for the prevention and/or treatment of
symptoms and/or diseases caused by MCH or otherwise causally connected
to MCH. In particular, the aim of this invention is to provide pharmaceutical
compositions for the treatment of metabolic disorders such as obesity and/or
diabetes as well as diseases and/or disorders which are associated with
obesity and diabetes. Other objectives of the present invention are concerned
with demonstrating advantageous uses of the compounds according to the
invention. The invention also sets out to provide a process for preparing the
alkyne compounds according to the invention. Other aims of the present
invention will be immediately apparent to the skilled man from the foregoing
remarks and those that follow.
Subject matter of the invention
A first object of the present invention comprises alkyne compounds of general
formula I
R'
R2~N-X-Y- Z W-A-B I
wherein
R1, R2 independently of one another denote H, a C1-8-alkyl or C3_7-
cycloalkyl group optionally substituted by the group R11, while a
-CH2- group in position 3 or 4 of a 5-, 6- or 7-membered cycloalkyl
group may be replaced by -0-, -S- or -NR13 -, or a phenyl or
pyridinyl group optionally mono- or polysubstituted by the group R12
CA 02504160 2005-04-28
Boehringer Ingelheim 6 Case 1-1406 if
CA 02504160 2005-04-28
and/or monosubstituted by nitro, or
R1 and R2 form a C2_8-alkylene bridge wherein
- one or two -CH2- groups may be replaced independently of one
another by -0-, -S-, -SO-, -(SO2)-, -C=N-R18-, -C=N-O-R18-,
-CO-, -C(=CH2)- or -NR13- in such a way that heteroatoms are
not directly connected to one another,
while in the above-defined alkylene bridge one or more H atoms
may be replaced by R14, and
while the above-defined alkylene bridge may be substituted by one
or two identical or different carbo- or heterocyclic groups Cy in such
a way that the bond between the alkylene bridge and the group
Cy is formed
- via a single or double bond,
- via a common C atom forming a spirocyclic ring system,
- via two common, adjacent C and/or N atoms forming a fused
bicyclic ring system or
- via three or more C and/or N atoms forming a bridged ring
system,
X denotes a single bond or a C1.6-alkylene bridge wherein
- a -CH2- group may be replaced by -CH=CH- or -C=C- and/or
- one or two -CH2- groups may be replaced independently of one
another by -0-, -S-, -(SO)-, -(SO2)-, -CO- or -NR4- in such a way
that in each case two 0, S or N atoms or an 0 and an S atom
are not directly connected to one another,
while the bridge X may be attached to R1 including the N atom
attached to R1 and X forming a heterocyclic group, while the
bridge X may additionally also be attached to R2 , including the N-
atom attached to R2 and X , forming a heterocyclic group, and
Boehringer Ingelheim 7 Case 1-1406 if
CA 02504160 2005-04-28
two C atoms or one C and one N atom of the alkylene bridge may
be joined together by an additional C1.4-alkylene bridge, and
a C atom may be substituted by R10 and/or one or two C atoms in
each case may be substituted with one or two identical or different
substituents selected from C1_6-alkyl, C2_6-alkenyl, C2_6-alkynyl, C3_7-
cycloalkyl, C3_7-cycloalkyl-C1.3-alkyl, C4_7-cycloalkenyl and C4_7-
cycloalkenyl-C1.3-alkyl, while two alkyl and/or alkenyl substituents
may be joined together, forming a carbocyclic ring system,
and
W, z independently of one another denote a single bond or a C1_4-
alkylene bridge,
while in the group W and/or Z a -CH2- group not adjacent to the
-C=C- group may be replaced by -0- or -NR5-, and
two adjacent C atoms or one C atom and an adjacent N atom may
be joined together by an additional C1_4-alkylene bridge, and
in the alkylene bridge and/or in the additional alkylene bridge a C
atom may be substituted by R10 and/or one or two C atoms
independently of one another may be substituted by one or two
identical or different C1_6-alkyl groups, while two alkyl groups may
be joined together, forming a carbocyclic ring, and
Y denotes one of the meanings given for Cy,
while R1 may be attached to Y including the group X and the N
atom attached to R1 and X , forming a heterocyclic group fused to
Y, and/or
Boehringer Ingelheim 8 Case 1-1406 if
CA 02504160 2005-04-28
X may be attached to Y forming a carbo- or heterocyclic group
fused to Y, and
A denotes one of the meanings given for Cy and
B denotes one of the meanings given for Cy or
C1-6-alkyl, C1-6-alkenyl, C1-6-alkynyl, C3-7-cycloalkyl-C1-3-alkyl, C3-7-
cycloalkenyl-C1-3-alkyl, C3-7-cycloalkyl-C1-3-alkenyl or C3-7-
cycloalkyl-Cl-3-alkynyl, wherein one or more C atoms may be
mono- or polysubstituted by halogen and/ or may be
monosubstituted by hydroxy or cyano and/ or cyclic groups may be
mono- or polysubstituted by R20,
Cy denotes a carbo- or heterocyclic group selected from one of the
following meanings
a saturated 3- to 7-membered carbocyclic group,
an unsaturated 4- to 7-membered carbocyclic group,
a phenyl group,
a saturated 4- to 7-membered or unsaturated 5- to 7-membered
heterocyclic group with an N, 0 or S atom as heteroatom,
a saturated or unsaturated 5- to 7-membered heterocyclic group
with two or more N atoms or with one or two N atoms and an 0
or S atom as heteroatoms,
an aromatic heterocyclic 5- or 6-membered group with one or
more identical or different heteroatoms selected from N, 0
and/or S,
while the above-mentioned 4-, 5-, 6- or 7-membered groups may
be attached via two common, adjacent C atoms fused to a phenyl
or pyridine ring, and
Boehringer Ingelheim 9 Case 1-1406 if
CA 02504160 2005-04-28
in the above-mentioned 5-, 6- or 7-membered groups one or two
non-adjacent -CH2- groups may be replaced independently of one
another by a -CO-, -C(=CH2)-, -(SO)- or -(SO2)- group, and
the above-mentioned saturated 6- or 7-membered groups may also
be present as bridged ring systems with an imino, (C1_4-alkyl)-
imino, methylene, (C1-4-alkyl)-methylene or di-(C1_4-alkyl)-
methylene bridge, and
the above-mentioned cyclic groups may be mono- or
polysubstituted at one or more C atoms with R20, in the case of a
phenyl group they may also additionally be monosubstituted with
nitro, and/or one or more NH groups may be substituted with R21,
R4, R5 independently of one another have one of the meanings given for
R17
R10 denotes hydroxy, w-hydroxy-C1_3-alkyl, C1-4-alkoxy, co-(C1.4-alkoxy)-
C1_3-alkyl, carboxy, C1-4-alkoxycarbonyl, amino, C1.4-alkyl-amino, di-
(C1-4-alkyl)-amino, cyclo-C3_6-alkyleneimino, amino-C1.3-alkyl, C1.4-
alkyl-amino-C1.3-alkyl, di-(C1-4-alkyl)-amino-C1_3-alkyl, cyclo-C3.6-
alkyleneimino-C1_3-alkyl, amino-C2-3-alkoxy, C1-4-alkyl-amino-C2_3-
alkoxy, di-(C1-4-alkyl)-amino-C2_3-alkoxy, cyclo-C3_6-alkyleneimino-
C2_3-alkoxy, aminocarbonyl, C1.4-alkyl-aminocarbonyl, di-(C1.4-
alkyl)-aminocarbonyl, cyclo-C3_6-alkyleneimino-carbonyl,
R11 denotes C2_6-alkenyl, C2_6-alkynyl, R15-O, R15-O-CO, R'5-CO-O,
R16R17 N, R18R'9N-CO or Cy,
R12 has one of the meanings given for R20,
R13 has one of the meanings given for R", with the exception of
carboxy,
Boehringer Ingelheim 10 Case 1-1406 if
CA 02504160 2005-04-28
R14 denotes halogen, C1-6-alkyl, C2-6-alkenyl, C2_6-alkynyl, R15-O, R15-O-
CO, R15-CO, R15-CO-O, R16R17N, R18R19N-CO, R15-O-C1-3-alkyl ,
R15-O-CO-C1.3-alkyl, R15-O-CO-NH, R15-SO2-NH, R15-O-CO-NH-
C1-3-alkyl, R15-SO2-NH-C1-3-alkyl, R15-CO-C1.3-alkyl, R15-CO-O-C1-3-
alkyl, R16R17N-C1-3-alkyl, R18R19N-CO-C1-3-alkyl or Cy-C1.3-alkyl,
R15 denotes H, C1-4-alkyl, C3-7-cycloalkyl, C3_7-cycloalkyl-C1-3-alkyl,
phenyl, phenyl-C1-3-alkyl, pyridinyl or pyridinyl-C1-3-alkyl,
R16 denotes H, C1-6-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, C4_7-
cycloalkenyl, C4-7-cycloalkenyl-C1_3-alkyl, w-hydroxy-C2_3-alkyl,
w-(C1-4-alkoxy)-C2-3-alkyl, amino-C2_6-alkyl, C1-4-alkyl-amino-C2-6-
alkyl, di-(C1-4-alkyl)-amino-C2-6-alkyl or cyclo-C3-6-alkyleneimino-
C2-6-alkyl,
R17 has one of the meanings given for R16 or denotes phenyl, phenyl-
C1_3-alkyl, pyridinyl, dioxolan-2-yl, -CHO, C1-4-alkylcarbonyl,
carboxy, hydroxycarbonyl-C1-3-alkyl, C1-4-alkoxycarbonyl,
C1-4-alkoxycarbonyl-C1-3-alkyl, C1-alkylcarbonylamino-C2-3-alkyl,
N-(C1-4-alkylcarbonyl)-N-(C1.4-alkyl)-amino-C2_3-alkyl,
C1_4-alkylsulphonyl, C1-4-alkylsulphonylamino-C2-3-alkyl or
N-(C1-4-alkylsulphonyl)-N-(C1-4-alkyl)-amino-C2_3-alkyl
R18, R19 independently of one another denote H or C1-6-alkyl,
R20 denotes halogen, hydroxy, cyano, C1-6-alkyl, C2-6-alkenyl, C2-6-
alkynyl, C3_7-cycloalkyl, C3-7-cycloalkyl- C1-3-alkyl, hydroxy-C1-3-
alkyl, R22-C1.3-alkyl or has one of the meanings given for R22,
R21 denotes C1-4-alkyl, w-hydroxy-C2-6-alkyl, w-C1-4-alkoxy-C2-6-alkyl,
w-C1_4-alkyl-amino-C2-6-alkyl, w-di-(C1-4-alkyl)-amino-C2-6-alkyl, w-
cyclo-C3-6-alkyleneimino-C2-6-alkyl, phenyl, phenyl-C1-3-alkyl, C1_4-
Boehringer Ingelheim 11 Case 1-1406 if
CA 02504160 2005-04-28
alkyl-carbonyl, C1_4-alkoxy-carbonyl, C1-4-alkylsulphonyl,
phenylcarbonyl or phenyl-C1_3-alkyl-carbonyl,
R22 denotes pyridinyl, phenyl, phenyl-C1_3-alkoxy, OHC, HO-N=HC,
C1_4-alkoxy-N=HC, C14-alkoxy, C1_4-alkylthio, carboxy,
C1-4-alkylcarbonyl, C1-4-alkoxycarbonyl, aminocarbonyl,
C1_4-alkylaminocarbonyl, di-(C1_4-alkyl)-aminocarbonyl, cyclo-C3-6-
alkyl-amino-carbonyl, cyclo-C3-6-alkyleneimino-carbonyl, cyclo-C3-6-
alkyleneimino-C2-4-alkyl-aminocarbonyl, C1-4-alkyl-sulphonyl, C1-4-
alkyl-sulphinyl, C1-4-alkyl-sulphonylamino, amino, C1_4-alkylamino,
di-(C1-4-alkyl)-amino, C1-4-alkyl-carbonyl-amino, cyclo-C3-6-
alkyleneimino, phenyl-C1-3-alkylamino, N-(C1_4-alkyl)-
phenyl-C1-3-alkylamino, acetylamino, propionylamino,
phenylcarbonyl, phenylcarbonylamino, phenylcarbonylmethyl-
amino, hydroxy-C2_3-alkylaminocarbonyl, (4-morpholinyl)carbonyl,
(1-pyrrolidinyl)carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1-
azepinyl)carbonyl, (4-methyl-1-piperazinyl)carbonyl,
methylenedioxy, aminocarbonylamino or alkylaminocarbonylamino,
while in the above-mentioned groups and residues, particularly in A, B, W, X,
Y, Z, R1 to R5 and R10 to R22, in each case one or more C atoms may
additionally be mono- or polysubstituted by F and/or in each case one or two
C atoms independently of one another may additionally be monosubstituted
by Cl or Br and/or in each case one or more phenyl rings independently of
one another additionally have one, two or three substituents selected from
among F, Cl, Br, I, cyano, C1-4-alkyl, C1-4-alkoxy, difluoromethyl,
trifluoromethyl, hydroxy, amino, C1_3-alkylamino, di-(C1-3-alkyl)-amino,
acetylamino, aminocarbonyl, difluoromethoxy, trifluoromethoxy, amino-
C1.3-alkyl, C1-3-alkylamino-Cl-3-alkyl- and di-(C1-3-alkyl)-amino-C1.3-alkyl-
and/or may be monosubstituted by nitro, and
the H atom of any carboxy group present or an H atom bound to an N atom
may each be replaced by a group which can be cleaved in vivo,
CA 02504160 2011-02-03
25771-1022
12
the tautomers, the diastereomers, the enantiomers, the mixtures thereof and
the salts thereof.
According to one aspect of the present invention, there is provided an alkyne
compound of general formula I
R1
R2/ N-X-Y- Z W-A-B
wherein
R1, R2 independently of one another denote H, a C1_8-alkyl or C3.7-
cycloalkyl group optionally substituted by the group R", while a
-CH2- group in position 3 or 4 of a 5-, 6- or 7-membered cycloalkyl
group may be replaced by -0-, -S- or -NR13 -, or a phenyl or
pyridinyl group optionally mono- or polysubstituted by the group R12
and/or monosubstituted by nitro, or
R1 and R2 form a C2_8-alkylene bridge wherein
one or two -CH2- groups independently of one another may be
replaced by -CH=N- or -CH=CH- and/or
- one or two -CH2- groups may be replaced independently of one
another by -0-, -S-, -SO-, -(SO2)-, -C=N-R18-, -C=N-O-R18-
-CO-, -C(=CH2)- or -NR13- in such a way that heteroatoms are
not directly connected to one another,
while in the above-defined alkylene bridge one or more H atoms
may be replaced by R14, and
while the above-defined alkylene bridge may be substituted by one
or two identical or different carbo- or heterocyclic groups Cy in such
CA 02504160 2011-02-03
25771-1022
12a
a way that the bond between the alkylene bridge and the group Cy
is formed
- via a single or double bond,
- via a common C atom forming a spirocyclic ring system,
- via two common, adjacent C and/or N atoms forming a fused
bicyclic ring system, wherein Cy, is selected from the group
consisting of C4_7-cycloalkyl, phenyl and thienyl; or
- via three or more C and/or N atoms forming a bridged ring
system,
X denotes a single bond or a C1_6-alkylene bridge wherein
- a -CH2- group may be replaced by -CH=CH- or -C=C- and/or
- one or two -CH2- groups may be replaced independently of one
another by -0,-, -S-, -(SO)-, -(SO2)-, -CO- or -NR4- in such a way
that in each case two 0, S or N atoms or an 0 and an S atom
are not directly connected to one another,
while the bridge X may be attached to R1 including the N atom
attached to R1 and X forming a heterocyclic group, while the bridge
X may additionally also be attached to R2, including the N-atom
attached to R2 and X, forming a heterocyclic group, and
two C atoms or one C and one N atom of the alkylene bridge may
be joined together by an additional C1_4-alkylene bridge, and
a C atom may be substituted by R10 and/or one or two C atoms in
each case may be substituted with,one or two identical or different
substituents selected from C1_6-alkyl, C2_6-alkenyl, C2_6-alkynyl, C3_7-
cycloalkyl, C3_7-cycloalkyl-C1_3-alkyl, C4_7-cycloalkenyl and C4_7-
cycloalkenyl-C1_3-alkyl, while two alkyl and/or alkenyl substituents
may be joined together, forming a carbocyclic ring system,
CA 02504160 2011-02-03
25771-1022
12b
and
W, z independently of one another denote a single bond or a C1_4-
alkylene bridge,
while in the group W and/or Z a -CH2- group not adjacent to the
-C=C group may be replaced by -O or -NR5-, and
two adjacent C atoms or one C atom and an adjacent N atom may
be joined together by an additional C1_4-alkylene bridge, and
in the alkylene bridge and/or in the additional alkylene bridge a C
atom may be substituted by R10 and/or one or two C atoms
independently of one another may be substituted by one or two
identical or different C1_6-alkyl groups, while two alkyl groups may
be joined together, forming a carbocyclic ring, and
Y is selected from the group consisting of
N N
N N
N N
N-N
N
CA 02504160 2011-02-03
25771-1022
12c
N-
N
N N
N
N-
N
N
N
O
O
0
CA 02504160 2011-02-03
25771-1022
12d
N
P
N
N N
N O
N N and
I
NZ\ / N
/
N -Q
O N
while the above-mentioned cyclic groups may be mono- or
polysubstituted by R20 at one or more C atoms, and in the case of
a phenyl group may also additionally be monosubstituted by nitro,
and/or one or more NH groups may be substituted by R21;
A is selected from the group consisting of
CA 02504160 2011-02-03
25771-1022
12e
N N
N
and
N N
N=N
while the above-mentioned cyclic groups may be mono- or
polysubstituted by R20 at one or more C atoms, and in the case of
a phenyl group may also additionally be monosubstituted by nitro;
B denotes one of the meanings given for Cy or
C1_6-alkyl, C1_6-alkenyl, C1_6-alkynyl, C3-7-cycloalkyl-C1_3-alkyl, C3_7-
cycloalkenyl-C1_3-alkyl, C3_7-cycloalkyl-C1_3-alkenyl or C3_7-
cycloalkyl-C1_3-alkynyl, wherein one or more C atoms may be
mono- or polysubstituted by halogen and/ or may be
monosubstituted by hydroxy or cyano and/ or cyclic groups may be
mono- or polysubstituted by R20,
Cy denotes a carbo- or heterocyclic group selected from one of the
following meanings
a saturated 3- to 7-membered carbocyclic group,
an unsaturated 4- to 7-membered carbocyclic group,
a phenyl group,
a saturated 4- to 7-membered or unsaturated 5- to 7-membered
heterocyclic group with an N, 0 or S atom as heteroatom,
a saturated or unsaturated 5- to'7-membered heterocyclic group
with two or more N atoms or with one or two N atoms and an 0
or S atom as heteroatoms,
CA 02504160 2011-02-03
25771-1022
12f
an aromatic heterocyclic 5- or 6-membered group with one or
more identical or different heteroatoms selected from N, 0
and/or S,
while the above-mentioned 4-, 5-, 6- or 7-membered groups may
be attached via two common, adjacent C atoms fused to a phenyl
or pyridine ring, and
in the above-mentioned 5-, 6- or 7-membered groups one or two
non-adjacent -CH2- groups may be replaced independently of one
another by a -CO-, -C(=CH2)-, -(SO)- or -(SO2)- group, and
the above-mentioned saturated 6- or 7-membered groups may also
be present as bridged ring systems with an imino, (C1-4-alkyl)-
imino, methylene, (C1_4-alkyl)-methylene or di-(C1-4-alkyl)-
methylene bridge, and
the above-mentioned cyclic groups may be mono- or
polysubstituted at one or more C.atoms with R20, in the case of a
phenyl group they may also additionally be monosubstituted with
nitro, and/or one or more NH groups may be substituted with R21,
R4, R5 independently of one another have one of the meanings given for
R17
R10 denotes hydroxy, w-hydroxy-C1-3-alkyl, C1_4-alkoxy, w-(C1-4-alkoxy)-
C1-3-alkyl, carboxy, C1_4-alkoxycarbonyl, amino, C14-alkyl-amino, di-
(C1.4-alkyl)-amino, cyclo-C3_6-alkyleneimino, amino-C1-3-alkyl, C1-4-
alkyl-amino-C1-3-alkyl, di-(C1-4-alkyl)-amino-C1_3-alkyl, cyclo-C3-6-
alkyleneimino-Cl-3-alkyl, amino-C2-3-alkoxy, C1_4-alkyl-amino-C2-3-
alkoxy, di-(C1-4-alkyl)-amino-C2-3-alkoxy, cyclo-C3_6-alkyleneimino-
C2-3-alkoxy, aminocarbonyl, C1_4-alkyl-aminocarbonyl, di-(C1-4-
CA 02504160 2011-02-03
25771-1022
12g
alkyl)-aminocarbonyl, cyclo-C3_6-alkyleneimino-carbonyl,
R" denotes C2.6-alkenyl, C2-6-alkynyl, R15-O, R15-O-CO, R15-CO-O,
R16R17N R18R19N-CO or Cy,
R12 has one,of the meanings given for R20,
R13 has one of the meanings given for R17, with the exception of
carboxy,
R14 denotes. halogen, C1-6-alkyl, C2.6-alkenyl, C2-6-alkynyl, R15-O, R15-O-
CO, R15-CO, R15-CO-O, R16R17N, R18R19N-CO, R15-O-C1-3-alkyl,
R15-O-CO-C1-3-alkyl, R15-O-CO-NH, R15-SO2-NH, R15-O-CO-NH-
C1-3-alkyl, R15-SO2-NH-C1-3-alkyl, R15-CO-C1.3-alkyl, R15-CO-O-C1-3-
alkyl, R16R17N-C1-3-alkyl, R18R'9N-CO-C1-3-alkyl or Cy-C1.3-alkyl,
R15 denotes H, C1-4-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl,
phenyl, phenyl-C1-3-alkyl, pyridinyl or pyridinyl-C1-3-alkyl,
R16 denotes H, C1-6-alkyl, C3-7-cycloalkyl, C3_7-cycloalkyl-Cl-3-alkyl, C4-7-
cycloalkenyl, C4-7-cycloalkenyl-C1-3-alkyl, (o-hydroxy-C2-3-alkyl,
0)-(C1-4-alkoxy)-C2-3-alkyl, amino-C2-6-alkyl, C1-4-alkyl-amino-C2-6-
alkyl, di-(C1-4-alkyl)-amino-C2-6-alkyl or cyclo-C3-6-alkyleneimino-
C2.6-alkyl,
R17 has one of the meanings given for R16 or denotes phenyl, phenyl-
C1.3-alkyl, pyridinyl, dioxolan-2-yl, -CHO, C1-4-alkylcarbonyl,
carboxy, hydroxycarbonyl-C1-3-alkyl, C1-4-alkoxycarbonyl,
C1.4-alkoxycarbonyl-C1-3-alkyl, C1:4-alkylcarbonylamino-C2-3-alkyl,
N-(C1-4-alkylcarbonyl)-N-(C1-4-alkyl)-amino-C2-3-alkyl,
C1-4-alkylsulphonyl, C1-4-alkylsulphonylamino-C2-3-alkyl or
N-(C1_4-alkylsulphonyl)-N-(C1-4-alkyl)-amino-C2-3-alkyl
CA 02504160 2011-02-03
25771-1022
12h
R18, R19 independently of one another denote H or C1-6-alkyl,
R20 denotes halogen, hydroxy, cyano, C1_6-alkyl, C2_6-alkenyl, C2_6-
alkynyl, C3_7-cycloalkyl, C3_7-cycloalkyl- C1_3-alkyl, hydroxy-C1_3-
alkyl, R22-C1.3-alkyl or has one of the meanings given for R22,
R21 denotes C1_4-alkyl, co-hydroxy-C2_6-alkyl, co-C1_4-alkoxy-C2_6-alkyl,
co-C1_4-alkyl-amino-C2_6-alkyl, w-di-(C1_4-alkyl)-amino-C2_6-alkyl, co-
cyclo-C3_6-alkyleneimino-C2_6-alkyl, phenyl, phenyl-C1_3-alkyl, C1_4-
alkyl-carbonyl, C1.4-alkoxy-carbonyl, C1-4-alkylsulphonyl,
phenylcarbonyl or phenyl-C1_3-alkyl-carbonyl,
R22 denotes pyridinyl, phenyl, phenyl-C1_3-alkoxy, OHC, HO-N=HC,
C1_4-alkoxy-N=HC, C1_4-alkoxy, C1_4-alkylthio, carboxy,
C1_4-alkylcarbonyl, C1_4-alkoxycarbonyl, aminocarbonyl,
C1_4-alkylaminocarbonyl, di-(C1_4-alkyl)-aminocarbonyl, cyclo-C3_6-
alkyl-amino-carbonyl, cyclo-C3.6-alkyleneimino-carbonyl, cyclo-C3_6-
alkyleneimino-C2_4-alkyl-aminocarbonyl, C1_4-alkyl-sulphonyl, C1_4-
alkyl-sulphinyl, C1_4-alkyl-sulphonylamino, amino, C1_4-alkylamino,
di-(C1_4-alkyl)-amino, C1_4-alkyl-carbonyl-amino, cyclo-C3_6-
alkyleneimino, phenyl-C1_3-alkylamino, N-(C1_4-alkyl)-
phenyl-C1_3-alkylamino, acetylamino, propionylamino,
phenylcarbonyl, phenylcarbonylamino,
phenylcarbonylmethylamino, hydroxy-C2_3-alkylaminocarbonyl,
(4-morpholinyl)carbonyl, (1-pyrrolidinyl)carbonyl,
(1-piperidinyl)carbonyl, (hexahydro-l-azepinyl)carbonyl, (4-methyl-
1-piperazinyl)carbonyl, methylenedioxy, aminocarbonylamino or
alkylaminocarbonylamino,
while in the above-mentioned groups and residues A, B, W, X, Y, Z, R1 to R5
and R10 to R22, in each case one or more C atoms may additionally be mono-
or polysubstituted by F and/or in each case one or two C atoms independently
of one another may additionally be monosubstituted by Cl or Br and/or in each
CA 02504160 2011-02-03
25771-1022
12i
case one or more phenyl rings independently of one another additionally have
one, two or three substituents selected from among F, Cl, Br, I, cyano, C1_4-
alkyl, C14-alkoxy, difluoromethyl, trifluoromethyl, hydroxy, amino,
C1_3-alkylamino, di-(C1_3-alkyl)-amino, acetylamino, aminocarbonyl,
difluoromethoxy, trifluoromethoxy, amino-C1_3-alkyl, C1_3-alkylamino-C1_3-
alkyl-
and di-(C1_3-alkyl)-amino-C1_3-alkyl- and/or may be monosubstituted by nitro,
or
a tautomer thereof, a diastereomer thereof, a enantiomer thereof, a mixture of
enantiomers thereof or a salt thereof;
with the proviso that the following compounds are excluded:
tert-butyl 4-(5-{[5-(trifluoromethyl)pyridin-2-yl]ethynyl}pyridin-2-
yl)piperazin-1-
carboxylate; and
1 -(m ethyl sulfonyl)-4-(5-{[5-(trifluoromethyl)pyridin-2-yl]ethynyl}pyridinyl-
2-
yl)piperazine.
CA 02504160 2011-02-03
25771-1022
12j
The invention also relates to the compounds in the form of the individual
optical isomers, mixtures of the individual enantiomers or racemates, in the
form of the tautomers and in the form of the free bases or the corresponding
acid addition salts with pharmacologically safe acids. The subject of the
invention also includes the compounds according to the invention, including
the salts thereof, wherein one or more hydrogen atoms are replaced by
deuterium.
This invention also includes the physiologically acceptable salts of the
alkyne
compounds according to the invention as described above and hereinafter.
This invention also relates to compositions containing at least one alkyne
compound according to the invention and/or a salt according to the invention
optionally together with one or more physiologically acceptable excipients.
Also covered by this invention are pharmaceutical compositions containing at
least one alkyne compound according to the invention and/ or a salt according
to the invention optionally together with one or more inert carriers and/or
diluents.
This invention also relates to the use of at,least one alkyne compound
according to the invention and/or a salt according to the invention for
influencing the eating behaviour of a mammal. '
The invention further relates to the use of at least one alkyne compound
according to the invention and/or a salt according to the invention for
reducing
the body weight and/ or for preventing an increase in the body weight of a
mammal.
The invention also relates to the use of at least one alkyne compound
according to the invention and/or a salt according to the invention for
Boehringer Ingelheim 13 Case 1-1406 ff
CA 02504160 2005-04-28
preparing a pharmaceutical composition with an MCH receptor-antagonistic
activity, particularly with an MCH-1 receptor-antagonistic activity.
This invention also relates to the use of at least one alkyne compound
according to the invention and/or a salt according to the invention for
preparing a pharmaceutical composition which is suitable for the prevention
and/or treatment of symptoms and/or diseases which are caused by MCH or
are otherwise causally connected with MCH.
A further object of this invention is the use of at least one alkyne compound
according to the invention and/or a salt according to the invention for
preparing a pharmaceutical composition which is suitable for the prevention
and/or treatment of metabolic disorders and/or eating disorders, particularly
obesity, bulimia, bulimia nervosa, cachexia, anorexia, anorexia nervosa and
hyperphagia
The invention also relates to the use of at least one alkyne compound
according to the invention and/or a salt according to the invention for
preparing a pharmaceutical composition which is suitable for the prevention
and/or treatment of diseases and/or disorders associated with obesity,
particularly diabetes, especially type II diabetes, complications of diabetes
including diabetic retinopathy, diabetic neuropathy, diabetic nephropathy,
insulin resistance, pathological glucose tolerance, encephalorrhagia, cardiac
insufficiency, cardiovascular diseases, particularly arteriosclerosis and high
blood pressure, arthritis and gonitis.
In addition the present invention relates to the use of at least one alkyne
compound according to the invention and/or a salt according to the invention
for preparing a pharmaceutical composition which is suitable for the
prevention and/or treatment of hyperlipidaemia, cellulitis, fat accumulation,
malignant mastocytosis, systemic mastocytosis, emotional disorders, affective
disorders, depression, anxiety, sleep disorders, reproductive disorders,
sexual disorders, memory disorders, epilepsy, forms of dementia and
hormonal disorders.
Boehringer Ingelheim 14 Case 1-1406 if
CA 02504160 2005-04-28
The invention also relates to the use of at least one alkyne compound
according to the invention and/or a salt according to the invention for
preparing a pharmaceutical composition which is suitable for the prevention
and/or treatment of urinary problems, such as for example urinary
incontinence, overactive bladder, urgency, nycturia and enuresis.
The invention further relates to processes for preparing for preparing a
pharmaceutical composition according to the invention, characterised in that
at least one alkyne compound according to the invention and/ or a salt
according to the invention is incorporated in one or more inert carriers
and/or
diluents by a non-chemical method.
The invention also relates to a pharmaceutical composition containing a first
active substance which is selected from the alkyne compounds according to
the invention and/or the corresponding salts as well as a second active
substance which is selected from the group consisting of active substances
for the treatment of diabetes, active substances for the treatment of diabetic
complications, active substances for the treatment of obesity, preferably
other
than MCH antagonists, active substances for the treatment of high blood
pressure, active substances for the treatment of hyperlipidaemia, including
arteriosclerosis, active substances for the treatment of arthritis, active
substances for the treatment of anxiety states and active substances for the
treatment of depression, optionally together with one or more inert carriers
and/or diluents.
This invention further relates to a process for preparing alkyne compounds of
formula A.5
R1R2N-X-Y-C=C-W-A-B (A.5)
while in formulae A.1, A.2, A.3, A.4 and A.5 R1, R2, X, Y, W, A and B have
one of the meanings given hereinbefore and hereinafter and Y denotes aryl or
heteroaryl,
Boehringer Ingelheim 15 Case 1-1406 ff
wherein a halogen compound of formula A.1
HO-X-Y-Hal (A.1)
wherein Hal denotes chlorine, bromine or iodine, preferably bromine or iodine,
is reacted with an alkyne compound of formula A.2
H-C=C-W-A-B (A.2)
in the presence of a suitable palladium catalyst, a suitable base and
copper(I)iodide in a suitable solvent, and
the resulting compound of formula A.3
HO-X-Y-C=C-W-A-B (A.3)
is reacted with methanesulphonic acid chloride (MsCI) to form the
methanesulphonate derivative A.4,
MsO-X-Y-C=C-W-A-B (A.4)
which is further reacted with an amine of formula H-NR1R2 to obtain the end
product A.5.
This invention further relates to a process for preparing alkyne compounds of
formula B.5
R'R2N-X-Y-Z-C=C-A-B (B.5)
while in formulae B.1, B.2, B.3, B.4 and B.5 R1, R2, X, Y, Z, A and B have one
of the meanings given hereinbefore and hereinafter and A particularly denotes
CA 02504160 2005-04-28
Boehringer Ingelheim 16 Case 1-1406 if
CA 02504160 2005-04-28
aryl or heteroaryl ,
wherein a halogen compound of formula B.1
Hal-A-B (B.1)
wherein Hal denotes chlorine, bromine or iodine, preferably bromine or iodine,
is reacted with an alkyne compound of formula B.2
HO-X-Y-Z-C=C-H (B.2)
in the presence of a suitable palladium catalyst, a suitable base and
copper(I)iodide in a suitable solvent, and
the resulting compound of formula B.3
HO-X-Y-Z-C=C-A-B (B.3)
is reacted with methanesulphonic acid chloride (MsCI) to form the
methanesulphonate derivative B.4,
MsO-X-Y-Z-C=C-A-B (B.4)
which is further reacted with an amine of formula H-NR1R2 to obtain the end
product B.5.
Moreover this invention relates to a process for preparing alkyne compounds
of formula C.3
R1 R2N-X-Y-C=C-W-A-B (C.3)
while in formulae C.1, C.2 and C.3 R1, R2, X, Y, W, A and B have one of the
meanings given hereinbefore and hereinafter and Y denotes aryl or
Boehringer Ingelheim 17 Case 1-1406 if
CA 02504160 2005-04-28
heteroaryl,
wherein a halogen compound of formula C.1
R'R2N-X-Y-Hal (C.1)
wherein Hal denotes chlorine, bromine or iodine, preferably bromine or iodine,
is further reacted with an alkyne compound of formula C.2
H-C=C-W-A-B (C.2)
in the presence of a suitable palladium catalyst, a suitable base and
copper(I)iodide in a suitable solvent to obtain the end product C.3.
This invention further relates to a process for preparing alkyne compounds of
formula D.3
R'R2N-X-Y-Z-C=C-A-B (D.3)
while in formulae D.1, D.2 and D.3 R1, R2, X, Y, Z, A and B have one of the
meanings given hereinbefore and hereinafter and A particularly denotes aryl
or heteroaryl,
wherein a halogen compound of formula D.2
Hal-A-B (D.2)
wherein Hal denotes chlorine, bromine or iodine, preferably bromine or iodine,
is reacted with an alkyne compound of formula D.1
R'R2N-X-Y-Z-C-C-H (D.1)
Boehringer Ingelheim 18 Case 1-1406 if
CA 02504160 2005-04-28
in the presence of a suitable palladium catalyst, a suitable base and
copper(I)iodide in a suitable solvent to obtain the end product D.3.
More detailed description of the invention
Unless otherwise specified the groups, residues and substituents, particularly
A, B, W, X, Y, Z, R1 to R5 and R10 to R22, have the meanings given
hereinbefore and hereinafter.
According to one embodiment of the invention the groups R', R2, X, W, Z, B,
R10, R13, R14, R15 R1', R20, R22 have the following meanings:
R1, R2 independently of one another denote H, a C1.8-alkyl or C3_7-
cycloalkyl group optionally substituted by the group R11 or a
phenyl group optionally mono- or polysubstituted by the group
R12 and/or monosubstituted by nitro, or
R1 and R2 form a C2_8-alkylene bridge, wherein
- one or two -CH2- groups independently of one another may
be replaced by -CH=N- or -CH=CH- and/or
- one or two -CH2- groups independently of one another may
be replaced by -0-, -S-, -CO-, -C(=CH2)- or -NR13- in such a
way that heteroatoms are not directly joined together,
while in the alkylene bridge defined hereinbefore one or more H
atoms may be replaced by R14, and
the alkylene bridge defined hereinbefore may be substituted by
one or two identical or different carbo- or heterocyclic groups Cy
in such a way that the bond betwen the alkylene bridge and the
group Cy is made
- via a single or double bond,
- via a common C atom forming a spirocyclic ring system,
Boehringer Ingelheim 19 Case 1-1406 ff
CA 02504160 2005-04-28
- via two common adjacent C- and/or N atoms forming a
fused bicyclic ring system or
- via three or more C- and/or N atoms forming a bridged ring
system,
X denotes a single bond or a C1_6-alkylene bridge, wherein
- a -CH2- group may be replaced by -CH=CH- or -C=C- and/or
- one or two -CH2- groups independently of one another may
be replaced by -0-, -S-, -(SO)-, -(SO2)-, -CO- or -NR4- in
such a way that in each case two 0, S or N atoms or an 0
and an S atom are not directly joined together,
while the bridge X may be attached to R1 including the N atom
attached to R1 and X, forming a heterocyclic group, and
while two C atoms or a C and an N atom of the alkylene bridge
may be joined together by an additional C1-4-alkylene bridge,
and
a C atom may be substituted by R10 and/or one or two C atoms
in each case may be substituted by one or two identical or
different C1_6-alkyl groups, and
W, z independently of one another denote a single bond or a C1_4-
alkylene bridge,
while in the group W and/or Z a -CH2- group not adjacent to the
-C-C- group may be replaced by -0- or -NR5-, and
two adjacent C atoms or a C atom and an adjacent N atom
may be joined together by an additional C1-a-alkylene bridge,
and
Boehringer Ingelheim 20 Case 1-1406 if
CA 02504160 2005-04-28
in the alkylene bridge and/or in the additional alkylene bridge a
C atom may be substituted by R10 and/or one or two C atoms
independently of one another may be substituted by one or two
identical or different C1_6-alkyl groups, and
B has one of the meanings given for Cy or
denotes C1.6-alkyl, C1.6-alkenyl, C1.6-alkynyl, C3_7-cycloalkyl-C1-3-
alkyl, C3_7-cycloalkenyl-C1.3-alkyl, C3_7-cycloalkyl-C1_3-alkenyl or
C3_7-cycloalkyl-C1_3-alkynyl, wherein one or more C atoms may
be mono- or polysubstituted by fluorine and cyclic groups may
be mono- or polysubstituted by R20,
R10 denotes hydroxy, (o-hydroxy-C1.3-alkyl, C1-4-alkoxy,
w-(C1-4-alkoxy)-C1.3-alkyl, amino, C1.4-alkyl-amino, di-(C1_4-alkyl)-
amino, cyclo-C3_6-alkyleneimino, amino-C1_3-alkyl, C1.4-alkyl-
amino-C1_3-alkyl, di-(C1-4-alkyl)-amino-C1.3-alkyl, cyclo-C3.6-
alkyleneimino-C1_3-alkyl, amino-C2-3-alkoxy, C1_4-alkyl-amino-
C2_3-alkoxy, di-(C1.4-alkyl)-amino-C2_3-alkoxy or cyclo-C3.6-
alkyleneimino-C2_3-alkoxy,
R13 has one of the meanings given for R17,
R14 denotes halogen, C1_6-alkyl, R15-O, R15-O-CO, R15-CO, R'5-CO-
0, R16R17N, R18R19N-CO, R15-O-C1.3-alkyl , R15-O-CO-C1.3-alkyl,
R15-CO-C1_3-alkyl, R15-CO-O-C1.3-alkyl, R16R17N-C1.3-alkyl,
R18R19N-CO-C1.3-alkyl or Cy-C1.3-alkyl,
R15 denotes H, C1.4-alkyl, C3.7-cycloalkyl, C3.7-cycloalkyl-C1_3-alkyl,
phenyl or phenyl-C1_3-alkyl,
R17 has one of the meanings given for R16 or denotes
phenyl, phenyl-C1_3-alkyl, C1"4-alkylcarbonyl,
Boehringer Ingelheim 21 Case 1-1406 ff
CA 02504160 2005-04-28
hydroxycarbonyl-C1-3-alkyl, C1_4-alkylcarbonylamino-C2-3-alkyl,
N-(C1.4-alkylcarbonyl)-N-(C1.4-alkyl )-amino-C2_3-alkyl,
C1_4-alkylsulphonyl, C1-alkylsulphonylamino-C2_3-alkyl or
N -(C 1.4-a l kyl s u l p h o n yl)-N (-C 1.4-alkyl)-amino-C2_3-alkyl
R20 denotes halogen, hydroxy, cyano, C1_6-alkyl, C3_7-cycloalkyl, C3.7-
cycloalkyl- C1_3-alkyl, hydroxy-C1.3-alkyl, R22-C1-3-alkyl or has one
of the meanings given for R22,
R22 denotes phenyl, phenyl-C1.3-alkoxy, C1-4-alkoxy, C1_4-alkylthio,
carboxy, C1.4-alkylcarbonyl, C1_4-alkoxycarbonyl, aminocarbonyl,
C1_4-alkylaminocarbonyl, di-(C1.4-alkyl)-aminocarbonyl, cyclo-
C3_6-alkyleneimino-carbonyl, C1_4-alkyl-sulphonyl, C1.4-alkyl-
sulphinyl, C1.4-alkyl-sulphonylamino, amino, C1.4-alkylamino, di-
(C1.4-alkyl)-amino, cyclo-C3.6-alkyleneimino,
phenyl-C1_3-alkylamino, N-(C1_4-alkyl)-phenyl-CI_3-alkylamino,
acetylamino, propionylamino, phenylcarbonyl,
phenylcarbonylamino, phenylcarbonylmethylamino, hydroxy-
alkylaminocarbonyl, (4-morpholinyl)carbonyl, (1-pyrrolidinyl)-
carbonyl, (1-piperidinyl)carbonyl, (hexahydro-1-
azepinyl)carbonyl, (4-methyl-1-piperazinyl)carbonyl,
methylenedioxy, aminocarbonylamino or
alkylaminocarbonylamino,
while R4, R", R12, R16, R18, R19 and Cy are as hereinbefore defined.
If R1 and R2 are not joined together via an alkylene bridge, R' and R2
independently of one another preferably denote a C1_8-alkyl or C3-7-cycloalkyl
group optionally substituted by the group R", while a -CH2- group in position
3 or 4 of a 5-, 6- or 7-membered cycloalkyl group may be replaced by -0-, -S-
or -NH-, -N(C1.4-alkyl)- or -N(CO-O-C1.4-alkyl)-, or phenyl or pyridinyl group
optionally mono- or polysubstituted by the group R12 and/or monosubstituted
by nitro, and one of the groups R1 and R2 may also denote H.
Boehringer Ingelheim 22 Case 1-1406 if
CA 02504160 2005-04-28
Preferably, the groups R1, R2 independently of one another represent H, C1-6-
alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-Cl-3-alkyl, w-hydroxy-C2_3-alkyl,
w-(C1-4-alkoxy)-C2-3-alkyl, C1-4-alkoxy-carbonyl-C1-4-alkyl, carboxyl-C1-4-
alkyl,
amino-C2.4-alkyl, C1_4-alkyl-amino-C2-4-alkyl, di-(C1-4-alkyl)-amino-C2-4-
alkyl,
cyclo-C3-6-alkyleneimino-C2-4-alkyl, pyrrolidin-3-yl, N-(C1-4-alkyl)-
pyrrolidinyl,
pyrrolidinyl-C1-3-alkyl, N-(C1-4-alkyl)-pyrrolidinyl-C1-3-alkyl, piperidinyl,
N-(C1-4-
alkyl)-piperidinyl, piperidinyl-C1-3-alkyl, N-(C1-4-alkyl)-piperidinyl-Cl-3-
alkyl,
phenyl, phenyl-C1-3-alkyl, pyridyl or pyridyl-Cl-3-alkyl, while in the above-
mentioned groups and residues one or more C atoms may be mono- or
polysubstituted by F and/or one or two C atoms may be monosubstituted
independently of one another by Cl or Br, and the phenyl or pyridyl group
may be mono- or polysubstituted by the above-defined group R12 and/or may
be monosubstituted by nitro. Preferred substituents of the above-mentioned
phenyl or pyridyl groups are selected from among F, Cl, Br, I, cyano, C1-4-
alkyl, C1..4-alkoxy, difluoromethyl, trifluoromethyl, hydroxy, amino,
C1-3-alkylamino, di-(C1.3-alkyl)-amino, acetylamino, aminocarbonyl,
difluoromethoxy, trifluoromethoxy, amino-C1-3-alkyl, C1-3-alkylamino-Cl-3-
alkyl-
and di-(C1_3-alkyl)-amino-Cl-3-alkyl, while a phenyl group may also be
monosubstituted by nitro.
Particularly preferably, at least one of the groups R1, R2, and most
particularly
preferably both groups, have a meaning other than H.
If R1 and R2 form an alkylene bridge, it is preferably a C3-7-alkylene bridge,
wherein
- a -CH2- group not adjacent to the N atom of the R'R2N group may be
replaced by -CH=N- or -CH=CH- and/or
- a -CH2- group which is preferably not adjacent to the N atom of the R1 R2N
group may be replaced by -0-, -S-, -C(=N-R18)-, -C-O, -C(=CH2)- or -
NR13- in such a way that heteroatoms are not directly joined together,
while in the alkylene bridge defined hereinbefore one or more H atoms may
be replaced by R14, and
Boehringer Ingelheim 23 Case 1-1406 ff
the alkylene bridge defined hereinbefore may be substituted by a carbo- or
heterocyclic group Cy in such a way that the bond betwen the alkylene bridge
and the group Cy is made
- via a single bond,
- via a common C atom forming a spirocyclic ring system,
- via two common adjacent C and/or N atoms forming a fused bicyclic ring
system or
- via three or more C and/or N atoms forming a bridged ring system.
Also preferably, R1 and R2 form an alkylene bridge in such a way that R1R2N-
denotes a group selected from azetidine, pyrrolidine, piperidine, azepan, 2,5 -
dihydro-1 H-pyrrole, 1,2,3,6-tetrahydro-pyridine, 2,3,4,7-tetrahydro-1 H-
azepine, 2,3,6,7-tetrahydro-1 H-azepine, piperazine, wherein the free imine
function is substituted by R13, piperidin-4-one, piperidin-4-one-oxime,
piperidin-4-one-O-C14-alkyl-oxime, morpholine and thiomorpholine, while
according to the general definition of R1 and R2 one or more H atoms may be
replaced by R14, and/ or the above-mentioned groups may be substituted by
one or two identical or different carbo- or heterocyclic groups Cy in a manner
specified according to the general definition of R1 and R2. Particularly
preferred groups Cy are C3.7-cycloalkyl, aza-C4_7-cycloalkyl, particularly
cyclo-
C3_6-alkyleneimino, as well as 1-C1_4-alkyl-aza-C4.7-cycloalkyl.
The C2_8-alkylene bridge formed by R1 and R2, wherein -CH2- groups may be
replaced as specified, may be substituted by one or two identical or different
carbo- or heterocyclic groups Cy, as described.
In the event that the alkylene bridge is linked to a group Cy via a single
bond,
Cy is preferably selected from among C3_7-cycloalkyl, cyclo-C3.6-
alkyleneimino, 1 H-imidazole, thienyl and phenyl.
In the event that the alkylene bridge is linked to a group Cy via a common C
atom forming a spirocyclic ring system, Cy is preferably selected from
CA 02504160 2005-04-28
Boehringer Ingelheim 24 Case 1-1406 if
CA 02504160 2005-04-28
among C3-7-cycloalkyl, aza-C4-8-cycloalkyl, oxa-C4-5-cycloalkyl, 2,3-dihydro-
1 H-quinazolin-4-one.
In the event that the alkylene bridge is linked to a group Cy via two common
adjacent C and/or N atoms forming a fused bicyclic ring system, Cy is
preferably selected from among C4-7-cycloalkyl, phenyl, thienyl.
In the event that the alkylene bridge is linked to a group Cy via three or
more
C and/or N atoms forming a bridged ring system, Cy preferably denotes C4-8-
cycloalkyl or aza-C4-8-cycloalkyl.
X
R N
Particularly preferably, the group
R2
is defined according to one of the following partial formulae
N-X- ON-X- CN-x
CN-CNXH \ N-X
R13 N N-X-;
ON - X-T ON - X-;
C~-CN-X=
N N-X-;
0- \-/ I
N R'$ O, ,
N-X N N-X-;
0 N-X-~ N-X- N
-X-.
U
Boehringer Ingelheim 25 Case 1-1406 ff
R21
111
S N-X-1 N
N-X-
R21 NN -X- N-x
R21~N
CN N-X-; CN-CN-x
R21 N
N
N-X- N-X-q
QN'
N
-X-- N--X-4
N Nom)
R21
\N
N-X
R21
R21N N-X
N
N-X-
CA 02504160 2005-04-28
Boehringer Ingelheim 26 Case 1-1406 ff
R21
\N N N-X-
:)C
R21"
N-X=
OCN -X-; R21 N N-X---7
O
N
&N>CNX'
$N-XH N-X N-X
S
8N-X= IN-X-,
R? N X" = R? N R? N
X" P
X' -
R? N X" R 2 N P 7
X
N
Na
X", N X,2'. NX
wherein one or more H atoms of the heterocycle formed by the group R1 R2N-
may be replaced by R14 and the ring attached to the heterocycle formed by
CA 02504160 2005-04-28
Boehringer Ingelheim 27 Case 1-1406 if
the group R1R2N- may be mono- or polysubstituted by R20 at one or more C
atoms, in the case of a phenyl ring may also additionally be monosubstituted
by nitro and
X', X" independently of one another denote a single bond or C1.3-alkylene
and
in the event that the group Y is linked to Xor X" via a C atom, also
denotes -C1_3-alkylene-O-, -C1_3-alkylene-NH- or
-C1_3-alkylene-N(C1_3-alkyl)-, and
X" additionally also denotes -O-C1_3-alkylene-, -NH-C1_3-alkylene- or
-N(C1_3-alkyl)-C1_3-alkylene- and
in the event that the group Y is linked to X" via a C atom, also
denotes -NH-, -N(C1.3-alkyl)- or -0-,
while in the meanings given for X', X" hereinbefore, in each case a
C atom may be substituted by R10, preferably by a hydroxy,
w-hydroxy-C1_3-alkyl, w-(C1_4-alkoxy)-C1_3-alkyl and/or C1.4-alkoxy
group, and/or one or two C atoms in each case may be substituted
by one or two identical or different substituents selected from C1_6-
alkyl, C2_6-alkenyl, C2_6-alkynyl, C3_7-cycloalkyl, C3-7-cycloalkyl-C1_3-
alkyl, C4_7-cycloalkenyl and C4_7-cycloalkenyl-C1_3-alkyl, while two
alkyl and/or alkenyl substituents may be joined together, forming a
carbocyclic ring system, and
in X', X" independently of one another in each case one or more C
atoms may be mono- or polysubstituted by F and/or in each case
one or two C atoms independently of one another may be
monosubstituted by Cl or Br and
CA 02504160 2005-04-28
Boehringer Ingelheim 28 Case 1-1406 ff
CA 02504160 2005-04-28
wherein R2, R10, R13, R14, R20, R21 and X have the meanings given above and
hereinafter.
In the preferred and particularly preferred meanings of R'R2N listed above the
following definitions of the substituent R14 are preferred: C1_4-alkyl, C2_4-
alkenyl, C2_4-alkynyl, C3.7-cycloalkyl, C3_7-cycloalkyl-C1_3-alkyl, hydroxy,
w-hydroxy-C1_3-alkyl, C1_4-alkoxy, (O-(C1.4-alkoxy)-C1.3-alkyl, C1_4-alkyl-
carbonyl, carboxy, C1_4-alkoxycarbonyl, hydroxy-carbonyl-C1_3-alkyl,
C1_4-alkoxycarbonyl-C1_3-alkyl, C1_4-alkoxy-carbonylamino, C1_4-alkoxy-
carbonylamino-C1_3-alkyl, amino, C1_4-alkyl-amino, C3.7-cycloalkyl-amino, N-
(C8_7-cycloalkyl)-N-(C1.4-alkyl)-amino, di-(C1.4-alkyl)-amino, amino-C1_3-
alkyl,
C1_4-alkyl-amino-C1_3-alkyl, C3.7-cycloalkyl-amino-C1.3-alkyl, N-(C8_7-
cycloalkyl)-
N-(C1.4-alkyl)-amino-C1_3-alkyl, di-(C1.4-alkyl)-amino-C1.3-alkyl, cyclo-C3_6-
alkyleneimino-C1_3-alkyl, aminocarbonyl, C1.4-alkyl-amino-carbonyl, C3_7-
cycloalkyl-amino-carbonyl, N-(C8_7-cycloalkyl)-N-(C1-4-alkyl)-amino-carbonyl,
di-(C1_4-alkyl)-amino-carbonyl, pyridinyl-oxy, pyridinyl-amino, pyridinyl-C1_3-
alkyl-amino.
Most particularly preferred meanings of the substituent R14 are C1.4-alkyl,
hydroxy, w-hydroxy-C1.3-alkyl, C1_4-alkoxy and w-(C1_4-alkoxy)-C1.3-alkyl.
Preferably X denotes a single bond or a C1-4-alkylene bridge, wherein
- a -CH2- group may be replaced by -CH=CH- or -C-C- and/or
- a -CH2- group may be replaced by -0-, -S-, -CO- or -NR4- in such a way
that in each case two 0, S or N atoms or an 0 and an S atom are not
directly joined together,
while the bridge X may be attached to R1 including the N atom attached to R1
and X, forming a heterocyclic group, while the bridge X may additionally also
be linked to R2 including the N atom attached to R2 and X, forming a
heterocyclic group, and
Boehringer Ingelheim 29 Case 1-1406 if
while two C atoms or a C and an N atom of the alkylene bridge may be joined
together by an additional C1.4-alkylene bridge, and
a C atom may be substituted by R10 and/or one or two C atoms in each case
may be substituted by one or two identical or different substituents selected
from C1_6-alkyl, C2_6-alkenyl, C2_6-alkynyl, C3_7-cycloalkyl, C3_7-cycloalkyl-
C1_3-
alkyl, C4_7-cycloalkenyl and C4_7-cycloalkenyl-C1_3-alkyl, while two alkyl
and/or
alkenyl substituents may be joined together, forming a carbocyclic ring
system, particularly a cyclopropyl, cyclobutyl or cyclopentyl group.
If in the group X a -CH2- group of the alkylene bridge is replaced according
to
the invention, this -CH2- group is preferably not attached directly to a
heteroatom, a double or triple bond.
Preferably the alkylene bridge X, X or X" has no or at most one imino group.
The position of the imino group within the alkylene bridge X, X or X" is
preferably selected so that no aminal function is formed together with the
amino group NR1R2 or another adjacent amino group or two N atoms are not
adjacent to each other.
Preferably X denotes a single bond or C1_4-alkylene and
in the event that the group Y is linked to X via a C atom, it also denotes
-CH2-CH=CH-, -CH2-C=C-, C2_4-alkylenoxy, C2_4-alkylene-NR4,
C2_4-alkylene-NR4-C2_4-alkylene-O, 1,2- or 1,3-pyrrolidinylene or 1,2-, 1,3-
or
1,4-piperidinylene, while the pyrrolidinylene and piperidinylene groups are
bound to Y via the imino group,
while the bridge X may be attached to R1 including the N atom attached to R1
and X, forming a heterocyclic group, and the bridge X may additionally also
be attached to R2 , including the N atom attached to R2 and X, forming a
heterocyclic group , and
CA 02504160 2005-04-28
Boehringer Ingelheim 30 Case 1-1406 if
CA 02504160 2005-04-28
in X a C atom may be substituted by R10, preferably a hydroxy,
w-hydroxy-C1-3-alkyl, w-(C1-4-alkoxy)-C1-3-alkyl- and/or C1_4-alkoxy group,
and/or one or two C atoms in each case may be substituted by one or two
identical or different substituents selected from C1-6-alkyl, C2-6-alkenyl, C2-
6-
alkynyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-3-alkyl, C4-7-cycloalkenyl and
C4_7-
cycloalkenyl-C1-3-alkyl, while two alkyl and/or alkenyl substituents may be
joined together, forming a carbocyclic ring system, and
in the above-mentioned groups and residues one or more C atoms may be
mono- or polysubstituted by F and/or one or two C atoms independently of
one another may be monosubstituted by Cl or Br and
R1, R4 and R10 are as hereinbefore defined.
Particularly preferably X denotes -CH2-, -CH2-CH2- or -CH2-CH2-CH2- and in
the event that the group Y is bonded to X via a C atom, it also denotes
-CH2-C=C- -CH2-CH2-O-, -CH2-CH2-NR4- or 1,3-pyrrolidinylene, while the
pyrrolidinylene group is linked to Y via the imino group, and
the bridge X may be attached to R1 including the N atom attached to R1 and
X, forming a heterocyclic group, and the bridge X may additionally also be
attached to R2 , including the N atom attached to R2 and X , forming a
heterocyclic group, and
in X a C atom may be substituted by R10, preferably a hydroxy,
w-hydroxy-C1-3-alkyl, co-(C1_4-alkoxy)-C1-3-alkyl and/or C1_4-alkoxy group,
and/or one or two C atoms in each case may be substituted by one or two
identical or different substituents selected from C1-6-alkyl, C2_6-alkenyl,
C2_6-
alkynyl, C3-7-cycloalkyl, C3_7-cycloalkyl-C1-3-alkyl, C4-7-cycloalkenyl and C4-
7-
cycloalkenyl-C1-3-alkyl, while two alkyl and/or alkenyl substituents may be
joined together, forming a carbocyclic ring system, and
Boehringer Ingelheim 31 Case 1-1406 if
in each case one or more C atoms may be mono- or polysubstituted by F
and/or in each case one or two C atoms independently of one another may be
monosubstituted by Cl or Br.
If in the group X, X or X" one or more C atoms is or are substituted by a
hydroxy and/or C1_4-alkoxy group, the substituted C atom is preferably not
directly adjacent to another heteroatom.
If in X, X or X" a C atom is substituted, preferred substituents are selected
from among C1_4-alkyl, C2_4-alkenyl, C2_4-alkynyl, C3_7-cycloalkyl, C3_7-
cycloalkyl-C1_3-alkyl, hydroxy, w-hydroxy-C1.3-alkyl, w-(C1_4-aIkoxy)-C1_3-
alkyl-
and C1_4-alkoxy groups. Moreover in X, Xor X" a C atom may be
disubstituted and/or one or two C atoms may be mono- or disubstituted, while
preferred substituents are selected from among C1.4-alkyl, C2_4-alkenyl, C24-
alkynyl, C3_7-cycloalkyl and C3_7-cycloalkyl-C1_3-alkyl, and two C1-4-alkyl
and/or
C2_4-alkenyl substituents may also be joined together, forming a saturated or
monounsaturated carbocyclic ring.
Most particularly preferred substituents of one or two C atoms in X, X or X"
are selected from methyl, ethyl, n-propyl, i-propyl, cyclopropyl,
cyclopropylmethyl, while two alkyl substituents may also be joined together at
a C atom, forming a carbocyclic ring.
If X denotes an alkylene bridge , the -CH2- group adjacent to the R1R2N-
group is preferably not replaced by -0-, -S-, -(SO)-, -(SO2)-, -CO- or -NR4-.
Most particularly preferably, X denotes -CH2-, -CH2-CH2- or -CH2-CH2-CH2-
and in the event that the group Y is attached to X via a C atom, also denotes
-CH2-CH2-O-, -CH(CH3)-CH2-O-, -CH2-CH(CH3)-O-, -CH2-CH2-NH-,
-CH(CH3)-CH2-NH- or -CH2-CH2-N(CH3)-. In the event that R1 and/or R2 have
an amine function, which may also be substituted, another particularly
preferred meaning of X is a single bond.
CA 02504160 2005-04-28
Boehringer Ingelheim 32 Case 1-1406 if
CA 02504160 2005-04-28
According to a first preferred embodiment according to the invention Z
denotes a single bond.
In a second preferred embodiment according to the invention Z is a C1_4-
alkylene bridge, which may be substituted and/ or wherein a -CH2- group may
be replaced as specified.
Preferred definitions of the groups W and/or Z, particularly the group Z, are,
independently of one another, a single bond or a bridge selected from among
-CH2-, -CH2-CH2-, -CH2-CH(CH3)-, -CH2-C(CH3)2-, -CH(CH3)-CH2-, -C(CH3)2-
CH2-, cyclopropylene, -CH2-CH(R10)- and -CH(R10)-CH2-. Additional
particularly preferred definitions of the group W are also -CH2-O- or -CH2-NR4-
. Additional particularly preferred definitions of the group Z are also -O-CH2-
or -NR4-CH2-.
According to one preferred embodiment according to the invention W denotes
a single bond.
Preferably W and/or Z independently of one another represent a single bond,
-CH2-, -CH2-CH2-, -CH2-CH2-CH2-, 1,1-cyclopropylene or 1,2-cyclopropylene.
W may preferably additionally also represent -CH2-O-, -CH2-CH2-O-, -CH2-
NR4- or -CH2-CH2-NR4-.
In addition to the definitions given above Z may also preferably represent
-O-CH2-, -O-CH2-CH2-, -NR4-CH2- or -NR4-CH2-CH2-.
In the above-mentioned definitions of the groups W and Z a C atom may be
substituted by R10, preferably by a hydroxy, e)-hydroxy-C1_3-alkyl,
ow-(C1.4-alkoxy)-C1_3-alkyl and/or C14-alkoxy group, and/or one or two C atoms
may each independently of one another be substituted by one or two identical
or different C1.4-alkyl groups, while two alkyl groups may be joined together,
forming a carbocyclic group, particularly a cyclopropyl, cyclobutyl or
Boehringer Ingelheim 33 Case 1-1406 if
cyclopentyl group. Moreover in each case one or more C atoms in the groups
W and Z may be mono- or polysubstituted by F and/or in each case one or
two C atoms may each independently of one another be monosubstituted by
Cl or Br.
In the event that the bridge X comprises a carbonyl group, W and Z preferably
do not contain an -0- bridge.
In the definitions of the groups W and/or Z, R4 has the meanings given above,
preferably -H, methyl, ethyl, propyl or iso-propyl.
In the definitions of the groups W and/or Z, R10 has the meanings given
above, preferably -OH, N-pyrrolidinyl, amino-ethoxy, C1-4-alkyl-amino-ethoxy
or di-(C1.4-alkyl)-amino-ethoxy.
In the above-mentioned definitions of the groups W and/or Z in each case one
or more C atoms may be mono- or polysubstituted by F and/or in each case
one or two C atoms independently of one another may be monosubstituted by
Cl or Br.
If in the group W and/or Z one or two C atoms are substituted by a hydroxy
and/or C1_3-alkoxy group, the substituted C atom is preferably not immediately
adjacent to another heteroatom.
According to one embodiment compounds of formula I according to the
invention have W and Z bridges, while precisely one or both of the bridges W
and Z represent a single bond.
A preferred definition of the group Y is aryl or heteroaryl.
The group Y preferably has a meaning which is selected from the group of the
bivalent cyclic groups phenyl, naphthyl, thienyl, benzothienyl,
tetrahydronaphthyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, indolyl,
dihydroindolyl, dihydroindolonyl, quinolinyl, tetrahydroquinolinyl,
isoquinolinyl,
CA 02504160 2005-04-28
Boehringer Ingelheim 34 Case 1-1406 if
CA 02504160 2005-04-28
tetrahydroisoquinolinyl, indazolyl, benzimidazolyl, benzofuranyl or
benzoxazolyl, while the above-mentioned cyclic groups may be mono- or
polysubstituted at one or more C atoms by R20, or in the case of a phenyl
group may also additionally be monosubstituted by nitro, and/or substituted by
R21 at one or more N atoms. R1 may be attached to Y and/or X may be
attached to Y as hereinbefore defined.
Particularly preferably, a definition of the group Y is selected from among
the
bivalent cyclic groups
N
-N N
N
N N-
- N N
N-N
dN-
N_
\ / N N
Boehringer Ingelheim 35 Case 1-1406 if
CA 02504160 2005-04-28
N
O
N
N N
N N
N N
N
O
OII
N /
N
CP
Boehringer Ingelheim 36 Case 1-1406 ff
N N
N N
N:
N
N
p N
The cyclic groups listed above may be mono- or polysubstituted by R20 at one
or more C atoms, and in the case of a phenyl group may also additionally be
monosubstituted by nitro, and/or one or more NH groups may be substituted
by R21.
Most particularly preferably, Y is one of the groups listed below
N-
N
N
CA 02504160 2005-04-28
Boehringer Ingelheim 37 Case 1-1406 if
N N
O N
pN
IN
N
particularly a 1,4-phenylene group, while the groups listed may be substituted
as specified.
Particularly preferred substituents R20 of the group Y are selected from among
fluorine, chlorine, bromine, C1_4-alkyl, C2_6-alkenyl, -CHO, hydroxy,
w-hydroxy-C1_3-alkyl, C1_4-alkoxy, trifluoromethyl, trifluoromethoxy, C2_4-
alkynyl, carboxy, C1.4-alkoxycarbonyl, w-(C1_4-alkoxy)-C1_3-alkyl, C1_4-alkoxy-
carbonylamino, amino, C1-4-alkyl-amino, di-(C1_4-alkyl)-amino, aminocarbonyl,
C1_4-alkyl-amino-carbonyl, di-(C1_4-alkyl)-amino-carbonyl, -CH=N-OH and
-CH=N-O-C1_4-alkyl.
A preferred definition of the group A is aryl or heteroaryl.
Preferably the group A is selected from among the bivalent cyclic groups
phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, which may be may be
mono- or polysubstituted at one or more C atoms by R20, and in the case of a
phenyl ring may also additionally be monosubstituted by nitro.
Most particularly preferably, A is one of the groups listed below
N
CA 02504160 2005-04-28
Boehringer Ingelheim 38 Case 1-1406 ff
CA 02504160 2005-04-28
-N N
N
CN N=
NH
N
N-N
N
particularly or
N-N
while the groups listed may be substituted as specified hereinbefore.
Particularly preferred substituents R20 of the group A are fluorine, chlorine,
bromine, methoxy and C1_3-alkyl.
Preferably the groups A and/or Y are unsubstituted or monosubstituted by R20
as specified. The group A is preferably unsubstituted or monofluorinated.
According to a first embodiment, the definition of the group B is preferably
selected from among the unsaturated carbo- and heterocycles phenyl, thienyl
and furanyl. Particularly preferably, the group B denotes phenyl. The group B
in the definitions provided may be mono- or polysubstituted by R20, a phenyl
group may additionally also be monosubstituted by nitro. Preferably the group
B is mono-, di- or trisubstituted, particularly mono- or disubstituted. In the
case
of a monosubstitution the substituent is preferably in the para position to
the
group A.
Particularly preferred substituents R20 of the group B are selected from among
fluorine, chlorine, bromine, cyano, nitro, C14-alkyl, hydroxy,
Boehringer Ingelheim 39 Case 1-1406 if
CA 02504160 2005-04-28
w-hydroxy-C1_3-alkyl, C1-4-alkoxy, difluoromethyl, trifluoromethyl,
difluoromethoxy, trifluoromethoxy, C2_4-alkynyl, carboxy, C1_4-alkoxycarbonyl,
w-(C1.4-alkoxy)-C1_3-alkyl, C1_4-alkoxy-carbonylamino, amino, C1.4-alkyl-
amino,
di-(C1_4-alkyl)-amino, aminocarbonyl, C1.4-alkyl-amino-carbonyl and di-(C1-4-
alkyl )-amino-carbonyl.
Most particularly preferred substituents R20 of the group B are selected from
among fluorine, chlorine, bromine, CF3, C1_3-alkyl and C1.4-alkoxy.
According to a second embodiment the definition of the group B is preferably
selected from C1.6-alkyl, C2_6-alkenyl, C2_6-alkynyl, C3.7-cycloalkyl-C1.3-
alkyl,
C3.7-cycloalkenyl-C1_3-alkyl, C3.7-cycloalkyl-C1_3-alkenyl, C3.7-cycloalkyl-
C1_3-
alkynyl, while one or more C atoms in the groups mentioned for B
hereinbefore may be mono- or polysubstituted by fluorine.
In the cyclic groups according to the embodiment mentioned hereinbefore one
or more C atoms may be substituted by R20.
Particularly preferred according to this embodiment are the groups C3_6-alkyl,
C3_6-alkenyl, C3_6-alkynyl, cyclopentyl, cyclopentenyl, cyclohexyl,
cyclohexenyl,
cycloheptyl, cycloheptenyl, cyclopentyl-C1_3-alkyl, cyclopentenyl-C1.3-alkyl,
cyclohexyl-C1.3-alkyl, cyclohexenyl-C1_3-alkyl, cycloheptyl-C1_3-alkyl,
cycloheptenyl-C1_3-alkyl, while one or more C atoms in the groups mentioned
for B hereinbefore may be mono- or polysubstituted by fluorine.
R4 and/or R5 have one of the meanings given for R17, preferably for R16
Particularly preferred meanings of R4 and/or R5 are H, C1_4-alkyl, C3.7-
cycloalkyl and C3_7-cycloalkyl-C1_3-alkyl.
If R11 is a C2.6-alkenyl or C2_6-alkynyl group, the meanings -CH=CH2,
-CH=CH(CH3), -CH=C(CH3)2 and -C-CH, -C-=C-CH3 are preferred.
Boehringer Ingelheim 40 Case 1-1406 ff
CA 02504160 2005-04-28
Preferred definitions of the group R20 are halogen, hydroxy, cyano, C1_4-
alkyl,
C14-alkoxy, C$_7-cycloalkyl and C1.4-alkoxy-C1.3-alkyl, while C atoms may be
mono- or polysubstituted by fluorine and monosubstituted by Cl or Br.
Particularly preferably, R20 denotes F, Cl, Br, I, OH, cyano, methyl,
difluoromethyl, trifluoromethyl, ethyl, n-propyl, iso-propyl, methoxy,
difluoromethoxy, trifluoromethoxy, ethoxy, n-propoxy or iso-propoxy.
Preferred definitions of the group R21 are C1.4-alkyl, C1.4-alkylcarbonyl,
C1.4-
alkylsulphonyl, -S02-NH2, -S02-NH-C1_3-alkyl, -SO2-N(C1.3-alkyl)2 and cyclo-
C3.6-alkyleneimino-sulphonyl.
Cy preferably denotes a C3.7-cycloalkyl, particularly a C5_7-cycloalkyl group,
a
C5_7-cycloalkenyl group, aryl or heteroaryl, while aryl or heteroaryl
preferably
denotes a monocyclic or fused bicyclic ring system, and the above-mentioned
cyclic groups may be mono- or polysubstituted by R20at one or more C atoms,
and in the case of a phenyl group may also additionally be monosubstituted
by nitro, and/or one or more NH groups may be substituted by R21.
Preferred compounds according to the invention are those wherein one or
more of the groups, residues, substituents and/or indices have one of the
meanings mentioned above as being preferred.
Particularly preferred compounds according to the invention are those
wherein
Y has one of the meanings mentioned above as being preferred,
most preferably a group selected from
Boehringer Ingelheim 41 Case 1-1406 ff
CA 02504160 2005-04-28
N-
N N
N
N
N
O N
~. ~
O N
N \ /
N
and/or
A has one of the meanings mentioned above as being preferred, and
most preferably denotes
or and/or
N-N
B has one of the meanings mentioned above as being preferred,
most preferably phenyl,
while A, B and/or Y may be mono- or disubstituted, B may also be
trisubstituted by, or substituted by R20at one or more C atoms, and in the
case
of a phenyl ring may also additionally be monosubstituted by nitro.
Boehringer Ingelheim 42 Case 1-1406 if
Most particularly preferred compounds according to the invention are those
wherein A, B, X, Y, Z, R', R2 and W independently of one another have the
preferred meanings given above.
Particularly preferred compounds according to the invention are therefore
described by one of general formulae Ila to IIL
(L1)m (L2)n /
R1 L3/P
2 N-X Z-C\ IIa
R N
(L)m (L2)n
R' (L3)p
2N-X / \ Z \ Ilb
R - N-N
(L)m (L2)n
1 (L3)P
R Q
/ \ Ilc
R2/N-X - Z- / a
N N
(L)m (L2)n 3
R \ / ~ Zl i d
N-X N
(L4)4
CA 02504160 2005-04-28
Boehringer Ingelheim 43 Case 1-1406 if
(L)m (L)n 3(L )p
Q
N Z Ile
R1
NX N
Rzi
(L4 )q
(L1)m (L2),
l_; Q a (L3)p
R\ N Z/ Ilf
NX N
R2i
(L4)q
(L)m (L2)" 3
R\ Q _ (L )p
R2/N-X N Z -CX IIg
N
(L4)q
(L)m (L2), (L3)p
Q
Z~~ Ilh
R\ N
N -X
R2/
a
L
(L)m (L2)" 3
R\ Q _ (L )p
R2/N-X N ZX / / Ili
N
(L4 )q
CA 02504160 2005-04-28
Boehringer Ingelheim 44 Case 1-1406 if
(L1)m (L)n
3
R~ Q - (L)p
2 N_X Z~ I l j
R2i N N
N
La
(L)m (L2)n _ (L 3
R\ / Q p
N_X Ilk
R2i N Z-=_=-~\
N
O ~,~ N
L5
(L)m (L2)n _ (L 3
R\ Q IlL
R2iN_X N z X
a/\N N
L
wherein
R1, R2, X and Z have the above-mentioned meanings and
Q denotes -CH- or N, preferably -CH-, and
L1, L2,
L3, L4 denote H or have one of the meanings given for R20, and
L5 denote H or has one of the meanings given for R21, and
m, n,
p, q independently of one another represent the values 0, 1 or 2, and p
may also have the value 3.
CA 02504160 2005-04-28
Boehringer Ingelheim 45 Case 1-1406 if
One group of most particularly preferred compounds can be described by the
formula Ila wherein the group Q denotes -CH-.
Preferably, particularly in formulae Ila to IIL, the above-mentioned groups
have the following meanings:
X denotes -CH2-, -CH2-CH2- or -CH2-CH2-CH2-,
in formulae Ila to Ile it also denotes -CH2-C=C-, -CH2-CH2-O-,
-CH2-CH2-NR4- or 1,3-pyrrolidinylene, while the pyrrolidinylene
group is linked to Y via the imino group,
while in the definitions given hereinbefore one or two -CH2- groups
may be substituted by one or two methyl groups,
while the bridge X may be connected to R1 including the N atom
attached to R1 and X, forming a heterocyclic group, and
Z denotes a single bond or a bridge selected from among -CH2-,
-CH2-CH2-, -CH2-CH(CH3)-, -CH2-C(CH3)2-, -CH(CH3)-CH2-,
-C(CH3)2-CH2-, cyclopropylene, -CH2-CH(R10)- and -CH(R10)-CH2-,
-O-CH2- or -NR4-CH2-.
In the definitions of X and Z provided hereinbefore, in each case a C atom
may be substituted by a hydroxy, w-hydroxy-C1_3-alkyl, w-(C1_4-alkoxy)-
C1_3-alkyl and/or C1_4-alkoxy group, and/or one or two C atoms independently
of one another may each be substituted by one or two identical or different
C1_4-alkyl groups, while the alkyl groups may be joined together, forming a
carbocyclic ring. In addition, in the groups X and Z in each case one or more
C atoms may be mono- or polysubstituted by F and/or in each case one or
two C atoms independently of one another may be monosubstituted by Cl or
Br.
CA 02504160 2005-04-28
Boehringer Ingelheim 46 Case 1-1406 if
In the definitions of X and Z R4 has the meanings given hereinbefore,
preferably -H, methyl, ethyl, propyl or iso-propyl.
In the definitions of X and Z R10 has the meanings given hereinbefore,
preferably -OH, N-pyrrolidinyl, amino-ethoxy, C1-4-alkyl-amino-ethoxy or
d i-(C 1.4-alkyl)-amino-eth oxy.
Most particularly preferably,
X denotes -CH2-, -CH2-CH2- or -CH2-CH2-CH2-,
and in formulae Ila to Ile it also denotes -CH2-CH=CH-, -CH2-C=C-,
-CH2-CH2-O-, -CH(CH3)-CH2-O- or -CH2-CH(CH3)-O-, and/or
Z denotes a single bond, -CH2-, -CH2-CH2- or -O-CH2-, particularly a
single bond or -CH2-CH2- and/or
L1, L2,
L3, L4, independently of one another denote F, Cl, Br, I, OH, cyano, C1-4-
alkyl, C2-4-alkynyl, C1.4-alkoxy, difluoromethyl, trifluoromethyl,
amino, C1-4-alkylamino, di-(C1-4-alkyl)-amino, acetylamino,
aminocarbonyl, difluoromethoxy, trifluoromethoxy, amino-C1-3-alkyl,
C1_4-alkylamino-C1_3-alkyl or di-(C1.4-alkyl)-amino-C1-3-alkyl or nitro,
with the proviso that a phenyl may only be monosubstituted by
nitro, and/or
L1 additionally also denotes -CH=N-OH or -CH=N-O-C1.4-alkyl,
m, n, q denote 0 or 1 and/or
p denotes 1, 2 or 3, particularly 1 or 2.
CA 02504160 2005-04-28
Boehringer Ingelheim 47 Case 1-1406 if
The following individual compounds are particularly preferred:
N
N
CI
5-(4-chloro-phenyl)-2-[5-(2-pyrrolidin-1-yl-ethoxy)- pyridin-2-yl-ethynyl]-
pyridine
(2)
ci
N
N~~
O
O
[(R)-1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-
pyrrolid in-2-yl]-methanol
CA 02504160 2005-04-28
Boehringer Ingelheim 48 Case 1-1406 if
CA 02504160 2005-04-28
M C
)N O
N
Cl
5-(4-chloro-phenyl)-2-[2-(4-methyl-piperidin-1 -ylmethyl)-benzofuran-5-
ylethynyl]-pyridine
(4) cl
N
O=<N
N
r-j
N
U
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1-(2-pyrrolidin-1-yl-ethyl)-1,3-
dihydro-benzimidazol-2-one
Cl
i
(5) N
HO
N~\O
[1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-
Boehringer Ingelheim 49 Case 1-1406 if
piperidin-4-yl]-methanol
Cl
N
(6) JC
HO N-"-\O
CH3
1-(2-{4-[5-(4-chioro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-
piperidin-3-ol
(7) I cl
N
ON
CH3
N-{4-[5-(4-chioro-phenyl)-pyridin-2-ylethynyl]-phenyl}-2-pyrroIidin-1 -yl-
propionamide
(81~N I ~
~ N
oCI
1-{3-[5-(4-chloro-phenyl)-pyridin-2-yl]-prop-2-ynyl}-5-pyrrolidin-1-
ylmethyl-1 H-indole
CA 02504160 2005-04-28
Boehringer Ingelheim 50 Case 1-1406 if
L7N N
(9)
CI
2-[4-(4-azetidin-1 -ylmethyl-phenyl)-but-1-ynyl]-5-(4-chloro-phenyl)-
pyridine
C'N NI
(10)
CI
5-(4-chloro-phenyl)-2-[4-(4-piperidin-1 -ylmethyl-phenyl)-but-1-ynyl]-
pyridine
N
ON
(11) / I \
Br
5-(4-bromo-phenyl)-2-[4-(4-pyrrolidin-1 -ylmethyl-phenyl)-but-1 -ynyl]-
pyridine
CH3 I \ \
N
N / I \
CI
2-[(4-{4-[5-(4-chloro-phenyl)-pyrid in-2-yl]-but-3-ynyl}-benzyl)-methyl-
amino]-ethanol
CA 02504160 2005-04-28
Boehringer Ingelheim 51 Case 1-1406 if
(13)
ON
N
O
CI
5-(4-chloro-phenyl)-2-{4-[4-((S)-2-methoxymethyl-pyrrolidin-1-ylmethyl)-
phenyl]-but-1-ynyl}-pyridine
(14) Cl
N
CH3 N_,~ o
5-(4-chloro-phenyl)-2-{4-[2-(4-propyl-piperidin-1-yl)-ethoxy]-
phenylethynyl}-pyridine
(15) CI
<DN N i
5'-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-3-pyrrolidin-1-yl-3,4,5,6-
tetrahydro-2H-[1,2']bipyridinyl
CA 02504160 2005-04-28
Boehringer Ingelheim 52 Case 1-1406 if
CA 02504160 2005-04-28
(1 ) N N
H3C
Cl
5-(4-chloro-phenyl)-2-{4-[4-(2-methyl-pyrrolidin-1-ylmethyl)-phenyl]-but-1-
ynyl}-pyridine
Cl
(17) N*-N
3-(4-chloro-phenyl)-6-[4-(4-pyrrolidin-1 -ylmethyl-phenyl)-but-1 -ynyl]-
pyridazine
CAN
(18)
Cl
5-(4-chloro-phenyl)-2-[4-(4-pyrrolidin-1 -ylmethyl-phenyl)-but-1-ynyl]-
pyridine
Cl
jf",5~
CH3 \ N
N I /
,,O
CH3 CH3
Boehringer Ingelheim 53 Case 1-1406 if
5-(4-chloro-phenyl)-2-{4-[2-(2,6-dimethyl-piperidin-1 -yl)-ethoxy]-3-methyl-
phenylethynyl}-pyridine
CH3
O O
N~/O I \
(20)
N
Cl
methyl 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-l -yl-
ethoxy)-benzoate
Cl
N
I'DN
-,-\ O
CH3
5-(4-chloro-phenyl)-2-[3-methyl-4-(2-piperidin-1 -yl-ethoxy)-
phenylethynyl]-pyridine
/ CI
N
(2 \
I/
CH3
CA 02504160 2005-04-28
Boehringer Ingelheim 54 Case 1-1406 if
5-(4-chloro-phenyl)-2-[3-methyl-4-(2-pyrrolidin-1-yl-ethoxy)-
phenylethynyl]-pyridine
Fi3C
N
N ~
(23)
Cl
5-(4-chloro-phenyl)-2-{4-[4-(4-methyl-piperidin-1 -ylmethyl)-phenyl]-but-1-
ynyl}-pyridine
Cl
N
N~\p /
CHs
1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-
piperidin-4-ol
Cl
N
(25)
CH3
GN
5-(4-chloro-phenyl)-2-{3-methyl-4-[2-(2-pyrrolidin-1-ylmethyl-piperidin-1-
yl)-ethoxy]-phenylethynyl}-pyridine
CA 02504160 2005-04-28
Boehringer Ingelheim 55 Case 1-1406 if
CA 02504160 2005-04-28
CI
(26) N
IDN
N N
{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-(2-piperidin-1-yl-
ethyl)-amine
O~ N
N
(27)
CI
4-(4-{4-[5-(4-chloro-phenyl)-pyrid in-2-yl]-but-3-ynyl}-benzyl)-morpholi ne
CH3 I ~ ~ \
N
NI
a8)
CI
(4-{4-[5-(4-chloro-phenyl)-pyridin-2-yl]-but-3-ynyl}-benzyl)-methyl -
piperidin-4-yl-amine
/ cI
(29) N
O
5-(4-chloro-phenyl)-2-[3-(4-pyrrolidin-1 -ylmethyl-phenoxy)-prop-1-ynyl]-
Boehringer Ingelheim 56 Case 1-1406 if
CA 02504160 2005-04-28
pyridine
cl
N
(30)
N
N'~,~
6-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-pyrrolidin-1 -ylmethyl-1,2,3,4-
tetrahydro-quinoline
CI
N
(31/x)
H3C
N
H3C
(1-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-pyrrolidin-3-yl)-
dimethyl-amine
ci
(32) N
<DN
O
O
H
[(S)-1-(2-{4-[5-(4-chloro-phenyl)-pyrid in-2-ylethynyl]-2-methyl-phenoxy}-
Boehringer Ingelheim 57 Case 1-1406 if
CA 02504160 2005-04-28
ethyl)-pyrrolidin-2-yi]-methanol
NH2
0
(33)
Cl
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-
phenylamine
CH3
N N
GN
(34)
Cl
{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-(2-pyrrolidin-1-yl-
propyl)-amine
H 2 N
bN 1
(35) N
Cl
1-(4-{4-[5-(4-chloro-phenyl)-pyridin-2-yi]-but-3-ynyl}-benzyl)-pyrrolidin-3-
ylamine
Boehringer Ingelheim 58 Case 1-1406 if
CA 02504160 2005-04-28
Br
C
N
(36)
Cl
2-[3-bromo-4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-5-(4-chloro-
phenyl)-pyridine
Cl
N
)N 0
CH3
1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-
azepan
GN ~ \ \
(38)
N
Cl
5-(4-chloro-phenyl)-2-(6-pyrrolidin-1-ylmethyl-naphthalen-2-ylethynyl)-
pyridine
Boehringer Ingelheim 59 Case 1-1406 if
CH3
0 N
~/0 I (39)
c
N
Cl
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-N-methyl-2-(2-pyrrolidin-1-yl-
ethoxy)-benzamide
Cl
CH3 N
(40)
N 0 I /
CH3
(2-{4-[5-(4-ch loro-phenyl)-pyrid in-2-ylethynyl]-2-methyl-phenoxy}-ethyl )-
cyclopropylmethyl-propyl-amine
Cl
1)OH N
3 N JC)X
O
1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-4-methyl-
piperidin-4-oi
CA 02504160 2005-04-28
Boehringer Ingelheim 60 Case 1-1406 if
CA 02504160 2005-04-28
Cl
N
"""NO
CH3
5-(4-ch loro-phenyl)-2-{3-methyl-4-[2-(4-methyl-piperid in-1-yl)-ethoxy]-
phenylethynyl}-pyridine
/
Cl
F C aCH3
(43)
N
5-(4-chloro-phenyl)-3-fluoro-2-{4-[2-(4-methyl-piperidin-1-yl)-ethoxy]-
phenylethynyl}-pyridine
(44) Cl
N
N
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1-(2-pyrrolidin-1-yl-ethyl)-1 H-
indole
Boehringer Ingelheim 61 Case 1-1406 if
CA 02504160 2005-04-28
(45) Cl
N
ON
{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-(2-pyrrolidin-1-yl-
ethyl)-amine
(46) Cl
N
O \
H3C
O O
N I /
CH3
methyl [1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-
phenoxy}-ethyl)-piperid in-4-yl]-acetate
(47) Cl
N
ON~\ CNJNX
1
CH3
{5-[5-(4-chloro-phenyl)-pyrid in-2-ylethynyl]-pyridin-2-yl}-methyl-(2-
pyrrolidin-1-yl-ethyl)-amine
Boehringer Ingelheim 62 Case 1-1406 if
CA 02504160 2005-04-28
(48) Cl
CH3
H3C4 O \ % N
H3C 04 N--ON
tert-butyl [1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-
ethyl)-pyrrolidin-3-yl]-carbaminate
(49) CH3
O
CN
N
Cl
5-(4-chloro-phenyl)-2-[3-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-
phenylethynyl]-pyridine
(50) Cl
N
C ./\O JC
5-(4-chloro-phenyl)-2-[4-(2-piperidin-1-yl-ethoxy)-phenylethynyl]-pyridine
Boehringer Ingelheim 63 Case 1-1406 if
(51) CI
N
N
\N
N
0
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1-(2-pyrrolidin-1-yl-ethyl)-1 H-
indazole
(52) , CI
N
CN \/\ I /
O
2-[4-(2-azetidin-1-yl-ethoxy)-phenylethynyl]-5-(4-chloro-phenyl)-pyridine
(53) ci
ON
N -O
/
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-
benzaldehyde 0-methyl-oxime
CA 02504160 2005-04-28
Boehringer Ingelheim 64 Case 1-1406 ff
(54) Cl
N
N--~N N
1'-{5-[5-(4-ch loro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-
[1,3']bipyrrolidinyl
(55) CH3 I
N 11
N
H3CN
Cl
(4-{4-[5-(4-chloro-phenyl)-pyridin-2-yl]-but-3-ynyl}-benzyl)-methyl-(1-
methyl-piperidin-4-yl)-amine
(56) Cl
N
ON
~\O
Cl
5-(4-chloro-phenyl)-2-[3-chloro-4-(2-pyrrolidin-1-yl-ethoxy)-
phenylethynyl]-pyridine
CA 02504160 2005-04-28
Boehringer Ingelheim 65 Case 1-1406 if
(57) ci
N
O N /\
O
(S)-1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-
ethyl)-pyrrolidin-3-o1
(58) ` cl
N
Cl, \ ~
N N~~O
CH3
[1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-
ethyl)-piperidin-4-yl]-pyridin-2-yl-amine
(59) Br
N
ON
5-(4-bromo-phenyl)-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-pyridine
CA 02504160 2005-04-28
Boehringer Ingelheim 66 Case 1-1406 if
CA 02504160 2005-04-28
(60) Cl
CH3
H3C1~ Nlj~0 I i
N
N~\O
N-[1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-
pipe ridin-4-ylmethyi]-N-methyl-acetamide
(6 I \ N
N
CI CI
5-(2,4-dichloro-phenyl)-2-[4-(4-pyrrolidin-1-ylmethyl-phenyl)-but-1-ynyl]-
pyridine
(62) cl
N
H3C
5-(4-chloro-phenyl)-2-{4-[2-(4-ethyl-piperidin-1-yl)-ethoxy]-phenylethynyl}-
pyridine
Boehringer Ingelheim 67 Case 1-1406 if
CA 02504160 2005-04-28
(63) Cl
N
HO `
NO
CH3
[1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-
ethyl)-piperidin-4-yl]-methanol
(64) Cl
N
CAN
O 1
5-(4-chloro-phenyl)-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-pyridine
(65) Cl
N
ON I \
--,~ 0
5-(4-chloro-phenyl)-2-{4-[2-(3,6-dihydro-2H-pyridine-1-yi)-ethoxy]-
phenylethynyl}-pyrid ine
(66)
Boehringer Ingelheim 68 Case 1-1406 ff
Cl
N
9N H3C
5-(4-chloro-phenyl)-2-{4-[2-(2-methyl-pyrrolidin-1-yl)-ethoxy]-
phenylethynyl}-pyridine
N
(67) N
Cl
(4-{4-[5-(4-chloro-phenyl)-pyridin-2-yl]-but-3-ynyl}-benzyl)-
cyclopropylmethyl-amine
CAN
(68) N / NI
Cl
5-(4-chloro-phenyl)-2-{4-[4-(4-pyrrolidin-1-yl-piperidin-1-ylmethyl)-
phenyl]-but-1-ynyl}-pyridine
CA 02504160 2005-04-28
Boehringer Ingelheim 69 Case 1-1406 if
N
N O
/ I \
(69)
0
1
CH3
5-(4-methoxy-phenyl)-2-[4-(4-pyrrolidin-1-ylmethyl-phenyl)-but-1-ynyl]-
pyridine
ON
(70)
F
F
5-(3 ,4-d ifluoro-phenyl)-2-[4-(4-pyrrolidin-1-ylmethyl-phenyl)-but-1-ynyl]-
pyridine
/ Cl
N
(71 \
H3C 0
CH3
1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-
4-methyl-piperidin-4-ol
CA 02504160 2005-04-28
Boehringer Ingelheim 70 Case 1-1406 if
CA 02504160 2005-04-28
N
(72) N
0
ci
5-(4-chIoro-phenyl)-2-{4-[4-((R)-2-methoxymethyl-pyrrolidin-1-ylmethyl)-
phenyl]-but-1-ynyl}-pyridine
Cl
(73)
ON
N
6-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-pyrrolidin-1-ylmethyl-
quinoline
N
F13C~l
N
(74)
CI
1-(4-{4-[5-(4-chloro-phenyl)-pyridin-2-yi]-but-3-ynyl}-benzyl)-4-methyl-
piperazine
CI
(75) \ / N
N /
N N
Boehringer Ingelheim 71 Case 1-1406 if
{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-(2-pyrrolidin-1-yl-
ethyl)-amine
(76) CI
N
/ N N./~ I /
CHs
5-(4-chloro-phenyl)-2-(3-methyl-4-{2-[4-(pyrid in-2-yloxy)-piperidin-1-yl]-
ethoxy}-phenylethynyl)-pyridine
(77) Cl
N
C)N.~~O
CH3
5-(4-chloro-phenyl)-2-{4-[2-(3,6-dihydro-2H-pyridine-1-yl)-ethoxy]-3-
methyl-phenylethynyl}-pyridine
CA 02504160 2005-04-28
Boehringer Ingeiheim 72 Case 1-1406 if
(78) ci
N
0.,....
(R)-1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-
ethyl)-pyrrolid in-3-ol
(79) cI
N
N /
f-j
N
HO
1-(2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-indol-1-yl}-ethyl)-
piperidin-4-ol
(80) CI
HO
N
N~~O
1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-piperid in-
CA 02504160 2005-04-28
Boehringer Ingelheim 73 Case 1-1406 ff
CA 02504160 2005-04-28
4-ol
(81) ~ Cl
~ I\
N
HO
O
CH3
1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-
4-phenyl-piperidin-4-ol
(82) Cl
N I i
N
N~~
1 - (2-{4- [5- (4-ch loro-phenyl)-pyrid in-2-ylethynyl]-phenoxy}-ethyl)-
[4,4']bipiperidinyl
(83) Cl
N
CNo
CH
5-(4-chloro-phenyl)-2-[3-ethynyl-4-(2-pyrrolidin-1-yl-ethoxy)-
phenylethynyl]-pyridine
Boehringer Ingelheim 74 Case 1-1406 if
CA 02504160 2005-04-28
(8 N
N
CI
Cl
5-(3,4-dichloro-phenyl)-2-[4-(4-pyrrolidin-1-ylmethyl-phenyl)-but-1-ynyl]-
pyridine
(85) Cl
H N3C N
2
N0
CHs
1 -(2 -{4-[5-(4-ch loro-phenyl)-pyrid in-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-
4-methyl-piperidin-4-ylamine
(86) cl
N
<DN
O
N
O H
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolid in-1-yl-ethoxy)-
benzaldehyde-oxime
Boehringer Ingelheim 75 Case 1-1406 if
CA 02504160 2005-04-28
(87) Cl
N
CH3 N,~\ O
CH3
5-(4-chloro-phenyl)-2-{4-[2-(2,6-dimethyl-piperidin-1-yl)-ethoxy]-
phenylethynyl}-pyridine
(88) Cl
ff \
N I i
N
O
CH3
5-(4-chloro-phenyl)-2-(4-{2-[4-(1 H-imidazol-4-yl)-piperidin-1-yl]-ethoxy}-3-
methyl-phenylethynyl)-pyridine
(89) Cl
N
NO
CH3
HO
[1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-
ethyl)-piperidin-2-yl]-methanol
Boehringer Ingelheim 76 Case 1-1406 ff
CA 02504160 2005-04-28
H3
N (17N
N
CI
(4-{4-[5-(4-chloro-phenyl)-pyridin-2-yl]-but-3-ynyl}-benzyl)-methyl-pyridin-
2-ylmethyl-amine
(91) I CI
NHz I N
O
NO
1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-piperidin-
4-carboxylic acid amide
(92) CI
CH3
HOO
2-[(2-{4-[5-(4-chloro-phenyl)-pyrid in -2-ylethynyl)-p hen oxy}-ethyl)-m ethyl-
amino]-ethanol
Boehringer Ingelheim 77 Case 1-1406 ff
CA 02504160 2005-04-28
(93) CI
N
H3C
5-(4-ch loro-phenyl)-2-{4-[2-(4-methyl-piperidin-1-yl)-ethoxy]-
phenylethynyl}-pyrid ine
(94) Cl
H3C
N
H3CN
CH3
{2-[1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-
ethyl)-piperidin-4-yl]-ethyl}-diethyl-amine
(95) I CI
N
H3C CH3
N 0
CH3
5-(4-chloro-phenyl)-2-{4-[2-(2,4,6-trimethyl-piperidin-1-yl)-ethoxy]-
phenylethynyl}-pyridine
Boehringer Ingelheim 78 Case 1-1406 if
CA 02504160 2005-04-28
(96) Cl
CH3 N
H3C N0
CH3
5-(4-chloro-phenyl)-2-{4-[2-(3,5-dimethyl-piperidin-1-yl)-ethoxy]-3-methyl-
phenylethynyl}-pyridine
(97) Cl
H N
H N
cis-2-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-
decahydro-isoquinoline
(98) Cl
H3C
N N
CH3
6-(2-{4-[5-(4-chloro-phenyl)-pyrid in-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-
2-methyl-2, 6-d iaza-sp iro[3.4]octa ne
Boehringer Ingelheim 79 Case 1-1406 if
CA 02504160 2005-04-28
(99) Cl
N
N
G
N
P3CH
HO
1-(2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-indol-1-yl}-ethyl)-4-
methyl-piperidin-4-ol
(100) cl
N
h13C\
N--~N I
H3C /
~\O
CH3
[1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-
ethyl)-pyrrolidin-3-yl]-dimethyl-amine
(101) F
G I
N
Cl
Boehringer Ingelheim 80 Case 1-1406 ff
CA 02504160 2005-04-28
5-(4-chloro-phenyl)-2-[3-fluoro-4-(2-pyrrolidin-1-yi-ethoxy)-phenylethynyl]-
pyridine
(102) Cl
CH3 N
N \
"")
N
CH3
[1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-
ethyl)-piperidin-4-yl]-cyclopentyl-methyl-amine
(103) Cl
N
N
0
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1-(2-pyrrolidin-1-yl-ethyl)-2, 3-
dihydro-1 H-indole
(104) Cl
<DN
N
~~O
Boehringer Ingelheim Case 1-1406 if
CA 02504160 2005-04-28
5-(4-chloro-phenyl)-2-{4-[2-(4-pyrrolidin-1-yl-piperidin-1-yl)-ethoxy]-
phenylethynyl}-pyridine
(105) Cl
N
CN
5-(4-chloro-phenyl)-2-{4-[2-(2, 5-dihydro-pyrrol-1-yl)-ethoxy]-
phenylethynyl}-pyrid ine
(106) Cl
H3Cl- NlCH3
N
NO
[ 1-(2-{4-[5-(4-ch loro-phenyl)-pyrid in-2-ylethynyl]-phenoxy}-ethyl)-
piperidin-4-ylmethyl]-dimethyl-amine
Boehringer Ingeiheim 82 Case 1-1406 if
(107) CI
N
H3C~ JCJ 0
O 1-(2-{4-[5-(4-chloro-phenyl)-pyrid in-2-ylethynyl]-phenoxy}-ethyl)-4-methyl-
piperazine
I
N N N
CI
(4-{4-[5-(4-chloro-phenyl)-pyrid in-2-yl]-but-3-ynyl}-benzyl)-pyrid in-2-
ylmethyl-amine
(109) CI
O
N N
\ I I \
N 1-1 "1
CH3
1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-
spiro[piperidin-4,2'(1 H')-quinazolin]-4'(3'H)one
CA 02504160 2005-04-28
Boehringer Ingelheim 83 Case 1-1406 if
(110) CI
N
HO
CH3
NO
CH3
4-{[(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-
ethyl)-methyl-amino]-methyl}-phenol
(111) / CI
N
CNN
5-(4-chloro-phenyl)-2-[4-(3-piperidin-1-yl-pyrrolidin-1-yl)-phenylethynyl]-
pyridine
(112) CI
N
CN
N /
5-(4-chloro-phenyl)-2-[2-(2-pyrrolidin-1-yi-ethoxy)-pyridin-5-yl-ethynyl]-
pyridine
CA 02504160 2005-04-28
Boehringer Ingelheim 84 Case 1-1406 ff
CA 02504160 2005-04-28
(113) Cl
H3Cll N N
N~\
O
CH3
3-(2-{4-[5-(4-chloro-phenyl)-pyrid in-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-
9-methyl-3,9-diaza-spiro[5.5]undecane
(114) Cl
N
H3C~CH3
H3C NO
I
CH3 CH3
(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-
diisopropyl-amine
(115} I \ CI
N
<DN
5-(4-chloro-phenyl)-2-[4-(3-pyrrolidin-1-yl-propyl)-phenylethynyl]-pyridine
Boehringer Ingelheim 85 Case 1-1406 if
(116) CI
N
`
cc
2-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-1,2,3,4-
tetrahydro-isoquinoline
(1 N~/O I ~
Cl
3-(4-chloro-phenyl)-6-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-
pyridazine
(118) c
CNCJ
N
o
(R)-1-(2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-indol-1-yl}-ethyl)-
pyrrolidin-3-ol
CA 02504160 2005-04-28
Boehringer Ingelheim 86 Case 1-1406 ff
(119) Cl
H3C N
0=< N
N
r-I
N
0
5-[5-(4-chloro-phenyl)-pyrid i n-2-ylethynyl]-3-methyl-1-(2-pyrrolidin-1-yl-
ethyl)-1,3-dihydro-benzimidazol-2-one
(120) Cl
N
N
N
N
0
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1-(2-pyrrolidin-1-yl-ethyl)-1 H-
benzimidazole
(1 N / N
N N
CH3
2-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1-methyl-5-pyrrolidin-1-
ylmethyl-1 H-benzimidazole
CA 02504160 2005-04-28
Boehringer Ingelheim 87 Case 1-1406 If
CA 02504160 2005-04-28
(122) I CI
6H N
H N 0
trans-2-(2-{4-[5-(4-chloro-phenyl)-pyrid in-2-ylethynyl]-phenoxy}-ethyl)-
decahydro-isoquinoline
including the tautomers, the diastereomers, the enantiomers, the mixtures
thereof and the salts thereof.
Some expressions used hereinbefore and below to describe the compounds
according to the invention will now be defined more fully.
The term halogen denotes an atom selected from among F, Cl, Br and I,
particularly F, CI and Br.
The term Cl_n-alkyl, where n has a value of 3 to 8, denotes a saturated,
branched or unbranched hydrocarbon group with 1 to n C atoms. Examples of
such groups include methyl, ethyl, n-propyl, iso-propyl, butyl, iso-butyl, sec-
butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl, tert-pentyl, n-hexyl, iso-
hexyl,
etc.
The term C1_n-alkylene, where n may have a value of 1 to 8, denotes a
saturated, branched or unbranched hydrocarbon bridge with 1 to n C atoms.
Examples of such groups include methylene (-CH2-), ethylene (-CH2-CH2-), 1-
methyl-ethylene (-CH(CH3)-CH2-), 1,1-dimethyl-ethylene (-C(CH3)2-CH2-), n-
prop-1,3-ylene (-CH2-CH2-CH2-), 1-methylprop-1,3-ylene (-CH(CH3)-CH2-CH2-
), 2-methylprop-1,3-ylene (-CH2-CH(CH3)-CH2-), etc., as well as the
corresponding mirror-symmetrical forms.
Boehringer Ingelheim $$.. A,... Case 1-1406 if
The term C2_n-alkenyl, where n has a value of 3 to 6, denotes a branched or
unbranched hydrocarbon group with 2 to n C atoms and at least one C=C-
double bond. Examples of such groups include vinyl, 1-propenyl, 2-propenyl,
iso-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methyl-1-propenyl, 1-
pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 3-methyl-2-butenyl, 1-hexenyl,
2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl etc.
The term C2-n-alkynyl, where n has a value of 3 to 6, denotes a branched or
unbranched hydrocarbon group with 2 to n C atoms and a C=C triple bond.
Examples of such groups include ethynyl, 1-propynyl, 2-propynyl, iso-
propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 2-methyl-1-propynyl, 1-pentynyl, 2-
pentynyl, 3-pentynyl, 4-pentynyl, 3-methyl-2-butynyl, 1-hexynyl, 2-hexynyl, 3-
hexynyl, 4-hexynyl, 5-hexynyl etc.
The term C1-n-alkoxy denotes a C1-n-alkyl-O- group, wherein C1-n-alkyl is
defined as above. Examples of such groups include methoxy, ethoxy, n-
propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, n-
pentoxy, iso-pentoxy, neo-pentoxy, tert-pentoxy, n-hexoxy, iso-hexoxy etc.
The term C1-n-alkylthio denotes a C1_n-alkyl-S- group, wherein C1-n-alkyl is
defined as above. Examples of such groups include methylthio, ethylthio, n-
propylthio, iso-propylthio, n-butylthio, iso-butylthio, sec-butylthio, tert-
butylthio,
n-pentylthio, iso-pentylthio, neo-pentylthio, tert-pentylthio, n-hexylthio,
iso-
hexylthio, etc.
The term C1-n-alkylcarbonyl denotes a C1-n-alkyl-C(=O)- group, wherein C1_n-
alkyl is defined as above. Examples of such groups include methylcarbonyl,
ethylcarbonyl, n-propylcarbonyl, iso-propylcarbonyl, n-butylcarbonyl, iso-
butylcarbonyl, sec-butylcarbonyl, tert-butylcarbonyl, n-pentylcarbonyl, iso-
pentylcarbonyl, neo-pentylcarbonyl, tert-pentylcarbonyl, n-hexylcarbonyl, iso-
hexylcarbonyl, etc.
CA 02504160 2005-04-28
Boehringer Ingelheim 89 Case 1-1406 if
CA 02504160 2005-04-28
The term C3_n-cycloalkyl denotes a saturated mono-, bi-, tri- or
spirocarbocyclic group with 3 to n C atoms. Examples of such groups include
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl,
cyclononyl, cyclododecyl, bicyclo[3.2.1.]octyl, spiro[4.5]decyl, norpinyl,
norbonyl, norcaryl, adamantyl, etc. Preferably, the term C3_7-cycloalkyl
includes saturated monocyclic groups.
The term C5_n-cycloalkenyl denotes a monounsaturated mono-, bi-, tri- or
spirocarbocyclic group with 5 to n C atoms. Examples of such groups include
cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, etc.
The term C3_n-cycloalkylcarbonyl denotes a C3_n-cycloalkyl-C(=O) group,
wherein C3_n-cycloalkyl is defined as above.
The term aryl denotes a carbocyclic, aromatic ring system, such as for
example phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl,
indenyl, pentalenyl, azulenyl, biphenylenyl, etc. A particularly preferred
meaning of "aryl" is phenyl.
The term cyclo-C3_7-alkyleneimino denotes a 4- to 7-membered ring which has
3 to 7 methylene units as well as an imino group, the bond to the rest of the
molecule being made via the imino group.
The term cyclo-C3_7-alkyleneimino-carbonyl denotes a cyclo-C3_7-
alkyleneimino ring as defined hereinbefore which is linked to a carbonyl group
via the imino group.
The term heteroaryl used in this application denotes a heterocyclic, aromatic
ring system which comprises in addition to at least one C atom one or more
heteroatoms selected from N, 0 and/or S. Examples of such groups are
furanyl, thiophenyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, isoxazolyl,
isothiazolyl, 1,2,3-triazolyl, 1,3,5-triazolyl, pyranyl, pyridyl, pyridazinyl,
pyrimidinyl, pyrazinyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl,
1,2,3-
oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,3-
Boehringer Ingelheim 90 Case 1-1406 ff
thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl,
tetrazolyl,
thiadiazinyl, indolyl, isoindolyl, benzofuranyl, benzothiophenyl
(thianaphthenyl), indazolyl, benzimidazolyl, benzthiazolyl, benzisothiazolyl,
benzoxazolyl, benzisoxazolyl, purinyl, quinazolinyl, quinozilinyl, quinolinyl,
isoquinolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, azepinyl,
diazepinyl, acridinyl, etc. The term heteroaryl also comprises the partially
hydrogenated heterocyclic, aromatic ring systems, particularly those listed
above. Examples of such partially hydrogenated ring systems are 2,3-
dihydrobenzofuranyl, pyrolinyl, pyrazolinyl, indolinyl, oxazolidinyl,
oxazolinyl,
oxazepinyl, etc. Particularly preferably, heteroaryl denotes a heteroaromatic
mono- or bicyclic ring system.
Terms such as aryl-C1_n-alkyl, heteroaryl-C1_n-alkyl, etc. refer to C1_n-
alkyl, as
defined above, which is substituted with an aryl or heteroaryl group.
Many of the terms given above may be used repeatedly in the definition of a
formula or group and in each case have one of the meanings given above,
independently of one another.
The term "unsaturated carbocyclic group" or "unsaturated heterocyclic group",
as used particularly in the definition of the group Cy, comprises, in addition
to
the totally unsaturated groups, the corresponding, only partially unsaturated
groups, particularly the mono- and diunsaturated groups.
The term "optionally substituted" used in this application indicates that the
group thus designated is either unsubstituted or mono- or polysubstituted by
the substituents specified. If the group in question is polysubstituted, the
substituents may be identical or different.
The H atom of any carboxy group present or an H atom (imino or amino
group) bonded to an N atom may in each case be replaced by a group which
can be cleaved in vivo. By a group which can be cleaved in vivo from an N
atom is meant for example a hydroxy group, an acyl group such as the
benzoyl or pyridinoyl group or a C1.16-alkanoyl group such as the formyl,
CA 02504160 2005-04-28
Boehringer Ingelheim 91 Case 1-1406 if
CA 02504160 2005-04-28
acetyl, propionyl, butanoyl, pentanoyl or hexanoyl group, an allyloxycarbonyl
group, a C1_16-alkoxycarbonyl group such as the methoxycarbonyl,
ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl,
tert.butoxycarbonyl, pentoxycarbonyl, hexyloxycarbonyl, octyloxycarbonyl,
nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl,
dodecyloxycarbonyl or hexadecyloxycarbonyl group, a phenyl-
C1_6-alkoxycarbonyl group such as the benzyloxycarbonyl,
phenylethoxycarbonyl or phenylpropoxycarbonyl group, a C1_3-alkylsulphonyl-
C2_4-alkoxycarbonyl, C1_3-alkoxy-C2_4-alkoxy-C2_4-alkoxycarbonyl or ReCO-O-
(RfCRg)-O-CO group wherein
Re denotes a C1_8-alkyl, C5_7-cycloalkyl, phenyl or phenyl- C1.3-alkyl
group,
Rf denotes a hydrogen atom, a C1.3-alkyl, C5_7-cycloalkyl or phenyl group
and
Rg denotes a hydrogen atom, a C1.3-alkyl or ReCO-O-(RfCRg)-O group
wherein Re to R. are as hereinbefore defined,
while additionally the phthalimido group is a possibility for an amino group,
and the above-mentioned ester groups may also be used as groups which
can be converted into a carboxy group in vivo.
The residues and substituents described above may be mono- or
polysubstituted by fluorine as described. Preferred fluorinated alkyl groups
are
fluoromethyl, difluoromethyl and trifluoromethyl. Preferred fluorinated alkoxy
groups are fluoromethoxy, difluoromethoxy and trifluoromethoxy. Preferred
fluorinated alkylsulphinyl and alkylsulphonyl groups are
trifluoromethylsulphinyl and trifluoromethylsulphonyl.
The compounds of general formula I according to the invention may have acid
groups, predominantly carboxyl groups, and/or basic groups such as e.g.
amino functions. Compounds of general formula I may therefore be present
Boehringer Ingelheim 92 Case 1-1406 ff
CA 02504160 2005-04-28
as internal salts, as salts with pharmaceutically useable inorganic acids such
as hydrochloric acid, sulphuric acid, phosphoric acid, sulphonic acid or
organic acids (such as for example maleic acid, fumaric acid, citric acid,
tartaric acid or acetic acid) or as salts with pharmaceutically useable bases
such as alkali or alkaline earth metal hydroxides or carbonates, zinc or
ammonium hydroxides or organic amines such as e.g. diethylamine,
triethylamine, triethanolamine inter alia.
The compounds according to the invention may be obtained using methods of
synthesis which are known in principle. Preferably the compounds are
obtained by the methods of preparation according to the invention, which are
described more fully hereinafter.
The two reaction plans A and B which follow illustrate the synthesis of the
compounds A.5 and B.5 according to the invention, wherein R', R2, X, Y, Z,
W, A and B have one of the meanings described hereinbefore. In reaction
plan A the group Y denotes an aryl or heteroaryl group, whereas in reaction
plan B the group A denotes an aryl or heteroaryl group. Hal denotes chlorine,
bromine or iodine, particularly bromine or iodine, particularly preferably
iodine.
According to reaction plan A the halogen compound A.1 is reacted with the
alkyne compound A.2 in a molar ratio of about 1.5 : 1 to 1 : 1.5 under a
protective gas atmosphere in the presence of a suitable palladium catalyst, a
suitable base and copper(I)iodide in a suitable solvent.
A preferred amount of copper(I)iodide is in the range from 1 to 15 mol%,
particularly from 5 to 10 mol% based on the educt A. 1.
Suitable palladium catalysts are for example Pd(PPh3)4, Pd2(dba)3, Pd(OAc)2,
Pd(PPh3)2CI2, Pd(CH3CN)2CI2, Pd(dppf)C12. The palladium catalyst is
preferably used in an amount of from 1 to 15 mol%, particularly 5 to 10 mol%
based on the educt A.1.
Suitable bases are particularly amines, such as for example triethylamine or
ethyldiisopropylamine, as well as Cs2CO3. The base is preferably used in at
least equimolar amounts based on the educt A.1, in excess or as the solvent
Boehringer Ingelheim 93 Case 1-1406 if
CA 02504160 2005-04-28
as well. Other suitable solvents are dimethylformamide or ethers, such as for
example tetrahydrofuran, including the mixtures thereof. The reaction is
carried out over a period of about 2 to 24 hours in a temperature range from
about 20 to 90 C.
The alkyne compound A.3 obtained is reacted directly or after previous
purification with methanesuiphonic acid chloride to form the
methanesulphonate derivative A.4. The reaction conditions required are
known as such to the skilled man. Advantageous solvents are halogenated
hydrocarbons, such as for example dichloromethane. Suitable reaction
temperatures are normally in the range from 0 to 30 C.
The reaction solution containing the methanesulphonate derivative A.4, or the
purified methanesulphonate derivative A.4, dissolved in a suitable solvent, is
reacted with an amine H-NR1R2 to obtain the end product A.5 and then
optionally purified. If the amine H-NR1R2 has another primary or secondary
amine function, this is advantageously protected beforehand by a protective
group which can be cleaved again after the reaction has ended, using
methods known from the literature. The product thus obtained may for
example be converted into the salt form by reaction with a corresponding acid.
A preferred molar ratio of the derivative A.4 to the amine compound is in the
range from 1.5 : 1 to 1 : 1.5. Suitable solvents are dimethylformamide or
ether, such as for example tetrahydrofuran, including the mixtures thereof.
The reaction to obtain the product A.5 is advantageously carried out in a
temperature range of about 20 to 90 C.
Boehringer Ingelheim 94 Case 1-1406 if
CA 02504160 2005-04-28
Reaction plan A:
HO-X-Y-Hal + H-C=C-W-A-B
(A.1) (A.2)
Cul [Pd]
HO-X-Y-C-C-W-A-B (A.3)
MsCi
MsO-X-Y-C =C-W-A-B (A.4)
HNRIR2
R1R2N- X-Y-CSC-W-A-B (A.5)
According to reaction plan B the halogen compound B.2 is reacted with the
alkyne compound B.1 in a molar ratio of about 1.5 : 1 to 1 : 1.5 under a
protective gas atmosphere in the presence of a suitable palladium catalyst, a
suitable base and copper(I)iodide in a suitable solvent. Details of suitable
reaction conditions, including catalysts, bases and solvents, may be found in
the description of reaction plan A.
The alkyne compound B.3 obtained is reacted with methanesuiphonic acid
chloride directly or after previous purification, to form the
methanesuIphonate
derivative B.4. The reaction conditions required can again be found in the
description relating to Reaction plan A.
Boehringer ingelheim 95 Case 1-1406 if
CA 02504160 2005-04-28
The reaction solution containing the methanesulphonate derivative B.4, or the
purified methanesulphonate derivative B.4, dissolved in a suitable solvent, is
reacted with an amine H-NR'R2 to obtain the end product B.5 and then
optionally purified. Once again, the remarks relating to Reaction plan A
apply.
Reaction plan B:
HO-X-Y-Z- C=C-H + Hal-A-B
(B.1) (B.2)
Cul [Pd]
HO-X-Y-Z- C=C-A-B (B.3)
MsCI
MsO-X-Y-Z- C=C-A-B (B.4)
HNR'R2
R'R2N-X-Y-Z- C=C-A-B (B.5)
According to the additional reaction plan C the halogen compound C.1 is
reacted directly with the alkyne compound C.2 in a molar ratio of about 1.5 :
1
to 1 : 1.5 under a protective gas atmosphere in the presence of a suitable
palladium catalyst, a suitable base and copper(I)iodide in a suitable solvent
to
obtain the product C.3. Details of suitable reaction conditions, including
Boehringer Ingelheim 96 Case 1-1406 if
catalysts, bases and solvents, may be found in the description of reaction
plan
A.
Reaction plan C:
RIR2N- X-Y-Hal + H-CSC-W-A-B
(C.1) (C.2)
Cul [Pd]
R1 R2N- X-Y-C -C-W-A-B (C.3)
An alternative method of synthesis is shown in reaction plan D. According to
this the halogen compound D.2 is reacted directly with the alkyne compound
D.1 in a molar ratio of about 1.5 : 1 to 1 : 1.5 under a protective gas
atmosphere in the presence of a suitable palladium catalyst, a suitable base
and copper(I)iodide in a suitable solvent to form the product D.3. Once again,
details of suitable reaction conditions, including catalysts, bases and
solvents,
may be found in the description of reaction plan A.
Reaction plan D:
R'R2N-X-Y-Z- C^C-H + Hal-A-B
(D.1) (D.2)
Cul [Pd]
R1 R 2 N -X-Y-Z- C EC-A-B (D.3)
The reactions according to plans A, B, C and D may be carried out to
particular advantage with the corresponding iodine compounds A. 1, B.2, C. 1
and D.2. In the event that Hal denotes bromine in compounds A.1, B.2, C.1
CA 02504160 2005-04-28
Boehringer Ingelheim 97 Case 1-1406 if
and D.2, it is advantageous to convert it into the corresponding iodine
compound beforehand. A particularly advantageous process is the Aryl-
Finkelstein reaction (Klapars, Artis; Buchwald, Stephen L.. Copper-Catalyzed
Halogen Exchange in Aryl Halides: An Aromatic Finkelstein Reaction. Journal
of the American Chemical Society (2002), 124(50), 14844-14845). Thus for
example the halogen compound A.1, B.2, C.1 bzw. D.2 may be reacted with
sodium iodide in the presence of N,N'-dimethyl-ethylenediamine and
copper(I)iodide in a suitable solvent to obtain the corresponding iodine
compound. An advantageous molar ratio of the halogen compound to sodium
iodide is 1 : 1.8 to 1 : 2.3. N,N'-dimethyl-ethylenediamine is advantageously
used in a molar ratio of 10 to 30 mol% based on the halogen compound A.1,
B.2, C.1 or D.2. Preferred amounts of copper(I)iodide are in the range from 5
to 20 mol% based on the halogen compound A.1, B.2, C.1 or D.2. A suitable
solvent is 1,4-dioxane, for example. Suitable reaction temperatures are in the
range from about 20 to 110 C. The reaction is substantially complete after 2
to 72 hours.
The compounds according to the invention may advantageously also be
obtained using methods described in the following Examples, which may also
be combined with methods known to the skilled man from the literature, for
example.
Stereoisomeric compounds of formula (I) may be separated in principle by
conventional methods. The diastereomers may be separated on the basis of
their different physico-chemical properties, e.g. by fractional
crystallisation
from suitable solvents, by high pressure liquid or column chromatography,
using chiral or preferably non-chiral stationary phases.
Racemates covered by general formula (I) may be separated for example by
HPLC on suitable chiral stationary phases (e.g. Chiral AGP, Chiralpak AD).
Racemates which contain a basic or acidic function can also be separated via
the diastereomeric, optically active salts which are produced on reacting with
an optically active acid, for example (+) or (-)-tartaric acid, (+) or (-)-
diacetyl
tartaric acid, (+) or (-)-monomethyl tartrate or (+)-camphorsulphonic acid, or
CA 02504160 2005-04-28
Boehringer Ingelheim 98 Case 1-1406 if
CA 02504160 2005-04-28
an optically active base, for example with (R)-(+)-1-phenylethylamine, (S)-(-)-
1 -phenylethylamine or (S)-brucine.
According to a conventional method of separating isomers, the racemate of a
compound of general formula (I) is reacted with one of the above-mentioned
optically active acids or bases in equimolar amounts in a solvent and the
resulting crystalline, diastereomeric, optically active salts thereof are
separated using their different solubilities. This reaction may be carried out
in
any type of solvents provided that they show sufficient differences in terms
of
the solubility of the salts. Preferably, methanol, ethanol or mixtures
thereof, for
example in a ratio by volume of 50:50, are used. Then each of the optically
active salts is dissolved in water, carefully neutralised with a base such as
sodium carbonate or potassium carbonate, or with a suitable acid, e.g. with
dilute hydrochloric acid or aqueous methanesulphonic acid, and in this way
the corresponding free compound is obtained in the (+) or (-) form.
The (R) or (S) enantiomer alone or a mixture of two optically active
diastereomeric compounds covered by general formula I may also be
obtained by performing the syntheses described above with a suitable
reaction component in the (R) or (S) configuration.
As already mentioned, the compounds of formula (I) may be converted into
the salts thereof, particularly for pharmaceutical use into the
physiologically
and pharmacologically acceptable salts thereof. These salts may be present
on the one hand as physiologically and pharmacologically acceptable acid
addition salts of the compounds of formula (I) with inorganic or organic
acids.
On the other hand, in the case of acidically bound hydrogen, the compound of
formula (I) may also be converted by reaction with inorganic bases into
physiologically and pharmacologically acceptable salts with alkali or alkaline
earth metal cations as counter-ion. The acid addition salts may be prepared,
for example, using hydrochloric acid, hydrobromic acid, sulphuric acid,
phosphoric acid, methanesulphonic acid, ethanesulphonic acid,
toluenesulphonic acid, benzenesulphonic acid, acetic acid, fumaric acid,
succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.
Moreover,
Boehringer Ingelheim 99 Case 1-1406 if
CA 02504160 2005-04-28
mixtures of the above mentioned acids may be used. To prepare the alkali
and alkaline earth metal salts of the compound of formula (I) with acidically
bound hydrogen the alkali and alkaline earth metal hydroxides and hydrides
are preferably used, while the hydroxides and hydrides of the alkali metals,
particularly sodium and potassium are preferred and sodium and potassium
hydroxide are most preferred.
The compounds according to the present invention, including the
physiologically acceptable salts, are effective as antagonists of the MCH
receptor, particularly the MCH-1 receptor, and exhibit good affinity in MCH
receptor binding studies. Pharmacological test systems for MCH-antagonistic
properties are described in the following experimental section.
As antagonists of the MCH receptor the compounds according to the
invention are advantageously suitable as pharmaceutical active substances
for the prevention and/or treatment of symptoms and/or diseases caused by
MCH or causally connected with MCH in some other way. Generally the
compounds according to the invention have low toxicity, they are well
absorbed by oral route and have an intracerebral transitivity, particularly
brain
accessibility.
Therefore, MCH antagonists which contain at least one compound according
to the invention, are particularly suitable in mammals, such as for example
rats, mice, guinea pigs, hares, dogs, cats, sheep, horses, pigs, cattle,
monkeys and also humans, for the treatment and/or prevention of symptoms
and/or diseases which are caused by MCH or are otherwise causally
connected with MCH.
Diseases caused by MCH or otherwise causally connected with MCH are
particularly metabolic disorders, such as for example obesity, and eating
disorders, such as for example bulimia, including bulimia nervosa. The
indication obesity includes in particular exogenic obesity, hyperinsulinaemic
obesity, hyperplasmic obesity, hyperphyseal adiposity, hypoplasmic obesity,
hypothyroid obesity, hypothalamic obesity, symptomatic obesity, infantile
Boehringer Ingelheim 100 Case 1-1406 if
CA 02504160 2005-04-28
obesity, upper body obesity, alimentary obesity, hypogonadal obesity and
central obesity. This range of indications also includes cachexia, anorexia
and hyperphagia.
Compounds according to the invention may, in particular, be suitable for
reducing hunger, curbing appetite, controlling eating behaviour and/or
promoting a feeling of satiety.
In addition, the diseases caused by MCH or otherwise causally connected
with MCH also include hyperlipidaemia, cellulitis, fat accumulation, malignant
mastocytosis, systemic mastocytosis, emotional disorders, affectivity
disorders, depression, anxiety states, sleep disoreders, reproductive
disorders, sexual disorders, memory disorders, epilepsy, forms of dementia
and hormonal disorders.
Compounds according to the invention are also suitable as active substances
for the prevention and/or treatment of other illnesses and/or disorders,
particularly those which accompany obesity, such as, for example, diabetes,
diabetes mellitus, especially type II diabetes, hyperglycaemia, particularly
chronic hyperglycaemia, complications of diabetes including diabetic
retinopathy, diabetic neuropathy, diabetic nephropathy, etc., insulin
resistance, pathological glucose tolerance, encephalorrhagia, cardiac
insufficiency, cardiovascular diseases, particularly arteriosclerosis and high
blood pressure, arthritis and gonitis.
MCH antagonists and formulations according to the invention may
advantageously be used in combination with a dietary therapy, such as for
example a dietary diabetes treatment, and exercise.
Another range of indications for which the compounds according to the
invention are advantageously suitable is the prevention and/or treatment of
urinary disorders, such as for example urinary incontinence, overactive
bladder, urgency, nycturia and enuresis, while the overactive bladder and
urgency may or may not be connected with benign prostatic hyperplasia.
Boehringer Ingeiheim 101 Case 1-1406 if
CA 02504160 2005-04-28
The dosage required to achieve such an effect is conveniently, by intravenous
or subcutaneous route, 0.001 to 30 mg/kg of body weight, preferably 0.01 to 5
mg/kg of body weight, and by oral or nasal route or by inhalation, 0.01 to 50
mg/kg of body weight, preferably 0.1 to 30 mg/kg of body weight, in each case
once to three times a day.
For this purpose, the compounds of formula I prepared according to the
invention may be formulated, optionally together with other active substances
as described hereinafter, together with one or more inert conventional
carriers
and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline
cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric
acid,
water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene
glycol,
propylene glycol, cetylstearyl alcohol, carboxymethylcelIulose or fatty
substances such as hard fat or suitable mixtures thereof, to produce
conventional galenic preparations such as plain or coated tablets, capsules,
powders, granules, solutions, emulsions, syrups, aerosols for inhalation,
ointments or suppositories.
In addition to pharmaceutical compositions the invention also covers
compositions containing at least one alkyne compound according to the
invention and/ or a salt according to the invention optionally together with
one
or more physiologically acceptable excipients. Such compositions may also
be foods, for example, which may be solid or liquid, in which the compound
according to the invention is incorporated.
For the above mentioned combinations it is possible to use as additional
active substances particularly those which for example potentiate the
therapeutic effect of an MCH antagonist according to the invention in terms of
one of the indications mentioned above and/or which make it possible to
reduce the dosage of an MCH antagonist according to the invention.
Preferably one or more additional active substances are selected from among
active substances for the treatment of diabetes,
active substances for the treatment of diabetic complications,
Boehringer Ingelheim 102 Case 1-1406 if
CA 02504160 2005-04-28
active substances for the treatment of obesity, preferably other than MCH
antagonists,
active substances for the treatment of high blood pressure,
active substances for the treatment of hyperlipidaemia, including
arteriosclerosis,
active substances for the treatment of arthritis,
active substances for the treatment of anxiety states,
active substances for the treatment of depression.
The above mentioned categories of active substances will now be explained
in more detail by means of examples.
Examples of active substances for the treatment of diabetes are insulin
sensitisers, insulin secretion accelerators, biguanides, insulins, a-
glucosidase
inhibitors, (33 adreno-receptor agonists.
Insulin sensitisers include pioglitazone and its salts (preferably
hydrochloride), troglitazone, rosiglitazone and its salts (preferably
maleate), JTT-501, GI-262570, MCC-555, YM-440, DRF-2593, BM-13-
1258, KRP-297, R-119702, GW-1929.
Insulin secretion accelerators include sulphonylureas, such as for
example tolbutamide, chloropropamide, tolzamide, acetohexamide,
glyclopyramide and its ammonium salts, glibenclamide, gliclazide,
glimepiride. Further examples of insulin secretion accelerators are
repaglinide, nateglinide, mitiglinide (KAD-1229) and JTT-608.
Biguanides include metformin, buformin and phenformin.
Insulins include those obtained from animals, particularly cattle or pigs,
semisynthetic human insulins which are synthesised enzymatically from
insulin obtained from animals, human insulin obtained by genetic
engineering, e.g. from Escherichia coli or yeasts. Moreover, the term
Boehringer Ingelheim 103 Case 1-1406 if
insulin also includes insulin-zinc (containing 0.45 to 0.9 percent by
weight of zinc) and protamine-insulin-zinc obtainable from zinc chloride,
protamine sulphate and insulin. Insulation may also be obtained from
insulin fragments or derivatives (for example INS-1, etc.).
Insulin may also include different kinds, e.g. with regard to the onset time
and duration of effect ("ultra immediate action type", "immediate action
type", "two phase type", "intermediate type", "prolonged action type",
etc.), which are selected depending on the pathological condition of the
patient.
a-Glucosidase inhibitors include acarbose, voglibose, miglitol, emiglitate.
Rs Adreno receptor agonists include AJ-9677, BMS-1 96085, SB-226552,
AZ40140.
Active substances for the treatment of diabetes other than those
mentioned above include ergoset, pramlintide, leptin, BAY-27-9955 as
well as glycogen phosphorylase inhibitors, sorbitol dehydrogenase
inhibitors, protein tyrosine phosphatase 1B inhibitors, dipeptidyl protease
inhibitors, glipazid, glyburide.
Active substances for the treatment of diabetic complications include for
example aldose reductase inhibitors, glycation inhibitors and protein kinase C
inhibitors.
Aldose reductase inhibitors are for example tolrestat, epalrestat,
imirestat, zenarestat, SNK-860, zopolrestat, ARI-50i, AS-3201.
An example of a glycation inhibitor is pimagedine.
Protein Kinase C inhibitors are for example NGF, LY-333531.
CA 02504160 2005-04-28
Boehringer Ingelheim 104 Case 1-1406 if
CA 02504160 2005-04-28
Active substances other than those mentioned above for the treatment of
diabetic complications include alprostadil, thiapride hydrochloride,
cilostazol, mexiletine hydrochloride, ethyl eicosapentate, memantine,
pimagedine (ALT-71 1).
Active substances for the treatment of obesity, preferably other than MCH
antagonists, include lipase inhibitors and anorectics.
A preferred example of a lipase inhibitor is orlistat.
Examples of preferred anorectics are phentermine, mazindol,
dexfenfluramine, fluoxetine, sibutramine, baiamine, (S)-sibutramine, SR-
141716, NGD-95-1.
Active substances other than those mentioned above for the treatment of
obesity include lipstatin.
Moreover for the purposes of this application the active substance group
of anti-obesity active substances also includes the anorectics, of which
the (33 agonists, thyromimetic active substances and NPY antagonists
should be emphasised. The scope of the anti-obesity or anorectic active
substances which are preferred here is indicated by the following
additional list, by way of example: phenylpropanolamine, ephedrine,
pseudoephedrine, phentermine, a cholecystokinin-A (hereinafter referred
to as CCK-A) agonist, a monoamine reuptake inhibitor (such as for
example sibutramine), a sympathomimetic active substance, a
serotonergic active substance (such as for example dexfenfluramine or
fenfluramine), a dopamine antagonist (such as for example
bromocriptine), a melanocyte-stimulating hormone receptor agonist or
mimetic, an analogue of melanocyte-stimulating hormone, a cannabinoid
receptor antagonist, an MCH antagonist, the OB protein (hereinafter
referred to as leptin), a leptin analogue, a leptin receptor agonist, a
galanine antagonist, a GI lipase inhibitor or reducer (such as for example
Boehringer Ingelheim 105 Case 1-1406 ff
CA 02504160 2005-04-28
orlistat). Other anorectics include bombesin agonists,
dehydroepiandrosterone or its analogues, glucocorticoid receptor
agonists and antagonists, orexin receptor antagonists, urocortin binding
protein antagonists, agonists of the Glucagon-like Peptide-1 receptor,
such as for example exendin and ciliary neurotrophic factors, such as for
example axokine.
Active substances for the treatment of high blood pressure include inhibitors
of angiotensin converting enzyme, calcium antagonists, potassium channel
openers and angiotensin II antagonists.
Inhibitors of angiotensin converting enzyme include captopril, enalapril,
alacepril, delapril (hydrochloride), lisinopril, imidapril, benazepril,
cilazapril, temocapril, trandolapril, manidipine (hydrochloride).
Examples of calcium antagonists are nifedipine, amlodipine, efonidipine,
nicardipine.
Potassium channel openers include levcromakalim, L-27152, AL0671,
NIP-121.
Angiotensin II antagonists include telmisartan, losartan, candesartan
cilexetil, valsartan, irbesartan, CS-866, E4177.
Active substances for the treatment of hyperlipidaemia, including
arteriosclerosis, include HMG-CoA reductase inhibitors, fibrate compounds.
HMG-CoA reductase inhibitors include pravastatin, simvastatin,
lovastatin, atorvastatin, fluvastatin, lipantil, cerivastatin, itavastatin, ZD-
4522 and the salts thereof.
Fibrate compounds include bezafibrate, clinofibrate, clofibrate and
simfibrate.
Boehringer Ingelheim 106 Case 1-1406 if
CA 02504160 2005-04-28
Active substances for the treatment of arthritis include ibuprofen.
Active substances for the treatment of anxiety states include
chlord iazepoxide, diazepam, oxazolam, medazepam, cloxazolam,
bromazepam, lorazepam, alprazolam, fludiazepam.
Active substances for the treatment of depression include fluoxetine,
fluvoxamine, imipramine, paroxetine, sertraline.
The dosage for these active substances is conveniently 1 /5 of the lowest
normal recommended dose up to 1/1 of the normal recommended dose.
In another embodiment the invention also relates to the use of at least one
alkyne compound according to the invention and/or a salt according to the
invention for influencing the eating behaviour of a mammal. This use is based
particularly on the fact that compounds according to the invention may be
suitable for reducing hunger, curbing appetite, controlling eating behaviour
and/or promoting a feeling of satiety. The eating behaviour is advantageously
influenced in such a way as to reduce food intake. Therefore, the
compounds according to the invention are advantageously used for reducing
body weight. A further use according to the invention is the prevention of
increases in body weight, for example in people who have previously taken
steps to reduce their weight and are then interested in maintaining their
reduced body weight. According to this embodiment it is preferably a non-
therapeutic use. Such a non-therapeutic use may be a cosmetic use, for
example for altering the outer appearance, or an application for improving the
general feeling of wellbeing. The compounds according to the invention are
preferably used in a non-therapeutic capacity for mammals, particularly
humans, who have no diagnosed disorders of eating behaviour, no diagnosed
obesity, bulimia, diabetes and/ or no diagnosed urinary problems, particularly
urinary incontinence. Preferably the compounds according to the invention are
suitable for non-therapeutic use in humans whose body mass index (BMI =
body mass index), which is defined as the body weight measured in kilograms
Boehringer Ingelheim 107 Case 1-1406 if
divided by the height (in metres) squared, is less than 30, particularly less
than 25.
The Examples that follow are intended to illustrate the invention:
Preliminary remarks:
As a rule, IR, 1 H-NMR and/or mass spectra have been obtained for the
compounds prepared. Unless otherwise stated the Rf values are determined
using ready-made silica gel 60 TLC plates F254 (E. Merck, Darmstadt, Item
no. 1.05714) without chamber saturation. The Rf values obtained under the
name Alox are determined using ready-made aluminium oxide 60 F254 TLC
plates (E. Merck, Darmstadt, Item no. 1.05713) without chamber saturation.
The ratios given for the eluants relate to units by volume of the solvent in
question. The units by volume for NH3 relate to a concentrated solution of
NH3 in water. Silica gel made by Millipore (MATREXTM, 35-70 my) is used for
chromatographic purification. Alox (E. Merck, Darmstadt, aluminium oxide 90
standardised, 63-200 pm, Item no. 1.01097.9050) is used for chromatographic
purification. The HPLC data given are measured under the following
parameters:
Analytical columns: Zorbax column (Agilent Technologies), SB (Stable Bond) -
C18; 3.5 pm; 4.6 x 75 mm; column temperature: 30 C; flow: 0.8 mL / min;
injection volume: 5 pL; detection at 254 nm (methods A and B)
Symmetry 300 (Waters), 3.5 pm; 4.6 x 75 mm; column temperature: 30 C;
flow: 0.8 mL / min; injection volume: 5 pL; detection at 254 nm (method C)
method A: water:acetonitrile:formic acid 9:1:0.01 to 1:9:0.01 over 9 min
method B: water:acetonitrile:formic acid 9:1:0.01 to 1:9:0.01 over 4 min,
then 6 min 1:9:0.01
method C: water:acetonitrile:formic acid 9:1:0.01 to 1:9:0.01 over 4 min,
then 6 min 1:9:0.01
Preparative column: Zorbax column (Agilent Technologies), SB (Stable Bond)
- C18; 3.5 pm; 30 x 100 mm; column temperature: ambient temperature; flow:
30 mL / min; detection at 254 nm.
CA 02504160 2005-04-28
Boehringer Ingelheim 108 Case 1-1406 If
CA 02504160 2005-04-28
In preparative HPLC purifications, as a rule, the same gradients are used as
were used to raise the analytical HPLC data.
The products are collected under mass control, the fractions containing
product are combined and freeze-dried.
If there is no specific information as to the configuration, it is not clear
whether
there are pure enantiomers or whether partial or even total racemisation has
taken place.
The following abbreviations are used above and hereinafter:
CDI carbonyidiimidazole
cyc cyclohexane
DCM dichloromethane
DMF dimethylformamide
DMSO dimethylsulphoxide
dppf 1,1 '-bis(diphenylphosphino)ferrocene
EtOAc ethyl acetate
EtOH ethanol
Fp melting point
i.vac. in vacuo
MeOH methanol
PE petroleum ether
PPh3 triphenylphosphane
RT ambient temperature
TBAF tetrabutylammoniumfluoride trihydrate
THF tetrahydrofuran
General experimental method I (Sonogashira couplings)
Under an argon atmosphere, a suitable palladium catalyst (e.g. Pd(PPh3)4 (5
mol%), Pd(PPh3)2CI2 (5 mol%), Pd(CH3CN)CI2 (5 mol%) or Pd(dppf)C12 (5 or
mol%)), a suitable base (e.g. caesium carbonate (1.5 eq) or triethylamine
(1.5 eq.)) and Cul (5 or 10 mol%) are added successively to a solution of the
aryl or heteroaryl iodide or bromide (1.0 eq) and the alkyne (1.05 eq) in THE
Boehringer Ingelheim 109 Case 1-1406 if
or DMF. The reaction solution is stirred at RT to 90 C for between 2-24 h,
filtered and the solvent is eliminated i.vac.. Further purification is carried
out
by column chromatography or by purification using HPLC-MS.
General experimental method 11 (bromine-iodine exchange)
Nal (2.0 eq), N,N'-dimethyl-ethylenediamine (0.2 eq.) and Cul (0.1 eq.) are
added successively to a solution of the aryl or heteroaryl bromide (1.0 eq.)
in
1,4-dioxane under argon. The reaction is stirred for 2-72 h at RT to 110 C and
then diluted with NH3. The aqueous phase is extracted with DCM, the organic
phase is dried over MgSO4 and the solvent is eliminated i.vac.. If necessary
further purification is carried out by column chromatography.
CA 02504160 2005-04-28
Boehringer Ingelheim 110 Case 1-1406 if
CA 02504160 2005-04-28
Example 1
Diethyl-(2-{4-[5-(4-methoxy-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-amine
0'-
\ \ I
l a [2-(4-bromo-phenoxy)-ethyl]-diethyl-amine
A suspension of 31.4 g (178 mmol) 4-bromophenol, 30.6 g (178 mmol) (2-
chloro-ethyl)-diethyl-amine (used as the hydrochloride) and 61.5 g (445 mmol)
K2CO3 in 300 mL DMF is heated to 80 C for 8 h. The solvent is evaporated
down i.vac. , the residue combined with water, the aqueous phase
exhaustively extracted with EtOAc , the combined organic phases washed
with water again and dried over MgSO4. After the desiccant and solvent have
been eliminated the residue is purified by chromatography (silica gel,
EtOAc/MeOH/NH3 90:10:1).
Yield: 28.0 g (58% of theory)
C12H18BrNO (M= 272.187)
Calc.: molpeak (M+H)+: 272/274 Found: molpeak (M+H)+: 272/274
Rf value: 0.25 (silica gel, EtOAc/MeOH/NH3 90:10:1)
lb diethyl-[2-(4-trimethylsilanylethynyl-phenoxy)-ethyl]-amine
Under a nitrogen atmosphere a mixture of 5.44 g (20 mmol) [2-(4-bromo-
phenoxy)-ethyl]-diethyl-amine, 3.11 mL (22 mmol) ethynyl-trimethyl-silane,
462 mg (0.4 mmol) tetrakis-triphenylphosphane-palladium, 76 mg (0.4 mmol)
Cul in 50 mL piperidine is heated to 70 C for 21 h. The solvent is distilled
off
i.vac., the residue is taken up in water, exhaustively extracted with EtOAc
and dried over Na2SO4. After the desiccant and solvent have been eliminated
the residue is purified on silica gel (EtOAc/MeOH/NH3 95:5:0.5).
Yield: 1.4 g (24% of theory)
C17H27NOSi (M= 289.497)
Calc.: molpeak (M+H)+: 290 Found: molpeak (M+H)+: 290
Rf value: 0.67 (silica gel, EtOAc/MeOH/NH3 95:5:0.5)
Boehringer Ingelheim 111 Case 1-1406 if
CA 02504160 2005-04-28
1c diethyl-[2-(4-ethynyl-phenoxy)-ethyl]-amine
Under a nitrogen atmosphere a solution of 1.4 g (4.8 mmol) diethyl-[2-(4-
trimethylsilanylethynyl-phenoxy)-ethyl]-amine in 50 mL THE is combined with
1.68 g (5.3 mmol) TBAF and stirred overnight at RT. The solvent is distilled
off
i.vac., the residue is taken up in water, exhaustively extracted with EtOAc
and dried over Na2SO4. After the desiccant and solvent have been eliminated
the residue is purified on silica gel (EtOAc/MeOH 95:5).
Yield: 0.5 g (47% of theory)
C14H19NO (M= 217.314)
Cale.: molpeak (M+H)+: 218 Found: molpeak (M+H)+: 218
Rf value: 0.46 (silica gel, EtOAc/MeOH/NH3 95:5:0.5)
l d {2-[4-(5-bromo-pyridin-2-ylethynyl)-phenoxy]-ethyl}-diethyl-amine
A mixture of 500 mg (2.30 mmol) diethyl-[2-(4-ethynyl-phenoxy)-ethyl]-amine,
545 mg (2.30 mmol) 2,5-dibromopyridine, 161 mg (0.23 mmol) tetrakis-
triphenylphosphane-palladium, 13 mg (0.07 mmol) Cul, 2 mL
ethyldiisopropylamine and 2 mL diisopropylamine in 50 mL DMF is heated for
20 h at 100 C under a nitrogen atmosphere. The solvent is distilled off
i.vac.,
the residue is taken up in water, exhaustively extracted with EtOAc and dried
over Na2SO4. After the desiccant and solvent have been eliminated the
residue is purified on silica gel (EtOAc/MeOH/NH3 95:5:0.5).
Yield: 200 mg (23% of theory)
C19H21 BrN2O (M= 373.296)
Cale.: molpeak (M+H)+: 373/375 Found: molpeak (M+H)+: 373/375
Rf value: 0.50 (silica gel, EtOAc/MeOH/NH3 90:10:1)
le diethyl-(2-{4-[5-(4-methoxy-phenyl)-pyridin-2-ylethynyl]-phenoxy}-
ethyl)-amine
A mixture of 200 mg (0.54 mmol) {2-[4-(5-bromo-pyridin-2-ylethynyl)-
phenoxy]-ethyl}-diethyl-amine, 163 mg (1.07 mmol) 4-methoxy-phenylboric
acid, 31 mg (0.03 mmol) tetra kis-triphenylphosphane-palladium and 0.27 mL
of a 2 M aqueous Na2CO3 solution in 5 mL 1,4-dioxane is heated for 20 h at
Boehringer Ingelheim 112 Case 1-1406 if
110 C under a nitrogen atmosphere. The solvent is distilled off i.vac., the
residue is taken up in water, exhaustively extracted with EtOAc and dried
over Na2SO4. After the desiccant and solvent have been eliminated the
residue is purified on silica gel (EtOAc/MeOH/NH3 95:5:0.5). The product
fractions are evaporated down, the residue is triturated with diethyl ether,
suction filtered and washed with diisopropylether.
Yield: 30 mg (14% of theory)
C26H28N202 (M= 400.525)
Calc.: molpeak (M+H)+: 401 Found: molpeak (M+H)+: 401
Rf value: 0.46 (silica gel, EtOAc/MeOH/NH3 95:5:0.5)
Example 1.1
d iethyl-(2-{4-[5-(2-methoxy-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-
amine
~I \
The product is obtained analogously to Example 1 e from 200 mg (0.54 mmol)
{2-[4-(5-bromo-pyridin-2-ylethynyl)-phenoxy]-ethyl}-diethyl-amine and 163 mg
(1.07 mmol) 2-methoxy-phenylboric acid.
Yield: 40 mg (14% of theory)
C26H28N202 (M= 400.525)
Caic.: molpeak (M+H)+: 401 Found: molpeak (M+H)+: 401
Rf value: 0.23 (silica gel, EtOAc/MeOH/NH3 95:5:0.5)
Example 1.2
(2-{4-[5-(4-ethoxy-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-diethyl-amine
CA 02504160 2005-04-28
Boehringer (ngelheim 113 Case 1-1406 if
CA 02504160 2005-04-28
The product is obtained analogously to Example 1e from 200 mg (0.54 mmol)
{2-[4-(5-bromo-pyridin-2-ylethynyl)-phenoxy]-ethyl}-diethyl-amine and 178 mg
(1.07 mmol) 4-ethoxy-phenylboric acid.
Yield: 83 mg (37% of theory)
C27H30N202 (M= 414.552)
Calc.: molpeak (M+H)+: 414 Found: molpeak (M+H)+: 414
Rf value: 0.26 (silica gel, EtOAc/MeOH/NH3 95:5:0.5)
Example 1.3
(2-{4-[5-(3,4-d ifluoro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-d iethyl-
amine
F
\ / N
The product is obtained analogously to Example le from 200 mg (0.54 mmol)
{2-[4-(5-bromo-pyridin-2-ylethynyl)-phenoxy]-ethyl}-diethyl-amine and 169 mg
(1.07 mmol) 3,4-difluoro-phenylboric acid.
Yield: 35 mg (16% of theory)
C25H24F2N20 (M= 406.480)
Calc.: molpeak (M+H)+: 407 Found: molpeak (M+H)+: 407
Rf value: 0.34 (silica gel, EtOAc/MeOH/NH3 95:5:0.5)
Example 1.4
(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl )-diethyl-amine
ojcf
The product is obtained analogously to Example le from 200 mg (0.54 mmol)
{2-[4-(5-bromo-pyridin-2-ylethynyl)-phenoxy]-ethyl}-diethyl-amine and 167 mg
(1.07 mmol) 4-chloro-phenylboric acid.
Yield: 51 mg (24% of theory)
Boehringer Ingelheim 114 Case 1-1406 ff
CA 02504160 2005-04-28
C25H25CIN20 (M= 404.944)
Caic.: molpeak (M+H)+: 405/407 Found: molpeak (M+H)+: 405/407
Rf value: 0.26 (silica gel, EtOAc/MeOH/NH3 95:5:0.5)
Example 1.5
diethyl-(2-{4-[5-(4-methoxy-phenyl)-pyrimidine-2-ylethynyl]-phenoxy}-ethyl )-
amine
The product is obtained analogously to Example 1d from 434 mg (2.0 mmol)
diethyl-[2-(4-ethynyl-phenoxy)-ethyl]-amine and 441 mg (2.0 mmol) 2-chloro-
5-(4-methoxy-phenyl)-pyrimidine.
Yield: 100 mg (13% of theory)
C25H27N302 (M= 401.513)
Calc.: molpeak (M+H)+: 402 Found: molpeak (M+H)+: 402
Rf value: 0.65 (silica gel, EtOAc/MeOH/NH3 90:10:1)
Example 1.6
5-(4-chloro-phenyl)-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-pyridine
i J
1.6a 1-[2-(4-iodo-phenoxy)-ethyl]-pyrrolidine
A suspension of 22 g (100 mmol) 4-iodophenol, 17 g (100 mmol) 1-(2-chloro-
ethyl)-pyrrolidine (used as the hydrochloride) and 55.3 g (400 mmol) K2CO3 in
400 mL DMF is stirred for 48 h at RT. The solvent is evaporated down i.vac. ,
the residue is combined with water, the aqueous phase exhaustively extracted
with EtOAc , the combined organic phases are washed with saturated,
Boehringer Ingelheim 115 Case 1-1406 ff
CA 02504160 2005-04-28
aqueous NaCl solution and dried over Na2SO4. After the desiccant and
solvent have been eliminated the residue is purified on silica gel
(EtOAc/MeOH/NH3 85:15:1.5).
Yield: 18.0 g (57% of theory)
C12H161NO (M= 317.172)
Calc.: molpeak (M+H)+: 318 Found: molpeak (M+H)+: 318
Rf value: 0.59 (silica gel, EtOAc/MeOH/NH3 80:20:2)
1.6b 1-[2-(4-trimethylsilanylethynyl-phenoxy)-ethyl]-pyrrolidine
Under a nitrogen atmosphere 7.0 mL (49.5 mmol) ethynyl-trimethyl-silane is
slowly added to a mixture of 14.3 g (45 mmol) 1-[2-(4-iodo-phenoxy)-ethyl]-
pyrrolidine, 1.04 g (0.9 mmol) tetrakis-triphenylphosphane-palladium and 171
mg (0.4 mmol) Cul in 140 mL piperidine (exothermic reaction) and stirred for
30 minutes. The solvent is distilled off i.vac., the residue is taken up in
water,
exhaustively extracted with EtOAc and dried over Na2SO4. After the
desiccant and solvent have been eliminated the residue is purified on silica
gel (EtOAc/MeOH/NH3 95:5:0.5).
Yield: 12.8 g (99% of theory)
C17H25NOSi (M= 287.481)
Calc.: molpeak (M+H)+: 288 Found: molpeak (M+H)+: 288
Rf value: 0.42 (silica gel, EtOAc/MeOH/NH3 90:10:1)
1.6c 1-[2-(4-ethynyl-phenoxy)-ethyl]-pyrrolidine
Under a nitrogen atmosphere a solution of 12.8 g (44.5 mmol) 1-[2-(4-
trimethylsilanylethynyl-phenoxy)-ethyl]-pyrrolidine in 200 mL THE is combined
with 15.5 g (49.0 mmol) TBAF and stirred for 3 h at RT. The solvent is
distilled
off i.vac., the residue taken up in EtOAc, the organic phase is washed with
saturated, aqueous NaCl solution and dried over Na2SO4. After the desiccant
and solvent have been eliminated the product is further reacted without any
purification.
Yield: 9.6 g (100% of theory)
C14H17NO (M= 215.298)
Caic.: molpeak (M+H)+: 216 Found: molpeak (M+H)+: 216
Boehringer Ingelheim 116 Case 1-1406 if
CA 02504160 2005-04-28
Rf value: 0.76 (silica gel, EtOAc/MeOH/NH3 80:20:2)
1.6d 5-bromo-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-pyridine
A mixture of 9.6 g (44.6 mmol) 1-[2-(4-ethynyl-phenoxy)-ethyl]-pyrrolidine,
10.6 g (44.6 mmol) 2,5-dibromopyridine, 626 mg (0.9 mmol) tetrakis-
triphenylphosphane-palladium, 170 mg (0.9 mmol) CuCI and 12.6 mL
diisopropylamine in 500 mL THE is heated for 3 h at 40 C under an argon
atmosphere. The solvent is distilled off i.vac., the residue is taken up in
EtOAc, the organic phase is washed with water and saturated, aqueous NaCl
solution and dried over Na2SO4. After the desiccant and solvent have been
eliminated the residue is purified on silica gel (EtOAc/MeOH/NH3 90:10:1).
Yield: 8.9 g (54% of theory)
C19H19BrN2O (M= 371.280)
Calc.: molpeak (M+H)+: 371/373 Found: molpeak (M+H)+: 371/373
Rf value: 0.47 (silica gel, EtOAc/MeOH/NH3 90:10:1)
1.6e 5-(4-chloro-phenyl)-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-
pyridine
A mixture of 2.97 g (8.0 mmol) 5-bromo-2-[4-(2-pyrrolidin-1-yl-ethoxy)-
phenylethynyl]-pyridine, 2.50 g (16.0 mmol) 4-chloro-phenylboric acid, 462 mg
(0.4 mmol) tetra kis-triphenyl phosphane-palladium and 8.0 mL of a 2M
aqueous Na2CO3 solution in 100 mL 1,4-dioxane is heated for 4 h at 100 C
under an argon atmosphere. The solvent is distilled off i.vac., the residue is
stirred with water/EtOAc (1 /1,v/v), suction filtered through a fibreglass
filter,
the organic phase is washed with saturated, aqueous NaCl solution and dried
over Na2SO4. After the desiccant and solvent have been eliminated the
residue is purified by chromatography (Alox, cyc/EtOAc 2:1). The product
fractions are evaporated down, the residue is triturated with diethyl ether,
suction filtered and washed with diethyl ether.
Yield: 1.95 g (60% of theory)
C25H23CIN2O (M= 402.928)
Caic.: molpeak (M+H)+: 403/405 Found: molpeak (M+H)+: 403/405
Rf value: 0.47 (Alox, cyc/EtOAc 2:1)
Boehringer Ingelheim 117 Case 1-1406 ff
Example 1.7
5-(4-fluoro-phenyl)-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-pyridine
D F
The product is obtained analogously to Example 1.6e from 297 mg (0.8 mmol)
5-bromo-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-pyridine and 224 mg
(1.6 mmol) 4-fluoro-phenylboric acid.
Yield: 37 mg (12% of theory)
C25H23FN20 (M= 386.473)
Cale.: molpeak (M+H)+: 387 Found: molpeak (M+H)+: 387
Rf value: 0.41 (Alox, cyc/EtOAc 2:1)
Example 1.8
5-(4-bromo-phenyl)-2-[4-(2-ppyrrolidin-1-yl-ethoxy)-phenylethynyl]-pyridine
Br
0
The product is obtained analogously to Example 1.6e from 297 mg (0.8 mmol)
5-bromo-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-pyridine and 321 mg
(1.6 mmol) 4-bromo-phenylboric acid. Purification is carried out using neutral
Alox (Merck aluminium oxide 90 standardised, 63-200my; cyc/EtOAc 4:1).
The product thus obtained is recrystallised from EtOH.
Yield: 40 mg (11 % of theory)
C25H23BrN2O (M= 447.379)
Cale.: molpeak (M+H)+: 447/449 Found: molpeak (M+H)+: 447/449
Rf value: 0.45 (Alox, cyc/EtOAc 2:1)
Example 1.9
CA 02504160 2005-04-28
Boehringer Ingelheim 118 Case 1-1406 if
CA 02504160 2005-04-28
2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-5-(4-trifluoromethoxy-phenyl)-
pyridine
0, CF,
\ \ I
N
I
The product is obtained analogously to Example 1.6e from 297 mg (0.8 mmol)
5-bromo-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-pyridine and 329 mg
(1.6 mmol) 4-trifluoromethoxy-phenylboric acid. Purification is carried out
using neutral Alox (Merck aluminium oxide 90 standardised, 63-200my;
cyc/EtOAc 4:1). The product thus obtained is stirred with n-hexane and
suction filtered.
Yield: 190 mg (53% of theory)
C26H23F3N202 (M= 452.481)
Calc.: molpeak (M+H)+: 453 Found: molpeak (M+H)+: 453
Rf value: 0.46 (Alox, cyc/EtOAc 2:1)
Example 1.10
2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-5-(4-methoxy-phenyl)-pyridine
N
O
The product is obtained analogously to Example 1.9 from 297 mg (0.8 mmol)
5-bromo-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-pyridine and 243 mg
(1.6 mmol) 4-methoxy-phenylboric acid.
Yield: 115 mg (53% of theory)
C26H26N202 (M= 398.509)
Calc.: molpeak (M+H)+: 399 Found: molpeak (M+H)+: 399
Rf value: 0.30 (Alox, cyc/EtOAc 2:1)
Example 1.11
Boehringer Ingelheim 119 Case 1-1406 ff
CA 02504160 2005-04-28
2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-5-(4-trifluoromethyl-phenyl)-
pyridine
CF3
N
The product is obtained analogously to Example 1.9 from 297 mg (0.8 mmol)
5-bromo-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-pyridine and 304 mg
(1.6 mmol) 4-trifluoromethyl -phenylboric acid.
Yield: 150 mg (43% of theory)
C26H23F3N20 (M= 436.481)
Calc.: molpeak (M+H)+: 437 Found: molpeak (M+H)+: 437
Rf value: 0.45 (Alox, cyc/EtOAc 2:1)
Example 2
5-(4-chloro-phenyl)-2-[4-(4-pyrrolidin-1 -ylmethyl-phenyl)-but-1 -ynyl]-
pyridine
Cl
N
2a 1-(4-bromo-benzyl)-pyrrolidine
A solution of 12.5 g (50 mmol) 4-bromobenzylbromide is slowly added
dropwise to a solution of 4.52 mL (55 mmol) pyrrolidine and 10.3 mL (60
mmol) ethyldiisopropylamine in 100 mL THE and stirred overnight at RT. The
precipitate is filtered off and the solvent is eliminated i.vac.. The product
is
obtained as a light-brown liquid which is further reacted without
purification.
Yield: 9.0 g (75% of theory)
C11 H14BrN (M= 240.145)
Calc.: molpeak (M+H)+: 241/243 Found: molpeak (M+H)+: 241/243
Rf value: 0.74 (silica gel, EtOAc/MeOH/NH3 90:10:1)
Boehringer Ingelheim 120 Case 1-1406 if
CA 02504160 2005-04-28
2b 3-(4-pyrrolidin-1 -ylmethyl-phenyl)-prop-2-yn-1-ol
A mixture of 4.8 g (20.0 mmol) 1-(4-bromo-benzyl)-pyrrolidine, 1.75 mL (30.0
mmol) propargylalcohol, 2.31 g (2.0 mmol) tetrakis-triphenylphosphane-
palladium, 381 mg (2.0 mmol) Cul and 7.07 mL diisopropylamine in 100 mL
acetonitrile is heated for 14 h at 60 C under an argon atmosphere. The
solvent is distilled off i.vac., the residue is taken up in water,
exhaustively
extracted with EtOAc and the organic phase is dried over Na2SO4. After the
desiccant and solvent have been eliminated the residue is purified on silica
gel (EtOAc/MeOH/NH3 95:5:0.5).
Yield: 1.55 g (36% of theory)
C14H17NO (M= 215.298)
Calc.: molpeak (M+H)+: 216 Found: molpeak (M+H)+: 216
Rf value: 0.48 (silica gel, EtOAc/MeOH/NH3 90:10:1)
2c 3-(4-pyrrolidin-1-ylmethyl-phenyl)-propan-1-ol
A solution of 1.65 g (7.66 mmol) 3-(4-pyrrolidin-1 -ylmethyl-phenyl)-prop-2-yn-
1-ol in 20 mL EtOH is combined with 200 mg 10% Pd/C and hydrogenated in
the autoclave at RT and 30 psi H2 until the theoretical uptake of hydrogen is
achieved. The catalyst is suction filtered, the filtrate concentrated by
evaporation and the residue is purified on silica gel
(EtOAc/MeOH/NH3 90:10:1).
Yield: 0.81 g (48% of theory)
C1 41-121 NO (M= 219.330)
Calc.: molpeak (M+H)+: 220 Found: molpeak (M+H)+: 220
Rf value: 0.2 (silica gel, EtOAc/MeOH/NH3 90:10:1)
2d 3-(4-pyrrolidin-1-ylmethyl-phenyl)-propionaldehyde
2.87 mL (35.56 mmol) pyridine and 2.11 g (4.98 mmol) Dess-Martin
periodinane are added to a solution of 780 mg (3.56 mmol) 3-(4-pyrrolidin-1-
ylmethyl-phenyl)-propan-l-ol in 30 mL DCM. The reaction mixture is stirred for
4 h at RT, then added to 100 mL saturated, aqueous NaHCO3 solution,
exhaustively extracted with tert-butylmethylether, the organic phase is washed
with saturated, aqueous NaCl solution and dried over Na2SO4. After the
Boehringer Ingelheim 121 Case 1-1406 ff
CA 02504160 2005-04-28
desiccant and solvent have been eliminated the crude product is further
reacted without purification.
Yield: 750 mg (97% of theory)
2e 1-(4-but-3-ynyl-benzyl)-pyrrolidine
815 mg (4.2 mmol) dimethyl (1-diazo-2-oxo-propyl)-phosphonate is added to
a mixture of 760 mg (3.5 mmol) 3-(4-pyrrolidin-1-ylmethyl-phenyl)-
propionaldehyde and 970 mg (7.0 mmol) K2CO3 in 100 mL dry MeOH under
an argon atmosphere and stirred overnight at RT. The reaction mixture is
diluted with diethyl ether, the organic phase is washed with saturated,
aqueous NaHCO3 solution and dried over Na2SO4. After the desiccant and
solvent have been eliminated the residue is purified on silica gel
(EtOAc/MeOH/NH3 95:5:0.5).
Yield: 200 mg (27% of theory)
C15H19N (M= 213.325)
Calc.: molpeak (M+H)+: 214 Found: molpeak (M+H)+: 214
Rf value: 0.74 (silica gel, EtOAc/MeOH/NH3 95:5:0.5)
2f 5-bromo-2-[4-(4-pyrrolidin-1 -ylmethyl-phenyl)-but-1-ynyl]-pyridine
A mixture of 200 mg (0.94 mmol) 1-(4-but-3-ynyl-benzyl)-pyrrolidine, 222 mg
(0.94 mmol) 2,5-dibromopyridine, 13.2 mg (0.02 mmol) tetrakis-
triphenylphosphane-palladium, 3.6 mg (0.02 mmol) Cul and 0.27 mL
diisopropylamine in 10 mL THE is heated for 4 h at 40 C under an argon
atmosphere. The reaction mixture is diluted with water, exhaustively extracted
with EtOAc , the organic phase is washed with saturated, aqueous NaCI
solution and dried over Na2SO4. After the desiccant and solvent have been
eliminated the residue is purified on silica gel (EtOAc/MeOH/NH3 95:5:0.5).
Yield: 110 mg (32% of theory)
C20H21 BrN2 (M= 369.308)
Calc.: molpeak (M+H)+: 369/371 Found: molpeak (M+H)+: 369/371
Rf value: 0.44 (silica gel, EtOAc/MeOH/NH3 95:5:0.5)
Boehringer Ingelheim 122 Case 1-1406 if
CA 02504160 2005-04-28
2g 5-(4-chloro-phenyl)-2-[4-(4-pyrrolidin-1 -ylmethyl-phenyl)-but-1-ynylJ-
pyridine
A mixture of 100 mg (0.27 mmol) 5-bromo-2-[4-(4-pyrrolidin-1-ylmethyl-
phenyl)-but-1-ynyl]-pyridine, 85 mg (0.54 mmol) 4-chloro-phenylboric acid,
15.7 mg (0.014 mmol) tetrakis-triphenylphosphane-palladium, 0.28 mL of a 2
M aqueous Na2CO3 solution in 10 mL 1,4-dioxane is heated for 8 h at 100 C
under an argon atmosphere. The solvent is distilled off i.vac., the residue is
taken up in water, exhaustively extracted with EtOAc and dried over Na2SO4.
After the desiccant and solvent have been eliminated the residue is purified
over neutral Alox (ICN Alumina N + 5% H2O; cyc/EtOAc 7:3). The product
fractions are evaporated down, the residue is triturated with PE and suction
filtered.
Yield: 12 mg (11 % of theory)
C26H25CIN2 (M= 400.956)
Calc.: molpeak (M+H)+: 401/403 Found: molpeak (M+H)+: 401/403
Rf value: 0.41 (Alox, cyc/EtOAc 7:3)
Example 2.1
5-(4-chloro-phenyl)-2-[4-(4-piperidin-1-ylmethyl-phenyl)-but-1-ynyl]-pyridine
ci
2.1a 3-(4-hydroxymethyl-phenyl)-propionaldehyde
10.5 mL (152.8 mmol) allylalcohol, 18.8 g (62.2 mmol) Tetrabutylammonium
chloride monohydrate, 12.8 g (152.8 mmol) NaHCO3 and 0.75 g (3.1 mmol)
Pd(OAc)2 is added to a solution of 15.0 g (62.2 mmol) 4-iodobenzylalcohol in
100 mL DMF at RT under an N2 atmosphere and the reaction solution is
heated to 60 C for 3 h. The solvent is eliminated i.vac., the residue combined
with 250 mL EtOAc and 80 mL water and suction filtered through a fibreglass
filter. 80 mL NaCl solution are added to the filtrate, the phases are
separated
and the organic phase is dried over MgSO4. After the desiccant and solvent
Boehringer Ingelheim 123 Case 1-1406 if
CA 02504160 2005-04-28
have been eliminated the residue is purified by column chromatography on
silica gel (gradient: cyc/EtOAc 3:1 after cyc/EtOAc 1:1).
Yield: 7.43 g (72.7 % of theory)
C1OH1202 (M= 164.206)
Calc.: molpeak (M+H-H2O)+: 147 Found: molpeak (M+H-H2O)+: 147
HPLC retention time: 5.26 min (method A)
2.1 b (4-but-3-ynyl-phenyl)-methanol
8.5 g (61.5 mmol) K2CO3 are added to a solution of 5.0 g (30.4 mmol) 3-(4-
hydroxymethyl-phenyl)-propionaldehyde in 100 mL MeOH and then a solution
of 7.0 g (36.4 mmol) dimethyl (1-diazo-2-oxo-propyl)-phosphonate in 50 mL
MeOH is added dropwise and stirred for 3 h at RT. The reaction mixture is
diluted with 200 mL EtOAc, washed with 80 mL saturated NaHCO3 solution,
the aqueous phase extracted with 100 mL EtOAc and the combined organic
phases are dried over Na2SO4. After the desiccant and solvent have been
eliminated the residue is purified by chromatography on silica gel (cyc/EtOAc
3:1).
Yield: 3.42 g (70.1 % of theory)
C11 H120 (M= 160.218)
Calc.: molpeak (M+H-H2O)+: 143 Found: molpeak (M+H)+: (M+H-H2O)+:
143
Rf value: 0.36 (silica gel, cyc/EtOAc 2:1)
2.1c (4-{4-[5-(4-chloro-phenyl)-pyridin-2-yl]-but-3-ynyl}-phenyl)-methanol
Under a nitrogen atmosphere 76 mg (0.4 mmol) Cul and 281 mg (0.4 mmol)
Pd(PPh3)2C12 are added to a solution of 1.27 g (7.92 mmol) (4-but-3-ynyl-
phenyl)-methanol and 2.5 g (7.92 mmol) 5-(4-chloro-phenyl)-2-iodo-pyridine
in 40 mL triethylamine and 20 mL DMF and the reaction mixture is stirred for 2
h at 65 C. The solvent is eliminated in vacuo, the residue is dissolved in a
little EtOAc and MeOH and purified by chromatography on silica gel (gradient:
cyc/EtOAc 3:1 to cyc/EtOAc 1:1).
Yield: 1.48 g (53.6 % of theory)
C22H18 LINO (M= 347.848)
Boehringer Ingelheim 124 Case 1-1406 if
CA 02504160 2005-04-28
Calc.: molpeak (M+H)+: 348/350 Found: molpeak (M+H)+: 348/350
Rf value: 0.23 (silica gel, cyc/EtOAc 2:1)
2.1d 5-(4-chloro-phenyl)-2-[4-(4-piperidin-l-ylmethyl-phenyl)-but-1-ynyl]-
pyridine
20 pL (0.26 mmol) methanesulphonic acid chloride and 45 pL (0.26 mmol)
ethyldiisopropylamine are added to a solution, cooled to 0 C, of 75 mg (0.22
mmol) 4-{4-[5-(4-chloro-phenyl)-pyridin-2-yl]-but-3-ynyl}-phenyl)-methanol in
5
mL DCM and stirred at this temperature for 30 min. Then 108 pL (1.09 mmol)
piperidine are added and the reaction mixture is stirred for 72 h at RT. The
reaction solution is evaporated down i.vac. and the residue is purified by
HPLC.
Yield: 9.3 mg (53.6 % of theory)
C27H27 CIN2 (M= 414.983)
Calc.: molpeak (M+H)+: 415/417 Found: molpeak (M+H)+: 415/417
HPLC retention time: 7.62 min (method A)
The following compounds are prepared as described in Example 2.1d:
CI
R
Example R Yield (%) empirical mass HPLC retention time
formula spectrum in min
(method)
2.2 DN 19.3 C25H23CIN2 387/389 7.04 (A)
[M+H]+
2.3 24.4 C31H34CIN3 484/486 5.96 (A)
ON \
N [M+H]
Boehringer Ingelheim 125 Case 1-1406 if
2.4"3
13.1 C25H25CIN20 405/407 6.95 (A)
H~Oi~/N y
[M+H]+
2.5 cH, 22.4 C29H26CIN3 452/454 7.71 (A)
[M+H] +
2.6 H,G, N 11.4 C27H28CIN3 430/432 6.87 (A)
[M+H] +
2.7 25.9 C31H27CIN2 463/465 8.26 (A)
N
[M+H]+
2.8 24.7 C27H27CIN2 415/417 7.53 (A)
[M+H]+
2.9 H 28.1 C28H24CIN3 438/440 7.47 (A)
N
N [M+H]+
2.10 , 15.7 C29H32CIN3 458/460 5.82 (A)
N,`
H c'N [M+H]+
2.11 19.7 C28H29CIN20 445/447 7.81 (A)
N
\ 0 ` = [M+H]+
2.12 10.1 C28H29CIN20 445/447 7.83 (A)
N
\0 [M+H] +
2.13 040 21.4 C31H34CIN302 516/518 8.18 (A)
HNN [M+H]+
2.14 25.1 C28H27CIN202 459/461 7.56 (A)
N
0 [M+H]
0
2.15 23.8 C28H29CIN2 429/431 8.18 (A)
[M+H]+
CA 02504160 2005-04-28
Boehringer Ingelheim 126 Case 1-1406 if
Example 2.16
tert-butyl 4-[(4-{4-[5-(4-chloro-phenyl)-pyrid in-2-yl]-but-3-ynyl}-benzyl)-
methyl-
amino]-piperidin-1-carboxylate
N
N
0yNV,~
O
Prepared analogously to Example 2.1d from 75 mg (0.22 mmol) 4-{4-[5-(4-
chlorophenyl)-pyridin-2-yl]-but-3-ynyl}-phenyl)-methanol and 20 pL (1.09
mmol) 4 tert-butyl-methylamino-piperidin-1-carboxylate, stirring for 7 days at
RT. To complete the reaction the reaction sequence described is repeated
again using the same amount of reagents and after 24 h reaction the mixture
is worked up.
Yield: 8.5 mg (7.2 % of theory)
C331-138 CIN302 (M= 544.143)
Calc.: molpeak (M+H)+: 544/546 Found: molpeak (M+H)+: 544/546
HPLC retention time: 8.46 min (method A)
Example 2.17
(4-{4-[5-(4-chloro-phenyl)-pyridin-2-yl]-but-3-ynyl}-benzyl)-methyl-piperidin-
4-
yl-amine
CI
/N
H~ JY
N
0.5 mL trifluoroacetic acid are added to a solution of 35 mg (0.06 mmol) tert-
butyl4-[(4-{4-[5-(4-ch loro-phenyl)-pyrid i n-2-yl]-but-3-ynyl}-benzyl )-
methyl-
amino]-piperidin-1-carboxylate in 3 mL DCM and the reaction mixture is
stirred for 3 h at RT. The mixture is evaporated down i. vac., the residue is
combined with 10 mL NaHCO3 solution, extracted with 20 mL DCM and the
CA 02504160 2005-04-28
Boehringer Ingelheim 127 Case 1-1406 if
organic phase is dried over Na2SO4. After the desiccant and solvent have
been eliminated the desired product is obtained.
Yield: 8.0 mg (28.2 % of theory)
C28H30 CIN3 (M= 444.024)
Calc.: molpeak (M+H)+: 444/446 Found: molpeak (M+H)+: 444/446
HPLC retention time: 5.83 min (method A)
Example 2.18
1-(4-{4-[5-(4-chloro-phenyl)-pyridin-2-yl]-but-3-ynyl}-benzyl )-pyrrolidin-3-
ylamine
CI
I
N
H2N
N
Prepared analogously to Example 2.17 from 17 mg (0.03 mmol) tert-butyl [1-
(4-{4-[5-(4-chloro-phenyl)-pyrid i n-2-yl]-but-3-ynyl}-benzyl)-pyrrol id i n-3-
yl]-
carbaminate (Example 2.13).
Yield: 12.0 mg (87.4 % of theory)
C26H26 CIN3 (M= 415.970)
Calc.: molpeak (M+H)+: 416/418 Found: molpeak (M+H)+: 416/418
HPLC retention time: 5.83 min (method A)
Example 2.19
1-(4-{4-[5-(4-chloro-phenyl)-pyrid i n-2-yl]-but-3-ynyl}-benzyl)-pyrrol id i n
e-2-
carboxylic acid
CI
N
H
O
O
0.5 mL 1 M NaOH solution are added to a solution of 33 mg (0.07 mmol)
methyl 1-(4-{4-[5-(4-chloro-phenyl)-pyrid in-2-yl]-but-3-ynyl}-benzyl)-
CA 02504160 2005-04-28
Boehringer Ingelheim 128 Case 1-1406 ff
pyrrolidine-2-carboxylate (Example 2.14) in 5 mL MeOH and the reaction
mixture is stirred for 4 hat RT. The mixture is evaporated down i. vac.,
combined with 5 mL water, extracted with 10 mL EtOAc and the aqueous
phase is saturated with NaCl, during which time the product is precipitated.
It
is evaporated down again i. vac., the residue is combined with EtOH, filtered
and the solvent is eliminated.
Yield: 30.0 mg (93.6 % of theory)
C27H25 CIN202 (M= 444.966)
CaIc.: molpeak (M+H)+: 445/447 Found: molpeak (M+H)+: 445/447
HPLC retention time: 7.28 min (method A)
Example 2.20
5-(2,4-dichloro-phenyl)-2-[4-(4-pyrrolidin-1 -ylmethyl-phenyl)-but-1 -ynyl]-
pyridine
C1
N
N
2.20a {4-[4-(5-bromo-pyridin-2-yl)-but-3-ynyl]-phenyl}-methanol
Under an N2 atmosphere 130 mg (0.67 mmol) Cul and 300 mg (0.42 mmol)
Pd(PPh3)2C12 are added to a solution of 2.0 g (12.48 mmol) (4-but-3-ynyl-
phenyl)-methanol and 3.2 g (13.1 mmol) 2,5-dibromopyridine in 80 mL
triethylamine and the reaction mixture is stirred for 1.5 In at 50 C. The
solvent
is eliminated in vacuo, the residue dissolved in a little DCM and purified by
chromatography on silica gel (gradient: cyc/EtOAc 4:1 to cyc/EtOAc 3:1).
Yield: 2.76 g (66.6 % of theory)
C16H14 BrNO (M= 316.20)
CaIc.: molpeak (M+H)+: 316/318 Found: molpeak (M+H)+: 316/318
Rf value: 0.28 (silica gel, cyc/EtOAc 2:1)
2.20b 5-bromo-2-[4-(4-pyrrolidin-l-ylmethyl-phenyl)-but-l-ynyl]-pyridine
0.24 mL (3.04 mmol) methanesulphonic acid chloride are added to a solution,
cooled to 0 C, of 800 mg (2.53 mmol) {4-[4-(5-bromo-pyridin-2-yi)-but-3-ynyl]-
CA 02504160 2005-04-28
Boehringer Ingelheim 129 Case 1-1406 if
CA 02504160 2005-04-28
phenyl}-methanol in 17 mL DCM and then a solution of 0.52 mL
ethyldiisopropylamine in 3 mL DCM is added dropwise. The mixture is stirred
for a further 30 min at 0 C, 0.51 mL (6.08 mmol) pyrrolidine is added, the
reaction mixture is heated to RT and kept at this temperature for 5 h. To
complete the reaction another 0.26 mL (3 mmol) pyrrolidine are added and
stirred for 1 h at RT. The mixture is evaporated down i. vac., combined with
mL water and 20 ml EtOAc, acidified with 1 M HCI and the organic phase
is separated off. The aqueous phase is made alkaline with 2 M Na2CO3
solution, extracted with 20 mL EtOAc, the organic phase is separated off and
dried over Na2SO4. After the desiccant and solvent have been eliminated the
desired product is obtained.
Yield: 630.0 mg (67.4 % of theory)
C20H21 BrN2 (M= 369.308)
Calc.: molpeak (M+H)+: 369/371 Found: molpeak (M+H)+: 369/371
HPLC retention time: 6.08 min (method A)
2.20c 5-(2,4-dichloro-phenyl)-2-[4-(4-pyrrolidin-1-ylmethyl-phenyl)-but-1-
ynyl]-
pyridine
10 mg (0.01 mmol) tetrakis-triphenylphosphane-palladium are added to a
suspension of 60 mg (0.16 mmol) 5-bromo-2-[4-(4-pyrrolidin-1-ylmethyl-
phenyl)-but-1-ynyl]-pyridine and 63 mg (0.32 mmol) 2,4-dichlorophenylboric
acid in 4 mL 1,4-dioxane and 1 mL 2 M Na2CO3 solution and the reaction
mixture is stirred for 1 h at 110 C. The mixture is evaporated down i. vac.
and
the residue is extracted twice with in each case 15 mL EtOH. The solvent is
removed and the residue is purified by HPLC.
Yield: 22.7 mg (32.2 % of theory)
C26H24 CI2N2 (M= 435.401)
Calc.: molpeak (M+H)+: 435/437/439 Found: molpeak (M+H)+:
435/437/439
HPLC retention time: 5.53 min (method C)
The following compounds are prepared as described in Example 2.20c:
Boehringer Ingelheim 130 Case 1-1406 if
R
I ~\JJY
N
Example R Yield (%) empirical mass HPLC retention
formula spectrum time in min
(method)
2.21 13.0 C26H25BrN2 445/447 5.53 (C)
[M+H]+
2.22 0 41.4 C27H28N20 397 3.39 (C)
[M+H]+
2.23 30.8 C26H24C12N2 435/437/43 3.70 (A)
ci 9
[M+H] +
2.24 21.8 C261-1241721\12 403 7.21 (A)
aF [M+H]+
2.25 7.5 C28H30N2O 411 7.30 (A)
[M+H]+
Example 2.26
5-(4-methoxy-phenyl)-2-[4-(4-pyrrolidin-1-ylmethyl-phenyl)-but-1-ynyl]-
pyridine
N
I
N
Prepared analogously to Example 2.20c, after the reaction has ended the
reaction mixture is combined with 10 mL water and 20 mL EtOAc, filtered
through a fibreglass filter, the organic phase is separated off and dried over
Na2SO4. The solvent is removed and the residue is purified by HPLC.
Yield: 17.4 mg (23.1 % of theory)
CA 02504160 2005-04-28
Boehringer Ingelheim 131 Case 1-1406 if
CA 02504160 2005-04-28
C27H28N202 (M= 396.537)
Calc.: molpeak (M+H)+: 397 Found: molpeak (M+H)+: 397
HPLC retention time: 8.15 min (method A)
Example 2.27
4-(4-{4-[5-(4-ch loro-phenyl)-pyrid in-2-yl]-but-3-ynyl}-benzyl)-morpholine
I J
2.27a 4-{4-[4-(5-bromo-pyridin-2-yl)-but-3-ynyl]-benzyl}-morpholine
36 pL (0.46 mmol) methanesulphonic acid chloride are added to a solution,
cooled to 0 C, of 120 mg (0.38 mmol) {4-[4-(5-bromo-pyridin-2-yl)-but-3-ynyl]-
phenyl}-methanol (Example 2.20a) in 5 mL DCM. A solution of 78 pL (0.46
mmol) ethyldiisopropylamine in 1 mL DCM is slowly added dropwise, the
mixture is stirred for a further 30 min at 0 C, then 80 pL (0.92 mmol) of
morpholine are added, the mixture is allowed to come up to RT and kept at
RT for 2 h. The mixture is evaporated down i. vac., the residue is combined
with 20 mL EtOAc and 10 mL water, acidified with 1 M HCI and the phases
are separated. The aqueous phase is combined with 2 M Na2CO3 solution,
extracted with 20 mL EtOAc and the organic phase is dried over Na2SO4.
After the desiccant and solvent have been eliminated the product is obtained.
Yield: 146 mg (100 % of theory)
C20H21 BrN2O (M= 385.307)
Calc.: molpeak (M+H)+: 385/387 Found: molpeak (M+H)+: 385/387
HPLC retention time: 5.92 min (method A)
2.27b 4-(4-{4-[5-(4-chloro-phenyl)-pyridin-2-yl]-but-3-ynyl}-benzyl)-
morpholine
Prepared analogously to Example 2.20c from 90 mg (0.23 mmol) 4-{4-[4-(5-
bromo-pyridin-2-yl)-but-3-ynyl]-benzyl}-morpholine and 73 mg (0.47 mmol) 4-
chlorophenyl boric acid.
Yield: 17.5 mg (17.9 % of theory)
C26H25CIN20 (M= 416.955)
Boehringer Ingelheim 132 Case 1-1406 if
CA 02504160 2005-04-28
Cale.: molpeak (M+H)+: 417/419 Found: molpeak (M+H)+: 417/419
HPLC retention time: 7.51 min (method A)
Example 2.28
(4-{4-[5-(4-chloro-phenyl)-pyridin-2-yl]-but-3-ynyl}-benzyl)-cyclopropylmethyl-
amine
ci
H
~N
2.28a (4-{4-[4-(5-bromo-pyridin-2-yl)-but-3-ynyl]-benzyl)-cyclopropylmethyl-
amine
36 pL (0.46 mmol) methanesulphonic acid chloride are added to a solution,
cooled to 0 C, of 120 mg (0.38 mmol) {4-[4-(5-bromo-pyridin-2-yl)-but-3-ynyl]-
phenyl}-methanol (Example 2.20a) in 5 mL DCM. A solution of 78 pL (0.46
mmol) ethyldiisopropylamine in I mL DCM is slowly added dropwise, stirred
for a further 30 min at 0 C, then 70 pL (0.92 mmol) C-cyclopropyl-
methylamine are added, the reaction mixture is allowed to come up to RT and
kept at RT for 21 h. To complete the reaction another 78 pL C-cyclopropyl-
methylamine are added and stirred for another 5.5 h at RT. The reaction
mixture is evaporated down i.vac. and the residue purified by
chromatography on silica gel (gradient: cyc/EtOAc 2:1 to cyc/EtOAc 1:1).
Yield: 70.0 mg (49.9 % of theory)
C20H21 BrN2 (M= 369.308)
Cale.: molpeak (M+H)+: 369/371 Found: molpeak (M+H)+: 369/371
HPLC retention time: 6.55 min (method A)
2.28b (4-{4-[5-(4-chloro-phenyl)-pyridin-2-yl]-but-3-ynyl}-benzyl)-
cyclopropylmethyl-amine
Prepared analogously to Example 2.20c from 65 mg (0.18 mmol) (4-{4-[4-(5-
bromo-pyridin-2-yl)-but-3-ynyl]-benzyl)-cyclopropylmethyl-amine and 55 mg
(0.35 mmol) ) 4-chloro-phenylboric acid.
Yield: 15.4 mg (21.8 % of theory)
Boehringer Ingelheim 133 Case 1-1406 if
CA 02504160 2005-04-28
C26H25CIN2 (M= 400.956)
Caic.: molpeak (M+H)+: 401/403 Found: molpeak (M+H)+: 401/403
HPLC retention time: 7.63 min (method A)
Example 2.29
3-(4-chloro-phenyl)-6-[4-(4-pyrrolidin-1 -ylmethyl-phenyl)-but-1 -ynyl]-
pyridazine
CI
N/N
ON
2.29a 3-chloro-6-(4-chloro-phenyl)-pyridazine
Under an argon atmosphere a solution of 1.08 g (7.05 mmol) 3,6-dichloro-
pyridazin, 10 mL 2 M Na2CO3 solution and 80 mg (0.14 mmol) chlorine(di-2-
norbornylphosphino)(2'-dimethylamino-1-1 '-biphenyl-2-yl)palladium(I I) in 150
mL 1,4-dioxane is heated to 110 C. At this temperature a solution of 1.13 g
(7.05 mmol) 4-chlorophenyl-boric acid in 50 mL 1,4-dioxane is added
dropwise within 2 h and the reaction mixture is heated for another hour. After
cooling it is combined with 100 mL water, extracted with 100 mL EtOAc and
the organic phase is dried over Na2SO4. After the desiccant and solvent have
been eliminated the residue is purified by chromatography (silica gel,
cyc/EtOAc 8:2).
Yield: 567 mg (35.7 % of theory)
Ci0H6C12N2 (M= 225.079)
Calc.: molpeak (M+H)+: 225/227 Found: molpeak (M+H)+: 225/227
Rf value: 0.29 (silica gel, cyc/EtOAc 8:2)
2.29b 3-(4-chloro-phenyl)-6-[4-(4-pyrrolidin-l -ylmethyl-phenyl)-but-1-ynyl]-
pyridazin
Under an argon atmosphere 0.1 mL (0.72 mmol) triethylamine, 3 mg (0.02
mmol) Cul and 8 mg (0.01 mmol) bis-triphenylphosphane-palladium(Il)-
chloride are added to a solution of 77 mg (0.34 mmol) 3-chloro-6-(4-chloro-
phenyl)-pyridazine and 73 mg (0.34 mmol) 1-(4-but-3-ynyl-benzyl)-pyrrolidine
Boehringer Ingelheim 134 Case 1-1406 if
CA 02504160 2005-04-28
(Example 2e) in 4 mL DMF and the reaction mixture is stirred for 20 min at
100 C and at 300 W in the microwave. The reaction mixture is combined with
mL water, extracted with 10 mL EtOAc and the organic phase is washed
with water and dried over Na2SO4. After the desiccant and solvent have been
eliminated the residue is purified by chromatography (silica gel,
EtOAc/MeOH/NH3 90:10:1).
Yield: 6 mg (4.4 % of theory)
C25H24BrN3 (M= 401.943)
Calc.: molpeak (M+H)+: 402/404 Found: molpeak (M+H)+: 402/404
Rf value: 0.66 (silica gel, EtOAc/MeOH/NH3 90:10:1)
Example 2.30
5-(4-chloro-phenyl)-2-[4-(4-pyrrolid in-l-ylmethyl-phenyl)-but-l-ynyl]-
nicotinonitrile
N
j N
ON
Under an argon atmosphere 1.9 mg (0.1 mmol) Cul and 7 mg (0.1 mmol)
Pd(PPh3)2C12 are added to a solution of 50 mg (0.2 mmol) 2-chloro-5-(4-
chloro-phenyl)-nicotinonitrile and 43 mg (0.2 mmol) 1-(4-but-3-ynyl-benzyl)-
pyrrolidine in 2 mL DMF and 5 mL (20 mmol) triethylamine and the reaction
mixture is stirred for 18 h at 50 C. The mixture is evaporated down i. vac.,
the
residue is taken up in water, extracted exhaustively with EtOAc and the
organic phase is dried over Na2SO4. After the desiccant and solvent have
been eliminated the residue is is purified by HPLC.
Yield: 6.5 mg (7.6 % of theory)
C27H24BrN3 (M= 425.965)
Calc.: molpeak (M+H)+: 425 Found: molpeak (M+H)+: 425
HPLC retention time: 6.80 min (method A)
Boehringer Ingelheim 135 Case 1-1406 ff
Example 3.1:
5-(4-chloro-phenyl)-2-[3-chloro-4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-
pyridine
C
CI
3.1a 5-(4-chloro-phenyl)-pyridin-2-ylamine
300 mL (600 mmol) of a 2 M Na2CO3 solution and 3.45 g (3.0 mmol) tetrakis-
triphenyiphosphane-palladium are added successively to a solution of 53.5 g
(300 mmol) 2-amino-5-bromopyridine and 50.0 g (313 mmol) 4-
chlorophenyl boric acid in 1.0 L 1,4-dioxane and 250 mL methanol under
argon. The reaction mixture is stirred for 2.5 h at 110 C. The solvent is
eliminated i.vac., the residue is taken up in EtOAc and water. The organic
phase is dried over Na2SO4 and the solvent is eliminated i.vac.. Further
purification is carried out by column chromatography on silica gel (gradient:
DCM to DCM/MeOH 20:1).
Yield: 47 g (76.5 % of theory)
C11 H9CIN2 (M= 204.661)
Calc.: molpeak (M+H)+: 205/207 Found: molpeak (M+H)+: 205/207
HPLC retention time: 5.15 min (method A)
3.1 b 5-(4-chloro-phenyl)-2-iodo-pyridine
40.5 mL (33 mmol) tert-butylnitrite and 54 g (210 mmol) iodine are added to a
solution of 38 g (190 mmol) 5-(4-chloro-phenyl)-pyridin-2-ylamine in 400 mL
carbon tetrachloride in a flask protected from light and the mixture is
stirred for
72 hat RT. A further 40.5 mL (33 mmol) tert-butylnitrite, 54 g (210 mmol)
iodine and 100 mL DCM are added. The reaction solution is stirred for a
further 24 h at RT. The solvent is eliminated i.vac. and the residue taken up
in
CA 02504160 2005-04-28
Boehringer Ingelheim 136 Case 1-1406 if
CA 02504160 2005-04-28
125 mL EtOAc and 50 mL water. The aqueous phase is extracted once with
EtOAc. The organic phase is dried over Na2SO4 and stirred for one night over
activated charcoal. After filtration the solvent is eliminated i.vac.. Further
purification is carried out by column chromatography on silica gel (PE/EtOAc
9:1).
Yield: 35 g (58.4 % of theory)
C11 H7CIIN (M= 315.543)
Calc.: molpeak (M+H)+: 316/318 Found: molpeak (M+H)+: 316/318
Rf value: 0.87 (silica gel, PE/EtOAc 6:4)
3.1 c 5-(4-chloro-phenyl)-2-trimethylsilanylethynyl-pyridine
34.9 mL (250 mmol) triethylamine and 20.8 mL (150.0 mmol) ethynyl-
trimethyl-silane are added successively to a solution of 34 g (110 mmol) 5-(4-
chloro-phenyl)-2-iodo-pyridine in 300 mL acetonitrile and 150 mL THE under
an argon atmosphere. Then 803 mg (1.10 mmol) Pd(dppf)C12 and 209 mg
(1.10 mmol) Cul are added. The reaction solution is stirred overnight at RT.
The solvent is eliminated i.vac. and further purification is carried out by
column chromatography on silica gel (PE/EtOAc 8:2).
Yield: 15.3 g (48.7 % of theory)
C16H16CINSi (M= 285.852)
Calc.: molpeak (M+H)+: 286/288 Found: molpeak (M+H)+: 286/288
HPLC retention time: 7.10 min (method A)
3.1d 5-(4-chloro-phenyl)-2-ethynyl-pyridine
Under an argon atmosphere 6.6 g (21.0 mmol) TBAF are added to a solution
of 5.8 g (20.3 mmol) 5-(4-chloro-phenyl)-2-trimethylsilanylethynyl-pyridine in
200 mL DCM at 0 C. The reaction solution is stirred for 3 h, while the
reaction
temperature slowly rises to RT. It is added to 50 mL water and the organic
phase is extracted four times with 50 mL water, dried over MgSO4 and filtered
over activated charcoal. The solvent is eliminated i.vac. and further
Boehringer Ingelheim 137 Case 1-1406 if
CA 02504160 2005-04-28
purification is carried out by column chromatography on silica gel (PE/EtOAc
1:1).
Yield: 3.9 g (90.0 % of theory)
C13H8CIN (M= 213.668)
Calc.: molpeak (M+H)+: 214/216 Found: molpeak (M+H)+: 214/216
Rf value: 0.87 (silica gel, cyc/EtOAc 8:2)
3.1 e 1-[2-(4-bromo-2-chloro-phenoxy)-ethyl]-pyrrolidine
415 mg (3.00 mmol) K2CO3 and 170 mg (1.00 mmol) N-(2-chloroethyl)-
pyrrolidine-hydrochloride is added to a solution of 207 mg (1.00 mmol) 4-
bromo-2-chloro-phenol in 5 mL DMF and the mixture is stirred for 24 h at RT.
The reaction mixture is diluted with 50 mL EtOAc, extracted once with 30 mL
water and twice with 30 mL semisaturated NaHCO3 solution. The organic
phase is dried over MgSO4 and the solvent is eliminated i.vac.. Further
purification is carried out by column chromatography on silica gel (gradient:
DCM to DCM/MeOH 9:1).
Yield: 100 mg (32.8 % of theory)
C12H15BrCINO (M= 304.616)
Calc.: molpeak (M+H)+: 304/306/308 Found: molpeak (M+H)+:
304/306/308
HPLC retention time: 5.59 min (method A)
3.1f 5-(4-chloro-phenyl)-2-[3-chloro-4-(2-pyrrolidin-1-yl-ethoxy)-
phenylethynyl]-pyridine
Under an argon atmosphere 0.14 mL (1.00 mmol) triethylamine, 11 mg (0.02
mmol) Pd(PPh3)2C12 and 2.9 mg (0.015 mmol) Cul are added successively to
a solution of 71 mg (0.33 mmol) 5-(4-chloro-phenyl)-2-ethynyl-pyridine and
100 mg (0.33 mmol) 1-[2-(4-bromo-2-chloro-phenoxy)-ethyl]-pyrrolidine in 3.0
mL DMF. The mixture is stirred for 10 min at 100 C and at 200 Watt in the
microwave. The reaction solution is diluted with 30 mL EtOAc, washed twice
with semisaturated NaCl solution and the organic phase is dried over MgSO4.
Boehringer Ingelheim 138 Case 1-1406 if
CA 02504160 2005-04-28
The solvent is eliminated i.vac. and further purification is carried out by
column chromatography with HPLC-MS.
Yield: 12 mg (8.3 % of theory)
C25H22C12N2O (M= 437.373)
Calc.: molpeak (M+H)+: 437/439/441 Found: molpeak (M+H)+:
437/439/441
Rf value: 0.28 (silica gel, DCM/MeOH 9:1)
Example 3.2
5-(4-chloro-phenyl)-2-[3, 5-dimethyl-4-(2-pyrrolidin-1-yl-ethoxy)-
phenylethynyl]-
pyridine
N
ON~\
3.2a 1-[2-(4-bromo-2,6-dimethyl -phenoxy)-ethyl]-pyrrolidine
The product is obtained analogously to Example 3.1e from 201 mg (1.00
mmol) 4-bromo-2,6-dimethyl-phenol and 170 mg (1.00 mmol) N-(2-
chloroethyl )-pyrrolidine-hydrochloride.
Yield: 200 mg (67.1 % of theory)
C14H2OBrNO (M= 298.226)
Calc.: molpeak (M+H)+: 298/300 Found: molpeak (M+H)+: 298/300
HPLC retention time: 5.76 min (method A)
3.2b 5-(4-chloro-phenyl)-2-[3,5-dimethyl-4-(2-pyrrolidin-1-yl-ethoxy)-
phenylethynyl]-pyridine
The product is obtained analogously to Example 3.1f from 200 mg (0.67
mmol) 1-[2-(4-bromo-2,6-dimethyl-phenoxy)-ethyl]-pyrrolidine and 143 mg
(0.67 mmol) 5-(4-chloro-phenyl)-2-ethynyl-pyridine.
Yield: 5 mg (1.7 % of theory)
Boehringer Ingelheim 139 Case 1-1406 if
CA 02504160 2005-04-28
C27H27CIN20 (M= 430.982)
Calc.: molpeak (M+H)+: 431/433 Found: molpeak (M+H)+: 431/433
Rf value: 0.29 (silica gel, DCM/MeOH 9:1)
Example 3.3
5-(4-chloro-phenyl)-2-[3-fluoro-4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-
pyridine
CI
F N
3.3a 1-[2-(4-bromo-2-fluoro-phenoxy)-ethyl]-pyrrolidine
The product is obtained analogously to Example 3.1e (acetonitrile instead of
DMF) from 0.57 mL (5.24 mmol) 4-bromo-2-fluoro-phenol and 1.02 g (6.00
mmol) N-(2-chloroethyl)-pyrrolidine-hydrochloride.
Yield: 1.16 g (76.6 % of theory)
C12H15BrFNO (M= 288.162)
Calc.: molpeak (M+H)+: 288/290 Found: molpeak (M+H)+: 288/290
Rf value: 0.21 (silica gel, EtOAc/MeOH 9:1).
3.3b 1-[2-(2-fluoro-4-iodo-phenoxy)-ethyl]-pyrrolidine
Prepared according to general working method II from 1-[2-(4-bromo-2-fluoro-
phenoxy)-ethyl]-pyrrolidine (1.10 g, 3.82 mmol).
Yield: 1.13 g (88.3 % of theory)
C12H15FINO (M= 335.162)
Calc.: molpeak (M+H)+: 336 Found: molpeak (M+H)+: 336
HPLC retention time: 4.79 min (method A)
3.3c 5-(4-chloro-phenyl)-2-[3-fluoro-4-(2-pyrrolidin-1-yl-ethoxy)-
phenylethynyl]-pyridine
Boehringer Ingelheim 140 Case 1-1406 ff
Prepared according to general working method I from 1-[2-(2-fluoro-4-iodo-
phenoxy)-ethyl]-pyrrolidine (300 mg, 0.90 mmol) and 5-(4-chloro-phenyl)-2-
ethynyl-pyridine (201 mg, 0.94 mmol).
Yield: 150 mg (39.8 % of theory)
C25H22CIFIN20 (M= 420.918)
Calc.: molpeak (M+H)+: 421/423 Found: molpeak (M+H)+: 421/423
HPLC retention time: 7.18 min (method A)
Example 3.4
methyl 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-
ethoxy)-
benzoate
c
o'
3.4a methyl 5- iodo-2-(2-pyrrolidin-1-yi-ethoxy)-benzoate
The product is obtained analogously to Example 3.1.e (acetonitrile instead of
DMF) from 10.0 g (36.0 mmol) methyl 5-iodo-salicylate and 6.12 g (36.0
mmol) N-(2-chloroethyl)-pyrrolidine-hydrochloride.
Yield: 12.0 g (88.8 % of theory)
C14H181NO3 (M= 375.209)
Calc.: molpeak (M+H)+: 376 Found: molpeak (M+H)+: 376
Rf value: 0.40 (silica gel, DCM/MeOH/NH3 9:1:0.1)
3.4b methyl 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-
ethoxy)-benzoate
Prepared according to general working method I from methyl 5-iodo-2-(2-
pyrrolidin-1-yl-ethoxy)-benzoate (3.0 g, 8.0 mmol) and 5-(4-chloro-phenyl)-2-
ethynyl-pyridine (1.76 g, 8.24 mmol).
Yield: 1.02 g (26.9 % of theory)
C27H25CIN203 (M= 460.965)
Calc.: molpeak (M+H)+: 461/463 Found: molpeak (M+H)+: 461/463
CA 02504160 2005-04-28
Boehringer Ingelheim 141 Case 1-1406 if
HPLC retention time: 7.49 min (method A)
Example 3.5
5-(4-chloro-phenyl)-2-[3-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-
pyridine
CI
3.5a 1-[2-(4-bromo-2-methoxy-phenoxy)-ethyl]-pyrrolidine
The product is obtained analogously to Example 3.1e (acetonitrile instead of
DMF) from 6.0 g (29.6 mmol) 4-bromo-2-methoxy-phenol and 5.63 g (33.1
mmol) N-(2-chloroethyl)-pyrrolidine-hydrochloride.
Yield: 3.96 g (44.6 % of theory)
C13H18BrNO2 (M= 300.198)
Calc.: molpeak (M+H)+: 300/302 Found: molpeak (M+H)+: 300/302
HPLC retention time: 4.67 min (method A)
3.5b 1-[2-(4-iodo-2-methoxy-phenoxy)-ethyl]-pyrrolidine
Prepared according to general working method 11 from 1-[2-(4-bromo-2-
methoxy-phenoxy)-ethyl]-pyrrolidine (3.90 g, 13.0 mmol).
Yield: 4.19 g (92.9 % of theory)
C13H1$1N02 (M= 347.198)
Calc.: molpeak (M+H)+: 348 Found: molpeak (M+H)+: 348
HPLC retention time: 4.65 min (method A)
3.5c 5-(4-chloro-phenyl)-2-[3-methoxy-4-(2-pyrrolidin-1-yl-ethoxy)-
phenylethynyl]-pyridine
Prepared according to general working method I from 1-[2-(4-iodo-2-methoxy-
phenoxy)-ethyl]-pyrrolidine (300 mg, 0.86 mmol) and 5-(4-chloro-phenyl)-2-
ethynyl-pyridine (194 mg, 0.91 mmol).
Yield: 106 mg (28.3 % of theory)
CA 02504160 2005-04-28
Boehringer Ingelheim 142 Case 1-1406 if
CA 02504160 2005-04-28
C26H25CIN202 (M= 432.954)
Calc.: molpeak (M+H)+: 433/435 Found: molpeak (M+H)+: 433/435
HPLC retention time: 7.44 min (method A)
Example 3.6
5-(4-chloro-phenyl)-2-[4-(2-pyrrolidin-1-yl-ethoxy)-3-trifluoromethoxy-
phenylethynyl]-pyrid ine
F\ F
i
N
ON 0
3.6a 4-bromo-2-trifluoromethoxy-phenol
1.55 mL (30.3 mmol) bromine in 50 mL DCM is added dropwise to a solution
of 5.0 g (28.1 mmol) 2-trifluoromethoxy-phenol in 70 mL DCM at -78 C. The
reaction solution is heated to RT and stirred for a further 48 h. Then 70 mL
Na2SO3 solution are added and the mixture is stirred until the orange colour
has disappeared. The solution is diluted with DCM, the organic phase is
washed with NaCl solution, dried over MgSO4 and the solvent is eliminated
i.vac.. The purification is carried out by column chromatography on silica gel
(gradient: PE to PE:EtOAc 4:1).
Yield: 5.36 g (74.3 % of theory)
C7H4BrF3O2 (M= 257.008)
Caic.: molpeak (M-H) 255/257 Found: molpeak (M-H)-: 255/257
HPLC retention time: 8.18 min (method A)
3.6b 1-[2-(4-bromo-2-trifluoromethoxy-phenoxy)-ethyl]-pyrrolidine
The product is obtained analogously to Example 3.1e (acetonitrile instead of
DMF) from 2.0 g (7.78 mmol) 4-bromo-2-trifluoromethoxy-phenol and 1.53 g
(33.1 mmol) N-(2-chIoroethyl)-pyrrolidine-hydrochloride.
Yield: 0.49 g (17.8 % of theory)
C13H15 BrF3NO2 (M= 354.169)
Calc.: molpeak (M+H)+: 354/356 Found: molpeak (M+H)+: 354/356
Boehringer Ingelheim 143 Case 1-1406 if
CA 02504160 2005-04-28
HPLC retention time: 5.82 min (method A)
3.6c 1-[2-(4-iodo-2-trifluoromethoxy-phenoxy)-ethyl]-pyrrolidine
Prepared according to general working method II from 1-[2-(4-bromo-2-
trifluoromethoxy-phenoxy)-ethyl]-pyrrolidine (476 mg, 1.34 mmol).
Yield: 540 mg (100.0 % of theory)
C131-115 F31NO2 (M= 401.170)
Calc.: molpeak (M+H)+: 402 Found: molpeak (M+H)+: 402
HPLC retention time: 6.07 min (method A)
3.6d 5-(4-chloro-phenyl)-2-[4-(2-pyrrolidin-1-yl-ethoxy)-3-trifluoromethoxy-
phenylethynyl]-pyridine
Prepared according to general working method I from 1-[2-(4-iodo-2-
trifluoromethoxy-phenoxy)-ethyl]-pyrrolidine (250 mg, 0.62 mmol) and 5-(4-
chloro-phenyl)-2-ethynyl-pyridine (140 mg, 0.65 mmol).
Yield: 116 mg (38.5 % of theory)
C26H22CIF3N2O2 (M= 486.926)
Calc.: molpeak (M+H)+: 487/489 Found: molpeak (M+H)+: 487/489
HPLC retention time: 8.09 min (method A)
Example 3.7
2-[3-bromo-4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-5-(4-chloro-phenyl)-
pyridine
Br N
0
3.7a 2-bromo-4-iodo-phenol
1.55 mL (30.3 mmol) bromine in 15 mL EtOAc is added dropwise to a solution
of 4.0 g (18.2 mmol) 4-iodo-phenol in 35 mL EtOAc at RT. The reaction
solution is stirred for 2 h at RT. Then 75 mL Na2SO3 solution is added and
stirred until the orange colour has disappeared. The solution is diluted with
Boehringer Ingelheim 144 Case 1-1406 if
CA 02504160 2005-04-28
DCM, the organic phase washed with NaCl solution, dried over MgSO4 and
the solvent is eliminated i.vac.. A 3.4:1.4:1.0 mixture of 2-bromo-4-iodo-
phenol : 2,4-dibromo-phenol : 4-bromo-phenol is obtained, which is further
reacted without any more purification.
Yield of 2-bromo-4-iodo-phenol: 2.60 g (47.9 % of theory)
C6H4BrIO (M= 298.907)
Calc.: molpeak (M-H)": 297/299 Found: molpeak (M-H) 297/299
Rf value: 0.40 (silica gel, EtOAc/MeOH 9:1)
3.7b 1-[2-(2-bromo-4-iodo-phenoxy)-ethyl]-pyrrolidine
The product is obtained analogously to Example 3.1 e from 1.0 g (1.15 mmol,
59%) 2-bromo-4-iodo-phenol and 626 mg (3.68 mmol) N-(2-chloroethyl)-
pyrrolidine-hydrochloride. A 4.7:1.0:1.0 mixture of 1-[2-(2-bromo-4-iodo-
phenoxy)-ethyl]-pyrrolidine : 1-[2-(2,4-dibromo-phenoxy)-ethyl]-pyrrolidine :
1-
[2-(2-bromo-phenoxy)-ethyl]-pyrrolidine is obtained, which is further reacted
without any more purification.
Yield 1-[2-(2-bromo-4-iodo-phenoxy)-ethyl]-pyrrolidine: 0.37 g (47.7 % of
theory)
C12H15 BrINO (M= 396.068)
Calc.: molpeak (M+H)+: 397/399 Found: molpeak (M+H)+: 397/399
Rf value: 0.25 (silica gel, EtOAc/MeOH 9:1)
3.7c 2-[3-bromo-4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-5-(4-chloro-
phenyl)-pyridine
Prepared according to general working method I from 1-[2-(2-bromo-4-iodo-
phenoxy)-ethyl]-pyrrolidine (278 mg, 0.34 mmol, 70%) and 5-(4-chloro-
phenyl)-2-ethynyl-pyridine (110 mg, 0.52 mmol).
Yield: 152 mg (64.3 % of theory)
C25H22BrCIN2O (M= 481.824)
Calc.: molpeak (M+H)+: 481/483/485 Found: molpeak (M+H)+:
481/483/485
Rf value: 0.25 (silica gel, DCM/MeOH/NH3 9:1:0.1)
Boehringer Ingelheim 145 Case 1-1406 ff
CA 02504160 2005-04-28
Example 3.8
5-(4-chloro-phenyl)-2-[4-(2-pyrrolidin-1-yl-ethoxy)-3-trifluoromethyl-
phenylethynyl]-pyrid ine
cI
~I
N T ~N~/gyp I ~
3.8a 4-bromo-2-trifluoromethyl-phenol
A solution of 3.0 g (11.8 mmol) 4-bromo-1-methoxy-2-trifluoromethyl-benzene
in 20 mL 1 M HBr in glacial acetic acid is stirred for 60 h at 90 C. The
reaction
solution is diluted with 300 mL water, adjusted to pH 7 with K2CO3. The
aqueous phase is extracted with EtOAc , the combined organic extracts are
with washed 40 mL quarter-saturated NaHCO3 solution and dried over
MgSO4. The solvent is eliminated i.vac. and the product is further reacted
without any more purification.
Yield: 1.20 g (42.3 % of theory)
C7H4BrF3O (M= 241.009)
Calc.: molpeak (M-H)-: 239/241 Found: molpeak (M-H)-: 239/241
HPLC retention time: 8.37 min (method A)
3.8b 1-[2-(4-bromo-2-trifluoromethyl-phenoxy)-ethyl]-pyrrolidine
The product is obtained analogously to Example 3.1e from 1.20 g (4.98 mmol)
4-bromo-2-trifluoromethyl-phenol and 850 mg (5.00 mmol) N-(2-chloroethyl)-
pyrrolidine-hydrochloride.
Yield: 400 mg (23.8 % of theory)
C13H15Br F3NO (M= 338.170)
Calc.: molpeak (M+H)+: 338/340 Found: molpeak (M+H)+: 338/340
HPLC retention time: 5.91 min (method A)
3.8c 1-[2-(4-iodo-2-trifluoromethyl-phenoxy)-ethyl]-pyrrolidine
Prepared according to general working method II from 1-[2-(4-bromo-2-
trifluoromethyl-phenoxy)-ethyl]-pyrrolidine (400 mg, 1.18 mmol).
Boehringer Ingelheim 146 Case 1-1406 if
CA 02504160 2005-04-28
Yield: 350 mg (76.8 % of theory)
C13H15 F3INO (M= 385.170)
Calc.: molpeak (M+H)+: 386 Found: molpeak (M+H)+: 386
HPLC retention time: 6.01 min (method A)
3.8d 5-(4-chloro-phenyl)-2-[4-(2-pyrrolidin-1-yi-ethoxy)-3-trifluoromethyl-
phenylethynyl]-pyridine
Prepared according to general working method I from 1-[2-(4-iodo-2-
trifluoromethyl-phenoxy)-ethyl]-pyrrolidine (180 mg, 0.47 mmol) and 5-(4-
chloro-phenyl)-2-ethynyl-pyridine (83 mg, 0.39 mmol).
Yield: 35 mg (19.1 % of theory)
C26H22CI F3N20 (M= 470.926)
Calc.: molpeak (M+H)+: 471/473 Found: molpeak (M+H)+: 471/473
HPLC retention time: 8.23 min (method A)
Example 3.9
5-(4-chloro-phenyl)-2-[2-methyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-
pyridine
CI
j N
CN~~
3.9a 1-[2-(4-bromo-3-methyl-phenoxy)-ethyl]-pyrrolidine
The product is obtained analogously to Example 3.1 a (acetonitrile instead of
DMF) from 1.0 g (5.35 mmol) 4-bromo-3-methyl-phenol and 909 mg (5.35
mmol) N-(2-chloroethyl)-pyrrolidine-hydrochloride.
Yield: 1.20 g (79.0 % of theory)
C13H18BrNO (M= 284.199)
Calc.: molpeak (M+H)+: 284/286 Found: molpeak (M+H)+: 284/286
HPLC retention time: 3.64 min (method B)
Boehringer Ingelheim 147 Case 1-1406 if
CA 02504160 2005-04-28
3.9b 5-(4-chloro-phenyl)-2-[2-methyl-4-(2-pyrrolidin-1-yl-ethoxy)-
phenylethynyl]-pyridine
0.13 mL (1.00 mmol) triethylamine, 22 mg (0.02 mmol) tetrakis-
triphenylphosphane-palladium and 3.7 mg (0.02 mmol) Cul are added
successively to a solution of 80 mg (0.37 mmol) 5-(4-chloro-phenyl)-2-ethynyl-
pyridine and 106 mg (0.37 mmol) 1-[2-(4-bromo-3-methyl-phenoxy)-ethyl]-
pyrrolidine in 3.0 mL DMF in an argon atmosphere. The mixture is stirred for
15 min at 100 C and at 200 Watt in the microwave. The reaction solution is
diluted with 30 mL EtOAc, washed with semisaturated NaHCO3 solution and
the organic phase is dried over MgSO4. The solvent is eliminated i.vac. and
the residue is triturated with tert-butylmethylether. The solvent is
eliminated
i.vac. and further purified by HPLC-MS.
Yield: 5.0 mg (3.2 % of theory)
C26H25CIN20 (M= 416.955)
Calc.: molpeak (M+H)+: 417/419 Found: molpeak (M+H)+: 417/419
Rf value: 0.38 (silica gel, DCM/MeOH/NH3 9:1:0.1)
Example 3.10
5-(4-chloro-phenyl)-2-[2-chloro-4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-
pyridine
cI
N
N
CI
3.10a 1-[2-(4-bromo-3-chloro-phenoxy)-ethyl]-pyrrolidine
The product is obtained analogously to Example 3.1e (acetonitrile instead of
DMF) from 820 mg (4.82 mmol) 4-bromo-3-chloro-phenol and 1.0 g (4.82
mmol) N-(2-chloroethyl)-pyrrolidine-hydrochloride.
Yield: 1.20 g (81.7 % of theory)
C12H15BrCINO (M= 304.616)
Boehringer Ingelheim 148 Case 1-1406 ff
CA 02504160 2005-04-28
Calc.: molpeak (M+H)+: 304/306/308 Found: molpeak (M+H)+:
304/306/308
HPLC retention time: 3.69 min (method B)
3.10b 5-(4-chloro-phenyl)-2-[2-chloro-4-(2-pyrrolidin-1-yl-ethoxy)-
phenylethynyl]-pyridine
Under an argon atmosphere 0.13 mL (1.00 mmol) triethylamine, 22 mg (0.02
mmol) tetra kis-triphenylphosphane-palladium and 3.7 mg (0.02 mmol) Cul are
added successively to a solution of 80 mg (0.37 mmol) 5-(4-chloro-phenyl)-2-
ethynyl-pyridine and 114 mg (0.37 mmol) 1-[2-(4-bromo-3-chloro-phenoxy)-
ethyl]-pyrrolidine in 3.0 mL DMF. The mixture is stirred for 15 min at 100 C
and at 200 W in the microwave. The reaction solution is diluted with 40 mL
EtOAc, washed twice with semisaturated NaHCO3 solution and the organic
phase is dried over MgSO4. The solvent is eliminated i.vac. and the residue is
triturated with tert-butylmethylether. The solvent is eliminated i.vac. and
further purification is carried out by column chromatography with HPLC-MS.
Yield: 12.0 mg (7.3 % of theory)
C251-122C121\120 (M= 437.373)
Calc.: molpeak (M+H)+: 437/439/441 Found: molpeak (M+H)+:
437/439/441
HPLC retention time: 4.91 min (method B)
Example 3.11
5-(4-chloro-phenyl)-2-[3-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-pyridine
N/~/Q ~ / N
G I,
3.11a 1-[2-(3-iodo-phenoxy)-ethyl]-pyrrolidine
Boehringer Ingelheim 149 Case 1-1406 if
CA 02504160 2005-04-28
The product is obtained analogously to Example 3.1 a (acetonitrile instead of
DMF) from 1.06 g (4.82 mmol) 3-iodo-phenol and 820 mg (4.82 mmol) N-(2-
chloroethyl)-pyrrolidine-hydrochloride.
Yield: 1.20 g (78.5 % of theory)
C12H161NO (M= 317.172)
Calc.: molpeak (M+H)+: 318 Found: molpeak (M+H)+: 318
HPLC retention time: 5.01 min (method A)
3.11b 5-(4-chloro-phenyl)-2-[3-(2-pyrroiidin-1-yi-ethoxy)-phenylethynyl]-
pyridine
Prepared according to general working method I from 1-[2-(3-iodo-phenoxy)-
ethyl]-pyrrolidine (119 mg, 0.37 mmol) and 5-(4-chloro-phenyl)-2-ethynyl-
pyridine (80 mg, 0.37 mmol).
Yield: 14 mg (9.3 % of theory)
C25H23CIN20 (M= 402.928)
Calc.: molpeak (M+H)+: 403/405 Found: molpeak (M+H)+: 403/405
HPLC retention time: 4.07 min (method A)
Example 3.12
5-(4-chloro-phenyl)-2-[3-(3-pyrroiidin-1-yl-propoxy)-phenylethynyl]-pyridine
\ ~ I
I N%
3.12a 1-[3-(3-iodo-phenoxy)-propyl]-pyrrolidine
The product is obtained analogously to Example 3.1e (acetonitrile instead of
DMF) from 2.7 g (12.2 mmol) 3-iodo-phenol and 1.80 mg (12.2 mmol) N-(3-
chloropropyl)-pyrrolidine.
Yield: 3.60 g (89.2 % of theory)
C13H181NO (M= 331.199)
Calc.: molpeak (M+H)+: 332 Found: molpeak (M+H)+: 332
Boehringer Ingelheim 150 Case 1-1406 if
HPLC retention time: 5.42 min (method A)
3.12b 5-(4-chloro-phenyl)-2-[3-(3-pyrrolidin-1-yl-propoxy)-phenylethynyl]-
pyridine
Prepared according to general working method I from 1-[3-(3-iodo-phenoxy)-
propyl]-pyrrolidine (124 mg, 0.37 mmol) and 5-(4-chloro-phenyl)-2-ethynyl-
pyridine (80 mg, 0.37 mmol).
Yield: 54 mg (34.6 % of theory)
C26H25CIN20 (M= 416.955)
Calc.: molpeak (M+H)+: 416/418 Found: molpeak (M+H)+: 416/418
HPLC retention time: 4.99 min (method B)
Example 3.13
5-(4-chloro-phenyl)-2-[3-nitro-4-(2-pyrrolidin-1 -yl-ethoxy)-phenylethynyl]-
pyridine
N N
01
ON-'-"--
O
3.13a 1-[2-(4-bromo-2-nitro-phenoxy)-ethyl]-pyrrolidine
The product is obtained analogously to Example Me (acetonitrile instead of
DMF) from 10.5 g (48.2 mmol) 4-bromo-3-nitro-phenol and 8.2 mg (48.2
mmol) N-(2-chloroethyl)-pyrrolidine-hydrochloride.
Yield: 1.0 g (6.6 % of theory)
C12H15BrN2O3 (M= 315.17)
Calc.: molpeak (M+H)+: 315/317 Found: molpeak (M+H)+: 315/317
Rf value: 0.30 (silica gel, DCM/MeOH/NH3 9:1:0.1)
3.13b 1-[2-(4-iodo-2-nitro-phenoxy)-ethyl]-pyrrolidine
Prepared according to general working method 11 from 1-[2-(4-bromo-2-nitro-
phenoxy)-ethyl]-pyrrolidine (1.0 g, 2.22 mmol).
CA 02504160 2005-04-28
Boehringer Ingelheim 151 Case 1-1406 if
Yield: 600 mg (74.6 % of theory)
C12H15 I N203 (M= 362.17)
Cale.: molpeak (M+H)+: 363 Found: molpeak (M+H)+: 363
Rf value: 0.35 (silica gel, DCM/MeOH/NH3 9:1:0.1)
3.13c 5-(4-chloro-phenyl)-2-[3-nitro-4-(2-pyrrolidin-1-yl-ethoxy)-
phenylethynyl]-pyrid ine
Prepared according to general working method I from 1-[2-(4-iodo-2-nitro-
phenoxy)-ethyl]-pyrrolidine (600 mg, 1.66 mmol) and 5-(4-chloro-phenyl)-2-
ethynyl-pyridine (363 mg, 1.70 mmol).
Yield: 100 mg (13.1 % of theory)
C25H22CIN3 03 (M= 447.93)
Cale.: molpeak (M+H)+: 448/450 Found: molpeak (M+H)+: 448/450
Rf value: 0.35 (silica gel, DCM/MeOH/NH3 9:1:0.1)
Example 3.14
methyl 5-[5-(4-chloro-phenyl )-pyridin-2-ylethynyl]-3-methyl-2-(2-pyrrolidin-1-
yl-
ethoxy)-benzoate
cI
IN
0 ~
3.14a 2-hydroxy-5-iodo-3-methyl-benzoic acid
14.9 mL (24.1 mmol) sodium hypochlorite solution (10 percent by weight in
water) is added dropwise to a solution of 4.0 g (24.1 mmol) methyl 2-hydroxy-
3-methyl-benzoate, 3.6 g (24.1 mmol) Nal, 0.96 g (24.1 mmol) NaOH in 100
mL MeOH at -5 C over 40 min. The reaction is stirred for 30 min at -5 C and 5
days at RT. The solvent is eliminated i.vac. and the residue is taken up in 80
mL water and 50 mL DCM. After the organic phase has been saturated with
NaCl it is extracted twice with DCM. The combined organic extracts are
CA 02504160 2005-04-28
Boehringer Ingelheim 152 Case 1-1406 if
CA 02504160 2005-04-28
filtered and the solvent is eliminated i.vac.. The product is further reacted
without any more purification.
Yield: 7.25 g (108 % of theory)
C8H71O3 (M= 278.048)
Calc.: molpeak (M+H)+: 279 Found: molpeak (M+H)+: 279
HPLC retention time: 8.41 min (method A)
3.14b methyl 2-hydroxy-5-iodo-3-methyl-benzoate
A solution of 2.0 g (7.19 mmol) 2-hydroxy-5-iodo-3-methyl-benzoic acid in 5.0
mL thionyl chloride (69.0 mmol) is stirred for 20 min at 80 C. Thionyl
chloride
is eliminated i.vac. and the residue is combined with 20 mL MeOH and stirred
for 20 min at RT. The product is precipitated out of the reaction. MeOH is
eliminated i.vac. down to 5 mL and the residue is suction filtered. The
product
is further reacted without any more purification.
Yield: 1.14 g (54.3 % of theory)
C9H91O3 (M= 292.075)
Calc.: molpeak (M-H)-: 291 Found: molpeak (M-H)-: 291
Rf value: 0.96 (silica gel, EtOAc)
3.14c methyl 5-iodo-3-methyl-2-(2-pyrrolidin-1-yl-ethoxy)-benzoate
The product is obtained analogously to Example 3.1 a from 1.1 g (3.77 mmol)
methyl 2-hydroxy-5-iodo-3-methyl-benzoate and 641 mg (3.77 mmol) N-(2-
chloroethyl)-pyrrolidine-hydrochloride.
Yield: 347 mg (23.7 % of theory)
C15H20IN03 (M= 389.236)
Calc.: molpeak (M+H)+: 390 Found: molpeak (M+H)+: 390
HPLC retention time: 6.20 min (method A)
3.14d methyl 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-3-methyl-2-(2-
pyrrolidin-1-yl-ethoxy)-benzoate
Prepared according to general working method I from methyl 5-iodo-3-methyl-
2-(2-pyrrolidin-1-yl-ethoxy)-benzoate (150 mg, 0.39 mmol) and 5-(4-chloro-
phenyl)-2-ethynyl-pyridine (112 mg, 0.53 mmol).
Boehringer ingeiheim 153 Case 1-1406 if
Yield: 31 mg (17.1 % of theory)
C28H27CIN203 (M= 474.992)
Calc.: molpeak (M+H)+: 475/477 Found: molpeak (M+H)+: 475/477
HPLC retention time: 8.11 min (method A)
Example 3.15
5-(4-chloro-phenyl)-2-[2-(2-pyrrolidin-1-yl-ethoxy)-pyridin-5-yl-ethynyl]-
pyridine
N
C
N~\
O N
3.15a 5-bromo-2-(2-pyrrolidin-1-yl-ethoxy)-pyridine
280 mg (7.00 mmol, 60%) NaH are added to a solution of 0.76 mL (6.14
mmol) N-(2-hydroxyethyl)pyrrolidine in 20 mL DMF at RT. The reaction
solution is stirred for 45 min at RT and then 1.35 g (5,53 mmol) 2,5-
dibromopyridine are added. The solution is stirred for 16 h at 70 C and the
solvent is eliminated i.vac.. The residue is taken up in 100 mL EtOAc and 50
mL water and the organic phase is extracted with 40 mL saturated NaCl
solution. The organic phase is dried over Na2SO4 and the solvent is
eliminated i.vac.. Further purification is carried out by column
chromatography
on silica gel (gradient: cyc/EtOAc 1:1 to EtOAc).
Yield: 926 mg (61.8 % of theory)
C11 H15BrN2O (M= 271.159)
Calc.: molpeak (M+H)+: 271/273 Found: molpeak (M+H)+: 271/273
Rf value: 0.05 (silica gel, cyc/EtOAc 2:1)
3.15b 5-(4-chloro-phenyl)-2-[2-(2-pyrrolidin-1-yl-ethoxy)-pyridin-5-yl-
ethynyl]-
pyridine
Prepared according to general working method I from 5-bromo-2-(2-pyrrolidin-
1-yl-ethoxy)-pyridine (90 mg, 0.33 mmol) and 5-(4-chloro-phenyl)-2-ethynyl-
pyridine (80 mg, 0.37 mmol).
CA 02504160 2005-04-28
Boehringer Ingelheim 154 Case 1-1406 if
Yield: 19 mg (13.8 % of theory)
C24H22CIN30 (M= 403.915)
Calc.: molpeak (M+H)+: 404/406 Found: molpeak (M+H)+: 404/406
Rf value: 0.38 (silica gel, DCM/MeOH/NH3 9:1:0.1)
Example 3.16
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-
pyrimidine
CI
N
NN
3.16a 5-bromo-2-(2-pyrrolidin-1-yl-ethoxy)-pyrimidine
50 mg (1.15 mmol, 60%) NaH are added to a solution of 0.17 mL (1.38 mmol)
N-(2-hydroxyethyl)pyrrolidine in 10 mL THE at RT. The reaction solution is
stirred for 15 min at RT and then 200 mg (1.03 mmol) 5-bromo-2-
chloropyrimidine are added. The solution is stirred for 16 h at RT. 10 mL
water
are added and the aqueous phase is extracted with 20 mL EtOAc. The
organic phase is dried over Na2SO4 and the solvent is eliminated i.vac..
Further purification is carried out by column chromatography on silica gel
(DCM/MeOH/NH3 9:1:0.1).
Yield: 200 mg (71.1 % of theory)
C10H14BrN3O (M= 272.147)
Calc.: molpeak (M+H)+: 272/274 Found: molpeak (M+H)+: 272/274
Rf value: 0.47 (silica gel, DCM/MeOH/NH3 9:1:0.1)
3.16b 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yi-ethoxy)-
pyrimidine
Under an argon atmosphere 0.11 mL (0.79 mmol) triethylamine, 7 mg (0.01
mmol) tetrakis-triphenylphosphane-palladium and 1.3 mg (0.01 mmol) Cul are
added successively to a solution of 56 mg (0.26 mmol) 5-(4-chloro-phenyl)-2-
CA 02504160 2005-04-28
Boehringer Ingelheim 155 Case 1-1406 if
CA 02504160 2005-04-28
ethynyl-pyridine and 71 mg (0.26 mmol) 5-bromo-2-(2-pyrrolidin-1-yl-ethoxy)-
pyrimidine in 3.0 mL DMF. The mixture is stirred for 20 min at 100 C and at
300 Watt in the microwave. The reaction solution is diluted with 10 mL water
and the aqueous phase is extracted with 20 mL EtOAc. The organic phase is
extracted with saturated NaCl solution and dried over Na2SO4. The solvent is
eliminated i.vac. and further purification is carried out by column
chromatography with HPLC-MS.
Yield: 7 mg (6.6 % of theory)
C23H21 CIN40 (M= 404.903)
Calc.: molpeak (M+H)+: 405/407 Found: molpeak (M+H)+: 405/407
Rf value: 0.39 (silica gel, DCM/MeOH/NH3 9:1:0.1)
Example 3.17
3-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-6-(2-pyrrolidin-1-yl-ethoxy)-
pyridazine
CI
N
ON
N N
3.17a 3-chloro-6-(2-pyrrolidin-1-yl-ethoxy)-pyridazine
175 mg (4.01 mmol, 55%) NaH are added to a solution of 0.50 mL (4.04
mmol) N-(2-hydroxyethyl)pyrrolidine in 50 mL THE at 0 C. The reaction
solution is stirred for 60 min and heated to RT. 500 mg (3.26 mmol) 3,6-
dichloro-pyridazine are added. The solution is stirred for 5 h at RT. 50 mL
water are added and the aqueous phase is extracted with 100 mL EtOAc. The
organic phase is extracted once with saturated NaCl solution and dried over
Na2SO4. The solvent is eliminated i.vac. and further purification is carried
out
by column chromatography on silica gel (gradient: EtOAc to
EtOAc/MeOH/NH3 9:1:0.1).
Yield: 652 mg (87.9 % of theory)
C 1 0H 14CIN30 (M= 227.696)
Boehringer Ingelheim 156 Case 1-1406 ff
CA 02504160 2005-04-28
Calc.: molpeak (M+H)+: 228/230 Found: molpeak (M+H)+: 228/230
Rf value: 0.45 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
3.17b 3-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-6-(2-pyrrolidin-1-yl-ethoxy)-
pyridazine
Under an argon atmosphere 0.11 mL (0.79 mmol) triethylamine, 4 mg (0.01
mmol) chlorine(di-2-norbornylphosphino)(2'-dimethylamino-1-1 '-biphenyl-2-
yl)palladium(Il) and 1.2 mg (0.01 mmol) Cul are added successively to a
solution of 57 mg (0.27 mmol) 5-(4-chloro-phenyl)-2-ethynyl-pyridine and 61
mg (0.26 mmol) 3-chloro-6-(2-pyrrolidin-1-yl-ethoxy)-pyridazine in 3.0 mL
DMF. The mixture is stirred for 20 min at 100 C and 300 Watt in the
microwave. The reaction solution is diluted with 10 mL water and the aqueous
phase is extracted with 20 mL EtOAc. The organic phase is extracted with
saturated NaCl solution and dried over Na2SO4. The solvent is eliminated
i.vac. and further purification is carried out by column chromatography with
HPLC-MS.
Yield: 3 mg (2.9 % of theory)
C23H21 CIN40 (M= 404.903)
Calc.: molpeak (M+H)+: 405/407 Found: molpeak (M+H)+: 405/407
HPLC retention time: 6.39 min (method A)
Example 3.18
5-(4-chloro-phenyl)-2-[4-(1-ethyl-piperidin-3-yloxy)-phenylethynyl]-pyridine
I
N
O
3.18a 3-(4-bromo-phenoxy)-1-ethyl-piperidine
652 mg (2.00 mmol) caesium carbonate, 36 mg (0.20 mmol) 1,10-
phenanthroline and 19 mg (0.10 mmol) Cul are added to a solution of 289 mg
(1.00 mmol) 1-bromo-4-iodobenzene and 0.27 mL (2.00 mmol) N-ethyl-3-
Boehringer Ingelheim 157 Case 1-1406 if
CA 02504160 2005-04-28
hydroxypiperidine in 1.0 mL toluene. The reaction mixture is stirred for 36 h
at
110 C and then combined with 10 mL water and 10 mL EtOAc. After filtration
the aqueous phase is extracted with 10 mL EtOAc and the combined organic
extracts are washed with saturated NaCl solution and dried over Na2SO4.
The solvent is eliminated i.vac. and further purification is carried out by
column chromatography on silica gel (EtOAc).
Yield: 100 mg (35.2 % of theory)
C1 3H18BrNO (M= 284.199)
Calc.: molpeak (M+H)+: 284/286 Found: molpeak (M+H)+: 284/286
Rf value: 0.50 (silica gel, EtOAc)
3.18b 5-(4-chloro-phenyl)-2-[4-(1-ethyl-piperidin-3-yloxy)-phenylethynyl]-
pyridine
Prepared according to general working method I from 3-(4-bromo-phenoxy)-1-
ethyl-piperidine (90 mg, 0.32 mmol) and 5-(4-chloro-phenyl)-2-ethynyl-
pyridine (68 mg, 0.32 mmol).
Yield: 24 mg (18.1 % of theory)
C26H25CIN20 (M= 416.955)
Calc.: molpeak (M+H)+: 417/419 Found: molpeak (M+H)+: 417/419
Rf value: 0.69 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
Example 3.19
(S)-3-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-1-aza-
bicyclo[2.2.2]octane
NJ
3.19a (S)-3-(4-bromo-phenoxy)-1-aza-bicyclo[2.2.2]octane
Boehringer Ingelheim 158 Case 1-1406 ff
CA 02504160 2005-04-28
The product is obtained analogously to Example 3.18a from 577 mg (2.00
mmol) 1-bromo-4-iodobenzene and 254 mg (2.00 mmol) (S)-(+)-3-
hydroxyquinuclidine.
Yield: 170 mg (30.1 % of theory)
C13H16BrNO (M= 282.183)
Calc.: molpeak (M+H)+: 282/284 Found: molpeak (M+H)+: 282/284
Rf value: 0.28 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
3.19b (S)-3-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-1-aza-
bicyclo[2.2.2]octane
Prepared according to general working method I from (S)-3-(4-bromo-
phenoxy)-1-aza-bicyclo[2.2.2]octane (170 mg, 0.62 mmol) and 5-(4-chloro-
phenyl)-2-ethynyl-pyridine (100 mg, 0.47 mmol).
Yield: 3.4 mg (1.8 % of theory)
C26H23CIN20 (M= 414.939)
Calc.: molpeak (M+H)+: 415/417 Found: molpeak (M+H)+: 415/417
Rf value: 0.11 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
Example 3.20
(2-{4-[5-(4-chloro-phenyl )-pyridin-2-ylethynyl]-phenoxy}-ethyl)-pyrid in-4-yl-
amine
H \
3.20a tert-butyl pyridin-4-yl-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-carbaminate
309 mg (7.72 mmol, 60%) NaH is added to a solution of 1.50 g (7.72 mmol)
tert-butyl pyridin-4-yl-carbaminate in 80 mL DMF at 0 C. The reaction is
stirred for 1 h and at the same time heated to RT. 2.09 g (10.00 mmol) 2-(2-
bromoethoxy)tetrahydro-2H-pyrane in 20 mL DMF is added within 10 min.
Boehringer Ingelheim 159 Case 1-1406 ff
The reaction mixture is stirred for 16 h at RT and combined with 50 mL water
and 100 mL EtOAc. The organic phase is dried over Na2SO4 and the solvent
is eliminated i.vac.. Further purification is carried out by column
chromatography on silica gel (cyc/EtOAc 7:3).
Yield: 1.08 g (43.4 % of theory)
C17H26BrN204 (M= 322.408)
Rf value: 0.25 (silica gel, EtOAc/cyc 8:2)
3.20b 2-(pyridin-4-ylamino)-ethanol
Trifluoroacetic acid is added to a solution of 1.08 g (3.35 mmol) tert-butyl
pyridin-4-yl-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-carbaminate in DCM at 0 C,
heated to RT and stirred for 16 h. The reaction mixture is cooled to 0 C and
made alkaline with saturated K2CO3 solution. The aqueous phase is extracted
with 50 mL EtOAc, the organic phase is dried over Na2SO4 and the solvent is
eliminated i.vac.. Further purification is carried out by column
chromatography
on silica gel (EtOAc/MeOH/NH3 9:1:0.1).
Yield: 120 mg (25.9 % of theory)
C7H 1 0N20 (M= 138.171)
Calc.: molpeak (M+H)+: 139 Found: molpeak (M+H)+: 139
Rf value: 0.18 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
3.20c [2-(4-bromo-phenoxy)-ethyl]-pyridin-4-yl-amine
The product is obtained analogously to Example 3.18a from 251 mg (0.87
mmol) 1-bromo-4-iodobenzene and 120 mg (0.86 mmol) 2-(pyridin-4-
ylamino)-ethanol.
Yield: 90 mg (35.4 % of theory)
C13H13BrN20 (M= 293.165)
Calc.: molpeak (M+H)+: 293/295 Found: molpeak (M+H)+: 293/295
Rf value: 0.50 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
3.20d [2-(4-iodo-phenoxy)-ethyl]-pyridin-4-yl-amine
Prepared according to general working method II from [2-(4-bromo-phenoxy)-
ethyl]-pyridin-4-yl-amine (90 mg, 0.31 mmol).
CA 02504160 2005-04-28
Boehringer Ingelheim 160 Case 1-1406 if
CA 02504160 2005-04-28
Yield: 95 mg (91.0 % of theory)
C13H131N2O (M= 340.166)
HPLC retention time: 5.86 min (method A)
3.20e (2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-pyridin-
4-yl-amine
Prepared according to general working method I from [2-(4-iodo-phenoxy)-
ethyl]-pyridin-4-yl-amine (95 mg, 0.28 mmol) and 5-(4-chloro-phenyl)-2-
ethynyl-pyridine (70 mg, 0.33 mmol).
Yield: 30 mg (25.2 % of theory)
C26H20CIN30 (M= 425.922)
Cale.: molpeak (M+H)+: 426/428 Found: molpeak (M+H)+: 426/428
Rf value: 0.38 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
Example 3.21
5-(4-chloro-phenyl)-2-{4-[2-(2,2,6,6-tetrameth yl-piperidin-1-yl)-ethoxy]-
phenylethynyl}-pyridine
cI
I
I J
3.21a 1-[2-(4-iodo-phenoxy)-ethyl]-2,2,6,6-tetramethyl-piperidine
The product is obtained analogously to Example 3.1 e from 500 mg (2.27
mmol) 4-iodo-phenol and 500 mg (2.08 mmol) 1-(2-chloro-ethyl)-2,2,6,6-
tetramethyl-piperidine.
Yield: 673 mg (83.5 % of theory)
C17H261NO (M= 387.307)
Cale.: molpeak (M+H)+: 388 Found: molpeak (M+H)+: 388
Rf value: 0.79 (silica gel, cyc/EtOAc 4:1)
3-21b 5-(4-chloro-phenyl)-2-{4-[2-(2,2,6,6-tetramethyl-piperidin-1-yl)-ethoxy]-
phenylethynyl}-pyridine
Boehringer Ingelheim 161 Case 1-1406 if
Prepared according to general working method I from 1-[2-(4-iodo-phenoxy)-
ethyl]-2,2,6,6-tetramethyl-piperidine (260 mg, 0.67 mmol) and 5-(4-chloro-
phenyl)-2-ethynyl-pyridine (155 mg, 0.73 mmol).
Yield: 31 mg (9.8 % of theory)
C30H33CIN2O (M= 473.063)
Calc.: molpeak (M+H)+: 473/475 Found: molpeak (M+H)+: 473/475
Rf value: 0.21 (silica gel, cyc/EtOAc 3:1)
Example 3.22
5-(4-chloro-phenyl)-2-[4-(3-pyrrolidin-1-yl-propyl)-phenylethynyl]-pyridine
N
CAN
3.22a 3-(4-bromo-phenyl)-propionaldehyde
210 mg (0.86 mmol) Pd(OAc)2, 5.23 g (17.32 mmol) tetra-n-butylammonium
chloride and 3.6 g NaHCO3 are added to a solution of 5.0 g (17.32 mmol) 4-
bromo-iodo-benzene and 3.0 mL (43.67 mmol) allylalcohol in 30 mL DMF.
The reaction solution is stirred for 2 h at 60 C and diluted with 50 mL water.
The aqueous phase is extracted with 50 mL EtOAc and the combined organic
extracts are washed with 50 mL saturated NaCl solution. The organic phase is
dried over Na2SO4 and the solvent is eliminated i.vac.. Further purification
is
carried out by column chromatography on silica gel (cyc/EtOAc 3:1 ).
Yield: 2.48 g (67.2 % of theory)
C9H9BrO (M= 213.075)
Calc.: molpeak (M-H)-: 211/213 Found: molpeak (M-H)-: 211/213
Rf value: 0.43 (silica gel, cyc/EtOAc 4:1)
3.22b 1-[3-(4-bromo-phenyl)-propyl]-pyrrolidine
A solution of 1.03 g (4.82 mmol) 3-(4-bromo-phenyl)-propionaldehyde and
0.41 mL (4.82 mmol) pyrrolidine in 50 mL MeOH is adjusted to pH 4-5 with
CA 02504160 2005-04-28
Boehringer Ingelheim 162 Case 1-1406 if
glacial acetic acid. Then 400 mg (6.05 mmol) NaBH3CN are added batchwise
and the reaction is stirred for 3 days at RT. The reaction solution is diluted
with 30 mL water and the aqueous phase is extracted with 50 mL EtOAc. The
organic phase is dried over Na2SO4 and the solvent is eliminated i.vac..
Further purification is carried out by column chromatography on silica gel
(EtOAc/MeOH/NH3 9:1:0.1).
Yield: 1.06 g (82.1 % of theory)
C13H18BrN (M= 268.199)
Calc.: molpeak (M+H)+: 268/270 Found: molpeak (M+H)+: 268/270
Rf value: 0.50 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
3.22c 5-(4-chloro-phenyl)-2-[4-(3-pyrrolidin-1-yl-propyl)-phenylethynyl]-
pyridine
The product is obtained analogously to Example 3.16b (Pd(PPh3)2CI2 instead
of tetrakis-triphenylphosphane-palladium) from 72 mg (0.27 mmol) 1-[3-(4-
bromo-phenyl)-propyl]-pyrrolidine and 57 mg (0.27 mmol) 5-(4-chloro-phenyl)-
2-ethynyl-pyridine.
Yield: 10 mg (9.6 % of theory)
C26H25CIN2 (M= 400.956)
Calc.: molpeak (M+H)+: 401/403 Found: molpeak (M+H)+: 401/403
HPLC retention time: 6.94 min (method A)
Example 3.23
5-(4-chloro-phenyl)-2-[4-(2-pyrrolidin-1 -yl-ethyl)-phenylethynyl]-pyridine
3.23a 1-[2-(4-bromo-phenyl)-ethyl]-pyrrolidine
0.51 mL (4.23 mmol) 1,4-dibromobutane in 20 mL acetonitrile is added slowly
to a solution of 1.0 g (4.23 mmol) 4-bromo-phenethylamine hydrochloride, 1.8
CA 02504160 2005-04-28
Boehringer Ingelheim 163 Case 1-1406 if
g (13.0 mmol) K2CO3 and 200 mg (1.20 mmol) KI in 100 mL acetonitrile at
75 C and the reaction mixture is stirred for a further 4 h at 75 C. The
reaction
solution is diluted with 100 mL water and the aqueous phase is extracted with
100 mL EtOAc. The combined organic extracts are washed with saturated
NaCl solution, the organic phase is dried over Na2SO4 and the solvent is
eliminated i.vac.. Further purification is carried out by column
chromatography
on silica gel (EtOAc/MeOH/NH3 9:1:0.1)
Yield: 540 mg (50.2 % of theory)
C12H16BrN (M= 254.172)
Calc.: molpeak (M+H)+: 254/256 Found: molpeak (M+H)+: 254/256
Rf value: 0.54 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
3.23b 5-(4-chloro-phenyl)-2-[4-(2-pyrrolidin-1-yl-ethyl)-phenylethynyl]-
pyridine
The product is obtained analogously to Example 3.16b from 60 mg (0.23
mmol) 1-[2-(4-bromo-phenyl)-ethyl]-pyrrolidine and 50 mg (0.23 mmol) 5-(4-
chloro-phenyl)-2-ethynyl-pyridine.
Yield: 8 mg (8.7 % of theory)
C25H23CIN2 (M= 386.928)
Calc.: molpeak (M+H)+: 387/389 Found: molpeak (M+H)+: 387/389
HPLC retention time: 6.45 min (method A)
Example 3.24
1-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-4-methyl-
[1,4]diazepan
CI
r--"N -N
3.24a 1-(5-bromo-pyridin-2-yl)-4-methyl-[1,4]diazepan
CA 02504160 2005-04-28
Boehringer Ingelheim 164 Case 1-1406 if
CA 02504160 2005-04-28
1.5 g (5.29 mmol) 5-bromo-2-iodobenzene and 1.5 mL (11.7 mmol) 1-
methylhomopiperazine are heated to 170 C for 1.5 h. After the reaction
mixture has cooled 40 mL semisaturated NaHCO3 solution and 100 mL
EtOAc are added. The organic phase is dried over Na2SO4 and the solvent is
eliminated i.vac.. Further purification is carried out by column
chromatography
on silica gel (EtOAc/MeOH/NH3 85:15:1).
Yield: 1.10 g (77.1 % of theory)
C11 H16BrN3 (M= 270.174)
Calc.: molpeak (M+H)+: 270/272 Found: molpeak (M+H)+: 270/272
Rf value: 0.57 (silica gel, EtOAc/MeOH/NH3 8:2:0.2)
3.24b 1-(5-iodo-pyridin-2-yl)-4-methyl-[1,4]diazepan
Prepared according to general working method II from 1-(5-bromo-pyridin-2-
yl)-4-methyl-[1,4]diazepan (472 mg, 1.75 mmol).
Yield: 546 mg (98.5 % of theory)
C11 H1 61N3 (M= 317.175)
HPLC retention time: 4.56 min (method A)
3.24c 1-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-4-methyl-
[1,4]diazepan
Prepared according to general working method I from 1-(5-iodo-pyridin-2-yl)-
4-methyl-[1,4]diazepan (237 mg, 0.75 mmol) and 5-(4-chloro-phenyl)-2-
ethynyl-pyridine (161 mg, 0.75 mmol).
Yield: 54 mg (17.9 % of theory)
C24H23CIN4 (M= 402.931)
Calc.: molpeak (M+H)+: 403/405 Found: molpeak (M+H)+: 403/405
HPLC retention time: 6.79 min (method A)
Example 3.25
1 -{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-4-methyl-
piperazine
Boehringer Ingelheim 165 Case 1-1406 ff
CA 02504160 2005-04-28
CI
N
N Ni
N
3.25a 1-(5-bromo-pyridin-2-yl)-4-methyl-piperazine
The product is obtained analogously to Example 3.24a is from 1.5 g (5.28
mmol) 5-bromo-2-iodopyridine and 1.3 mL (11.7 mmol) N-methylpiperazine.
Yield: 1.15 g (85.1 % of theory)
C10H14BrN3 (M= 256.147)
Calc.: molpeak (M+H)+: 256/258 Found: molpeak (M+H)+: 256/258
Rf value: 0.50 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
3.25b 1-(5-iodo-pyridin-2-yl)-4-methyl-piperazine
Prepared according to general working method II from 1-(5-bromo-pyridin-2-
yl)-4-methyl-piperazine (500 mg, 1.95 mmol).
Yield: 532 mg (89.9 % of theory)
C10H141N3 (M= 303.148)
HPLC retention time: 4.59 min (method A)
3.25c 1-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-4-methyl-
piperazine
Prepared according to general working method I from 1-(5-iodo-pyridin-2-yl)-
4-methyl-piperazine (235 mg, 0.78 mmol) and 5-(4-chloro-phenyl)-2-ethynyl-
pyridine (167 mg, 0.78 mmol).
Yield: 15 mg (5.0 % of theory)
C23H21 CIN4 (M= 388.904)
Calc.: molpeak (M+H)+: 389/391 Found: molpeak (M+H)+: 389/391
HPLC retention time: 6.79 min (method A)
Example 3.26
(1S, 4S)-2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-6-methyl-
2,6-diaza-bicyclo[2.2.1 ]heptane
Boehringer Ingelheim 166 Case 1-1406 ff
ci
N
\N N
3.26a (1S, 4S)-2-(5-bromo-pyridin-2-yl)-6-methyl-2,6-diaza-
bicyclo[2.2.1 ]heptane
A solution of 300 mg (1.10 mmol) (1S, 4S)-2-methyl-2,5-
diazabicylo[2.2.1]heptane dihydrobromide, 0.75 mL (4.40 mmol)
ethyldiisopropylamine and 270 mg (1.11 mmol) 2,5-dibromopyridine in 1.5 mL
n-butanol are stirred for 18 hat 115 C. The solvent is eliminated i.vac., the
residue is combined with 10 mL EtOAc and acidified with 1 M HCI. The
aqueous phase is twice made alkaline with 2 M K2CO3 solution and extracted
with 30 mL EtOAc. The combined organic extracts are dried over Na2SO4 and
the solvent is eliminated i.vac..
Yield: 70 mg (23.8 % of theory)
C11 H14BrN3 (M= 268.158)
HPLC retention time: 4.07 min (method A)
Rf value: 0.05 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
3.26b (IS, 4S)-2-(5-iodo-pyridin-2-yl)-6-methyl-2,6-diaza-
bicyclo[2.2.1 ]heptane
Prepared according to general working method II from (1S, 4S)-2-(5-bromo-
pyridin-2-yl)-6-methyl-2,6-diaza-bicyclo[2.2.1]heptane (70 mg, 0.26 mmol).
Yield: 45 mg (54.7 % of theory)
C11 H141N3 (M= 315.159)
HPLC retention time: 4.18 min (method A)
Rf value: 0.06 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
3.26c (IS, 4S)-2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-6-
methyl-2,6-diaza-bicyclo[2.2.1 ]heptane
CA 02504160 2005-04-28
Boehringer Ingelheim 167 Case 1-1406 if
Prepared according to general working method I from (1S, 4S)-2-(5-iodo-
pyridin-2-yl)-6-methyl-2,6-diaza-bicyclo[2.2.1]heptane (45 mg, 0.14 mmol) and
5-(4-chloro-phenyl)-2-ethynyl-pyridine (51 mg, 0.24 mmol).
Yield: 6 mg (10.3 % of theory)
C24H21 CIN4 (M= 400.915)
Calc.: molpeak (M+H)+: 401/403 Found: molpeak (M+H)+: 401/403
HPLC retention time: 6.44 min (method A)
Example 3.27
{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-methyl-(2-
pyrrolidin-1-
yl-ethyl)-amine
N'
i
N N
3.27a (5-bromo-pyridin-2-yl)-methyl-(2-pyrrolidin-1-yl-ethyl)-amine
The product is obtained analogously to Example 3.24a (reaction time 2.5 h)
from 11.5 g (40.5 mmol) 5-bromo-2-iodopyridine and 6.3 mL (11.7 mmol)
methyl-(2-pyrrolidin-1 -yl-ethyl)-amine.
Yield: 4.0 g (34.8 % of theory)
C12H18BrN3 (M= 284.201)
Calc.: molpeak (M+H)+: 284/286 Found: molpeak (M+H)+: 284/286
Rf value: 0.37 (silica gel, DCM/MeOH/NH3 9:1:0.1)
HPLC retention time: 5.09 min (method A)
3.27b (5-iodo-pyridin-2-yl)-methyl-(2-pyrrolidin-1-yl-ethyl)-amine
Prepared according to general working method II from (5-bromo-pyridin-2-yl)-
methyl-(2-pyrrolidin-1-yl-ethyl)-amine (1.1 g, 3.87 mmol).
Yield: 1.0 g (81.1 % of theory)
C12H181N3 (M= 331.202)
Calc.: molpeak (M+H)+: 332 Found: molpeak (M+H)+: 332
HPLC retention time: 5.19 min (method A)
CA 02504160 2005-04-28
Boehringer Ingelheim 168 Case 1-1406 if
3.27c {5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-methyl-(2-
pyrrolidin-1-yl-ethyl)-amine
Prepared according to general working method I from (5-iodo-pyridin-2-yl)-
methyl-(2-pyrrolidin-1-yl-ethyl)-amine (100 mg, 0.30 mmol) and 5-(4-chloro-
phenyl)-2-ethynyl-pyridine (65 mg, 0.30 mmol).
Yield: 43 mg (34.2 % of theory)
C25H25CIN4 (M= 416.958)
Calc.: molpeak (M+H)+: 417/419 Found: molpeak (M+H)+: 417/419
Rf value: 0.25 (Alox, cyc/EtOAc 2:1).
HPLC retention time: 7.57 min (method A)
Example 3.28
(1-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-pyrrolidin-3-yl)-
dimethyl-amine
CI
N ~N N
3.28a [1-(5-bromo-pyridin-2-yl)-pyrrolidin-3-yl]-dimethyl-amine
A solution of 215 mg (0.88 mmol) 2,5-dibromobenzene, 100 mg (0.88 mmol)
3-(dimethylamino)-pyrrolidine and 0.60 mL (3.51 mmol) ethyldiisopropylamine
in 0.5 mL n-butanol is stirred for 30 min in the microwave at 150 C. The
solvent is eliminated i.vac. and the residue is taken up in 20 mL EtOAc and 10
mL water. The aqueous phase is acidified with 1 M HCI. The phases are
separated and then the aqueous phase is made alkaline with 2 M Na2CO3
solution and extracted with 40 mL EtOAc. The organic phase is dried over
Na2SO4 and the solvent is eliminated i.vac..
Yield: 179 mg (75.6 % of theory)
C11 H16BrN3 (M= 270.174)
Calc.: molpeak (M+H)+: 270/272 Found: molpeak (M+H)+: 270/272
Rf value: 0.30 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
CA 02504160 2005-04-28
Boehringer Ingelheim 169 Case 1-1406 if
3.28b [1-(5-iodo-pyridin-2-yl)-pyrrolidin-3-yl]-dimethyl-amine
Prepared according to general working method II from [1-(5-bromo-pyridin-2-
yl)-pyrrolidin-3-yl]-dimethyl-amine (160 mg, 0.59 mmol).
Yield: 168 mg (89.5 % of theory)
C11 H1 61N3 (M= 317.175)
Calc.: molpeak (M+H)+: 318 Found: molpeak (M+H)+: 318
HPLC retention time: 3.56 min (method A)
3.28c (1-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-pyrrolidin-
3-
yl)-dimethyl-amine
Prepared according to general working method I from [1-(5-iodo-pyridin-2-yl)-
pyrrolidin-3-yl]-dimethyl-amine (160 mg, 0.50 mmol) and 5-(4-chloro-phenyl)-
2-ethynyl-pyridine (108 mg, 0.50 mmol).
Yield: 8 mg (3.9 % of theory)
C24H23CIN4 (M= 402.931)
Calc.: molpeak (M+H)+: 403/405 Found: molpeak (M+H)+: 403/405
HPLC retention time: 6.37 min (method A)
Example 3.29
{5-[5-(4-chloro-phenyl)-pyrid in-2-ylethynyl]-pyrid in-2-yl}-(2-pyrrolidin-1-
yl-
ethyl)-amine
C
N N
I
H
3.29a (5-bromo-pyridin-2-yl)-(2-pyrrolidin-1-yl-ethyl)-amine
13.8 g (100.0 mmol) K2CO3, 79 mg (0.12 mmol) 2,2'-bis(diphenylphosphino)-
1,1'-binaphthyl and 28 mg (0.12 mmol) Pd(OAc)2 are added successively to a
solution of 1.5 g (6.33 mmol) 2,5-dibromopyridine and 0.98 mL (7.60 mmol) 1-
(2-aminoethyl)-pyrrolidine in 60 mL toluene. The reaction is refluxed for 40
h.
CA 02504160 2005-04-28
Boehringer Ingelheim 170 Case 1-1406 if
CA 02504160 2005-04-28
The solvent is eliminated i.vac. and the residue is taken up in 150 mL EtOAc
and 100 mL water. The organic phase is dried over Na2SO4 and the solvent is
eliminated i.vac.. Purification is carried out by column chromatography on
silica gel (gradient: EtOAc/MeOH/NH3 19:1:0.1 to EtOAc/MeOH/NH3 9:1:0.1).
Yield: 145 mg (8.5 % of theory)
C11 H16BrN3 (M= 270.174)
Calc.: molpeak (M+H)+: 270/272 Found: molpeak (M+H)+: 270/272
Rf value: 0.05 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
3.29b {5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl)-(2-pyrrolidin-
1-
yl-ethyl)-amine
The product is obtained analogously to Example 3.16b is from 90 mg (0.33
mmol) (5-bromo-pyridin-2-yl)-(2-pyrrolidin-1-yl-ethyl)-amine and 88 mg (0.41
mmol) 5-(4-chloro-phenyl)-2-ethynyl-pyridine.
Yield: 4 mg (5.8 % of theory)
C24H23CIN4 (M= 402.931)
Calc.: molpeak (M+H)+: 403/405 Found: molpeak (M+H)+: 403/405
HPLC retention time: 6.71 min (method A)
Example 3.30
N-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-N-(2-pyrrolidin-1-
yl-
ethyl)-acetamide
N N
45 pL (0.48 mmol) acetic anhydride is added to a solution of 89 mg (0.22
mmol) {5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-(2-pyrrolidin-
1-
yl-ethyl)-amine in 2 mL DCM. The reaction solution is stirred for 16 h at RT.
The solvent is eliminated i.vac. and further purification is carried out by
HPLC-
MS.
Yield: 62 mg (63.0 % of theory)
Boehringer Ingelheim 171 Case 1-1406 if
C26H25CIN40 (M= 444.968)
Calc.: molpeak (M+H)+: 445/447 Found: molpeak (M+H)+: 445/447
Rf value: 0.38 (Alox, cyc/EtOAc 1:1).
Example 3.31
{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-(2-piperidin-1-yl-
ethyl)-
amine
Cl
N~\N N
3.31a (5-bromo-pyridin-2-yl)-(2-piperidin-1-yl-ethyl)-amine
800 mg (3.38 mmol) 2,5-dibrombenzene and 1.0 g (7.80 mmol) N-(2-
aminoethyl)piperidine are heated to 170 C for 45 min. After the reaction
mixture has cooled 80 mL EtOAc are added and filtered. The filtrate is
washed twice with 40 mL saturated NaHCO3 solution and dried over MgSO4.
After the desiccant and solvent have been eliminated the residue is purified
by
chromatography (silica gel, EtOAc/MeOH/NH3 85:15:2).
Yield: 720 mg (75.0 % of theory)
C12H18BrN3 (M= 284.201)
Calc.: molpeak (M+H)+: 284/286 Found: molpeak (M+H)+: 284/286
Rf value: 0.30 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
3.31b (5-iodo-pyridin-2-yl)-(2-piperidin-1-yl-ethyl)-amine
Prepared according to general working method II from (5-bromo-pyridin-2-yl)-
(2-piperidin-1-yl-ethyl)-amine (720 mg, 2.53 mmol).
Yield: 750 mg (89.4 % of theory)
C12H18IN3 (M= 331.202)
Calc.: molpeak (M+H)+: 332 Found: molpeak (M+H)+: 332
HPLC retention time: 4.32 min (method A)
CA 02504160 2005-04-28
Boehringer Ingelheim 172 Case 1-1406 ff
CA 02504160 2005-04-28
3.31c {5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-(2-piperidin-
1-
yl-ethyl)-amine
Prepared according to general working method I from (5-iodo-pyridin-2-yl)-(2-
piperidin-1-yl-ethyl)-amine (397 mg, 1.20 mmol) and 5-(4-chloro-phenyl)-2-
ethynyl-pyridine (256 mg, 1.20 mmol).
Yield: 230 mg (46.0 % of theory)
C25H25CIN4 (M= 416.958)
Calc.: molpeak (M+H)+: 417/419 Found: molpeak (M+H)+: 417/419
Rf value: 0.55 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
HPLC retention time: 7.26 min (method A)
Example 3.32
5'-[5-(4-chloro-phenyl )-pyridin-2-ylethynyl]-3-pyrrolidin-1-yl-3,4,5,6-
tetrahydro-
2H-[1,2']bipyridinyl
CI
N
N
3.32a 5'-bromo-3-pyrrolidin-1-yl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
The product is obtained analogously to Example 3.31 a (reaction time: 35 min
at 160 C) from 2.37 g (10.0 mmol) 2,5-dibromopyridine and 1.6 g (10.4
mmol) 3-pyrrolidin-1-yl-piperidine.
Yield: 700 mg (21.8 % of theory)
C14H2OBrN3 (M= 310.240)
Calc.: molpeak (M+H)+: 310/312 Found: molpeak (M+H)+: 310/312
HPLC retention time: 5.06 min (method B)
3.32b 5'-iodo-3-pyrrolidin-1-y1-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl
Prepared according to general working method II from 5'-bromo-3-pyrrolidin-1-
yl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl (700 mg, 2.26 mmol).
Yield: 700 mg (86.9 % of theory)
C14H201N3 (M= 357.240)
Boehringer Ingelheim 173 Case 1-1406 if
CA 02504160 2005-04-28
Calc.: molpeak (M+H)+: 358 Found: molpeak (M+H)+: 358
HPLC retention time: 5.20 min (method A)
3.32c 5'-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-3-pyrrolidin-1-yl-3,4,5,6-
tetrahydro-2H-[1,2']bipyridinyl
Prepared according to general working method I from 5'-iodo-3-pyrrolidin-1-yl-
3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl (179 mg, 0.50 mmol) and 5-(4-chloro-
phenyl)-2-ethynyl-pyridine (107 mg, 0.50 mmol).
Yield: 120 mg (54.2 % of theory)
C27H27CIN4 (M= 442.996)
Calc.: molpeak (M+H)+: 443/445 Found: molpeak (M+H)+: 443/445
Rf value: 0.38 (silica gel, DCM/MeOH/NH3 9:1:0.1)
HPLC retention time: 7.40 min (method A)
Example 3.33
1'-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-
[1,3']bipyrrolidinyl
N
CNN
3.33a 1'-benzyl-[l,3']bipyrrolidinyl
3.82 g (18.0 mmol) NaBH(OAc)3 are added to a solution of 1.23 mL (15.0
mmol) pyrrolidine and 2.41 mL (15.0 mmol) N-benzylpyrrolidinone in 100 mL
THE and acidified with 2 mL acetic acid. The reaction is stirred overnight at
RT. The reaction solution is combined with 200 mL saturated NaHCO3
solution and extracted twice with 200 mL EtOAc. The organic phase is dried
over MgSO4 and the solvent is eliminated i.vac.. The purification is carried
out
by column chromatography on silica gel (EtOAc/MeOH/NH3 8:2:0.2).
Yield: 1.80 g (52.1 % of theory)
C15H22N2 (M= 230.356)
Calc.: molpeak (M+H)+: 231 Found: molpeak (M+H)+: 231
Rf value: 0.05 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
Boehringer Ingelheim 174 Case 1-1406 if
CA 02504160 2005-04-28
3.33b [1,3']bipyrrolidinyl
180 mg 10% Pd/C are added to a solution of 1.80 g (7.42 mmol) 1'-benzyl-
[1,3']bipyrrolidinyl in 80 mL MeOH. The reaction solution is stirred for 5 h
at
RT and at 3 bar H2. Another 180 mg 10% Pd/C are added and after 4 h 100
mg palladium hydroxide are added. The reaction is stirred for a further 6 h at
RT and at 3 bar H2. The catalyst is suction filtered and the solvent is
eliminated i.vac..
Yield: 900 mg (86.5 % of theory)
C8H16N2 (M= 140.230)
Rf value: 0.05 (silica gel, EtOAc/MeOH/NH3 8:2:0.2)
3.33c 1'-(5-bromo-pyridin-2-yl)-[1,3']bipyrrolidinyl
The product is obtained analogously to Example 3.31 a (reaction time: 60 min
at 170 C) from 1.52 g (6.40 mmol) 2,5-dibromopyridine and 0.90 g (6.42
mmol) [1,3']bipyrrolidinyl.
Yield: 700 mg (36.8 % of theory)
C13H18BrN3 (M= 296.213)
Calc.: molpeak (M+H)+: 296/298 Found: molpeak (M+H)+: 296/298
Rf value: 0.42 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
3.33d 1'-(5-iodo-pyridin-2-yl)-[1,3']bipyrrolidinyl
Prepared according to general working method II from 1'-(5-bromo-pyridin-2-
yl)-[1,3']bipyrrolidinyl (700 mg, 2.36 mmol).
Yield: 650 mg (80.1 % of theory)
C13H181N3 (M= 343.213)
Calc.: molpeak (M+H)+: 344 Found: molpeak (M+H)+: 344
HPLC retention time: 3.95 min (method A)
3.33e 1'-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-
[1,3']bipyrrolidinyl
Boehringer Ingelheim 175 Case 1-1406 if
CA 02504160 2005-04-28
Prepared according to general working method I from 1'-(5-iodo-pyridin-2-yl)-
[1,3']bipyrrolidinyl (172 mg, 0.50 mmol) and 5-(4-chloro-phenyl)-2-ethynyl-
pyridine (107 mg, 0.50 mmol).
Yield: 65 mg (30.3 % of theory)
C26H25CIN4 (M= 428.969)
Calc.: molpeak (M+H)+: 429/431 Found: molpeak (M+H)+: 429/431
Rf value: 0.50 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
HPLC retention time: 6.71 min (method A)
Example 3.34
{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-(2-pyrrolidin-1-yl-
propyl)-amine
N
ON
\N N
H
3.34a N-(5-bromo-pyridin-2-yl)-2-chloro-propionamide
2.14 mL (22.0 mmol) 2-chloropropionic acid chloride in 5 mL DCM is added
dropwise to a solution of 3.46 g (20.0 mmol) 2-amino-5-bromopyridine and
6.12 mL (44.0 mmol) triethylamine in 80 mL DCM at 0 C. The ice bath is
removed and the reaction solution is stirred for a further 1.5 h at RT.
Another
0.40 mL (4.12 mmol) 2-chloropropionic acid chloride is added and the solution
is stirred for a further hour at RT. The reaction mixture is combined with 80
mL water, washed once with 80 mL saturated NaCl solution and dried over
MgSO4. The solvent is eliminated i.vac. and the residue is triturated with a
little EtOAc, suction filtered and dried.
Yield: 3.50 g (66.4 % of theory)
C8H8BrCIN2O (M= 263.523)
Calc.: molpeak (M+H)+: 263/265/267 Found: molpeak (M+H)+:
263/265/267
Rf value: 0.85 (silica gel, PE/EtOAc 6:4)
Boehringer Ingelheim 176 Case 1-1406 ff
CA 02504160 2005-04-28
3.34b N-(5-bromo-pyridin-2-yl)-2-pyrrolidin-1-yl-propionamide
4.01 g (29.0 mmol) K2CO3 and 1.19 mL (14.5 mmol) pyrrolidine are added
successively to a solution of 3.5 g (13.3 mmol) N-(5-bromo-pyridin-2-yl)-2-
chloro-propionamide in 50 mL DMF. The reaction is stirred for 3 days at RT
and combined with 150 mL water. The aqueous phase is extracted twice with
EtOAc and the organic phase is dried over MgSO4. After the desiccant and
solvent have been eliminated the residue is purified by chromatography (silica
gel, gradient: PE/EtOAc 4:6 after EtOAc).
Yield: 1.80 g (45.4 % of theory)
C12H16BrN3O3 (M= 298.185)
Calc.: molpeak (M+H)+: 298/300 Found: molpeak (M+H)+: 298/300
HPLC retention time: 4.21 min (method A)
3.34c (5-bromo-pyridin-2-yl)-(2-pyrrolidin-1-yl-propyl)-amine
Under a nitrogen atmosphere 6.00 mL (6.00 mmol) 1 M lithium aluminium
hydride solution in THE are added to a solution, cooled to 0 C, of 1.8 g (6.04
mmol) N-(5-bromo-pyridin-2-yl)-2-pyrrolidin-1-yl-propionamide in 30 mL THF,
in such a way that the internal temperature does not exceed 4 C. The reaction
solution is stirred for a further 20 min at 0 C. EtOAc is carefully added, the
aluminium complex is decomposed with 0.2 mL water, then with 0.2 mL 15%
sodium hydroxide solution solution and finally with 0.6 mL water. The
precipitate formed is suction filtered and the filtrate is diluted with 50 mL
EtOAc. The organic phase is washed with 30 mL saturated NaHCO3 solution
and dried over MgSO4. The solvent is eliminated i.vac. and further
purification
is carried out by column chromatography on silica gel (EtOAc/MeOH/NH3
9:1:0.1).
Yield: 700 mg (40.8 % of theory)
C12H18BrN3 (M= 284.201)
Calc.: molpeak (M+H)+: 284/286 Found: molpeak (M+H)+: 284/286
Rf value: 0.32 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
HPLC retention time: 4.63 min (method A)
3.34d (5-iodo-pyridin-2-yl)-(2-pyrrolidin-1-yl-propyl)-amine
Boehringer Ingelheim 177 Case 1-1406 if
CA 02504160 2005-04-28
Prepared according to general working method II from (5-bromo-pyridin-2-yl)-
(2-pyrrolidin-1-yl-propyl)-amine (600 mg, 2.11 mmol).
Yield: 560 mg (80.1 % of theory)
3.34e {5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-(2-pyrrolidin-
1-yl-propyl)-amine
Prepared according to general working method I from (5-iodo-pyridin-2-yl)-(2-
pyrrolidin-1-yl-propyl)-amine (250 mg, 0.76 mmol) and 5-(4-chloro-phenyl)-2-
ethynyl-pyridine (165 mg, 0.77 mmol).
Yield: 95 mg (29.5 % of theory)
C25H25CIN4 (M= 416.958)
Calc.: molpeak (M+H)+: 417/419 Found: molpeak (M+H)+: 417/419
HPLC retention time: 7.19 min (method A)
Example 3.35
N-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-2-pyrrolidin-1-yl-
propionamide
N
CN O
N
3.35a 4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenylamine
Prepared according to general working method I from 4-iodoaniline (732 mg,
3.28 mmol) and 5-(4-chloro-phenyl)-2-ethynyl-pyridine (700 mg, 3.28 mmol).
Yield: 440 mg (44.1 % of theory)
C19H13CIN2 (M= 304.782)
Calc.: molpeak (M+H)+: 305/307 Found: molpeak (M+H)+: 305/307
HPLC retention time: 5.70 min (method A)
3.35b N-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-2-pyrrolidin-1-yl-
propionamide
Boehringer Ingelheim 178 Case 1-1406 if
CA 02504160 2005-04-28
0.18 mL (1.31 mmol) triethylamine and 269 mg (0.84 mmol) TBTU are added
successively to a solution of 100 mg (0.70 mmol) 2-pyrrolidin-1-yl-propionic
acid in 10 mL THF. The solution is stirred for 1 h at RT and then 200 mg (0.66
mmol) 4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenylamine are added. The
reaction solution is stirred overnight at RT. The reaction is incomplete.
Therefore 100 mg (0.70 mmol) 2-pyrrolidin-1-yl-propionic acid in 10 mL THF is
added to the reaction mixture (activated for 1 h by stirring with 0.18 mL
(1.31
mmol) triethylamine and 269 mg (0.84 mmol) TBTU). The reaction solution is
stirred for a further 16 h and diluted with NaHCO3 solution. The aqueous
phase is extracted with EtOAc and the organic phase is dried over MgSO4.
The solvent is eliminated i.vac. and further purification is carried out by
column chromatography on silica gel (EtOAc/MeOH/NH3 8:2:0.2).
Yield: 40 mg (14.2 % of theory)
C26H24CIN30 (M= 429.954)
Calc.: molpeak (M+H)+: 430/432 Found: molpeak (M+H)+: 430/432
HPLC retention time: 7.29 min (method A)
Example 3.36
N-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-2-pyrrolidin-1-yl-
acetamide
ci
j N
CN 0 H
The product is obtained analogously to Example 3.35b from 200 mg (0.66
mmol) 4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenylamine and 100 mg
(0.77 mmol) pyrrolidin-1-yl-acetic acid.
Yield: 5 mg (1.8 % of theory)
C25H22CIN30 (M= 415.927)
Calc.: molpeak (M+H)+: 416/418 Found: molpeak (M+H)+: 416/418
HPLC retention time: 6.75 min (method B)
Boehringer Ingelheim 179 Case 1-1406 if
CA 02504160 2005-04-28
Example 3.37
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1-(2-pyrrolidin-1-yl-ethyl)-1,3-
d ihyd ro-benzimidazol-2-one
N / N
C>
3.37a (4-bromo-2-nitro-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine
4.42 g (32.0 mmol) K2CO3 are added to a solution of 5.00 g (22.7 mmol) 2-
bromo-5-fluoronitrobenzene and 2.59 g (22.7 mmol) 1-(2-amino)-pyrrolidine in
20 mL acetonitrile. The reaction solution is stirred overnight at RT. The
solution is filtered and the solvent is eliminated i.vac.. The purification is
carried out by column chromatography on silica gel (gradient: DCM to
DCM/MeOH 9:1).
Yield: 5.90 g (82.6 % of theory)
C12H16BrN3O2 (M= 314.184)
Calc.: molpeak (M+H)+: 314/316 Found: molpeak (M+H)+: 314/316
Rf value: 0.40 (silica gel, DCM/MeOH 9:1)
3.37b 4-bromo-N'-(2-pyrrolidin-1-yl-ethyl)-benzene-1,2-diamine
100 mg Raney Nickel are added to a solution of 1.00 g (3.18 mmol) (4-bromo-
2-nitro-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine in 100 mL MeOH. The reaction
solution is stirred for 15 min at 3 bar H2 and RT. After filtration the
solvent is
eliminated i.vac. and the product is further reacted without purification.
Yield: 850 mg (94.0 % of theory)
C12H18BrN3 (M= 284.201)
Calc.: molpeak (M+H)+: 284/286 Found: molpeak (M+H)+: 284/286
HPLC retention time: 4.56 min (method A)
3.37c 5-bromo-1-(2-pyrrolidin-1-yl-ethyl)-1,3-dihydro-benzimidazol-2-one
Boehringer Ingelheim 180 Case 1-1406 if
CA 02504160 2005-04-28
600 mg (3.70 mmol) CDI are added to a solution of 853 mg (3.00 mmol) 4-
bromo-N'-(2-pyrrolidin-1-yl-ethyl)-benzene-1,2-diamine in 20 mL THE at RT.
The reaction solution is heated to 40 C and stirred for 30 min at this
temperature. A further 600 mg (3.70 mmol) CDI are added and the reaction is
stirred for a further 30 min at 40 C. The solution is diluted with
semisaturated
NaHCO3 solution and the aqueous phase is extracted twice with EtOAc. The
organic phase is dried over MgSO4 and the solvent is eliminated i.vac.. The
residue is triturated with acetonitrile, the precipitate is filtered and dried
in the
air.
Yield: 500 mg (53.7 % of theory)
C13H16BrN3O (M= 310.196)
Calc.: molpeak (M+H)+: 310/312 Found: molpeak (M+H)+: 310/312
HPLC retention time: 4.30 min (method A)
3.37d 5-iodo-1-(2-pyrrolidin-1-yl-ethyl)-1,3-dihydro-benzimidazol-2-one
Prepared according to general working method II from 5-bromo-1-(2-
pyrrolidin-1-yl-ethyl)-1,3-dihydro-benzimidazol-2-one (150 mg, 0.48 mmol).
Yield: 140 mg (81.0 % of theory)
C13H161N30 (M= 357.196)
Calc.: molpeak (M+H)+: 358 Found: molpeak (M+H)+: 358
HPLC retention time: 4.53 min (method A)
3.37e 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1-(2-pyrrolidin-1-yl-ethyl)-
1,3-dihydro-benzimidazol-2-one
Prepared according to general working method I from 5-iodo-1-(2-pyrrolidin-1-
yl-ethyl)-1,3-dihydro-benzimidazol-2-one (140 mg, 0.39 mmol) and 5-(4-
chloro-phenyl)-2-ethynyl-pyridine (83 mg, 0.39 mmol).
Yield: 7 mg (3.7 % of theory)
C26H23CIN40 (M= 442.952)
Calc.: molpeak (M+H)+: 443/445 Found: molpeak (M+H)+: 443/445
HPLC retention time: 6.78 min (method A)
Example 3.38
Boehringer Ingelheim Case 1-1406 if
CA 02504160 2005-04-28
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-3-methyl-1 -(2-pyrrolidin-1 -yl-
ethyl)-
1,3-dihydro-benzoimidazol-2-one
GI
N ~
O
N ~
U
3.38a 5-bromo-3-methyl-1-(2-pyrrolidin-1-yl-ethyl)-1,3-dihydro-benzimidazol-
2-one
73 mg (0.65 mmol) potassium-tert-butoxide are added to a solution of 200 mg
(0.65 mmol) 5-bromo-1-(2-pyrrolidin-1-yi-ethyl)-1,3-dihydro-benzimidazol-2-
one in 4 mL DMSO at RT. The reaction solution is stirred for 30 min and then
40 pL (0.65 mmol) iodomethane are added and stirred for a further 30 min.
The mixture is combined with semisaturated NaHCO3 solution and the
aqueous phase is extracted twice with 30 mL EtOAc. The organic phase is
dried over MgSO4 and the solvent is eliminated i.vac..
Yield: 180 mg (86.1 % of theory)
C14H18BrN3O (M= 324.223)
Calc.: molpeak (M+H)+: 324/326 Found: molpeak (M+H)+: 324/326
HPLC retention time: 4.69 min (method B)
3.38b 5-iodo-3-methyl-1-(2-pyrrolidin-1-yl-ethyl)-1,3-dihydro-benzimidazol-2-
one
Prepared according to general working method II from 5-bromo-3-methyl-1-(2-
pyrrolidin-1-yl-ethyl)-1,3-dihydro-benzimidazol-2-one (160 mg, 0.49 mmol).
Yield: 120 mg (65.6 % of theory)
C14H181N30 (M= 371.223)
Calc.: molpeak (M+H)+: 372 Found: molpeak (M+H)+: 372
HPLC retention time: 5.02 min (method A)
3.38c 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-3-methyl-1-(2-pyrrolidin-1-
yl-
ethyl)-1,3-dihydro-benzimidazol-2-one
Boehringer Ingelheim 182 Case 1-1406 ff
Prepared according to general working method I from 5-iodo-3-methyl-1-(2-
pyrrolidin-1-yl-ethyl)-1,3-dihydro-benzimidazol-2-one (120 mg, 0.32 mmol)
and 5-(4-chloro-phenyl)-2-ethynyl-pyridine (68 mg, 0.32 mmol).
Yield: 15 mg (9.8 % of theory)
C27H25CIN40 (M= 456.980)
Calc.: molpeak (M+H)+: 457/459 Found: molpeak (M+H)+: 457/459
HPLC retention time: 7.11 min (method A)
Example 3.39
6-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-3-(2-pyrrofidin-1-yl-ethyl)-3H-
imidazo[4,5-b]pyridine
C
N
N
Fj
U
3.39a (5-bromo-3-nitro-pyridin-2-yl)-(2-pyrrofidin-1-yl-ethyl)-amine
0.86 mL (5.05 mmol) ethyldiiopropylamine are added to a solution of 600 mg
(2.53 mmol) 5-bromo-2-chloro-3-nitropyridine and 0.32 mL (2.53 mmol) 1-(2-
aminoethyl)-pyrrolidine in 3 mL n-butanol. The reaction is heated to 50 C and
stirred for one hour at this temperature. The solvent is eliminated i.vac. and
the residue is combined with 40 mL water and acidified with 1 M HCI. The
aqueous phase is extracted with 20 mL EtOAc and the aqueous phase is then
made alkaline with saturated K2CO3 solution. The aqueous phase is extracted
with 40 mL EtOAc. The organic phase is dried over Na2SO4 and the solvent is
eliminated i.vac..
Yield: 692 mg (86.9 % of theory)
C11 H15BrN4O2 (M= 315.172)
Calc.: molpeak (M+H)+: 315/317 Found: molpeak (M+H)+: 315/317
HPLC retention time: 5.00 min (method A)
Rf value: 0.08 (silica gel, cyc/EtOAc 2:1)
CA 02504160 2005-04-28
Boehringer fngelheim 183 Case 1-1406 if
CA 02504160 2005-04-28
3.39b 5-bromo-N2-(2-pyrrolidin-1-yl-ethyl)-pyridine-2,3-diamine
2.44 g (10.8 mmol) Zinn(II)chloride dihydrate and 2.20 g (26.2 mmol) NaHCO3
are added to a solution of 680 mg (2.16 mmol) (5-bromo-3-nitro-pyridin-2-yl)-
(2-pyrrolidin-1-yl-ethyl)-amine in 40 mL EtOAc at RT. The reaction is refluxed
for 1.5 h and then diluted with 20 mL water. The aqueous phase is acidified
with 1 M HCI and separated off from the organic phase. The aqueous phase
is made alkaline with saturated K2CO3 solution and extracted twice with 40 mL
EtOAc. The organic phase is dried over Na2SO4 and the solvent is eliminated
i.vac..
Yield: 479 mg (77.8 % of theory)
C11 H17BrN4 (M= 285.189)
Calc.: molpeak (M+H)+: 285/287 Found: molpeak (M+H)+: 285/287
HPLC retention time: 3.9 min (method A)
3.39c 6-bromo-3-(2-pyrrolidin-1-yl-ethyl)-3H-imidazo[4,5-b]pyridine
A solution of 470 mg (1.65 mmol) 5-bromo-N2-(2-pyrrolidin-1-yl-ethyl)-
pyridine-2,3-dia mine in 10 mL formic acid is refluxed for 1.5 h. The mixture
is
made alkaline with saturated K2CO3 solution and extracted with 40 mL EtOAc.
The organic phase is dried over Na2SO4 and the solvent is eliminated i.vac..
Yield: 466 mg (95.8 % of theory)
C12H15BrN4 (M= 295.184)
Calc.: molpeak (M+H)+: 295/297 Found: molpeak (M+H)+: 295/297
HPLC retention time: 4.0 min (method A)
3.39d 6-iodo-3-(2-pyrrolidin-1-yl-ethyl)-3H-imidazo[4,5-b]pyridine
Prepared according to general working method II from 6-bromo-3-(2-
pyrrolidin-1-yl-ethyl)-3H-imidazo[4,5-b]pyridine (450 mg, 1.52 mmol).
Yield: 510 mg (97.8 % of theory)
C12H151N4 (M= 342.185)
Calc.: molpeak (M+H)+: 343 Found: molpeak (M+H)+: 343
HPLC retention time: 4.08 min (method A)
Rf value: 0.09 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
Boehringer Ingelheim 184 Case 1-1406 ff
3.39e 6-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-3-(2-pyrrolidin-1-yl-ethyl)-
3H-imidazo[4,5-b]pyridine
Prepared according to general working method I from 6-iodo-3-(2-pyrrolidin-1-
yl-ethyl)-3H-imidazo[4,5-b]pyridine (300 mg, 0.88 mmol) and 5-(4-chloro-
phenyl)-2-ethynyl-pyridine (187 mg, 0.88 mmol).
Yield: 67 mg (17.9 % of theory)
C25H22CIN5 (M= 427.941)
CaIc.: molpeak (M+H)+: 428/430 Found: molpeak (M+H)+: 428/430
Rf value: 0.41 (silica gel, DCM/MeOH/NH3 9:1:0.1)
HPLC retention time: 6.52 min (method A)
Example 3.40
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-pyrrolidin-1-ylmethyl-1 H-
benzimidazole
a
N
ON
N
H
3.40a (5-nitro-1 H-benzimidazol-2-yl)-methanol
6.2 g (81.5 mmol) glycolic acid is added to a solution of 6.24 g (40.8 mmol) 4-
nitro-o-phenylenediamine in 80 mL semiconcentrated HCI. The reaction
solution is refluxed for 4 h and the solvent is eliminated i.vac.. The residue
is
taken up in water and made basic with 2 N NaOH. The product precipitates
out and is stirred for another 1 hour in the ice bath. The precipitate is
suction
filtered and washed successively with water and PE. The product is dried at
40 C. This still contains 40% 4-nitro-o-phenylenediamine. It is again taken up
in semiconcentrated HCI and after the addition of 6.5 mL glycolic acid (57% in
water) it is refluxed for 3 h and heated for a further 12 h at 80 C. The
solvent
is eliminated i.vac. and the residue is dissolved in water and made alkaline
with 6 N NaOH, during which time the product is precipitated. The precipitate
is suction filtered and washed successively with water and PE. The product is
dried in the circulating air dryer at 50 C.
Yield: 6.40 g (81.3 % of theory)
CA 02504160 2005-04-28
Boehringer Ingelheim 185 Case 1-1406 if
C8H7N303 (M= 193.163)
Calc.: molpeak (M+H)+: 194 Found: molpeak (M+H)+: 194
Rf value: 0.13 (silica gel, DCM/MeOH/NH3 9:1:0.1)
3.40b 2-chloromethyl-5-nitro-1 H-benzimidazole
20 mL (275 mmol) thionyl chloride are added slowly to a solution of 6.4 g
(33.1 mmol) (5-nitro-1 H-benzimidazol-2-yl)-methanol in 100 mL DCM at 10 C.
The reaction is stirred for 1 h at RT and the solvent is eliminated i.vac..
The
residue is triturated with DCM, suction filtered, washed with DCM and ether
and dried in the circulating air dryer at 35 C.
Yield: 7.01 g (100 % of theory)
C8H6CIN303 (M= 211.609)
Calc.: molpeak (M+H)+: 212/214 Found: molpeak (M+H)+: 212/214
HPLC retention time: 4.1 min (method B)
3.40c 5-nitro-2-pyrrolidin-1-ylmethyl-1H-benzimidazole
9.47 mL (113 mmol) pyrrolidine are added to a solution of 6.00 g (28.4 mmol)
2-chloromethyl-5-nitro-1H-benzimidazole in 100 mL DCM. The reaction is
stirred overnight at RT. The reaction solution is washed four times with
water.
The organic phase is dried over MgSO4 and the solvent is eliminated i.vac..
Yield: 5.50 g (78.8 % of theory)
C12H14N402 (M= 246.271)
Calc.: molpeak (M+H)+: 247 Found: molpeak (M+H)+: 247
Rf value: 0.22 (silica gel, EtOAc/MeOH 9:1)
3.40d 2-pyrrolidin-1-ylmethyl-1H-benzimidazol-5-ylamine
1.00 g Raney nickel is added to a solution of 5.50 g (22.3 mmol) 5-nitro-2-
pyrrolidin-1-ylmethyl-1H-benzimidazole in 50 mL MeOH. The reaction solution
is stirred for 30 h at 3 bar H2 and RT. After filtration the solvent is
eliminated
i.vac. and further purification is carried out by column chromatography on
silica gel (EtOAc/MeOH/NH3 8:2:0.2).
Yield: 3.10 g (64.2 % of theory)
C12H16N4 (M= 216.288)
CA 02504160 2005-04-28
Boehringer Ingelheim 186 Case 1-1406 if
Calc.: molpeak (M+H)+: 217 Found: molpeak (M+H)+: 217
3.40e 5-bromo-2-pyrrolidin-1-ylmethyl-1 H-benzimidazole
3.10 g (14.3 mmol) 2-pyrrolidin-1 -ylmethyl-1 H-benzimidazol-5-ylamine is
suspended in 32.2 mL 48% hydrobromic acid and 32.2 mL water and the
solution is cooled to 0 C. 2.5 M sodium nitrite solution (1.68 g in 9.7 mL
water)
is slowly added dropwise, so that the internal temperature does not exceed
C. The reaction is stirred for 10 min at 0 C and then 3.50 g (24.37 mmol)
CuBr in 11.3 mL 48% hydrobromic acid is added dropwise. The reaction is
heated to 60 C and stirred for one hour at this temperature. The solvent is
eliminated i.vac. and the residue triturated with isopropanol. The precipitate
is
suction filtered and washed with isopropanol. The purification is carried out
by
column chromatography on silica gel (MeOH/NH3 9:1).
Yield: 2.20 g (54.8 % of theory)
C12H14BrN3 (M= 280.169)
Calc.: molpeak (M+H)+: 280/282 Found: molpeak (M+H)+: 280/282
HPLC retention time: 4.47 min (method A)
3.40f 5-iodo-2-pyrrolidin-1-ylmethyl-1H-benzimidazole
Prepared according to general working method II from 5-bromo-2-pyrrolidin-1-
ylmethyl-1 H-benzimidazole (700 mg, 2.50 mmol).
Yield: 200 mg (24.5 % of theory)
C12H14IN3 (M= 327.170)
Calc.: molpeak (M+H)+: 328 Found: molpeak (M+H)+: 328
HPLC retention time: 4.55 min (method A)
3.40g 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-pyrrolidin-1 -ylmethyl-1 H-
benzimidazole
Prepared according to general working method I from 5-iodo-2-pyrrolidin-1-
ylmethyl-1 H-benzimidazole (200 mg, 0.61 mmol) and 5-(4-chloro-phenyl)-2-
ethynyl-pyridine (131 mg, 0.61 mmol).
Yield: 5 mg (2.0 % of theory)
C25H21 CIN4 (M= 412.926)
CA 02504160 2005-04-28
Boehringer Ingelheim 187 Case 1-1406 if
CaIc.: molpeak (M-H)-: 411/413 Found: molpeak (M-H)-: 411/413
HPLC retention time: 3.94 min (method A)
Example 3.41
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1-(2-pyrrolidin-1-yl-ethyl)-1 H-
benzimidazole
IN
\/
N
rj
U
3.41a 5-bromo-1-(2-pyrrolidin-1-yl-ethyl)-1 H-benzimidazole
A solution of 904 mg (3.18 mmol) 4-bromo-N'-(2-pyrrolidin-1-yl-ethyl)-
benzene-1,2-diamine in 5 mL formic acid is refluxed for 1.5 h. It is made
alkaline with semisaturated NaHCO3 solution and extracted twice with 70 mL
EtOAc. The organic phase is dried over MgSO4 and the solvent is eliminated
i.vac..
Yield: 750 mg (80.2 % of theory)
C13H16BrN3 (M= 294.197)
Calc.: molpeak (M+H)+: 294/296 Found: molpeak (M+H)+: 294/296
HPLC retention time: 3.78 min (method A)
3.41 b 5-iodo-1-(2-pyrrolidin-1-yl-ethyl)-1 H-benzimidazole
Prepared according to general working method II from 5-bromo-1-(2-
pyrrolidin-1-yl-ethyl)-1H-benzimidazole (750 mg, 2.55 mmol).
Yield: 680 mg (78.2 % of theory)
C13H161N3 (M= 341.197)
Calc.: molpeak (M+H)+: 342 Found: molpeak (M+H)+: 342
HPLC retention time: 4.04 min (method A)
3.41 c 5-[5-(4-ch loro-phenyl)-pyrid i n-2-ylethynyl]- 1 -(2-pyrrol id in- 1 -
yl -ethyl)-
1 H-benzimidazole
CA 02504160 2005-04-28
Boehringer Ingelheim 188 Case 1-1406 ff
Prepared according to general working method I from 5-iodo-1-(2-pyrrolidin-1-
yl-ethyl)-1H-benzimidazole (150 mg, 0.44 mmol) and 5-(4-chloro-phenyl)-2-
ethynyl-pyridine (94 mg, 0.44 mmol).
Yield: 26 mg (13.7 % of theory)
C26H23CIN4 (M= 426.953)
Calc.: molpeak (M+H)+: 427/429 Found: molpeak (M+H)+: 427/429
HPLC retention time: 6.51 min (method A)
Example 3.42
2-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1 -methyl-5-pyrrolidin-1 -ylmethyl-
1 H-
benzimidazole
CI
N
ON N
N
3.42a methyl-(2-nitro-4-pyrrolidin-1-ylmethyl-phenyl)-amine
5.55 g (78.0 mmol) pyrrolidine are added to a solution of 4.70 g (26.1 mmol)
4-methylamino-3-nitro-benzaldehyde in 100 mL THE and the reaction mixture
is acidified with glacial acetic acid. 6.36 g (30.0 mmol) NaBH(OAc)3 are added
and the reaction mixture is stirred overnight at RT. The mixture is combined
with saturated NaHCO3 solution and the aqueous phase is extracted twice
with EtOAc. The combined organic extracts are washed with 200 mL
semisaturated NaHCO3 solution and dried over MgSO4. The solvent is
eliminated i.vac. and further purification is carried out by column
chromatography on silica gel (gradient: DCM to DCM/MeOH 9:1).
Yield: 2.00 g (32.6 % of theory)
C12H17N302 (M= 235.288)
Caic.: molpeak (M+H)+: 236 Found: molpeak (M+H)+: 236
Rf value: 0.15 (silica gel, DCM/MeOH 9:1)
3.42b N'-methyl-4-pyrrolidin-1-ylmethyl-benzene-1,2-diamine
4.85 g (21.5 mmol) tin(II)chloride dihydrate and 4.45 g (53.0 mmol) NaHCO3
are added to a solution of 1.00 g (4.25 mmol) methyl-(2-nitro-4-pyrrolidin-1-
CA 02504160 2005-04-28
Boehringer Ingelheim 189 Case 1-1406 if
CA 02504160 2005-04-28
ylmethyl-phenyl)-amine in 60 mL EtOAc at RT. The reaction is refluxed for 2 h
and then diluted with 100 mL 1 M KHSO4 solution and some water. The
mixture is filtered. The aqueous phase is combined with K2CO3 and extracted
twice with 80 mL EtOAc. The organic phase is dried over MgSO4 and the
solvent is eliminated i.vac..
Yield: 850 mg (97.4 % of theory)
C12H19N3 (M= 205.305)
Calc.: molpeak (M+H)+: 206 Found: molpeak (M+H)+: 206
Rf value: 0.15 (silica gel, DCM/MeOH/NH3 9:1:0.1)
3.42c 1-methyl-5-pyrrolidin-1-ylmethyl-1H-benzimidazole
A solution of 850 mg (4.14 mmol) N'-methyl-4-pyrrolidin-1-ylmethyl-benzene-
1,2-diamine in 4 mL formic acid is refluxed for 1.5 h. It is made alkaline
with
250 mL semisaturated NaHCO3 solution and extracted twice with 70 mL
EtOAc. The organic phase is dried over MgSO4 and the solvent is eliminated
i.vac..
Yield: 650 mg (72.9 % of theory)
C13H17N3 (M= 215.301)
Calc.: molpeak (M+H)+: 216 Found: molpeak (M+H)+: 216
Rf value: 0.25 (silica gel, DCM/MeOH/NH3 9:1:0.1)
3.42d 2-iodo-1-methyl-5-pyrrolidin-1-ylmethyl-1 H-benzimidazole
0.80 mL (1.28 mmol) 1.6 M n-butyllithium solution in hexane are added to a
solution, cooled to -75 C, of 250 mg (1.16 mmol) 1-methyl-5-pyrrolidin-1-
ylmethyl-1 H-benzimidazole in 8 mL THF. The reaction mixture is stirred for 10
min at this temperature and then 288 mg (1.28 mmol) N-iodosuccinimide in 5
mL THE are added. The cooling bath is removed and the reaction stirred for 1
h at RT. 12 mL 0.1 M HCI are added and the aqueous phase is extracted with
EtOAc. The organic phase is dried over MgSO4 and the solvent is eliminated
i.vac.. The purification is carried out by column chromatography on silica gel
(gradient: DCM to DCM/MeOH/NH3 9:1:0.1).
Yield: 140 mg (22.2 % of theory)
C13H161N3 (M= 341.197)
Boehringer Ingelheim 190 Case 1-1406 if
Calc.: molpeak (M+H)+: 342 Found: molpeak (M+H)+: 342
Rf value: 0.20 (silica gel, DCM/MeOH/NH3 9:1:0.1)
HPLC retention time: 3.89 min (method A)
3.42e 2-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1-methyl-5-pyrrolidin-1-
ylmethyl-1 H-benzimidazole
Prepared according to general working method I from 2-iodo-1-methyl-5-
pyrrolidin-1-ylmethyl-1H-benzimidazole (100 mg, 0.29 mmol) and 5-(4-chloro-
phenyl)-2-ethynyl-pyridine (68 mg, 0.32 mmol).
Yield: 9 mg (7.2 % of theory)
C26H23CIN4 (M= 426.953)
Caic.: molpeak (M+H)+: 427/429 Found: molpeak (M+H)+: 427/429
Rf value: 0.20 (silica gel, DCM/MeOH/NH3 9:1:0.1)
HPLC retention time: 6.69 min (method A)
Example 3.43
5-(4-chloro-phenyl)-2-[2-fluoro-4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-
pyridine
N
N
F
3.43a 1-[2-(3-fluoro-4-iodo-phenoxy)-ethyl]-pyrrolidine
The product is obtained analogously to Example 3.1 e from 13.6 g (57.0 mmol)
3-fluoro-4-iodo-phenol and 9.69 g (57.0 mmol) N-(2-chloroethyl)-pyrrolidine
hydrochloride.
Yield: 17.1 g (89.6 % of theory)
C12H15FINO (M= 335.162)
Calc.: molpeak (M+H)+: 336 Found: molpeak (M+H)+: 336
Rf value: 0.57 (silica gel, EtOAc/MeOH/NH3 95:5:0.5).
3.43b 5-(4-chloro-phenyl)-2-[2-fluoro-4-(2-pyrrolidin-1-yl-ethoxy)-
phenylethynyl]-pyridine
CA 02504160 2005-04-28
Boehringer Ingelheim 191 Case 1-1406 ff
CA 02504160 2005-04-28
Prepared according to general working method I from 1-[2-(3-fluoro-4-iodo-
phenoxy)-ethyl]-pyrrolidine (500 mg, 0.75 mmol) and 5-(4-chloro-phenyl)-2-
ethynyl-pyridine (159 mg, 0.75 mmol).
Yield: 48 mg (15.4 % of theory)
C25H22CIFN20 (M= 420.918)
Calc.: molpeak (M+H)+: 421/423 Found: molpeak (M+H)+: 421/423
Rf value: 0.65 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
HPLC retention time: 7.74 min (method A)
Example 3.44
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-8-(2-pyrrolidin-1-yl-ethoxy)-
quinoline
ci
C N
C I~
3.44a 5-iodo-8-(2-pyrrolidin-1-yl-ethoxy)-quinoline
The product is obtained analogously to Example 3.1e from 700 mg (2.58
mmol) 5-iodo-quinolin-8-ol and 450 mg (2.59 mmol) N-(2-chloroethyl)-
pyrrolidine hydrochloride.
Yield: 829 mg (87.2 % of theory)
C15H17IN20 (M= 368.220)
Calc.: molpeak (M+H)+: 369 Found: molpeak (M+H)+: 369
HPLC retention time: 5.56 min (method B)
3.44b 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-8-(2-pyrrolidin-1-yl-ethoxy)-
quinoline
Prepared according to general working method I from 5-iodo-8-(2-pyrrolidin-1-
yl-ethoxy)-quinoline (200 mg, 0.54 mmol) and 5-(4-chloro-phenyl)-2-ethynyl-
pyridine (116 mg, 0.54 mmol).
Yield: 23 mg (9.4 % of theory)
C28H24CIN30 (M= 453.976)
Boehringer Ingelheim 192 Case 1-1406 if
CA 02504160 2005-04-28
Calc.: molpeak (M+H)+: 454/456 Found: molpeak (M+H)+: 454/456
HPLC retention time: 7.40 min (method A)
Example 3.45
6-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-pyrrolidin-1-ylmethyl-quinoline
\ I~ I
j N
3.45a 6-bromo-2-bromOmethyl-quinoline
148 mg (1.00 mmol) a,a-azoisobutyronitrile and 8.01 g (45.0 mmol) N-
bromosuccinimide are added successively to a solution of 10.0 g (45.0 mmol)
6-bromo-2-methyl-quinoline in 60 mL carbon tetrachloride. The reaction
mixture is refluxed for 8 h. It is filtered and the filtrate is washed twice
with
water. The organic phase is dried over MgSO4 and the solvent is eliminated
i.vac.. The purification is carried out by column chromatography on silica gel
(PE/EtOAc 4:1).
Yield: 5.10 g (37.7 % of theory)
C1OH7Br2N (M= 300.982)
Calc.: molpeak (M+H)+: 300/302/304 Found: molpeak (M+H)+:
300/302/304
HPLC retention time: 5.75 min (method B)
3.45b 6-bromo-2-pyrrolidin-1-ylmethyl-quinoline
4.60 g (15.28 mmol) 6-bromo-2-bromomethyl-quinoline are added to a
solution of 1.40 mL (16.8 mmol) pyrrolidine and 6.34 g (45.9 mmol) K2CO3 in
50 mL acetonitrile. The reaction is stirred overnight at RT and then the
inorganic salts are filtered off. The organic phase is washed with water and
the aqueous phase is extracted with EtOAc. The combined organic extracts
are dried over MgSO4 and the solvent is eliminated i.vac..
Yield: 4.45 g (100 % of theory)
C14H15BrN2 (M= 291.193)
Boehringer Ingelheim 193 Case 1-1406 ff
Calc.: molpeak (M+H)+: 291/293 Found: molpeak (M+H)+: 291/293
Rf value: 0.27 (silica gel, DCM/MeOH 9:1)
3.45c 6-iodo-2-pyrrolidin-1-ylmethyl-quinoline
Prepared according to general working method 11 from 6-bromo-2-pyrrolidin-1-
ylmethyl-quinoline (500 mg, 1.72 mmol).
Yield: 400 mg (59.9 % of theory)
C14H151N2 (M= 338.193)
Calc.: molpeak (M+H)+: 339 Found: molpeak (M+H)+: 339
HPLC retention time: 5.16 min (method A)
3.45d 6-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-pyrrolidin-1-ylmethyl-
quinoline
Prepared according to general working method I from 6-iodo-2-pyrrolidin-1-
ylmethyl-quinoline (151 mg, 0.45 mmol) and 5-(4-chloro-phenyl)-2-ethynyl-
pyridine (80 mg, 0.37 mmol).
Yield: 18 mg (11.4 % of theory)
C27H22CIN3 (M= 423.949)
Calc.: molpeak (M+H)+: 424/426 Found: molpeak (M+H)+: 424/426
HPLC retention time: 4.78 min (method B)
Example 3.46
6-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-pyrrolidin-1-ylmethyl-1,2,3,4-
tetrahydro-quinoline
a
C~I
N
N.
CN
3.46a 6-bromo-2-pyrrolidin-1-ylmethyl-1,2,3,4-tetrahydro-quinoline
Under an argon atmosphere 0.69 mL (6.87 mmol) borane-pyridine complex
are added to a solution of 500 mg (1.72 mmol) 6-bromo-2-pyrrolidin-1-
ylmethyl-quinoline (see 3.45b) in 10 mL acetic acid at RT. The mixture is
CA 02504160 2005-04-28
Boehringer Ingelheim 194 Case 1-1406 ff
CA 02504160 2005-04-28
stirred for 7 h at RT, again combined with 0.35 mL (3.46 mmol) borane-
pyridine complex and stirred for another hour at RT. It is cooled to 0 C and
the solution is made basic with 8% NaOH solution. The aqueous phase is
extracted with EtOAc and the solvent is eliminated i.vac.. The residue is
taken up with water and acidified with 12% HCI. The aqueous phase is
extracted with EtOAc and then made basic with 20% NaOH solution while
cooling with ice. The aqueous phase is extracted with EtOAc. The organic
phase is dried over MgSO4 and the solvent is eliminated i.vac..
Yield: 420 mg (82.9 % of theory)
C14H19BrN2 (M= 295.25)
CaIc.: molpeak (M+H)+: 295/297 Found: molpeak (M+H)+: 295/297
HPLC retention time: 5.01 min (method B)
3.46b 6-iodo-2-pyrrolidin-1-ylmethyl-1,2,3,4-tetrahydro-quinoline
Prepared according to general working method II from 6-bromo-2-pyrrolidin-1-
ylmethyl-1,2,3,4-tetrahydro-quinoline (280 mg, 0.95 mmol).
Yield: 260 mg (80.1 % of theory)
C14H19IN2 (M= 342.225)
Calc.: molpeak (M+H)+: 343 Found: molpeak (M+H)+: 343
HPLC retention time: 5.34 min (method A)
3.46c 6-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-pyrrolidin-1-ylmethyl-
1,2,3,4-tetrahydro-quinoline
Prepared according to general working method I from 6-iodo-2-pyrrolidin-1-
ylmethyl-1,2,3,4-tetrahydro-quinoline (260 mg, 0.76 mmol) and 5-(4-chloro-
phenyl)-2-ethynyl-pyridine (162 mg, 0.76 mmol).
Yield: 72 mg (22.1 % of theory)
C27H26CIN3 (M= 427.981)
Calc.: molpeak (M+H)+: 428 Found: molpeak (M+H)+: 428
HPLC retention time: 4.66 min (method B)
Example 3.47
5-(4-chloro-phenyl)-2-(6-pyrrolidin-1-ylmethyl-naphthalen-2-ylethynyl)-
pyridine
Boehringer Ingelheim 195 Case 1-1406 if
CA 02504160 2005-04-28
CI
3.47a (6-iodo-naphthalen-2-yl)-methanol
Prepared according to general working method II from (6-bromo-naphthalen-
2-yl)-methanol (500 mg, 2.11 mmol).
Yield: 450 mg (75.1 % of theory)
C11 H9IO (M= 284.10)
Calc.: molpeak (M+H)+: 284 Found: molpeak (M+H)+: 284
HPLC retention time: 8.30 min (method A)
3.47b {6-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-naphthalen-2-yl}-methanol
Prepared according to general working method I from (6-iodo-naphthalen-2-
yl)-methanol (450 mg, 1.58 mmol) and 5-(4-chloro-phenyl)-2-ethynyl-pyridine
(342 mg, 1.60 mmol).
Yield: 250 mg (42.8 % of theory)
C24H16CINO (M= 369.85)
Calc.: molpeak (M+H)+: 370/372 Found: molpeak (M+H)+: 370/372
Rf value: 0.25 (silica gel, DCM/MeOH 19:1)
3.47c 5-(4-chloro-phenyl)-2-(6-pyrrolidin-1-ylmethyl-naphthalen-2-ylethynyl)-
pyridine
58 pL (0.80 mmol) thionyl chloride are added at 0 C to a solution of 148 mg
(0.40 mmol) {6-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-naphthalen-2-yl}-
methanol in 5 mL DCM. The solution is heated to RT and stirred for 1 h at
this temperature. The reaction mixture is diluted with 30 mL DCM, combined
with ice water, made alkaline with saturated NaHCO3 solution and the organic
phase is washed with water. The organic phase is dried over MgSO4 and
filtered. 0.10 mL (1.20 mmol) pyrrolidine are added to the filtrate, which is
stirred for 2 h at RT and for I h at 40 C. The solvent is eliminated i.vac.
and
Boehringer Ingelheim 196 Case 1-1406 if
the purification is carried out by column chromatography on silica gel
(gradient: DCM to DCM/MeOH/NH3 5:1:0.1).
Yield: 40 mg (23.6 % of theory)
C28H23CIN2 (M= 422.96)
Calc.: molpeak (M+H)+: 423/425 Found: molpeak (M+H)+: 423/425
Rf value: 0.10 (silica gel, DCM/MeOH/NH3 19:1:0.1)
Example 3.48
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1-(2-pyrrolidin-1-yl-ethyl)-2,3-
dihydro-1 H-indole
CI
N
N 7I
f-j
/N
ID
3.48a 5-bromo-1-(2-pyrrolidin-1-yl-ethyl)-2,3-dihydro-1 H-indole
Under a nitrogen atmosphere 700 mg (3.46 mmol) 5-bromoindoline are added
to a solution of 722 mg (4.16 mmol) N-(2-chloroethyl)-pyrrolidine
hydrochloride and 1.19 mL (6.93 mmol) ethyldiisopropylamine in 10 mL DMF.
The reaction solution is stirred for 21 h at RT and again combined with N-(2-
chloroethyl)-pyrrolidine hydrochloride. The reaction solution is heated to 70
C
and stirred for 4 h at this temperature. The solvent is eliminated i.vac. and
the
residue taken up in 50 mL semisaturated NaCI solution and 50 mL EtOAc.
The aqueous phase is extracted twice with 50 mL DCM, the combined organic
extracts are dried over Na2SO4 and the solvent is eliminated i.vac..
Yield: 226 mg (22.1 % of theory)
C14H19BrN2 (M= 295.225)
Calc.: molpeak (M+H)+: 295/297 Found: molpeak (M+H)+: 295/297
HPLC retention time: 5.93 min (method A)
3.48b 5-lodo-1-(2-pyrrolidin-1-yl-ethyl)-2,3-dihydro-1 H-indole
CA 02504160 2005-04-28
Boehringer Ingelheim 197 Case 1-1406 ff
Prepared according to general working method II from 5-bromo-1-(2-
pyrrolidin-l -yl-ethyl)-2,3-dihydro-1 H-indole (226 mg, 0.77 mmol).
Yield: 142 mg (54.2 % of theory)
C14H19IN2 (M= 342.225)
HPLC retention time: 6.10 min (method A)
3.48c 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1-(2-pyrrolidin-1-yl-ethyl)-
2,3-dihydro-1 H-indole
Prepared according to general working method I from 5-iodo-1-(2-pyrrolidin-1-
yl-ethyl)-2,3-dihydro-1 H-indole (142 mg, 0.42 mmol) and 5-(4-chloro-phenyl)-
2-ethynyl-pyridine (89 mg, 0.42 mmol).
Yield: 39 mg (22.1 % of theory)
C27H26CIN3 (M= 427.981)
Calc.: molpeak (M+H)+: 428/430 Found: molpeak (M+H)+: 428/430
Rf value: 0.55 (Alox, cyc/EtOAc 2:1)
HPLC retention time: 7.98 min (method A)
Example 3.49
5-(4-chloro-phenyl)-2-[4-(1-methyl-2-piperidin-1 -yl-ethoxy)-phenylethynyl]-
pyridine
C1
3.49a 1-[2-(4-iodo-phenoxy)-propyl]-pipe ridine
1.54 g (7.00 mmol) iodobenzene and 2.75 g (10.5 mmol) triphenylphosphane
are added successively to a solution of 1.00 g (6.98 mmol) 1-piperidin-1-yl-
propan-2-ol in 20 mL DCM. 2.19 mL (10.5 mmol, 95%) diisopropyl
azodicarboxylate is added dropwise at RT and the reaction is stirred for 2 h
at
RT. It is diluted with water, the organic phase is washed with water and dried
over MgSO4. After the desiccant and solvent have been eliminated the
residue is purified by chromatography (silica gel, DCM/MeOH 9:1). The oily
CA 02504160 2005-04-28
Boehringer Ingelheim 198 Case 1-1406 if
CA 02504160 2005-04-28
residue is triturated with diisopropylether, filtered off from the insoluble
residue
and the filtrate is evaporated to dryness i.vac..
Yield: 500 mg (20.7 % of theory)
C14H201NO (M= 345.226)
Calc.: molpeak (M+H)+: 346 Found: molpeak (M+H)+: 346
Rf value: 0.32 (silica gel, DCM/MeOH 9:1)
3.49b 5-(4-chloro-phenyl)-2-[4-(1-methyl-2-piperidin-1-yl-ethoxy)-
phenylethynyl]-pyridine
Prepared according to general working method I from 1-[2-(4-iodo-phenoxy)-
propyl]-piperidine (173 mg, 0.50 mmol) and 5-(4-chloro-phenyl)-2-ethynyl-
pyridine (107 mg, 0.50 mmol).
Yield: 80 mg (37.1 % of theory)
C27H27CIN2O (M= 430.982)
Calc.: molpeak (M+H)+: 431/433 Found: molpeak (M+H)+: 431/433
Rf value: 0.25 (silica gel, EtOAc/MeOH 9:1)
HPLC retention time: 5.03 min (method A)
Example 3.50
5-(4-chloro-phenyl)-2-[4-(3-piperidin-1 -yl-pyrrolidin-1 -yl)-phenylethynyl]-
pyridine
N
ON--GN
3.50a 1-(1-benzyl-pyrrolidin-3-yl)-piperidine
12.7 g (60.0 mmol) NaBH(OAc)3 and 2.3 mL acetic acid are added to a
solution of 4.94 mL (50.0 mmol) piperidine and 8.03 mL (50.0 mmol) N-
benzylpyrrolidinone in 200 mL THF. The reaction is stirred overnight at RT.
The reaction solution is combined with 200 mL saturated NaHCO3 solution
and extracted twice with 200 mL EtOAc. The organic phase is dried over
Boehringer Ingelheim 199 Case 1-1406 if
CA 02504160 2005-04-28
MgSO4 and the solvent is eliminated i.vac.. The purification is carried out by
column chromatography on silica gel (EtOAc/MeOH/NH3 8:2:0.2).
Yield: 5.50 g (45.0 % of theory)
C16H24N2 (M= 244.383)
Calc.: molpeak (M+H)+: 245 Found: molpeak (M+H)+: 245
Rf value: 0.25 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
3.50b 1-pyrrolidin-3-yl-piperidine
550 mg 10% Pd/C are added to a solution of 5.50 g (22.5 mmol) 1-(1-benzyl-
pyrrolidin-3-yl)-piperidine in 200 mL MeOH. The reaction solution is stirred
for
h at RT and 3 bar H2. 550 mg palladiumhydroxide are added and the
reaction is stirred for a further 6 h at RT and 3 bar H2. The catalyst is
suction
filtered and the solvent is eliminated i.vac..
Yield: 900 mg (86.5 % of theory)
C9H18N2 (M= 154.257)
Calc.: molpeak (M+H)+: 155 Found: molpeak (M+H)+: 155
Rf value: 0.05 (silica gel, EtOAc/MeOH/NH3 8:2:0.2)
3.50c 1-[1-(4-bromo-phenyl)-pyrrolidin-3-yl]-piperidin
283 mg (1.00 mmol) 4-bromo-iodobenzene, 10 mg (0.05 mmol) Cul, 124 mg
(2.00 mmol) ethyleneglycol and 424 mg (2.00 mmol) potassium phosphate
are added to a reaction vessel, which is evacuated and rinsed with argon
several times. Then 154 mg (1.00 mmol) 1-pyrrolidin-3-yl-piperidine in 1 mL
isopropanol are added and the reaction is shaken for 15 h at 80 C. The
reaction solution is diluted with EtOAc and extracted twice with 5% ammonia
solution. The organic phase is dried over MgSO4 and the solvent is eliminated
i.vac..
Yield: 230 mg (74.4 % of theory)
C15H21BrN2 (M= 309.252)
Calc.: molpeak (M+H)+: 309/311 Found: molpeak (M+H)+: 309/311
Rf value: 0.73 (silica gel, DCM/MeOH/NH3 9:1:0.1)
3.50d 1-[1-(4-iodo-phenyl)-pyrrolidin-3-yl]-piperidine
Boehringer Ingelheim 200 Case 1-1406 if
Prepared according to general working method II from 1-[1-(4-bromo-phenyl)-
pyrrolidin-3-yl]-piperidine (200 mg, 0.65 mmol).
Yield: 120 mg (52.1 % of theory)
C15H211N2 (M= 356.252)
Calc.: molpeak (M+H)+: 357 Found: molpeak (M+H)+: 357
HPLC retention time: 6.13 min (method A)
3.50e 5-(4-chloro-phenyl)-2-[4-(3-piperidin-1-yl-pyrrolidin-1-yl)-
phenylethynyl]-pyridine
Prepared according to general working method I from 1-[1-(4-iodo-phenyl)-
pyrrolidin-3-yl]-piperidine (120 mg, 0.34 mmol) and 5-(4-chloro-phenyl)-2-
ethynyl-pyridine (73 mg, 0.34 mmol).
Yield: 75 mg (50.4 % of theory)
C28H28CIN3 (M= 442.008)
Calc.: molpeak (M+H)+: 442/444 Found: molpeak (M+H)+: 442/444
Rf value: 0.30 (silica gel, DCM/MeOH/NH3 9:1:0.1)
HPLC retention time: 4.94 min (method B)
Example 3.51
5-(4-chloro-phenyl)-2-[5-(2-pyrrolidin-1-yl-ethoxy)- pyridin-2-yl-ethynyl]-
pyridine
cI
(DN
O N
3.51a 2-bromo-5-(2-pyrrolidin-1-yl-ethoxy)-pyridine
The product is obtained analogously to Example 3.1 e (1:1 mixture of
acetone:acetonitrile instead of DMF) from 3.90 g (22.4 mmol) 6-bromo-
pyridin-3-ol and 4.25 g (25.0 mmol) N-(2-chloroethyl)-pyrrolidine
hydrochloride.
Yield: 4.70 g (69.3 % of theory)
C11 H15BrN2O (M= 271.159)
Calc.: molpeak (M+H)+: 271/273 Found: molpeak (M+H)+: 271/273
CA 02504160 2005-04-28
Boehringer Ingelheim 201 Case 1-1406 if
Rf value: 0.27 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
3.51b 5-(4-chloro-phenyl)-2-[5-(2-pyrrolidin-1-yl-ethoxy)- pyridin-2-yl-
ethynyl]-
pyridine
Prepared according to general working method I from 2-bromo-5-(2-pyrrolidin-
1 -yl-ethoxy)-pyridine (271 mg, 0.50 mmol) and 5-(4-chloro-phenyl)-2-ethynyl-
pyridine (106 mg, 0.50 mmol).
Yield: 22 mg (10.9 % of theory)
C24H22CIN3O (M= 403.915)
Calc.: molpeak (M+H)+: 404/406 Found: molpeak (M+H)+: 404/406
Rf value: 0.20 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
Example 3.52
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-
benzonitrile
/I
N\~ N
CN\/~
0
3.52a 5-bromo-2-(2-pyrrolidin-1-yl-ethoxy)-benzonitrile
The product is obtained analogously to Example 3.1e (acetonitrile instead of
DMF) from 2.00 g (10.1 mmol) 5-bromo-2-hydroxy-benzonitrile and 2.00 g
(11.8 mmol) N-(2-chloroethyl)-pyrrolidine hydrochloride.
Yield: 1.32 g (44.3 % of theory)
C13H15BrN2O (M= 295.181)
Calc.: molpeak (M+H)+: 295/297 Found: molpeak (M+H)+: 295/297
HPLC retention time: 4.91 min (method A)
3.52b 5-iodo-2-(2-pyrrolidin-1-yl-ethoxy)-benzonitrile
Prepared according to general working method II from 5-bromo-2-(2-
pyrrolidin-1-yl-ethoxy)-benzonitrile (350 mg, 1.19 mmol).
Yield: 324 mg (79.8 % of theory)
CA 02504160 2005-04-28
Boehringer Ingelheim 202 Case 1-1406 if
C13H151N2O (M= 342.182)
Caic.: molpeak (M+H)+: 343 Found: molpeak (M+H)+: 343
HPLC retention time: 5.14 min (method A)
3.52c 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-
benzonitrile
Prepared according to general working method I from 5-iodo-2-(2-pyrrolidin-1-
yl-ethoxy)-benzonitrile (300 mg, 0.88 mmol) and 5-(4-chloro-phenyl)-2-
ethynyl-pyridine (206 mg, 0.97 mmol).
Yield: 76 mg (20.3 % of theory)
C26H22CIN30 (M= 427.938)
CaIc.: molpeak (M+H)+: 428/430 Found: molpeak (M+H)+: 428/430
HPLC retention time: 7.31 min (method A)
Example 3.53
5-(4-chloro-phenyl)-2-[2-(4-methyl-piperid i n- 1 -ylmethyl)-benzofu ran-5-
ylethynyl]-pyridine
N
bN
0 ~
3.53a ethyl 5-bromo-benzofuran-2-carboxylate
13.8 g (100 mmol) Na2CO3 are added to a solution of 4.02 g (20.0 mmol) 5-
bromo-salicylaldehyde and 2.26 mL (20.0 mmol, 98%) ethyl bromoacetate in
50 mL DMF. The reaction mixture is heated to 80 C and stirred for 2 h at this
temperature. It is diluted with 200 mL water, the aqueous phase is extracted
three times with 100 mL tert-butylmethylether and the combined organic
extracts are washed twice with 50 mL water. The organic phase is dried over
MgSO4, filtered through activated charcoal and the solvent is eliminated
i.vac..
Yield: 3.80 g (70.6 % of theory)
C11 H9BrO3 (M= 269.097)
Calc.: molpeak (M+H)+: 269/271 Found: molpeak (M+H)+: 269/271
CA 02504160 2005-04-28
Boehringer Ingelheim 203 Case 1-1406 if
CA 02504160 2005-04-28
Rf value: 0.75 (silica gel, PE/EtOAc 8:2)
3.53b (5-bromo-benzofuran-2-yl)-methanol
7.0 mL (7.00 mmol) 1 M lithium aluminium hydride solution in THE is slowly
added dropwise at -5 C to a solution of 3.70 g (13.8 mmol) ethyl 5-bromo-
benzofuran-2-carboxylate in 50 mL THF. The reaction solution is heated to RT
and then cooled again to 10 C. Another 0.7 mL (0.70 mmol) 1 M lithium
aluminium hydride solution in THE are added dropwise and the reaction is
stirred for 1 h at RT. 1.0 mL water, 1.0 mL 15% NaOH and finally 3.0 mL
water are added successively to the reaction mixture and the insoluble
precipitate is filtered off. The organic phase is dried over MgSO4, filtered
through activated charcoal and the solvent is eliminated i.vac..
Yield: 2.10 g (67.3 % of theory)
C9H7BrO2 (M= 227.059)
Calc.: molpeak (M)+: 226/228 Found: molpeak (M)+: 226/228
Rf value: 0.15 (silica gel, PE/EtOAc 8:2)
3.53c (5-iodo-benzofuran-2-yl)-methanol
Prepared according to general working method II from (5-bromo-benzofuran-
2-yl)-methanol (2.10 g, 9.25 mmol).
Yield: 2.53 g (100 % of theory)
C9H7102 (M= 274.059)
Calc.: molpeak (M)+: 274 Found: molpeak (M)+: 274
Rf value: 0.26 (silica gel, PE/EtOAc 8:2)
3.53d {5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-benzofuran-2-yl}-methanol
Prepared according to general working method I from (5-iodo-benzofuran-2-
yl)-methanol (685 mg, 2.50 mmol) and 5-(4-chloro-phenyl)-2-ethynyl-pyridine
(534 mg, 2.50 mmol).
Yield: 400 mg (44.5 % of theory)
C22H14CIN02 (M= 359.815)
Calc.: molpeak (M+H)+: 360/362 Found: molpeak (M+H)+: 360/362
Rf value: 0.58 (silica gel, DCM/MeOH/NH3 9:1:0.1)
Boehringer Ingelheim 204 Case 1-1406 if
CA 02504160 2005-04-28
3.53e 5-(4-chloro-phenyl)-2-[2-(4-methyl-piperidin-l-ylmethyl)-benzofuran-5-
ylethynyl]-pyridine
32 pL (0.40 mmol) methanesulphonic acid chloride are added to a solution of
100 mg (0.28 mmol) {5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-benzofuran-2-
yl}-methanol and 69 pL (0.50 mmol) triethylamine in 5 mL DCM at 0 C and the
reaction is stirred for I h at this temperature. Another 70 pL (0.89 mmol)
methanesulphonic acid chloride are added and the reaction is stirred
overnight at RT. Then 0.24 ml (2.00 mmol) 4-methylpiperidine is added and
the reaction is stirred for 2 hours at RT. The reaction solution is diluted
with
water and the aqueous phase extracted twice with DCM. The organic phase is
dried over MgSO4 and the solvent is eliminated i.vac.. The purification is
carried out by column chromatography on silica gel (DCM/methanol 9:1).
Yield: 10 mg (8.1 % of theory)
C28H25CIN2O (M= 440.977)
Calc.: molpeak (M+H)+: 441/443 Found: molpeak (M+H)+: 441/443
Rf value: 0.27 (silica gel, DCM/MeOH 9:1)
Example 3.54
{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-(2-pyrrolidin-1-yl-ethyl)-
amine
a
N
V N\~~ /
3.54a 2-chloro-N-(4-iodo-phenyl)-acetamide
2.0 mL (25.1 mmol) chloro-acetylchioride in 5 mL DCM are added to a
solution of 5.00 g (22.83 mmol) 4-iodo-phenylamine and 7.0 mL (50.2 mmol)
triethylamine in 100 mL DCM at 0 C. The ice bath is removed and the
reaction is stirred for a further 1.5 h at RT. The reaction solution is
diluted with
80 mL water and the organic phase is washed with saturated NaCI solution.
The organic phase is dried over MgSO4 and the solvent is eliminated Lvac..
The residue is triturated with EtOAc, suction filtered and dried in the air.
Boehringer Ingelheim 205 Case 1-1406 if
CA 02504160 2005-04-28
Yield: 2.25 g (33.4 % of theory)
C8H7CIINO (M= 295.508)
Calc.: molpeak (M+H)+: 296/298 Found: molpeak (M+H)+: 296/298
HPLC retention time: 7.91 min (method A)
3.54b N-(4-iodo-phenyl)-2-pyrrolidin-1-yl-acetamide
1.53 mL (18.6 mmol) pyrrolidine are added to a solution of 2.20 g (7.45 mmol)
2-chloro-N-(4-iodo-phenyl)-acetamide in 50 mL DCM. The reaction solution is
stirred overnight at RT. The mixture is filtered, the filtrate dried over
MgSO4
and the solvent is eliminated i.vac..
Yield: 1.65 g (67.1 % of theory)
C12H15IN2O (M= 330.171)
Calc.: molpeak (M+H)+: 331 Found: molpeak (M+H)+: 331
HPLC retention time: 5.10 min (method A)
3.54c (4-iodo-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine
2.25 mL (2.25 mmol) 1 M lithium aluminium hydride solution are added to a
solution of 500 mg (1.51 mmol) N-(4-iodo-phenyl)-2-pyrrolidin-1-yl-acetamide
in 10 mL THE at 0 C and the reaction is stirred for 20 min at this
temperature.
EtOAc is added and then 85 pL water, 85 pL 15% NaOH solution and finally
256 pL water are added. The precipitate is removed by suction filtering and
the filtrate is diluted with 50 mL EtOAc. The organic phase is washed with 30
mL saturated NaHCO3 solution. The organic phase is dried over MgSO4 and
the solvent is eliminated i.vac..
Yield: 450 mg (94.0 % of theory)
C12H17IN2 (M= 316.187)
Calc.: molpeak (M+H)+: 317 Found: molpeak (M+H)+: 317
Rf value: 0.17 (silica gel, DCM/MeOH/NH3 9:1:0.1)
3.54d {4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenyl}-(2-pyrrolidin-1-yl-
ethyl)-amine
Boehringer Ingelheim 206 Case 1-1406 ff
Prepared according to general working method I from (4-iodo-phenyl)-(2-
pyrrolidin-1-yl-ethyl)-amine (450 mg, 1.42 mmol) and 5-(4-chloro-phenyl)-2-
ethynyl-pyridine (450 mg, 2.11 mmol).
Yield: 98 mg (17.1 % of theory)
C25H24CIN3 (M= 401.943)
Calc.: molpeak (M+H)+: 402/404 Found: molpeak (M+H)+: 402/404
HPLC retention time: 7.08 min (method A)
Example 3.55
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-
benzaldehyde
CI
0
C)N
3.55a 5-iodo-2-(2-pyrrolidin-1-yl-ethoxy)-benzaldehyde
The product is obtained analogously to Example 3.1e (acetonitrile instead of
DMF) from 8.93 g (36.0 mmol) 2-hydroxy-5-iodo-benzaldehyde and 7.14 g
(42.0 mmol) N-(2-chloroethyl)-pyrrolidine hydrochloride.
Yield: 4.80 g (38.6 % of theory)
C13H161NO2 (M= 345.182)
Calc.: molpeak (M+H)+: 346 Found: molpeak (M+H)+: 346
HPLC retention time: 5.27 min (method A)
3.55b 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-
benzaldehyde
Prepared according to general working method I from 5-iodo-2-(2-pyrrolidin-1-
yl-ethoxy)-benzaldehyde (1.50 g, 4.35 mmol) and 5-(4-chloro-phenyl)-2-
ethynyl-pyridine (214 mg, 5.00 mmol).
Yield: 320 mg (17.1 % of theory)
C26H23CIN202 (M= 430.938)
Calc.: molpeak (M+H)+: 431/433 Found: molpeak (M+H)+: 431/433
HPLC retention time: 7.31 min (method A)
CA 02504160 2005-04-28
Boehringer Ingelheim 207 Case 1-1406 ff
Example 3.56
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-
benzaldehyde-oxime
CI
C)N
O
NO~H
27 mg (0.38 mmol) hydroxylamine and 53 pL (0.38 mmol) triethylamine are
added to a solution of 200 mg (0.35 mmol) 5-[5-(4-chloro-phenyl)-pyridin-2-
ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-benzaldehyde (Example 3.55b) in 2 mL
of a 1:1 mixture of acetonitrile and MeOH. The reaction solution is heated to
85 C. After the reaction is complete the mixture is diluted with water and
saturated NaHCO3 solution and the organic phase is extracted with DCM. The
organic phase is dried over MgSO4 and the solvent is eliminated i.vac.. The
purification is carried out by column chromatography using HPLC-MS.
Yield: 5 mg (3.2 % of theory)
C26H24CIN302 (M= 445.953)
Calc.: molpeak (M+H)+: 446/448 Found: molpeak (M+H)+: 446/448
HPLC retention time: 5.25 min (method A)
Example 3.57
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-
benzaldehyde 0-methyl-oxime
N
ON
N "ru
CA 02504160 2005-04-28
Boehringer Ingelheim 208 Case 1-1406 if
The product is obtained analogously to Example 3.56a from 250 mg (0.44
mmol) 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-
benzaldehyde (Example 3.55b) and 50 mg (0.60 mmol) O-methyl-
hydroxylamine.
Yield: 40 mg (20.1 % of theory)
C27H26CIN302 (M= 459.980)
Calc.: molpeak (M+H)+: 460/462 Found: molpeak (M+H)+: 460/462
HPLC retention time: 8.11 min (method A)
Example 3.58
5-(4-chloro-phenyl)-2-[3-ethynyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-
pyridine
CI
ON
152 mg (0.79 mmol) dimethyl (1-diazo-2-oxo-propyl)-phosphate in 2 mL
MeOH are added to a solution of 300 mg (0.66 mmol) 5-[5-(4-chloro-phenyl)-
pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-benzaldehyde (Example 3.55b)
and 183 mg (1.32 mmol) K2CO3 in 9 mL MeOH. The reaction solution is
stirred for for 3 h at RT and diluted with 20 mL DCM. The organic phase is
extracted twice with saturated NaHCO3 solution. The organic phase is dried
over MgSO4 and the solvent is eliminated i.vac.. The purification is carried
out by HPLC-MS.
Yield: 104 mg (37.0 % of theory)
C27H23CIN20 (M= 426.950)
Calc.: molpeak (M+H)+: 427/429 Found: molpeak (M+H)+: 427/429
HPLC retention time: 7.69 min (method A)
Example 3.59
2-pyrrolidin-1-yl-ethyl 5-[5-(4-ch to ro-phenyl)-pyrid i n-2-yl ethyn yl]-2, 3-
d i hyd ro-
indole-1-carboxylate
CA 02504160 2005-04-28
Boehringer Ingelheim 209 Case 1-1406 if
CA 02504160 2005-04-28
CI
j N
3.59a 2-pyrrolidin-1-yl-ethyl 5-bromo-2,3-dihydro-indole-1-carboxylate
1.00 g (4.95 mmol) 5-bromoindoline is added to a solution of 868 mg (5.00
mmol) N-(2-chloroethyl)-pyrrolidine hydrochloride and 1.70 g (12.2 mmol)
K2CO3 in 15 mL DMF. The reaction solution is stirred for 4 h at 70 C and more
N-(2-chloroethyl)-pyrrolidine hydrochloride is added. The reaction solution is
stirred for a further 3 h at 70 C and then diluted with 25 mL water. The
aqueous phase is extracted twice with 30 mL EtOAc. The organic phase is
washed with saturated NaCl solution, dried over Na2SO4 and the solvent is
eliminated i.vac.. The purification is carried out by column chromatography on
silica gel (gradient: EtOAc/MeOH 9:1 to EtOAc/MeOH 4:1).
Yield: 687 mg (47.0 % of theory)
C15H19BrN202 (M= 339.235)
Calc.: molpeak (M+H)+: 339/341 Found: molpeak (M+H)+: 339/341
Rf value: 0.62 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
3.59b 2-pyrrolidin-1-yl-ethyl 5-iodo-2,3-d ihydro-indole-1-carboxylate
Prepared according to general working method II from 2-pyrrolidin-1-yl-ethyl
5-bromo-2,3-dihydro-indole-1-carboxylate (700 mg, 2.37 mmol).
Yield: 590 mg (64.4 % of theory)
C15H19IN202 (M= 386.235)
Calc.: molpeak (M+H)+: 387 Found: molpeak (M+H)+: 387
Rf value: 0.37 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
3.59c 2-pyrrolidin-1-yl-ethyl 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2,3-
dihydro-indole-l-carboxylate
Boehringer Ingelheim 210 Case 1-1406 ff
Prepared according to general working method I from 2-pyrrolidin-1-yl-ethyl 5-
iodo-2,3-dihydro-indole-1-carboxylate (120 mg, 0.31 mmol) and 5-(4-chloro-
phenyl)-2-ethynyl-pyridine (80 mg, 0.37 mmol).
Yield: 48 mg (32.8 % of theory)
C28H26CIN302 (M= 471.991)
Calc.: molpeak (M+H)+: 472/474 Found: molpeak (M+H)+: 472/474
HPLC retention time: 7.66 min (method A)
Example 3.60
3-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-6,7,8,9-tetrahydro-5H-10-this-7-
aza-benzo[a]azulene
~I
H,N
N
S
3.60a ethyl 4-bromo-5-oxo-azepan-1-carboxylate
79.9 g (500 mmol) bromine are added to a solution of 92.7 g (500 mmol) ethyl
4-oxo-azepan-1-carboxylate in 350 mL chloroform and the reaction is stirred
overnight. The reaction solution is washed three times with saturated NaHCO3
solution, the organic phase is dried over Na2SO4 and the solvent is eliminated
i.vac.. The product is further reacted without purification.
Yield: 118 g (89.3 % of theory)
CgH 14BrNO3 (M= 264.135)
3.60b ethyl 4-(4-bromo-phenylsulphanyl)-5-oxo-azepan-1-carboxylate
60.5 g (320 mmol) 4-bromothiophenol in 300 mL chloroform are added to a
solution of 84.5 g (320 mmol) ethyl 4-bromo-5-oxo-azepan-1-carboxylate
and 32.4 g (320 mmol) triethylamine in 80 mL chloroform over 45 min, so that
the internal temperature does not exceed 40 C. The reaction solution is
stirred for 1.5 h at RT. The reaction mixture is washed twice with dilute
ammonia solution and twice with water. The organic phase is dried over
Na2SO4 and K2CO3 and the solvent is eliminated i.vac.. The purification is
carried out by repeated column chromatography on silica gel.
CA 02504160 2005-04-28
Boehringer Ingelheim 211 Case 1-1406 if
CA 02504160 2005-04-28
Yield: 44.4 g (37.2 % of theory)
C15H18BrNO3S (M= 372.30)
Rf value: 0.33 (silica gel, chloroform/acetone 19:1)
3.60c ethyl 3-bromo-5,6,8,9-tetrahydro-10-thia-7-aza-benzo[a]azulen-7-
carboxylate
A solution of 44.3 g (119 mmol) ethyl 4-(4-bromo-phenylsulphanyl)-5-oxo-
azepan-1 -carboxylate in 443 g polyphosphoric acid is heated to 80 C for 45
min and then diluted with 1000 mL water. The aqueous phase is extracted
three times with chloroform. The organic phase is washed with water, dried
over Na2SO4 and the solvent is eliminated i.vac.. The purification is carried
out
by repeated column chromatography on silica gel (chloroform/EtOAc 19:1)
and by recrystallisation from MeOH/acetone.
Yield: 22.4 g (52.8 % of theory)
C15H16BrNO2S (M= 354.28)
melting point: 109 C
3.60d 3-bromo-6,7,8,9-tetrahydro-5H-10-thia-7-aza-benzo[a]azulene
30.0 g (53.5 mmol) KOH in 700 mL EtOH are added to a solution of 19.0 g
(53.5 mmol) ethyl 3-bromo-5,6,8,9-tetrahydro-10-thia-7-aza-benzo[a]azulen-7-
carboxylate. EtOH is distilled off at normal pressure and the residue is taken
up in water. The solution is acidified with HCI. Then it is made basic with
NaOH and the aqueous phase is extracted four times with chloroform. The
organic phase is dried over Na2SO4 and K2CO3 and the solvent is eliminated
i.vac.. The purification is carried out by repeated column chromatography on
silica gel.
Yield: 12.6 g (83.0 % of theory)
C12H12BrNS (M= 282.22)
melting point: 89 C
3.60e 3-iodo-6,7,8,9-tetrahydro-5H-10-thia-7-aza-benzo[a]azulene
Prepared according to general working method II from 3-bromo-6,7,8,9-
tetrahydro-5H-10-thia-7-aza-benzo[a]azulene (1.80 g, 6.38 mmol).
Boehringer Ingelheim 212 Case 1-1406 ff
CA 02504160 2005-04-28
Yield: 1.80 g (85.7 % of theory)
C12H12INS (M= 329.205)
Calc.: molpeak (M+H)+: 330 Found: molpeak (M+H)+: 330
HPLC retention time: 5.45 min (method A)
3.60f 3-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-6,7,8,9-tetrahydro-5H-10-
thia-7-aza-benzo[a]azulene
Prepared according to general working method I from 3-iodo-6,7,8,9-
tetrahydro-5H-10-thia-7-aza-benzo[a]azulene (770 mg, 2.34 mmol) and 5-(4-
chloro-phenyl)-2-ethynyl-pyridine (500 mg, 2.34 mmol).
Yield: 350 mg (36.0 % of theory)
C25H19CIN2S (M= 414.961)
Calc.: molpeak (M+H)+: 415/417 Found: molpeak (M+H)+: 415/417
HPLC retention time: 7.41 min (method A)
Example 3.61
3-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-7-methyl-6,7,8,9-tetrahydro-5H-10-
thia-7-aza-benzo[a]azulene
CI
N
N
0.18 mL (2.41 mmol) 37% formalin solution in water are added to a solution of
100 mg (0.24 mmol) 3-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-6,7,8,9-
tetrahydro-5H-10-thia-7-aza-benzo[a]azulene (see 3.60f) in 5 mL acetonitrile.
Then 60 mg (0.96 mmol) NaBH3CN and 56 pL (0.96 mmol) acetic acid are
added and the reaction mixture is stirred overnight. The solution is combined
with 2 M NaOH and extracted with EtOAc. The organic phase is dried over
MgSO4 and the solvent is eliminated i.vac.. The purification is carried out by
column chromatography by HPLC-MS.
Yield: 3 mg (2.9 % of theory)
C26H21 CIN2S (M= 428.988)
Calc.: molpeak (M+H)+: 429/431 Found: molpeak (M+H)+: 429/431
Boehringer Ingelheim 213 Case 1-1406 if
HPLC retention time: 4.97 min (method B)
Example 3.62
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1 -(2-pyrrolidin-1 -yl-ethyl)-1 H-
indazole
C
j NJ
3.62a 5-nitro-1-(2-pyrrolidin-1-yl-ethyl)-1H-indazole and 5-nitro-2-(2-
pyrrolidin-1-yl- ethyl)-2H-indazole
10.5 g (62.0 mmol) 1-(2-chloroethyl)-pyrrolidine hydrochloride and 12.9 g
(93.0 mmol) K2CO3 are added successively to a solution of 5.00 g (31.0
mmol) 5-nitroindazole in 100 mL acetonitrile. The reaction solution is stirred
for 2 h at RT and refluxed for a further 5 h. After the solution has cooled
the
insoluble salts are filtered off and the solvent is eliminated i.vac.. The
residue
is taken up in EtOAc and water. The organic phase is dried over MgSO4 and
the solvent is eliminated i.vac.. A 4:1 mixture of 5-nitro-1-(2-pyrrolidin-1-
yl-
ethyl)-1H-indazole and 5-nitro-2-(2-pyrrolidin-1-yl-ethyl)-2H-indazole is
obtained. The purification is carried out by column chromatography on Alox
(PE/EtOAc 3:2).
5-nitro-1-(2-pyrrolidin-1-yl-ethyl)-1 H-indazole
Yield: 4.00 g (49.6 % of theory)
C1 3H 16N402 (M= 260.298)
Caic.: molpeak (M+H)+: 261 Found: molpeak (M+H)+: 261
Rf value: 0.78 (Alox, PE/EtOAc 1:1)
5-nitro-2-(2-pyrrolidin-1-yl-ethyl)-2H-indazole
Yield: 1.00 g (12.4 % of theory)
C13H16N402 (M= 260.298)
Calc.: molpeak (M+H)+: 261 Found: molpeak (M+H)+: 261
Rf value: 0.61 (Alox, PE/EtOAc 1:1)
CA 02504160 2005-04-28
Boehringer Ingelheim 214 Case 1-1406 if
3.62b 1-(2-pyrrolidin-1-yl-ethyl)-1 H-indazol-5-ylamine
0.50 g Raney nickel are added to a solution of 3.50 g (13.4 mmol) 5-nitro-l-(2-
pyrrolidin-1 -yl-ethyl)-1 H-indazole in 50 mL EtOAc and the reaction mixture
is
stirred for 20 h at RT at 1.4 bar H2. After filtration the solvent is
eliminated
i.vac.. The product is further reacted without any more purification.
Yield: 2.90 g (93.6 % of theory)
C13H18N4 (M= 230.315)
Calc.: molpeak (M+H)+: 231 Found: molpeak (M+H)+: 231
3.62c 5-bromo-1-(2-pyrrolidin-1-yl-ethyl)-1 H-indazole
1.00 g (4.34 mmol) 1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-5-ylamine is
dissolved in 9.76 mL 48% hydrobromic acid and 9.76 mL water and the
solution is cooled to 0 C. 2.5 M sodium nitrite solution (300 mg in 1.74 mL
water) is slowly added dropwise. The reaction is stirred for 10 min at 0 C and
then a solution of 935 mg (6.51 mmol) CuBr in 3.42 mL 48% hydrobromic acid
is added dropwise. The reaction is heated to 60 C and stirred for one hour at
this temperature. The mixture is diluted with water and the aqueous phase is
extracted with EtOAc. The organic phase is discarded and the aqueous phase
is made alkaline with saturated NaHCO3 solution. The aqueous phase is
extracted with EtOAc and the organic phase is washed with water. The
organic phase is dried over MgSO4 and the solvent is eliminated i.vac..
Yield: 500 mg (39.1 % of theory)
C13H16BrN3 (M= 294.197)
Calc.: molpeak (M+H)+: 294/296 Found: molpeak (M+H)+: 294/296
Rf value: 0.59 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
3.62d 5-iodo-1-(2-pyrrolidin-1-yl-ethyl)-1 H-indazole
Prepared according to general working method II from 5-bromo-1-(2-
pyrrolidin-1 -yl-ethyl)-1 H-indazole (500 mg, 1.70 mmol).
Yield: 230 mg (39.7 % of theory)
C13H161N3 (M= 341.197)
Calc.: molpeak (M+H)+: 342 Found: molpeak (M+H)+: 342
CA 02504160 2005-04-28
Boehringer Ingelheim 215 Case 1-1406 if
CA 02504160 2005-04-28
Rf value: 0.55 (silica gel, DCM/MeOH 4:1)
3.62e 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1-(2-pyrrolidin-1-yl-ethyl)-
1 H-indazole hydriodide
Prepared according to general working method I from 5-iodo-1-(2-pyrrolidin-1-
yl-ethyl)-1 H-indazole (230 mg, 0.67 mmol) and 5-(4-chloro-phenyl)-2-ethynyl-
pyridine (144 mg, 0.67 mmol).
Yield: 90 mg (24.1 % of theory)
C26H23CIN4*Hl (M= 554.865)
Calc.: molpeak (M+H)+: 427/429 Found: molpeak (M+H)+: 427/429
HPLC retention time: 4.59 min (method B)
Example 3.63
5-[5-(4-chloro-phenyl )-pyridin-2-ylethynyl]-2-(2-pyrrolidin-l-yl-ethyl)-2H-
indazole
CI
CND N
3.63a 2-(2-pyrrolidin-1-yl-ethyl)-2H-indazol-5-ylamine
The product is obtained analogously to Example 3.62b from 1.0 g (3.84 mmol)
5-nitro-2-(2-pyrrolidin-l -yl-ethyl)-2H-indazole (see 3.62a).
Yield: 840 mg (94.9 % of theory)
C13H18N4 (M= 230.315)
Calc.: molpeak (M+H)+: 231 Found: molpeak (M+H)+: 231
3.63b 5-bromo-2-(2-pyrrolidin-1-yl-ethyl)-2H-indazole
The product is obtained analogously to Example 3.62c from 840 mg (3.65
mmol) 2-(2-pyrrolidin-1-yl-ethyl)-2H-indazol-5-ylamine.
Yield: 440 mg (41.0 % of theory)
C13H16BrN3 (M= 294.197)
Calc.: molpeak (M+H)+: 294/296 Found: molpeak (M+H)+: 294/296
Boehringer Ingelheim 216 Case 1-1406 if
HPLC retention time: 5.04 min (method A)
3.63c 5-iodo-2-(2-pyrrolidin-1-yl-ethyl)-2H-indazole
Prepared according to general working method II from 5-bromo-2-(2-
pyrrolidin-1-yl-ethyl)-2H-indazole (440 mg, 1.50 mmol).
Yield: 170 mg (33.3 % of theory)
C13H161N3 (M= 341.197)
Calc.: molpeak (M+H)+: 342 Found: molpeak (M+H)+: 342
Rf value: 0.40 (silica gel, DCM/MeOH 4:1)
3.63d 5-[5-(4-chloro-phenyl )-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethyl)-
2H-indazole
Prepared according to general working method I from 5-iodo-2-(2-pyrrolidin-1-
yl-ethyl)-2H-indazole (170 mg, 0.50 mmol) and 5-(4-chloro-phenyl)-2-ethynyl-
pyridine (106 mg, 0.50 mmol).
Yield: 100 mg (42.3 % of theory)
C26H23CIN4 (M= 426.953)
Calc.: molpeak (M+H)+: 427/429 Found: molpeak (M+H)+: 427/429
HPLC retention time: 4.61 min (method B)
Example 3.64
3-(4-chloro-phenyl)-6-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-pyridazine
c
~N
N
3.64a 3-chloro-6-(4-chloro-phenyl)-pyridazine
Under an argon atmosphere a solution of 11.3 g (70.5 mmol) 4-
chlorophenyl boric acid in 50 mL 1,4-dioxane is added to a solution of 10.8 g
(70.5 mmol) 3,6-dichloropyridazine, 10 mL (20 mmol) of a 2 M Na2CO3
solution and 600 mg (0.73 mmol) Pd(dppf)C12 in 150 mL 1,4-dioxane at 110 C
over 2 h. The reaction mixture is stirred for 1 h at 110 C. 100 mL water are
CA 02504160 2005-04-28
Boehringer Ingelheim 217 Case 1-1406 if
CA 02504160 2005-04-28
added and the aqueous phase is extracted with 100 mL EtOAc. The organic
phase is dried over Na2SO4 and the solvent is eliminated i.vac.. Purification
is
carried out by column chromatography on silica gel (cyc/EtOAc 4:1).
Yield: 8.00 g (50.4 % of theory)
C10H6CI2N2 (M= 225.079)
Calc.: molpeak (M+H)+: 225/227/229 Found: molpeak (M+H)+:
225/227/229
HPLC retention time: 5.20 min (method A)
3.64b 3-(4-chloro-phenyl)-6-trimethylsilanylethynyl-pyridazine
Under an argon atmosphere 3.48 mL (25.0 mmol) triethylamine and 2.08 mL
(15.0 mmol) ethynyl-trimethyl-silane are added successively to a solution of
2.25 g (10.0 mmol) 3-chloro-6-(4-chloro-phenyl)-pyridazine in 50 mL
acetonitrile and 20 mL THE Then 292 mg (0.40 mmol) Pd(dppf)C12 and 76 mg
(0.40 mmol) Cul are added. The reaction solution is stirred overnight at RT.
The solvent is eliminated i.vac, and further purification is carried out by
column chromatography on silica gel (PE/EtOAc 1:1).
Yield: 1.00 g (34.9 % of theory)
C15H15CIN2Si (M= 286.839)
Calc.: molpeak (M+H)+: 287/289 Found: molpeak (M+H)+: 287/289
Rf value: 0.45 (silica gel, DCM)
3.64c 3-(4-chloro-phenyl)-6-ethynyl-pyridazine
1.10 g (3.49 mmol) TBAF are added at 0 C to a solution of 1.00 g (3.49
mmol) 3-(4-chloro-phenyl)-6-trimethylsilanylethynyl-pyridazine in 10 mL DCM.
The ice bath is removed and the reaction solution is stirred for 30 min. Water
is added and the aqueous phase is extracted with EtOAc. The organic phase
is dried over MgSO4 and the solvent is eliminated i.vac.. The product is
reacted without any further purification.
Yield: 700 mg (93.5 % of theory)
C12H7CIN2 (M= 214.656)
Boehringer Ingelheim 218 Case 1-1406 ff
CA 02504160 2005-04-28
Calc.: molpeak (M+H)+: 215/217 Found: molpeak (M+H)+: 215/217
HPLC retention time: 5.16 min (method B)
3.64d 3-(4-chloro-phenyl)-6-[4-(2-pyrrolidin-1-yi-ethoxy)-phenylethynyl]-
pyridazine
Prepared according to general working method I from 1-[2-(4-iodo-phenoxy)-
ethyl]-pyrrolidine (200 mg, 0.63 mmol) and 3-(4-chloro-phenyl)-6-ethynyl-
pyridazine (135 mg, 0.63 mmol).
Yield: 15 mg (5.9 % of theory)
C24H22CIN30 (M= 403.915)
Calc.: molpeak (M+H)+: 404/406 Found: molpeak (M+H)+: 404/406
HPLC retention time: 5.01 min (method A)
Example 3.65
5-(4-chloro-ph enyl)-3-fluoro-2-{4-[2-(4-methyl -piperid in-1-yl)-ethoxy]-
phenylethynyl}-pyridine
CI
F
N
N~\ I ~
3.65a 1-[2-(4-iodo-phenoxy)-ethyl]-4-methyl-piperidine
The product is obtained analogously to Example 3.1 a from 5.72 g (26.0 mmol)
4-iodo-phenol and 4.20 g (26.0 mmol) 1-(2-chloro-ethyl)-4-methyl-piperidine.
Yield: 2.60 g (29.0 % of theory)
C14H201N0 (M= 345.226)
Caic.: molpeak (M+H)+: 346 Found: molpeak (M+H)+: 346
HPLC retention time: 5.70 min (method A)
3.65b 5-(4-chloro-phenyl)-3-nitro-pyridin-2-ol
23.5 g (150 mmol) 4-chlorophenyl-boric acid are added under argon to a
solution of 22.1 g (101 mmol) 5-bromo-3-nitro-pyridin-2-ol, 200 mL (400
Boehringer Ingelheim 219 Case 1-1406 if
CA 02504160 2005-04-28
mmol) of a 2 M Na2CO3 solution and 731 mg (1.00 mmol) Pd(dppf)C12 in 400
mL acetone and 80 mL water. The reaction mixture is stirred for 18 h at 60 C.
Acetone is eliminated i.vac. and the residue is adjusted to pH 7 with 160 mL 1
M citric acid. The aqueous phase is extracted three times with EtOAc and
once with MeOH. The organic phase is dried over MgSO4 and the solvent is
eliminated i.vac.. The residue is triturated with EtOAc.
Yield: 9.70 g (22.0 % of theory)
C11 H7CIN2O3 (M= 250.643)
Calc.: molpeak (M-H)-: 249/251 Found: molpeak (M-H)-: 249/251
HPLC retention time: 6.83 min (method A)
3.65c 2-bromo-5-(4-chloro-phenyl)-3-nitro-pyridine
13.2 g (93.0 mmol) phosphorus pentoxide are added to a solution of 9.70 g
(38.7 mmol) 5-(4-chloro-phenyl)-3-nitro-pyridin-2-ol and 14.5 mmol (45.0
mmol) tetrabutylammonium bromide in 100 mL toluene. The reaction mixture
is stirred for 1.5 h at 95 C. After cooling the toluene phase is decanted off
and
the residue is twice combined with toluene and decanted off. The combined
organic phases are washed with saturated NaHCO3 solution. The organic
phase is dried over MgSO4 and the solvent is eliminated i.vac.. The product is
further reacted without any more purification.
Yield: 4.90 g (40.4 % of theory)
C11 H6BrCIN2O2 (M= 313.540)
Calc.: molpeak (M+H)+: 313/315/317 Found: molpeak (M+H)+:
313/315/317
HPLC retention time: 6.01 min (method B)
3.65d 2-bromo-5-(4-chloro-phenyl)-pyridin-3-ylamine
A solution of 5.60 g (17.9 mmol) 2-bromo-5-(4-chloro-phenyl)-3-nitro-pyridine,
20.3 g (90.0 mmol) tin(ll)-chloride and 18.9 g (225 mmol) NaHCO3 in 300 mL
EtOAc is refluxed for30 h. After filtration the solvent is eliminated i.vac..
The
residue is triturated with DCM and after filtration the filter residue is
dried in
the air.
Boehringer Ingelheim 220 Case 1-1406 if
CA 02504160 2005-04-28
Yield: 3.50 g (69.1 % of theory)
C11 H8BrCIN2 (M= 283.557)
Calc.: molpeak (M+H)+: 283/285/287 Found: molpeak (M+H)+:
283/285/287
HPLC retention time: 5.45 min (method B)
3.65e 2-bromo-5-(4-chloro-phenyl)-3-fluoro-pyridine
243 mg (3.53 mmol) sodium nitrite in 0.5 mL water are added dropwise at
-5 C to a solution of 1.00 g (3.53 mmol) 2-bromo-5-(4-chloro-phenyl)-pyridin-
3-ylamine in 2 mL water and 2.04 mL concentrated HCI. Then at 0 C 1.56 mL
(10.6 mmol) 60% hexafluorophosphoric acid in water are added and the
reaction is stirred for a further hour at 0 C. The diazonium salt is suction
filtered, washed with cold water, isopropanol and ether and dried overnight in
the desiccator at RT and 7 mbar. This is then added batchwise at 90 C to 50
mL PE (boiling point 100-140 C). After the reaction solution has cooled the
mixture is made alkaline with saturated Na2CO3 solution. The aqueous phase
is extracted with EtOAc and the organic phase is washed successively with
saturated Na2CO3 solution and water. The organic phase is dried over
MgSO4 and the solvent is eliminated i.vac..
The purification is carried out by column chromatography on silica gel (PE).
Yield: 460 mg (45.5 % of theory)
C11H6BrCIFN (M= 286.533)
Calc.: molpeak (M+H)+: 286/288/290 Found: molpeak (M+H)+:
286/288/290
HPLC retention time: 6.24 min (method B)
3.65f 5-(4-chloro-phenyl)-3-fluoro-2-trimethylsilanylethynyl-pyridine
The product is obtained analogously to Example 3.64b from 460 mg (1.61
mmol) 2-bromo-5-(4-chloro-phenyl)-3-fluoro-pyridine and 0.33 mL (2.41 mmol)
ethynyl-trimethyl-silane.
Yield: 490 mg (100 % of theory)
C16H15CIFNSi (M= 303.842)
Calc.: molpeak (M+H)+: 304/306 Found: molpeak (M+H)+: 304/306
Boehringer Ingelheim ~-2~Z1Case 1-1406 ff
CA 02504160 2005-04-28
3.65g 5-(4-chloro-phenyl)-2-ethynyl-3-fluoro-pyridine
The product is obtained analogously to Example 3.64c from 490 mg (1.61
mmol) 5-(4-chloro-phenyl)-3-fluoro-2-trimethylsilanylethynyl-pyridine.
Yield: 300 mg (57.4 % of theory)
C13H7CIFN (M= 231.659)
Calc.: molpeak (M+H)+: 232/234 Found: molpeak (M+H)+: 232/234
3.65h 5-(4-chloro-phenyl)-3-fluoro-2-{4-[2-(4-methyl-piperidin-1-yl)-ethoxy]-
phenylethynyl}-pyridine
Prepared according to general working method I from 1-[2-(4-iodo-phenoxy)-
ethyl]-4-methyl-piperidine (164 mg, 0.48 mmol) and 5-(4-chloro-phenyl)-2-
ethynyl-3-fluoro-pyridine (110 mg, 0.48 mmol).
Yield: 14 mg (6.6 % of theory)
C27H26CIFN20 (M= 448.972)
Calc.: molpeak (M+H)+: 449/451 Found: molpeak (M+H)+: 449/451
HPLC retention time: 5.16 min (method B)
Example 3.66
6-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1-methanesulphony-2-pyrrolidin-1-
ylmethyl-1,2,3,4-tetrahydro-quinoline
J _ \
C)N
0 -u
0
0.13 mL (0.93 mmol) triethylamine and 36 pL (0.47 mmol) methanesulphonic
acid chloride are added successively at 0 C to a solution of 200 mg (0.47
mmol) 6-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-pyrrolidin-l-ylmethyl-
1,2,3,4-tetrahydro-quinoline (see Example 3.46) in 5 mL DCM. The reaction
mixture is heated to RT and stirred for a further hour at this temperature.
Another 36 pL (0.47 mmol) methanesulphonic acid chloride are added and the
mixture is stirred for a further hour at RT. The reaction mixture is poured
onto
Boehringer Ingelheim 222 Case 1-1406 if
water and exhaustively extracted with DCM. The organic phase is dried over
MgSO4 and the solvent is eliminated i.vac.. The purification is carried out by
column chromatography using HPLC-MS.
Yield: 9 mg (3.8 % of theory)
C28H28CIN302S (M= 506.071)
Calc.: molpeak (M+H)+: 506/508 Found: molpeak (M+H)+: 506/508
HPLC retention time: 5.26 min (column from method A; isocratic: 30%
acetonitrile)
Example 3.67
1-{6-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-pyrrolidin-1-ylmethyl-3,4-
dihydro-2H-quinolin-1-yl}-ethanone
j N
ON
74 pL (0.77 mmol) acetic anhydride are added to a solution of 220 mg (0.51
mmol) 6-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-pyrrolidin-1-ylmethyl-
1,2,3,4-tetrahydro-quinoline (see Example 3.46) in 5 mL DCM and the mixture
is stirred for 2 h at RT. Another 0.37 mL (3.85 mmol) acetic anhydride are
added and the reaction is stirred for a further 4 days at RT. The solvent is
eliminated i.vac.. The purification is carried out by column chromatography
using HPLC-MS.
Yield: 105 mg (43.5 % of theory)
C29H28CIN3O (M= 470.019)
Calc.: molpeak (M+H)+: 470/472 Found: molpeak (M+H)+: 470/472
HPLC retention time: 7.08 min (method A)
Example 3.68
5-(4-chloro-phenyl)-2-[3-pyridin-2-yl-4-(2-pyrrolidin-1-yl-ethoxy)-
phenylethynyl]-pyridine
CA 02504160 2005-04-28
Boehringer Ingelheim 223 Case 1-1406 if
CA 02504160 2005-04-28
CI
N
~
30 mg (0.24 mmol) pyridine-3-boric acid are added to a solution of 115 mg
(0.24 mmol) 2-[3-bromo-4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-5-(4-
chloro-phenyl)-pyridine (see Example 3.7), 0.5 mL (1.00 mmol) of a 2 M
Na2CO3 solution and 15 mg (0.24 mmol) tetrakis-triphenylphosphane-
palladium in 1 mL 1,4-dioxane and 0.3 mL methanol. The reaction mixture is
refluxed for 6 h. After filtration the solvent is eliminated i.vac.. The
purification
is carried out by column chromatography on silica gel (gradient: DCM to
DCM/MeOH/NH3 1:1:0.1).
Yield: 1.8 mg (1.6 % of theory)
C30H26CIN3O (M= 480.01)
Calc.: molpeak (M-H)-: 480/482 Found: molpeak (M-H)-: 480/482
HPLC retention time: 6.50 min (method A)
Example 3.69
5-(4-chloro-phenyl)-2-{4-[2-(4-methyl-piperidin-l -yl)-ethoxy]-naphthyl-1-
ylethynyl}-pyridine
CI
j N
3.69a 1-[2-(4-bromo-naphthyl-1-yloxy)-ethyl]-4-methyl-piperidin
The product is obtained analogously to Example 3.1 e from 1.0 g (5.35 mmol)
4-bromo-naphthyl-1-ol and 323 mg (2.00 mmol) 1-(2-chloro-ethyl)-4-methyl-
piperidine.
Yield: 530 mg (97.0 % of theory)
C18H22BrNO (M= 348.286)
Calc.: molpeak (M+H)+: 348/350 Found: molpeak (M+H)+: 348/350
Boehringer Ingelheim 224 Case 1-1406 if
CA 02504160 2005-04-28
HPLC retention time: 7.10 min (method A)
3.69b 1-[2-(4-iodo-naphthyl-1-yloxy)-ethyl]-4-methyl-piperidine
Prepared according to general working method II from 1-[2-(4-bromo-
naphthyl-1-yloxy)-ethyl]-4-methyl-piperidine (530 mg, 1.52 mmol).
Yield: 500 mg (83.1 % of theory)
C18H221NO (M= 395.287)
Calc.: molpeak (M+H)+: 396 Found: molpeak (M+H)+: 396
HPLC retention time: 6.74 min (method A)
3.69c 5-(4-chloro-phenyl)-2-{4-[2-(4-methyl-piperidin-l-yl)-ethoxy]-naphthyl-
1-ylethynyl}-pyridine
Prepared according to general working method I from 1-[2-(4-iodo-naphthyl-l-
yloxy)-ethyl]-4-methyl-piperidine (277 mg, 0.70 mmol) and 5-(4-chloro-
phenyl)-2-ethynyl-pyridine (150 mg, 0.70 mmol).
Yield: 66 mg (19.6 % of theory)
C31 H29CIN2O (M= 481.043)
Calc.: molpeak (M+H)+: 481/483 Found: molpeak (M+H)+: 481/483
Rf value: 0.60 (silica gel, EtOAc/MeOH/NH3 95:5:0.5)
Example 3.70
2-{4-[2-(4-methyl-piperidin-1 -yl)-ethoxy]-phenylethynyl}-5-phenyl-pyridine
N
N I
~~
O
3.70a 5-bromo-2-{4-[2-(4-methyl-piperidin-1 -yl)-ethoxy]-phenylethynyl}-
pyridine
Prepared according to general working method I from 1-[2-(4-iodo-phenoxy)-
ethyl]-4-methyl-piperidine (345 mg, 1.00 mmol) and 5-bromo-2-ethynyl-
pyridine (83 mg, 0.39 mmol).
Yield: 100 mg (25.0 % of theory)
C21 H23BrN2O (M= 399.334)
Boehringer Ingelheim 225 Case 1-1406 if
CA 02504160 2005-04-28
Calc.: molpeak (M+H)+: 399/401 Found: molpeak (M+H)+: 399/401
Rf value: 0.83 (silica gel, DCM/MeOH/NH3 95:5:0.5)
3.70.b 2-{4-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenylethynyl}-5-phenyl-
pyridine
Under an argon atmosphere 30 mg (0.25 mmol) phenylboric acid are added to
a solution of 100 mg (0.25 mmol) 5-bromo-2-{4-[2-(4-methyl-piperidin-1-yl)-
ethoxy]-phenylethynyl}-pyridine, 0.25 mL (0.50 mmol) of a 2 M Na2CO3
solution and 4 mg (0.01 mmol) Pd(dppf)CI2 in 5 mL 1,4-dioxane and 2 mL
MeOH. The reaction mixture is stirred for 3 days at 90 C. The reaction mixture
is diluted with EtOAc and the organic phase is washed with 40 mL water and
finally with saturated NaCl solution. The organic phase is dried over MgSO4
and the solvent is eliminated i.vac.. The purification is carried out using
HPLC-
MS and by column chromatography on silica gel (gradient: DCM/MeOH/NH3
95:5:0.5 to DCM/MeOH/NH3 9:1:0.1).
Yield: 27 mg (27.2 % of theory)
C27H28N20 (M= 396.537)
Calc.: molpeak (M+H)+: 397 Found: molpeak (M+H)+: 397
HPLC retention time: 7.61 min (method A)
Example 3.71
5-(4-chloro-p henyl)-2-{4-[2-(4-methyl- piperidin-1-yI)-propoxy]-
phenylethynyl}-
pyridine
I
v NY\O ~
3.71 a 1-(4-iodo-phenoxy)-propan-2-ol
The product is obtained analogously to Example 3.1e from 1.39 g (10.0 mmol)
1-bromo-2-propanol and 2.20 g (10.0 mmol) 4-iodophenol.
Yield: 2.00 g (71.9 % of theory)
Boehringer Ingelheim 226 Case 1-1406 if
CA 02504160 2005-04-28
C9H111O2 (M= 278.091)
Calc.: molpeak (M+Na)+: 301 Found: molpeak (M+Na)+: 301
Rf value: 0.20 (silica gel, PE/EtOAc 4:1)
3.71b 1-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-propan-2-ol
Prepared according to general working method I from 1-(4-iodo-phenoxy)-
propan-2-ol (2.00 g, 7.19 mmol) and 5-(4-chloro-phenyl)-2-ethynyl-pyridine
(1.54 g, 7.20 mmol).
Yield: 1.50 g (57.3 % of theory)
C22H18CIN02 (M= 363.847)
Calc.: molpeak (M+H)+: 364/366 Found: molpeak (M+H)+: 364/366
Rf value: 0.25 (silica gel, PE/EtOAc/DCM 1:1:8)
3.71c 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-1-methyl-ethyl
methanesulphonate
0.35 mL (4.50 mmol) methanesulphonic acid chloride are added at RT to a
solution of 1.50 g (4.12 mmol) 1-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-
phenoxy}-propan-2-ol and 1.14 mL (8.20 mmol) triethylamine in 80 mL THE
and the reaction is stirred for 3 h at this temperature. The solvent is
eliminated
i.vac. and the residue is combined with 40 mL tert-butylmethylether and 60
mL water. The precipitate is suction filtered and further purification is
carried
out by column chromatography on silica gel (EtOAc).
Yield: 1.00 g (54.9 % of theory)
C23H20CIN04S (M= 441.937)
Calc.: molpeak (M+H)+: 442/444 Found: molpeak (M+H)+: 442/444
Rf value: 0.78 (silica gel, PE/EtOAc/DCM 1:1:8)
3.71d 5-(4-chloro-phenyl)-2-{4-[2-(4-methyl-piperidin-1-yl)-propoxy]-
phenylethynyl}-pyridine
0.21 mL (1.80 mmol) 4-methylpiperidine are added to a solution of 133 mg
(0.30 mmol) 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-1-methyl-
ethyl methanesulphonate in 2 mL DMF and the mixture is stirred for 16 h at
Boehringer Ingelheim 227 Case 1-1406 if
CA 02504160 2005-04-28
60 C and 6 h at 80 C. The solvent is eliminated i.vac., the residue is
triturated
with isopropanol, suction filtered and dried at 30 C in the circulating air
dryer.
Yield: 65 mg (48.7 % of theory)
C28H29CIN20 (M= 445.009)
Calc.: molpeak (M+H)+: 445/447 Found: molpeak (M+H)+: 445/447
HPLC retention time: 5.37 min (method B)
Example 3.72
(1-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-pyrrolidin-3-yl)-
4-
methylpiperidine
N
N~N N~
3.72a (R)-1-(5-bromo-pyridin-2-yl)-pyrrolidin-3-ol
The product is obtained analogously to Example 3.31 a (reaction time: 60 min
at 140 C) from 2.72 g (11.5 mmol) 2,5-dibromopyridine and 1.00 g (11.5
mmol) (R)-3-pyrrolidinole.
Yield: 1.20 g (43.0 % of theory)
C9H11BrN2O (M= 243.105)
Calc.: molpeak (M+H)+: 242/244 Found: molpeak (M+H)+: 242/244
HPLC retention time: 3.43 min (method A)
3.72b (R)-1-(5-iodo-pyridin-2-yl)-pyrrolidin-3-ol
Prepared according to general working method II from (R)-1-(5-bromo-pyridin-
2-yI)-pyrrolidin-3-ol (1.20 g, 4.94 mmol).
Yield: 1.30 g (90.8 % of theory)
C91-11 11 N20 (M= 290.105)
Calc.: molpeak (M+H)+: 291 Found: molpeak (M+H)+: 291
HPLC retention time: 3.48 min (method A)
Boehringer Ingeiheim 228 Case 1-1406 if
CA 02504160 2005-04-28
3.72c (R)-1-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-
pyrrolidin-3-ol
Prepared according to general working method I from (R)-1-(5-iodo-pyridin-2-
yl)-pyrrolidin-3-ol (1.30 g, 4.48 mmol) and 5-(4-chloro-phenyl)-2-ethynyl-
pyridine (957 mg, 4.48 mmol).
Yield: 1.36 g (80.7 % of theory)
C22H18CIN30 (M= 375.861)
Calc.: molpeak (M+H)+: 376/378 Found: molpeak (M+H)+: 376/378
HPLC retention time: 6.76 min (method A)
3.72d 1-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-pyrrolidin-
3-
one
0.43 mL (5.32 mmol) pyridine and 2.26 g (0.80 mmol, 15 percent by weight)
Dess-Martin-periodinane in DCM are added to a solution of 200 mg (0.53
mmol) (R)-1-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-
pyrrolidin-
3-ol in 10 mL DCM. The reaction mixture is stirred for 3 h at RT and added to
a solution of semisaturated NaHCO3 solution and tert-butylmethylether. The
aqueous phase is extracted twice with EtOAc. The organic phase is dried over
MgSO4 and the solvent is eliminated i.vac.. The product is further reacted
without purification.
Yield: 100 mg (35.2 % of theory)
C22H16CIN30 (M= 373.845)
Calc.: molpeak (M+H)+: 374/376 Found: molpeak (M+H)+: 374/376
3.72e (1-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-pyridin-2-yl}-pyrrolidin-
3-
yl)-4-methylpiperidine
48 mg (0.22 mmol) NaBH(OAc)3 and 27 pL (0.47 mmol) acetic acid are added
to a solution of 100 mg (0.19 mmol, 70% purity) 1-{5-[5-(4-chloro-phenyl)-
pyridin-2-ylethynyl]-pyridin-2-yl}-pyrrolidin-3-one and 22 pL 4-
methylpiperidine
(0.19 mmol) in 5 mL THF. The reaction mixture is stirred overnight and
combined with saturated NaHCO3 solution. The organic phase is extracted
twice with EtOAc. The organic phase is dried over MgSO4 and the solvent is
Boehringer Ingelheim 229 Case 1-1406 if
eliminated i.vac.. Further purification is carried out by column
chromatography using HPLC-MS.
Yield: 11 mg (12.9 % of theory)
C28H29CIN4 (M= 457.023)
Calc.: molpeak (M+H)+: 457/459 Found: molpeak (M+H)+: 457/459
HPLC retention time: 5.19 min (method A)
Example 3.73
5-(4-chloro-phenyl)-2-[4-(3-pyrrolidin-1-yl-prop-1 -ynyl)-phenylethynyl]-
pyridine
I \.I \
2 Nj
CN,
3.73a 1-[3-(4-bromo-phenyl)-prop-2-ynyl]-pyrrolidine
Prepared according to general working method I from 4-bromo-iodobenzene
(10.9 g, 38.5 mmol) and 1-prop-2-ynyl-pyrrolidine (4.20 g, 71% purity, 27.3
mmol).
Yield: 6.40 g (88.7 % of theory)
C13H14BrN (M= 264.167)
Calc.: molpeak (M+H)+: 264/266 Found: molpeak (M+H)+: 264/266
3.73b 1-[3-(4-iodo-phenyl)-prop-2-ynyl]-pyrrolidine
Prepared according to general working method II from 1-[3-(4-bromo-phenyl)-
prop-2-ynyl]-pyrrolidine (3.2 g, 12.1 mmol).
Yield: 230 mg (4.6 % of theory)
C13H14IN (M= 311.168)
Calc.: molpeak (M+H)+: 312 Found: molpeak (M+H)+: 312
3.73c 5-(4-chloro-phenyl)-2-[4-(3-pyrrolidin-1-yl-prop-l -ynyl)-phenylethynyl]-
pyridine
CA 02504160 2005-04-28
Boehringer Ingelheim 230 Case 1-1406 if
Prepared according to general working method I from 1-[3-(4-iodo-phenyl)-
prop-2-ynyl]-pyrrolidine (230 mg, 75%, 0.55 mmol) and 5-(4-chloro-phenyl)-2-
ethynyl-pyridine (118 mg, 0.55 mmol).
Yield: 96 mg (43.7 % of theory)
C26H21 CIN2 (M= 396.924)
Calc.: molpeak (M+H)+: 397/399 Found: molpeak (M+H)+: 397/399
HPLC retention time: 5.03 min (method B)
Example 3.74
6-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1 -methyl-2-pyrrolidin-1 -ylmethyl-
1,2,3,4-tetrahydro-quinoline
~I
C'N
37 mg (1.23 mmol) paraformaldehyde in 1.8 mL THE are added to a solution
of 350 mg (0.82 mmol) 6-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-pyrrolidin-
1-ylmethyl-1,2,3,4-tetrahydro-quinoline (see Example 3.46) in 1.6 mL THF.
0.24 mL acetic acid and 1.2 mL THE are added to this mixture. Finally, 1.00 g
(2.05 mmol) cyanoborohydride resin (macroporous polystyrene, load: 2.04
mmol/g) are added and the mixture is stirred for 16 hat RT. After filtration
the
filtrate is combined with 1.50 g (2.15 mmol) toluenesulphonic acid resin
(macroporous polystyrene, load: 1.43 mmol/g), shaken for 30 min and suction
filtered. The solvent is eliminated i.vac. and purification is carried out by
column chromatography using HPLC-MS.
Yield: 33 mg (9.1 % of theory)
C28H28CIN3 (M= 442.008)
Caic.: molpeak (M+H)+: 442/444 Found: molpeak (M+H)+: 442/444
HPLC retention time: 5.22 min (method B)
Example 4
CA 02504160 2005-04-28
Boehringer Ingelheim 231 Case 1-1406 if
CA 02504160 2005-04-28
5-(4-chloro-phenyl)-2-{4-[2-(2,5-dihydro-pyrrol-1-yl)-ethoxy]-phenylethynyl}-
pyridine
I,
4a 2-(4-iodo-phenoxy)-ethanol
A suspension of 11 g (50 mmol) 4-iodophenol, 3.88 mL (55 mmol) 2-
bromoethanol and 8.3 g (60 mmol) K2CO3 in 60 mL acetone is refluxed for 24
h. The solvent is eliminated i.vac., the residue is combined with water,
exhaustively extracted with EtOAc and the organic phase is dried over
Na2SO4. After the desiccant and solvent have been eliminated the residue is
purified by chromatography on silica gel (cyc/EtOAc 7:3).
Yield: 2.9 g (22.0 % of theory)
C8H9102 (M= 264.064)
Caic.: molpeak (M+H)+: 264 Found: molpeak (M+H)+: 264
Rf value: 0.24 (silica gel, cyc/EtOAc 2:1)
4b 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethanol
Under an argon atmosphere 253 mg (0.22 mmol) tetrakis-
triphenylphosphane-palladium and 42 mg (0.22 mmol) Cul are added to a
solution of 2.9 g (11 mmol) 2-(4-iodo-phenoxy)-ethanol and 2.35 g (11 mmol)
5-(4-chloro-phenyl)-2-ethynyl-pyridine in 50 mL piperidine and the reaction
mixture is stirred for 30 min at RT. The solvent is eliminated i.vac., the
residue
is combined with water and stirred with EtOAc. The product precipitated is
suction filtered and dried.
Yield: 2.1 g (54.7 % of theory)
C21 H16CIN02 (M= 349.820)
Calc.: molpeak (M+H)+: 350 Found: molpeak (M+H)+: 350
Rf value: 0.42 (silica gel, cyc/EtOAc 1:1)
Boehringer Ingelheim 232 Case 1-1406 if
CA 02504160 2005-04-28
4c 5-(4-chloro-phenyl)-2-{4-[2-(2,5-dihydro-pyrrol-1-yl)-ethoxy]-
phenylethynyl}-pyridine
23 pL (0.29 mmol) methanesuiphonic acid chloride are added dropwise to a
solution, cooled to 0 C, of 85 mg (0.24 mmol) 2-{4-[5-(4-chloro-phenyl)-
pyrid in-2-ylethynyl]-phenoxy}-ethanol and 41 pL (0.29 mmol) triethylamine in
mL DCM and the reaction mixture is stirred for 1 h at this temperature. 46
pL (0.58 mmol) 2,5-dihydro-1 H-pyrrole are added dropwise, the mixture is
heated to RT and stirred overnight. 1 mL of DMF is added and the mixture is
heated for 8 h to 70 C. The mixture is evaporated down i. vac., the residue is
combined with water, extracted exhaustively with EtOAc and the organic
phase is dried over Na2SO4. After the desiccant and solvent have been
eliminated the residue is purified by chromatography on silica gel
(EtOAc/MeOH/NH3 95:5:0.5).
Yield: 16 mg (16.4 % of theory)
C25H21 CIN2O (M= 400.912)
Calc.: molpeak (M+H)+: 401/403 Found: molpeak (M+H)+: 401/403
Rf value: 0.16 (silica gel, DCM/MeOH 95:5)
Example 4.1
5-(4-chloro-phenyl)-2-[4-(2-piperidin-1-yl-ethoxy)-phenylethynyl]-pyridine
CI
4.1 a 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl
methanesuIphonate
0.59 mL (7.55 mmol) methanesulphonic acid chloride are added dropwise to a
solution, cooled to 0 C, of 2.2 g (6.29 mmol) 2-{4-[5-(4-chloro-phenyl)-
pyridin-
2-ylethynyl]-phenoxy}-ethanol and 1.74 mL (12.58 mmol) triethylamine in 25
mL THF. The reaction mixture is heated to RT and stirred for 2 h. To complete
the reaction 5 mL pyridine are added and kept at RT for a further 18 h. The
Boehringer Ingelheim 233 Case 1-1406 if
CA 02504160 2005-04-28
solvent is eliminated i.vac., the residue is combined with water and
triturated
with diethyl ether. The product precipitated is suction filtered and dried.
Yield: 2.4 g (89.2 % of theory)
C22H 18CIN04S (M= 427.910)
Cale.: molpeak (M+H)+: 428/430 Found: molpeak (M+H)+: 428/430
Rf value: 0.42 (silica gel, cyc/EtOAc 1:1)
4.1b 5-(4-chloro-phenyl)-2-[4-(2-piperidin-1-yl-ethoxy)-phenylethynyl]-
pyridine
99 pL (1.0 mmol) piperidine are added to a solution of 85.6 mg (0.2 mmol) of
2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl
methanesuIphonate in 2 mL DMF and the reaction mixture is stirred for 18 h
at RT. The solvent is distilled off i.vac., the residue is stirred with 5 mL
water
and 40 mL DCM, the organic phase is separated off and dried with Na2SO4.
After the desiccant and solvent have been eliminated the residue is triturated
with 20 mL diethyl ether and suction filtered.
Yield: 62 mg (74.3 % of theory)
C26H25CIN20 (M= 416.955)
Caic.: molpeak (M+H)+: 417/419 Found: molpeak (M+H)+: 417/419
HPLC retention time: 6.51 min (method A)
Boehringer Ingelheim 234 Case 1-1406 ff
The following compounds are prepared as described in Example 4.1 b:
CI
N
R~~~
0
Example R Yield (%) empirical mass HPLC retention
formula spectrum time in min
(method)
4.2 [1N 48.9 C241-121C1N20 389/391 6.15 (A)
[M+H] +
4.3 CH, 27.5 C281-124C1N30 454/456 7.25 (A)
N
[M+H]+
4.4 H 28.4 C27H22CIN30 440/442 7.46 (A)
N " [M+H]+
4.5 50.3 C27H27CIN2O2 447/449 7.46 (A)
N
0 [M+H]+
4.6 N 3 27.2 C28H30CIN30 460/462 5.86 (A)
[M+H]+
N
H3C'
4.7 69.9 C30H25CIN20 465/467 7.98 (A)
N,, [M+H] +
4.8 N 55.8 C25H23CIN20 403/405 6.24 (A)
[M+H]+
4.9 CN-CN 72.0 C301-132C1N30 486/488 5.54 (A)
[M+H]+
4.10 65.6 C25H23CIN202 418/420 6.38 (A)
N [M+H] +
4.11 3 ~ 48.6 C26H26CIN30 432/434 5.78 (A)
[M+H]+
CA 02504160 2005-04-28
Boehringer Ingelheim 235 Case 1-1406 if
CA 02504160 2005-04-28
4.12 50.3 C27H27CIN202 447/449 0.80
N
O-; [M+H]+ (EtOAc/MeOH/NH3
90:10:1)
4.13 N" 33.0 C32H36CIN3O3 546/548 0.75
[M+H] + (EtOAc/MeOH/NH3
a
90:10:1)
4.14 54.0 C26H25C1N20 417/419 0.78
N
[M+H]+ (EtOAc/MeOH/NH3
90:10:1)
The following compounds are prepared as described in Example 4.1 b, while
after the elimination of the solvent the reaction mixture is combined with 5
mL
saturated NaHCO3 solution, extracted with 40 mL DCM and after the organic
phase has been removed it is dried with Na2SO4. After the desiccant and
solvent have been eliminated the residue is purified by chromatography on
silica gel.
Example R Yield (%) empirical mass HPLC retention
formula spectrum time in min
(method)
4.15 A/ 57.9 C30H32CIN303 518/520 7.94 (A)
0 0 [M+H]+
HNN.
4.16 N 3 73.7 C24H23CIN202 407/409 6.29 (A)
Obi
[M+H]+
4.17 C, H, 61.8 C29H25CIN20 453/455 7.81 (A)
N [M+H] +
3 eq. of the corresponding amine are added to a solution of 1 eq. 2-{4-[5-(4-
chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl methanesulphonate in DMF
(2 mL/0.25 mmol) and the reaction mixture is stirred for 16-72 h at 60-70 C .
The working up is done by 2 alternative methods:
Boehringer Ingelheim 236 Case 1-1406 ff
CA 02504160 2005-04-28
Alternative A: The reaction mixture is purified directly by HPLC.
Alternative B: After the reaction mixture has cooled the precipitate formed is
combined with 1.5 mL isopropanol, suction filtered, washed with a little
isopropanol and dried overnight at 30 C in the circulating air dryer.
The following compounds are obtained by this method:
~cII
Example R Yield (%) empirical mass HPLC retention
(variant) formula spectrum time in min
(method)
4.18 53.6 C33H38CIN303 560/562 5.44 (B)
oN (A) [M+H] +
CH/3N
4.19 37.6 C311-34C1N303 532/534 5.24 (B)
O
H (A) [M+H]+
cN
4.20 0 42.1 C27H27CIN202 447/449 7.19 (A)
(A) [M+H]+
4.21 41.3 C281-129C1N20 445/447 7.95 (A)
N (A) [M+H]+
4.22 d 40.3 C27H27CIN2O2 447/449 4.68 (B)
(A) (M+H]+
4.23 69.3 C30H32CIN302 502/504 6.86 (A)
O N~
cH, N ~ (A) [M+H]+
Boehringer Ingelheim 237 Case 1-1406 if
4.24 70.2 C26H25CIN2O2 433/435 4.68 (A)
N
H, 0 (A) [M+H]+
4.25 27.0 C28H29CIN2O 445/447 5.30 (B)
(A) [M+H]+
4.26 23.4 C28H29CIN2O 445/447 8.09 (A)
(A) [M+H]+
4.27 -o' 70.7 C27H27CIN2O2 447/449 6.79 (A)
N (A) [M+H] +
4.28 20.0 C29H31CIN2O 459/461 5.49 (B)
N (B) [M+H]+
4.29 66.6 C36H42CIN3O3 600/602 5.70 (B)
0 C C (B) [M+H]+
4.30 Y 9.2 C27H29CIN2O 433/435 5.20 (B)
IN ' (A) [M+H] +
4.31 H 3 22.9 C30H34CIN3O 488/490 5.60 (A)
CH3 (A) [M+H] +
4.32 H, 0 87.0 C27H26CIN3O2 460/462 0.12
H (B) [M+H]+ (DCM/MeOH/NH3
95:5:0.5)
4.33 48.0 C26H25CIN2O2 433/435 0.13
N(B) [M+H]+ (DCM/MeOH/NH3
95:5:0.5)
4.34 39.0 C27H27CIN2O 431/433 0.28
N (B) [M+H]+ (DCM/MeOH/NH3
95:5:0.5)
4.35 61.7 C31H29CIN2O 493/495 0.35
N (B) [M+H]+ (DCM/MeOH/NH3
95:5:0.5)
CA 02504160 2005-04-28
Boehringer Ingelheim 238 Case 1-1406 ff
4.36 H 20.4 C30H31CIN2O 471/473 0.25
H (B) [M+H]+ (DCM/MeOH/NH3
N
95:5:0.5)
4.37 iTh H 75.6 C30H31CIN2O 471/473 0.23
H (B) [M+H]+ (DCM/MeOH/NH3
N
95:5:0.5)
4.38 69.0 C31H34CIN3O2 516/518 0.20
N.' (B) [M+H]+ (DCM/MeOH/NH3
N o 95:5:0.5)
4.39 40.5 C26H23CIN2O 415/417 0.22
CN
(B) [M+H]+ (DCM/MeOH/NH3
95:5:0.5)
4.40 63.5 C29H25CIN2O 485/487 0.18
s!n
N (B) S [M+H]+ (DCM/MeOH/NH3
9:1:0.1)
4.41 3 `Nh 38.8 C29H32CIN3O 474/476 0.09
CH3 N
(B) [M+H]+ (DCM/MeOH/NH3
95:5:0.5)
4.42 41.7 C30H31CIN2O 471/473 0.30
N (B) [M+H]+ (DCM/MeOH/NH3
95:5:0.5)
4.43 55.8 C29H31CIN2O 459/461 0.23
N ' (B) [M+H]+ (DCM/MeOH/NH3
95:5:0.5)
4.44 29.7 C28H29CIN2O 445/447 0.32
(B) [M+H]+ (DCM/MeOH/NH3
95:5:0.5)
Example 4.45
1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-
[4,4']bipiperidine
CA 02504160 2005-04-28
Boehringer Ingelheim 239 Case 1-1406 if
CA 02504160 2005-04-28
HEN/~ J
/N\/\~~
3 mL of a 5 N HCI solution in isopropanol are added to a solution of 200 mg
(0.33 mmol) tert-butyl 1'-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-
phenoxy}-ethyl)-[4,4']bipiperidinyl-1-carboxylate (Example 4.29) in 5 mL DCM
and the reaction mixture is stirred for 4 h at RT. It is diluted with 30 mL
DCM,
neutralised with saturated NaHCO3 solution, combined with 30 mL water, the
aqueous phase is extracted exhaustively with DCM and the combined organic
phases are dried over MgSO4. After the desiccant and solvent have been
eliminated the desired product is obtained.
Yield: 127 mg (76.3 % of theory)
C31 H34CIN30 (M= 500.089)
Calc.: molpeak (M+H)+: 500/502 Found: molpeak (M+H)+: 500/502
Rf value: 0.10 (silica gel, DCM/MeOH/NH3 9:1:0.1)
Example 4.46
(R)-1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-
piperidin-
3-ylamine
C1
H N 1H
j N
NO I
1.5 mL of a 5 N HCI solution in isopropanol are added to a solution of 110 mg
(0.21 mmol) tert-butyl [(R)-1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-
phenoxy}-ethyl)-piperidin-3-yl]-carbaminate (Example 4.19) in 5 mL DCM and
the reaction mixture is stirred for 4 h at RT. The precipitate formed is
combined with a little tert-butylmethylether, filtered, washed with tert-
butyl meth yl ether and dried at 30 C.
Yield: 104 mg (99.5 % of theory)
C26H26CIN3O*2HCI (M= 504.892)
Boehringer Ingelheim 240 Case 1-1406 if
CA 02504160 2005-04-28
Calc.: molpeak (M+H)+: 432/434 Found: molpeak (M+H)+: 432/434
Rf value: 0.27 (silica gel, DCM/MeOH/NH3 9:1:0.1)
Example 4.47
[1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-piperidin-4-
ylmethyl]-methyl-amine
N H
Prepared analogously to Example 4.46 from 160 mg (0.29 mmol) tert-butyl [1-
(2-{4-[5-(4-ch loro-phenyl)-pyrid in-2-ylethynyl]-phenoxy}-ethyl)-piperidin-4-
ylmethyl]-methyl-carbaminate (Example 4.18).
Yield: 156 mg (100 % of theory)
C28H30CIN30*2HCI (M= 532.946)
Calc.: molpeak (M+H)+: 460/462 Found: molpeak (M+H)+: 460/462
Rf value: 0.13 (silica gel, DCM/MeOH/NH3 9:1:0.1)
Example 4.48
1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-pyrrolidin-3-
ylamine
CI
N
'0
HzN
N-'~O
1 mL trifluoroacetic acid are added to a solution of 45 mg (0.09 mmol) tert-
butyl [1-(2-(4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-
pyrrolidin-3-yl]-carbaminate (Example 4.15) in 5 mL DCM and the reaction
mixture is stirred for 24 h at RT. The mixture is evaporated down i. vac., the
residue is combined with 20 mL DCM, the organic phase is washed with
saturated NaHCO3 solution and dried over Na2SO4. After the desiccant and
solvent have been eliminated the desired product is obtained.
Yield: 15 mg (41.3 % of theory)
Boehringer Ingelheim 241 Case 1-1406 if
C25H24CIN30 (M= 417.943)
Calc.: molpeak (M+H)+: 418/420 Found: molpeak (M+H)+: 418/420
HPLC retention time: 5.86 min (method A)
Example 4.49
(2-{4-[5-(4-chloro-phenyl)-pyrid in-2-ylethynyl]-phenoxy}-ethyl)-methyl-
piperidin-4-yl-amine
CI
H
60 pL (0.8 mmol) trifluoroacetic acid are added to a solution of 22 mg (0.04
mmol) tert-butyl 4-[(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-
ethyl)-methyl-amino]-piperidin-1-carboxylate in 5 mL DCM and the reaction
mixture is stirred for 24 h at RT. The mixture is evaporated down i. vac. and
the residue is stirred with diethyl ether. The precipitate is suction
filtered,
washed with diethyl ether and dried.
Yield: 12 mg (67.3 % of theory)
C27H28CIN30*CF3000H (M= 560.017)
Calc.: molpeak (M+H)+: 445/447 Found: molpeak (M+H)+: 445/447
Rf value: 0.07 (silica gel, EtOAc/MeOH/NH3 80:20:2)
Example 4.50
methyl 1-(2-{4-[5-(4-chloro-phenyl)-pyrid in-2-ylethynyl]-phenoxy}-ethyl )-
pyrrol idine-2-carboxylate
/ CI
oII,
~Oi \ j N
Nom., ~ /
0.15 mL ethyldiisopropylamine and 73 mg (0.44 mmol) proline-methyl ester
(used as the hydrochloride) are added to a solution of 171 mg (0.4 mmol) 2-
{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl methanesuIphonate
CA 02504160 2005-04-28
Boehringer Ingelheim 242 Case 1-1406 if
in 2 mL DMF and the reaction mixture is stirred for 18 h at RT. The mixture is
evaporated down i. vac. and the residue is purified by HPLC.
Yield: 10 mg (5.4 % of theory)
C27H25CIN203 (M= 460.965)
Calc.: molpeak (M+H)+: 461/463 Found: molpeak (M+H)+: 461/463
Rf value: 0.79 (silica gel, cyc/EtOAc 1:1)
The following compounds may be prepared by the methods described:
/ NJ
Example R
4.51
4.52 CF,
4.53
4.54 ",o
,lI
4.55
4.56
CA 02504160 2005-04-28
Boehringer Ingelheim 243 Case 1-1406 if
CA 02504160 2005-04-28
4.57
Example 4.58
[1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-piperidin-4-
ylmethyl]-dimethyl-amine hydrochloride
CI
H
H3C,N.,CH3 CI-
N
Saturated ethereal HCl solution is added to a solution of 15 mg (0.03 mmol)
[1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-phenoxy}-ethyl)-piperidin-4-
ylmethyl]-dimethyl-amine (Example 4.41) in 6 mL DCM and 4 mL acetone
until no more precipitate is formed during the addition. The salt formed is
suction filtered in a nitrogen current and dried.
Yield: 10 mg (61.2 % of theory)
C29H32CIN3O*HCI (M= 510.512)
Calc.: molpeak (M+H)+: 474/476 Found: molpeak (M+H)+: 474/476
Fp: >250 C
Example 5
5-(4-chloro-phenyl)-2-[3-methyl-4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-
pyridine
CI
\ \ I
N
O
5a 2-(4-iodo-2-methyl-phenoxy)-ethanol
Under an N2 atmosphere 2.34 g (10 mmol) 4-iodo-2-methyl-phenol are added
to a suspension batchwise, cooled to 0 C, of 0.48 g (11 mmol) NaH in 50 mL
THE and stirred for a further 30 min at this temperature. Then 0.85 mL (12
Boehringer Ingelheim 244 Case 1-1406 ff
mmol) 2-bromoethanol, dissolved in 5 mL THF, are added dropwise and the
mixture is stirred for 18 h at RT. 5 mL of DMF are added and the reaction
mixture is heated to 70 C for 8 h. The mixture is evaporated down i. vac., the
residue is taken up in water, extracted exhaustively with EtOAc and dried with
Na2SO4. After the desiccant and solvent have been eliminated the residue is
purified by chromatography on silica gel (cyc/EtOAc 7:3).
Yield: 0.39 g (14.0 % of theory)
C91-11 1102 (M= 278.091)
Calc.: molpeak (M+H)+: 279 Found: molpeak (M+H)+: 279
Rf value: 0.28 (silica gel, cyc/EtOAc 2:1)
5b 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-
ethanol
Prepared analogously to Example 4b from 380 mg (1.37 mmol) 2-(4-iodo-2-
methyl-phenoxy)-ethanol and 292 mg (1.37 mmol) 5-(4-chloro-phenyl)-2-
ethynyl-pyridine in 38 mL piperidine.
Yield: 340 mg (68.4 % of theory)
C22H 18CIN02 (M= 363.847)
Calc.: molpeak (M+H)+: 364 Found: molpeak (M+H)+: 364
Rf value: 0.26 (silica gel, cyc/EtOAc 1:1)
5c 2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl
methanesulphonate
Prepared analogously to Example 4.1a from 310 mg (0.93 mmol) 2-{4-[5-(4-
chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethanol and 88 pL (1.12
mmol) methanesulphonic acid chloride.
Yield: 300 mg (72.7 % of theory)
C23H2OCINO4S (M= 441.937)
Calc.: molpeak (M+H)+: 442/444 Found: molpeak (M+H)+: 442/444
Rf value: 0.35 (silica gel, cyc/EtOAc 1:1)
5d 5-(4-chloro-phenyl)-2-[3-methyl-4-(2-pyrrolidin-1-yl-ethoxy)-
phenylethynyl]-pyridine
CA 02504160 2005-04-28
Boehringer Ingelheim 245 Case 1-1406 ff
CA 02504160 2005-04-28
A solution of 110 mg (0.25 mmol) 2-{4-[5-(4-chloro-phenyl)-pyridin-2-
ylethynyl]-2-methyl-phenoxy}-ethyl methanesulphonate in 2.11 mL (25 mmol)
pyrrolidine is heated to 70 C for 3 h. The mixture is evaporated down i. vac.,
the residue is combined with water, extracted exhaustively with DCM and the
organic phase is dried over Na2SO4. After the desiccant and solvent have
been eliminated and after recrystallisation from EtOH the desired product is
obtained.
Yield: 55 mg (52.8 % of theory)
C26H25CIN2O (M= 416.955)
Calc.: molpeak (M+H)+: 417/419 Found: molpeak (M+H)+: 417/419
HPLC retention time: 7.19 min (method A)
Example 5.1
5-(4-chloro-phenyl)-2-{4-[2-(2,5-dihydro-pyrrol-1-yl)-ethoxy]-3-methyl-
phenylethynyl}-pyridine
CI
j N
N
C
Prepared analogously to Example 5d from 110 mg (0.25 mmol) 2-{4-[5-(4-
chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl
methanesulphonate and 1.92 mL (25 mmol) 2,5-dihydro-1 H-pyrrole.
Yield: 10 mg (9.6 % of theory)
C26H23CIN2O (M= 414.939)
Calc.: molpeak (M+H)+: 415/417 Found: molpeak (M+H)+: 415/417
Rf value: 0.50 (silica gel, EtOAc/MeOH/NH3 95:5:0.5)
Example 5.2
5-(4-chloro-phenyl)-2-{4-[2-(4-isopropyl-piperidin-1 -yl)-ethoxy]-3-methyl-
phenylethynyl}-pyridine
Boehringer Ingelheim 246 Case 1-1406 if
CI
{ / N
164 mg (1.0 mmol) 4-isopropyl-piperidine (used as the hydrochloride) are
added to a solution of 88 mg (0.2 mmol) 2-{4-[5-(4-chloro-phenyl)-pyridin-2-
ylethynyl]-2-methyl-phenoxy}-ethyl methanesuiphonate and 0.34 mL (2 mmol)
ethyldiisopropylamine in 1.8 mL DMF and the reaction mixture is stirred for 24
h at RT. It is filtered using an injection filter and the reaction mixture is
purified
by HPLC.
Yield: 18 mg (19.4 % of theory)
C30H33CIN20 (M= 473.063)
Calc.: molpeak (M+H)+: 473/475 Found: molpeak (M+H)+: 473/475
HPLC retention time: 5.70 min (method B)
The following compounds are prepared as described in Example 5.2:
CI
N-~
0
Example R Yield (%) empirical mass HPLC retention
formula spectrum time in min
(method)
5.3 N 18.3 C321-29C1N20 493/495 5.70 (B)
[M+H]+
5.4 H3C_N'/-~ 48.9 C281-130C1N30 460/462 4.22 (B)
\-/N [M+H] +
5.5 10.9 C291-131C1N20 459/461 5.49 (B)
N
[M+H]+
CA 02504160 2005-04-28
Boehringer Ingelheim 247 Case 1-1406 if
5.6 25.6 C33H31CIN20 507/509 5.73 (B)
ap [M+H] +
5.7 20.2 C27H25CIN202 445/447 4.82 (B)
\CN. [M+H] +
5.8 H 24.6 C27H27CIN202 447/449 4.69 (B)
N [M+H]+
5.9 17.3 C34H33CIN20 521/523 5.83 (B)
N
[M+H]+
5.10 N 40.1 C32H31CIN40 523/525 4.25 (B)
N N [M+H]+
5.11 ON 12.3 C27H27CIN202 447/449 4.89 (B) H [M+H]+
5.12 -0 31.0 C26H27CIN203 451/453 4.62 (B)
[M+H] +
5.13 " 17.7 C26H23CIN20 415/417 5.03 (B)
[M+H]+
5.14 29.8 C29H31CIN20 459/461 5.46 (B)
nJ
[M+H] +
5.15 3 N 52.9 C28H30CIN30 460/462 4.15 (B)
H3c [M+H] +
5.16 21.4 C31H34CIN303 532/534 5.43 (B)
[M+H]+
ON
5.17 19.8 C29H31CIN20 459/461 5.43 (B)
[M+H]
CA 02504160 2005-04-28
Boehringer Ingelheim 248 Case 1-1406 if
CA 02504160 2005-04-28
5.18 28.1 C28H28CIN302 474/476 4.66 (B)
o [M+H]+
N
5.19 o H 11.4 C33H38CIN303 560/562 5.60 (B)
t
[M+H]+
5.20 7.4 C28H30CIN303S 524/526 4.79 (B)
'S- N N
o' "0 [M+H]+
5.21 - 13.5 C30H31CIN203 503/505 5.16 (B)
O N
[M+HI+
5.22 14.0 C32H35CIN203 531/533 5.39 (B)
[M+H]+
N.
5.23 N 16.6 C31H36CIN30 502/504 4.15 (B)
N [M+H]+
5.24 24.5 C33H40CIN30 530/532 4.19 (B)
N
5.25 N 3 4.8 C33H38CIN30 528/530 4.22 (B)
N [M+H]+
5.26 24.0 C34H31CIN4O2 563/565 4.92 (B)
N
[M+H]+
NN
Boehringer Ingelheim 249 Case 1-1406 if
5.27 O=s=- 36.8 C35H34CIN3O3S 612/614 5.43 (B)
N
[M+H]+
N
The following compounds are prepared as described in Example 5.2, while
after the reaction has ended the reaction mixture is evaporated down i.vac. ,
the residue is combined with water, the aqueous phase is exhaustively
extracted with DCM and the organic phase is dried over Na2SO4. After the
desiccant and solvent have been eliminated the residue is purified by
chromatography on silica gel (DCM/MeOH 95:5 or 8:2).
R~\O
Example R Yield (%) empirical mass HPLC retention
formula spectrum time in min
(method)
5.28 H30\ 37.6 C29H30CIN3O 472/474 4.05 (B)
[M+H] +
N,
5.29 '0 35.8 C32H30CIN3O2 524/526 5.43 (B)
N N [M+H]+
5.30 60.7 C28H29CIN2O 446/448 5.26 (B)
OW, [M+H]+
5.31 i 0_H 37.1 C33H31CIN2O2 523/525 5.33 (B)
[M+H] +
CA 02504160 2005-04-28
Boehringer Ingelheim 250 Case 1-1406 if
5.32 53.2 C29H31CIN2O 459/461 5.53 (B)
[M+H] +
5.33 48.8 C28H29CIN2O 445/447 5.26 (B)
" M+H +
5.34 46.1 C30H25CIN2O 465/467 5.33 (B)
[M+H] +
The following compounds are prepared as described in Example 5.2, while
the reaction mixture is heated to 60 C for between 4 and 18 h as necessary.
After the reaction has ended the reaction mixture is evaporated down i.vac.,
the residue is combined with water, the aqueous phase is extracted
exhaustively with DCM and the organic phase is dried over Na2SO4. After the
desiccant and solvent have been eliminated the residue is purified by
chromatography on Alox.
Example R Yield (%) empirical mass Rf value on Alox
formula spectrum (eluant)
5.35 0 ` 64.7 C26H25CIN2O2 433/435 0.52
~N' = [M+H]+ (EtOAc)
5.36 O` 74.8 C28H29CIN2O2 461/463 0.31
[M+H]+ (cyc/EtOAc 1:1)
48.5 C26H25CIN2O2 433/435 0.52
5.37 0-ON
M+H]+ (cyc/EtOAc 1:2)
[
5.38 -0 78.1 C28H29CIN2O2 461/463 0.38
[M+H]+ (cyc/EtOAc 1:3)
5.39 11 65.3 C27H25CIN2O 429/431 0.70
N [M+H]+ (cyc/EtOAc 2:1)
CA 02504160 2005-04-28
Boehringer Ingelheim 251 Case 1-1406 if
5.40 49.7 C29H29CIN2O2 473/475 0.34
H " , [M+H]+ (cyc/EtOAc 1:1)
5.41 52.6 C27H27CIN2O2 447/449 0.21
H, N
. = [M+H]+ (cyc/EtOAc 1:1)
5.42 81.8 C28H26CIF3N202 499/501 0.57
" ~ = [M+H]+ (cyc/EtOAc 3:1)
5.43 47.0 C27H27CIN2O 431/433 0.72
CN [M+H]+ (cyc/EtOAc 2:1)
5.44 N H, 12.0 C26H25C1N20 417/419 0.52
[M+H]+ (cyc/EtOAc 4:1)
5.45 -o' 32.6 C27H26CIN3O2 461/463 0.27
[M+H]+ (cyc/EtOAc 1:1)
C
5.46 'o' 44.3 C28H28CIN3O2 474/476 0.25
N [M+H]+ (cyc/EtOAc 4:1)
The following compounds are prepared as described in Example 5.2, while
the reaction mixture is heated to 60 C for 18 h.
Example R Yield (%) empirical mass Rf value on Alox
formula spectrum (eluant)
5.47 ~0 28.2 C28H29CIN2O2 461/463 0.40
" [M+H]+ (cyc/EtOAc 1:1)
5.48 6.7 C281-131C1N20 447/449 0.63
" [M+H]+ (cyc/EtOAc 4:1)
The following compounds are prepared as described in Example 5.2, heating
the reaction mixture to 60 C for between 6 and 14 h as necessary. After the
reaction has ended the reaction mixture is evaporated down i. vac., the
CA 02504160 2005-04-28
Boehringer Ingeiheim 252 Case 1-1406 if
residue is combined with saturated K2CO3 solution, the aqueous phase
exhaustively extracted with DCM and the organic phase is dried over Na2SO4.
After the desiccant and solvent have been eliminated the residue is purified
by
chromatography on Alox.
Example R Yield (%) empirical mass Rf value on Alox
formula spectrum (eluant) or HPLC
retention time in
min
(method)
5.49 N 5.5 C30H29CIN4O 497/499 0.36
,N 4 [M+H]+ (cyc/EtOAc 1:1)
N
5.50 3 -N 8.3 C32H36CIN3O 514/516 4.12 (B)
N [M+H]+
5.51 3.9 C30H32CIN3O 486/488 4.46 (B)
ON
"EN [M+H]+
N
5.52 H' CH3 36.2 C30H27CIN2O2 483/485 0.54
N [M+H]+ (cyc/EtOAc 1:1)
The following compounds are prepared as described in Example 5.2, heating
the reaction mixture to 100 C for between 3 and 18 h as necessary. After the
reaction has ended the reaction mixture is evaporated down i. vac., the
residue is combined with saturated K2CO3 solution, the aqueous phase is
exhaustively extracted with DCM and the organic phase is dried over Na2SO4.
After the desiccant and solvent have been eliminated the residue is purified
by
chromatography on Alox.
CA 02504160 2005-04-28
Boehringer Ingelheim 253 Case 1-1406 if
Example R Yield (%) empirical mass Rf value on Alox
formula spectrum (eluant) or HPLC
retention time in
min
(method)
5.53 CH 75.7 C30H32CIN302 502/504 0.31
HC'N N, 3 [M+H]+ (cyc/EtOAc 1:1)
0
5.5423.3 C32H36CIN30 514/516 4.22 (B)
C~~No [M+H]+
5.55 15.2 C29H31CIN20 459/461 5.39 (B)
N [M+H]+
Example 5.56
1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-ethyl)-4-
methyl-piperidin-4-ylamine
CI
FIZN 1 \ / N
1 mL trifluoroacetic acid is added to a solution of 130 mg (0.23 mmol) tert.
butyl [1-(2-{4-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-methyl-phenoxy}-
ethyl)-4-methyl-piperidin-4-yl]-carbaminate (Example 5.19) in 10 mL DCM and
the reaction mixture is stirred for 14 h at RT. The mixture is evaporated down
i. vac. (water bath temperature max. 30 C), the residue is combined with
dilute K2CO3 solution, extracted exhaustively with DCM and the organic phase
is dried with Na2SO4. After the desiccant and solvent have been eliminated
the residue is triturated with diisopropylether, the precipitate is suction
filtered
and dried in the air.
Yield: 65 mg (60.9 % of theory)
CA 02504160 2005-04-28
Boehringer Ingelheim 254 Case 1-1406 if
CA 02504160 2005-04-28
C28H30CIN30 (M= 460.024)
Calc.: molpeak (M+H)+: 460/462 Found: molpeak (M+H)+: 460/462
HPLC retention time: 4.09 min (method B)
The following compounds may be prepared by the processes described:
Example R
5.57
5.58 CF,
5.59
5.60 H,0
5.61
5.62
5.63
Boehringer Ingelheim 255 Case 1-1406 ff
CA 02504160 2005-04-28
Example 6
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1-(2-pyrrolidin-1-yl-ethyl)-1 H-
indole
cI
I J
j N
`- N /
N ~
6a 2-(5-iodo-indol-1 -yl)-ethanol
Under an N2 atmosphere 30 g (121 mmol) 5-iodoindole are added to a
suspension of 27.1 g (484 mmol) KOH in 150 mL DMSO. The reaction
mixture is kept for 1 h at RT, cooled to 0 C with ice water, 9.7 mL (145 mmol)
of 2-chloroethanol in 30 mL DMSO are slowly added dropwise and stirred for
4.5 h at RT. The reaction mixture is combined with 1 L EtOAc, washed four
times with in each case 800 mL water and once with 400 mL saturated NaCl
solution and the organic phase is dried over Na2SO4. After the desiccant and
solvent have been eliminated the residue is purified by chromatography (silica
gel, cyc/EtOAc 3:1).
Yield: 20.5 g (59.1 % of theory)
C10H101NO (M= 287.102)
Calc.: molpeak (M+H)+: 288 Found: molpeak (M+H)+: 288
HPLC retention time: 7.98 min (method A)
6b 2-(5-trimethylsilanylethynyl-indol-1 -yl)-ethanol
398 mg (2.1 mmol) Cul and 1.47 g (2.1 mmol) Pd(PPh3)2C12 are added to a
solution, cooled to 0 C, of 30 g (104 mmol) 2-(5-iodo-indol-1-yl)-ethanol and
18 mL (125 mmol) ethynyl-trimethyl-silane in 480 mL triethylamine and 120
mL THE and stirred for 30 min at 0 C and 2 h at RT. The mixture is
evaporated down i. vac., the residue is taken up in 300 mL EtOAc, the organic
phase is washed with 150 mL water and dried over Na2SO4. After the
desiccant and solvent have been eliminated the residue is purified by
chromatography (silica gel, gradient: cyc/EtOAc 4:1 to 2:1).
Yield: 26.85 g (100 % of theory)
C15H19NOSi (M= 257.411)
Calc.: molpeak (M+H)+: 258 Found: molpeak (M+H)+: 258
Boehringer Ingelheim 256 Case 1-1406 if
CA 02504160 2005-04-28
Rf value: 0.25 (silica gel, cyc/EtOAc 2:1)
6c 2-(5-ethynyl-indol-1-yl)-ethanol
Under an N2 atmosphere 29 g (91.8 mmol) TBAF are added to a solution of
21.5 g (83.5 mmol) 2-(5-trimethylsilanylethynyl-indol-1-yl)-ethanol in 500 mL
THE and the reaction mixture is stirred for 1.5 h at RT. The mixture is
evaporated down i. vac., the residue is taken up in 300 mL EtOAc, the organic
phase is washed twice with in each case 200 mL water and once with 200 mL
saturated NaCl solution and dried over Na2SO4. After the desiccant and
solvent have been eliminated the desired product is obtained in the form of a
brown oil.
Yield: 15.46 g (100 % of theory)
C12H11 NO (M= 185.228)
Calc.: molpeak (M+H)+: 186 Found: molpeak (M+H)+: 186
HPLC retention time: 7.04 min (method A)
6d 2-(5-(5-bromo-pyridin-2-ylethynyl)-indol-1-yl)-ethanol
Under an N2 atmosphere 29.4 g (124 mmol) 2,5-dibromo-pyridine, 241 mg
(1.3 mmol) Cul and 888 mg (1.3 mmol) Pd(PPh3)2Cl2 are added to a solution
of 23.0 g (124 mmol) 2-(5-ethynyl-indol-1-yl)-ethanol and 35 mL (248 mmol)
diisopropylamine in 1150 mL THE and the reaction mixture is heated to 50 C
for 3.5 h. Another 241 mg Cul and 888 mg Pd(PPh3)2Cl2 and 9 g (38 mmol)
2,5-dibromo-pyridine are added, the mixture is stirred for a further 2.5 h at
50 C, 64 h at RT and a further 8 h at 60 C. The mixture is evaporated down i.
vac., the residue is combined with 500 mL 3% NH3 solution and 800 mL
EtOAc. The precipitate formed is filtered off, washed with water and dried at
50 C.
The two phases of the filtrate are separated and the organic phase is
evaporated down i.vac.. The residue is stirred vigorously with 500 mL
PE/diisopropylether (1:1) and suction filtered. The two product fractions are
then combined.
Yield: 24.96 g (58.9 % of theory)
C17H13BrN2O (M= 341.210)
Boehringer Ingelheim 257 Case 1-1406 ff
Calc.: molpeak (M+H)+: 340/342 Found: molpeak (M+H)+: 340/342
Rf value: 0.39 (silica gel, cyc/EtOAc 1:1)
6e 2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-indol-1-yl}-ethanol
Under an N2 atmosphere 56 mL 2 M Na2CO3 solution and 1.29 g (1.1 mmol)
tetra kis-triphenylphosphane-palladium are added to a solution of 19.0 g (55.7
mmol) 2-[5-(5-bromo-pyridin-2-ylethynyl)-indol-1-yl]-ethanol and 11.55 g (72.4
mmol) 4-chlorophenyl-boric acid in 320 mL 1,4-dioxane and 80 mL MeOH and
the reaction mixture is heated to 110 C for 16 h. The mixture is evaporated
down i. vac., the residue is combined with 300 mL water and the suspension
is stirred vigorously. The precipitate is filtered off and washed with 200 mL
water. The precipitate is suspended three times, each time with 600 mL
PE/DCM (5:1), suction filtered and finally dried in the air until a constant
weight is obtained.
Yield: 17.11 g (82.4 % of theory)
C23H17CIN20 (M= 372.858)
Calc.: molpeak (M+H)+: 373/375 Found: molpeak (M+H)+: 373/375
Rf value: 0.42 (silica gel, DCM/MeOH/NH3 19:1:0.1)
6f 2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-indol-1-yl}-ethyl
methanesuIphonate
Under an argon atmosphere 7.1 mL (51.5 mmol) triethylamine are added to a
solution of 16.0 g (42.9 mmol) 2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-
indol-1-yl}-ethanol in 480 mL THE and 30 mL pyridine and this is cooled to
0 C. Then a solution of 4 mL (51.5 mmol) methanesulphonic acid chloride in
20 mL THE is slowly added dropwise, the mixture is allowed to warm up to RT
and stirred for a further 2 h at RT. The reaction solution is filtered and
evaporated down i.vac.. The residue is combined with 1 L DCM, washed with
400 mL water and the organic phase is dried over Na2SO4. After the desiccant
and solvent have been eliminated the residue is suspended with 600 mL
PE/DCM (5:1), suction filtered and finally dried in the air until a constant
weight is obtained.
Yield: 17.10 g (88.4 % of theory)
CA 02504160 2005-04-28
Boehringer Ingelheim 258 Case 1-1406 ff
CA 02504160 2005-04-28
C24H 19CIN203S (M= 450.948)
Calc.: molpeak (M+H)+: 451/453 Found: molpeak (M+H)+: 451/453
Rf value: 0.9 (silica gel, EtOAc/MeOH/NH3 19:1:0.1)
6g 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-1-(2-pyrrolidin-1-yl-ethyl)-1 H-
indole
1.1 mL (13.3 mmol) pyrrolidine are added to a solution of 600 mg (1.33 mmol)
2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-indol-1-yl}-ethyl
methanesulphonate in 12 mL DMF and the reaction mixture is stirred for 24 h
at RT. The mixture is evaporated down i. vac., the residue is taken up in a
little DCM and the product is purified by chromatography (silica gel,
cyc/EtOAc 2:1)
Yield: 301 mg (53.1 % of theory)
C27H24CIN3 (M= 425.965)
Calc.: molpeak (M+H)+: 426/428 Found: molpeak (M+H)+: 426/428
Rf value: 0.44 (silica gel, cyc/EtOAc 2:1)
The following compounds are prepared as described in Example 6g, in each
case using 5-20 eq. of the amine and stirring the reaction mixture for 24 h at
RT (method A) or for 24 h at RT and for 24 h at 60 C (method B) or for 7.5 h
at 80 C (method C) or for 48 h at 80 C (method D). DCM and water are
added, the phases are separated and the organic phase is dried over Na2SO4.
After the desiccant and solvent have been eliminated the residue is purified
by
chromatography on Alox.
RN
Example R Yield (%) empirical mass Rf value on Alox
(method) formula spectrum (eluant) or HPLC
Boehringer Ingelheim 259 Case 1-1406 ff
retention time in min
(method)
6.1 33.1 C27H24CIN3O 442/444 0.24 01- (A) " [M+H]+ (DCM/MeOH/NH3
19:1:0.1)
6.2 0-O 35.2 C27H24CIN3O 442/444 0.46
(B) " [M+H]+ (DCM/MeOH/NH3
9:1:0.1)
6.3 34.7 C28H26CIN3O 456/458 0.32
(B) [M+H]+ (DCM/MeOH/NH3
9:1:0.1)
6.4 22.1 C28H26CIN3 440/442 0.85
(B) " [M+HJ+ (DCM/MeOH/NH3
9:1:0.1)
6.5 0 26.3 C28H26C1N30 456/458 0.42
(B) [M+H]+ (DCM/MeOH/NH3
19:1:0.1)
6.6 0 21.9 C29H28CIN3O 470/472 0.21
(B) [M+H]+ (DCM/MeOH/NH3
19:1:0.1)
6.7 ,~ 27.0 C29H28CIN3O 470/472 0.07
(B) " [M+H]+ (DCM/MeOH/NH3
19:1:0.1)
6.8 21.1 C28H26CIN3O 456/458 0.28 ,oj:: (B) H " [M+H]+ (DCM/MeOH/NH3
19:1:0.1)
6.9 17.2 C29H28CIN3 454/456 0.33
(B) " . [M+H]+ (DCM/MeOH/NH3
19:1:0.1)
6.10 55.7 C29H28CIN3 454/456 0.16
(C) ON- [M+H]+ (DCM/MeOH/NH3
19:1:0.1)
CA 02504160 2005-04-28
Boehringer Ingelheim 260 Case 1-1406 if
CA 02504160 2005-04-28
6.11 11.6 C301-130C1N3 468/470 0.18
(D) [M+H]+ (DCM/MeOH/NH3
19:1:0.1)
Example 6.12
(2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-indol-1-yl}-ethyl)-
cyclopropylmethyl-propyl-amine
CI
63 pL (0.44 mmol) cyclopropylmethyl-propyl-amine are added to a solution of
100 mg (0.22 mmol) 2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-indol-1-yl}-
ethyl methanesulphonate in 2 mL DMF and the reaction mixture is stirred for
16 h at 60 C. The mixture is evaporated down i. vac., the residue is taken up
in DCM, the organic phase is washed with water and dilute K2CO3 solution
and dried over Na2SO4. After the desiccant and solvent have been eliminated
the residue is purified twice by chromatography (Alox, cyc/EtOAc 8:2 and
cyc/DCM 1:1).
Yield: 21 mg (20.2 % of theory)
C30H30CIN3 (M= 468.047)
Calc.: molpeak (M+H)+: 468/470 Found: molpeak (M+H)+: 468/470
Rf value: 0.37 (Alox, cyc/EtOAc 8:2)
Example 6.13
(2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-indol-1-yl}-ethyl)-
cyclopropylmethyl-amine
Fi /
N
Boehringer Ingeiheim 2t" Case 1-1406 ff
0.46 mL (5.4 mmol) C-cyclopropyl-methylamine are added to a solution of
2.03 g (4.5 mmol) 2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-indol-l-yl}-
ethyl methanesuIphonate in 20 mL DMF and the reaction mixture is stirred for
4 h at 60 C. The mixture is evaporated down i. vac., the residue is stirred
with
DCM, the precipitate is suction filtered and dried in the air. The product is
precipitated as the methanesulphonic acid salt.
Yield: 600 mg (25.5 % of theory)
C27H24CIN3*CH4O3S (M= 522.07)
Calc.: molpeak (M+H)+: 426/428 Found: molpeak (M+H)+: 426/428
HPLC retention time: 5.23 min (method B)
Example 6.14
(2-{5-[5-(4-chloro-phenyl)-pyrid in-2-ylethynyl]-indol-l-yl}-ethyl)-bis-
cyclopropylmethyl-amine
CI
36 pL (0.47 mmol) cyclopropanecarbaldehyde are added to a solution of 100
mg (0.24 mmol) (2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-indol-l-yl}-
ethyl)-cyclopropylmethyl-amine in 20 mL MeOH at RT and 15 min later 59 mg
(0.94 mmol) NaBH4 and one drop of glacial acetic acid are added. The
mixture is stirred for 1 h at RT, evaporated down i.vac., the residue is taken
up in dilute K2CO3 solution, extracted exhaustively with EtOAc and dried over
Na2SO4. After the desiccant and solvent have been eliminated the residue is
triturated with PE, suction filtered and dried.
Yield: 105 mg (93.1 % of theory)
C31 H30CIN3 (M= 480.058)
Calc.: molpeak (M+H)+: 480/482 Found: molpeak (M+H)+: 480/482
HPLC retention time: 5.53 min (method B)
Example 6.15
CA 02504160 2005-04-28
Boehringer Ingelheim 262 Case 1-1406 ff
(2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-indol-1-yl}-ethyl)-
cyclopropylmethyl-isobutyl-amine
cI
N
N\~N
Prepared analogously to Example 6.14; after the working up described, the
crude product is purified by chromatography (Alox, cyc/EtOAc 4:1).
Yield: 35 mg (41.5 % of theory)
C31 H32CIN3 (M= 482.074)
Calc.: molpeak (M+H)+: 482/484 Found: molpeak (M+H)+: 482/484
Rf value: 0.83 (Alox, cyc/EtOAc 4:1)
HPLC retention time: 5.7 min (method B)
Example 6.16
(2-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-indol-1-yl}-ethyl)-
cyclopropylmethyl-prop-2-ynyl-amine
CI
N
N N
45 mg (0.33 mmol) K2CO3 and 13 pL (0.18 mmol) 3-bromo-propyne are
added at RT to a solution of 70 mg (0.16 mmol) (2-{5-[5-(4-chloro-phenyl)-
pyridin-2-ylethynyl]-indol-1-yl}-ethyl)-cyclopropylmethyl-amine in 2 mL DMF
and the reaction mixture is stirred for 4 h at RT. The mixture is evaporated
down i. vac., the residue is taken up in water, extracted exhaustively with
DCM and the organic phase is dried over Na2SO4. After the desiccant and
solvent have been eliminated the residue is purified by chromatography (Alox,
cyc/EtOAc 4:1).
Yield: 32 mg (42.1 % of theory)
C30H26CIN3 (M= 464.015)
Calc.: molpeak (M+H)+: 464/466 Found: molpeak (M+H)+: 464/466
CA 02504160 2005-04-28
Boehringer Ingelheim 263 Case 1-1406 if
Rf value: 0.35 (Alox, cyc/EtOAc 4:1)
HPLC retention time: 5.86 min (method B)
The following compounds may be prepared by the methods described in
Examples 6.14 and 6.16:
ci
/ I \
R N /,
Example R Yield (%) empirical mass HPLC retention time
formula spectrum in min
(method)
6.17
6.18 CF3\
6.19 30.1 C30H28CIN3 466/468 5.5 (B)
[M+H] +
6.20 ",0
6.21
Example 7
1-{3-[5-(4-chloro-phenyl)-pyridin-2-yl]-prop-2-ynyl}-5-pyrrolidin-1-ylmethyl-1
H-
indole
CA 02504160 2005-04-28
Boehringer Ingelheim 264 Case 1-1406 if
c
7a 1 -prop-2-ynyl-1 H-indole-5-carbaldehyde
0.65 g (50% in mineral oil, 13.5 mmol) NaH are batchwise added to a
solution, cooled to 0 C, of 2.0 g (13.5 mmol) 1 H-indole-5-carbaldehyde in 80
mL THE and after heating to RT stirred for 15 min. Then a solution of 1.6 mL
(80% in toluene, 15 mmol) propargyl bromide in 20 mL THE is slowly added
dropwise and the reaction mixture is stirred overnight at RT. The mixture is
evaporated down i. vac., the residue is combined with water, the aqueous
phase is exhaustively extracted with EtOAc and the organic phase is dried
over Na2SO4. After the desiccant and solvent have been eliminated the
residue is purified by chromatography (silica gel, gradient: cyc/EtOAc 4:1 to
2:1).
Yield: 0.65 g (26.4 % of theory)
C12H9NO (M= 183.212)
Calc.: molpeak (M+H)+: 184 Found: molpeak (M+H)+: 184
Rf value: 0.34 (silica gel, cyc/EtOAc 3:1)
7b 1-prop-2-ynyl-5-pyrrolidin-1-ylmethyl-1 H-indole
A solution of 250 mg (1.37 mmol) 1-prop-2-ynyl-1H-indole-5-carbaldehyde
and 200 pL (2.37 mmol) pyrrolidine in 50 mL THE is adjusted to pH 5 with
glacial acetic acid, combined with 550 mg (2.47 mmol) NaBH(OAc)3 and
stirred for 24 h at RT. 20 mL of saturated K2CO3 solution are added, the
mixture is extracted with 50 mL EtOAc and the organic phase is dried over
Na2SO4. After the desiccant and solvent have been eliminated the residue is
purified by chromatography (silica gel, EtOAc/MeOH/NH3 95:5:0.5).
Yield: 325 mg (100 % of theory)
C16H18N2 (M= 238.335)
Calc.: molpeak (M+H)+: 239 Found: molpeak (M+H)+: 239
Rf value: 0.38 (silica gel, EtOAc/MeOH/NH3 95:5:0.5)
CA 02504160 2005-04-28
Boehringer Ingelheim 265 Case 1-1406 if
7c 1-[3-(5-bromo-pyridin-2-yl)-prop-2-ynyl]-5-pyrrolidin-1-ylmethyl-1 H-
indole
Under an argon atmosphere 5 mg (0.03 mmol) Cul and 18 mg (0.03 mmol)
Pd(PPh3)2CI2 are added to a solution of 337 mg (1.41 mmol) 1-prop-2-ynyl-5-
pyrrolidin-1-ylmethyl-1H-indole and 345 mg (1.41 mmol) 2,5-dibromo-pyridine
in 50 mL THE and 0.4 mL diisopropyla mine and the reaction mixture is stirred
for 17 h at RT. The mixture is evaporated down i. vac., the residue is taken
up
in 30 mL EtOAc, the organic phase is washed with 30 mL water and 30 mL
saturated NaCl solution and dried over Na2SO4. After the desiccant and
solvent have been eliminated the residue is purified by chromatography (silica
gel, EtOAc/MeOH/NH3 95:5:0.5).
Yield: 145 mg (26.0 % of theory)
C21 H20BrN3 (M= 394.318)
Calc.: molpeak (M+H)+: 394/396 Found: molpeak (M+H)+: 394/396
Rf value: 0.62 (silica gel, EtOAc/MeOH/NH3 90:10:1)
7d 1-{3-[5-(4-chloro-phenyl)-pyridin-2-yl]-prop-2-ynyl}-5-pyrrolidin-1-
ylmethyl-1 H-indole
Under an argon atmosphere 0.5 mL 2 M Na2CO3 solution and 10 mg (0.01
mmol) tetrakis-triphenyiphosphane-palladium are added to a solution of 59 mg
(0.15 mmol)1-[3-(5-bromo-pyridin-2-yl)-prop-2-ynyl]-5-pyrrolidin-1-ylmethyl-
1 H-indole and 50 mg (0.32 mmol) 4-chlorophenyl-boric acid in 5 mL 1,4-
dioxane and the reaction mixture is stirred for 2.5 h at 110 C. The mixture is
evaporated down i. vac., the residue is combined with 3 mL water, extracted
with 5 mL EtOAc, the organic phase is washed with saturated NaCl solution
and dried over Na2SO4. After the desiccant and solvent have been eliminated
the residue is purified by HPLC.
Yield: 21.8 mg (34.1 % of theory)
C27H24CIN3 (M= 425.965)
Calc.: molpeak (M+H)+: 426/428 Found: molpeak (M+H)+: 426/428
HPLC retention time: 6.75 min (method A).
CA 02504160 2005-04-28
Boehringer Ingelheim 266 Case 1-1406 if
Example 8
5-(4-chloro-phenyl)-2-[3-(4-pyrrolidin-1 -ylmethyl-phenoxy)-prop-1-ynyl]-
pyridine
I
O % N
8a 3-[5-(4-chloro-phenyl)-pyridin-2-yl]-prop-2-yn-1-ol
Under an N2 atmosphere 1 mL (7.22 mmol) triethylamine, 23 mg (0.1 mmol)
Pd(OAc)2 and 57.5 mg (0.19 mmol) biphenyl-2-yl-di-tert-butyl-phosphane are
added to a solution of 500 mg (2.36 mmol) 3-(5-bromo-pyridin-2-yl)-prop-2-yn-
1-el and 600 mg (3.72 mmol) 4-chlorophenyl-boric acid in 10 mL DMF and 2.5
mL water and the reaction mixture is stirred for 8 h at 60 C. Then 400 mg
(2.48 mmol) 4-chlorophenyl-boric acid are added and the mixture is stirred for
a further 19 h at 60 C. The mixture is evaporated down i. vac., the residue is
combined with 10 mL water and 10 mL EtOAc, the aqueous phase is
saturated with NaCl, the organic phase is separated off and dried over
Na2SO4. After the desiccant and solvent have been eliminated the residue is
purified by chromatography (silica gel, cyc/EtOAc3 2:1).
Yield: 228 mg (39.6 % of theory)
C14H10CINO(M= 243.695)
Calc.: molpeak (M+H)+: 244/246 Found: molpeak (M+H)+: 244/246
Rf value: 0.23 (silica gel, cyc/EtOAc 1:1)
8b 5-(4-chloro-phenyl)-2-[3-(4-pyrrolidin-1 -ylmethyl-phenoxy)-prop-1 -ynyl]-
pyridine
131 mg (0.5 mmol) triphenylphosphane are added to a solution of 100 mg
(0.41 mmol) 3-[5-(4-chloro-phenyl)-pyridin-2-yl]-prop-2-yn-1-ol and 88 mg (0.5
mmol) 4-pyrrolidin-1-ylmethyl-phenol in 4 mL THF. Then 0.1 mL (0.5 mmol)
diisopropyl azo-dicarboxylate is slowly added dropwise and the reaction
mixture is stirred for 3 h at RT. The mixture is evaporated down i. vac., the
residue is taken up in 1 mL DMF and purified by HPLC. The product obtained,
which still contains triphenylphosphane oxide, is again purified by
chromatography (silica gel, EtOAc after EtOAc/MeOH/NH3 9:1:0.1).
CA 02504160 2005-04-28
Boehringer Ingelheim 267 Case 1-1406 if
Yield: 6.5 mg (3.9 % of theory)
C25H23CIN20(M= 402.928)
Calc.: molpeak (M+H)+: 403/405 Found: molpeak (M+H)+: 403/405
Rf value: 0.72 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
Example 9
5-(4-chloro-phenyl)-2-[3-methyl-3-(4-pyrrolidin-1-ylmethyl-phenoxy)-but-1-
ynyl]-pyridine
cI
I
/ N
N O
9a 4-(5-bromo-pyridin-2-yl)-2-methyl-but-3-yn-2-ol
Under an argon atmosphere 38 mg (0.2 mmol) Cul and 143 mg (0.2 mmol)
Pd(PPh3)2C12 are added to a solution of 0.99 mL (10.0 mmol) 2-methyl-but-3-
yn-2-ol and 2.44 g (10.0 mmol) 2,5-dibromo-pyridine in 50 mL THE and 2.8
mL (20 mmol) diisopropylamine and the reaction mixture is stirred for 15 min
at RT. The reaction mixture is combined with water, exhaustively extracted
with EtOAc and the organic phase is dried over Na2SO4. After the desiccant
and solvent have been eliminated the residue is purified by chromatography
(silica gel, cyc/EtOAc 2:1).
Yield: 2.0 g (83.3 % of theory)
C10H10BrNO (M= 240.101)
Calc.: molpeak (M+H)+: 240/242 Found: molpeak (M+H)+: 240/242
Rf value: 0.29 (silica gel, cyc/EtOAc 2:1)
9b 4-[5-(4-chloro-phenyl)-pyridin-2-yl]-2-methyl-but-3-yn-2-ol
Under an argon atmosphere 3 mL 2 M Na2CO3 solution and 173 mg (0.15
mmol) tetrakis-triphenylphosphane-palladium are added to a solution of 720
mg (3.0 mmol) 4-(5-bromo-pyridin-2-yl)-2-methyl- but-3-yn-2-ol and 593 mg
(3.6 mmol) 4-chlorophenyl-boric acid in 60 mL 1,4-dioxane and the reaction
mixture is stirred for 18 h at 85 C. The mixture is evaporated down i. vac.,
the
residue is combined with water, extracted exhaustively with EtOAc, the
CA 02504160 2005-04-28
Boehringer Ingeiheim 268 Case 1-1406 if
organic phase is washed with water and dried over Na2SO4. After the
desiccant and solvent have been eliminated the residue is purified by
chromatography (silica gel, PE/EtOAc 1:1).
Yield: 420 mg (51.5 % of theory)
C16H14CINO (M= 271.749)
Calc.: molpeak (M+H)+: 272/274 Found: molpeak (M+H)+: 272/274
Rf value: 0.42 (silica gel, PE/EtOAc 1:1)
9c 5-(4-chloro-phenyl)-2-[3-methyl-3-(4-pyrrolidin-1-ylmethyl-phenoxy)-
but-1-ynyl]-pyridine
131 mg (0.5 mmol) triphenylphosphane are added to a solution of 136 mg (0.5
mmol) 4-[5-(4-chloro-phenyl)-pyridin-2-yl]-2-methyl-but-3-yn-2-ol and 88 mg
(0.5 mmol) 4-pyrrolidin-1-ylmethyl-phenol in 20 ml THF. Then 0.1 mL (0.5
mmol) diisopropyl azo-dicarboxylate is slowly added dropwise and the
reaction mixture is stirred for 24 h at RT. The mixture is evaporated down i.
vac., the residue is taken up in water, extracted exhaustively with BOAC, the
organic phase is washed with saturated NaCl solution and dried over Na2SO4.
After the desiccant and solvent have been eliminated the residue is purified
by
HPLC.
Yield: 3 mg (1.4 % of theory)
C27H27CIN20 (M= 430.982)
Calc.: molpeak (M+H)+: 431/433 Found: molpeak (M+H)+: 431/433
HPLC retention time: 7.78 min (method A)
Example 10
5-(4-chloro-phenyl)-2-[3-(4-pyrrolidin-1-ylmethyl-phenyl)-prop-2-ynyloxy]-
pyridine
O N~
10a 5-(4-chloro-phenyl)-pyridin-2-ol
CA 02504160 2005-04-28
Boehringer Ingelheim 269 Case 1-1406 if
Under an N2 atmosphere 21.7 mL 2 M Na2CO3 solution and 250 mg (0.22
mmol) tetra kis-triphenyl phosphane-palladium are added to a solution of 8.0 g
(21.7 mmol) 5-iodo-pyridin-2-ol and 3.81 g (23.9 mmol) 4-chlorophenyl-boric
acid in 120 mL 1,4-dioxane and 30 mL dry MeOH and the reaction mixture is
stirred for 19 h at 110 C. The mixture is evaporated down i. vac., the residue
is combined with water, the precipitate is filtered off, washed with water and
dried at 40 C in the circulating air dryer until a constant weight is
obtained.
Yield: 3.8 g (85.1 % of theory)
C11 H8CINO (M= 205.646)
Caic.: molpeak (M+H)+: 206/208 Found: molpeak (M+H)+: 206/208
Rf value: 0.56 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
10b 5-(4-chioro-phenyl)-2-prop-2-ynyloxy-pyridine
2 mL (80% in toluene, 18.5 mmol) 3-bromo-propyne are added to a
suspension of 3.8 g (18.5 mmol) 5-(4-chioro-phenyl)-pyridin-2-ol and 5.1 g (37
mmol) K2CO3 in 50 mL DMF and the reaction mixture is stirred for 64 h at RT.
The mixture is evaporated down i. vac., the residue is combined with 80 mL
water, extracted with 150 mL EtOAc and the organic phase is dried over
Na2SO4. After the desiccant and solvent have been eliminated the residue is
purified by chromatography (silica gel, cyc/EtOAc 2:1).
Yield: 216 mg (4.8 % of theory)
C14H10CINO (M= 243.695)
Calc.: molpeak (M+H)+: 244/246 Found: molpeak (M+H)+: 244/246
Rf value: 0.16 (silica gel, cyc/EtOAc 2:1)
10c 5-(4-chioro-phenyl)-2-[3-(4-pyrrolidin-1 -ylmethyl-phenyl)-prop-2-
ynyloxy]-pyridine
Under an N2 atmosphere 221 mg (0.68 mmol) Cs2CO3, 4 mg (0.02 mmol) Cul
and 23 mg (0.02 mmol) tetrakis-triphenylphosphane-palladium are added to a
solution of 110 mg (0.45 mmol) 5-(4-chloro-phenyl)-2-prop-2-ynyloxy-pyridine
and 129 mg (0.45 mmol) 1-(4-iodo-benzyl)-pyrrolidine in 9 mL THE and the
reaction mixture is stirred for 4.5 h at RT. The mixture is evaporated down i.
vac., the residue is combined with 20 mL 3% NH3 solution and 40 mL EtOAc,
CA 02504160 2005-04-28
Boehringer Ingelheim 270 Case 1-1406 ff
the organic phase is separated off and dried over Na2SO4. After the desiccant
and solvent have been eliminated the residue is purified first by HPLC and
then by chromatography (silica gel, DCM/MeOH/NH3 19:1:0.1).
Yield: 28 mg (15.5 % of theory)
C25H23CIN2O (M= 402.928)
Calc.: molpeak (M+H)+: 403/405 Found: molpeak (M+H)+: 403/405
Rf value: 0.33 (silica gel, DCM/MeOH/NH3 19:1:0.1)
HPLC retention time: 6.43 min (method A)
Example 11
1-(2-{4-[4-(4-chloro-phenyl)-thiophen-2-ylethynyl]-phenoxy}-ethyl)-pyrrolidine
/`^ r s
11a (4-bromo-thiophen-2-ylethynyl)-trimethyl-silane
Under an argon atmosphere 0.37 g (1.94 mmol) Cul, 2.24 g (1.94 mmol)
tetrakis-triphenylphosphane-palladium and 16.2 mL triethylamine are added to
a solution of 10.0 g (38.85 mmol) 2,4-dibromothiophene in 300 mL THF, the
reaction mixture is cooled to -78 C and then at this temperature a solution of
5.6 mL (38.85 mmol) ) ethynyl-trimethyl-silane in 250 mL THE is slowly added
dropwise. After the addition has ended the mixture is allowed to heat up
slowly to RT and stirred overnight. The mixture is evaporated down i. vac.,
the
residue is combined with water, extracted exhaustively with DCM and the
combined organic phases are dried over MgSO4. After the desiccant and
solvent have been eliminated the residue is triturated with PE, filtered to
remove insoluble ingredients and the solvent is evaporated down. The residue
is purified by chromatography (silica gel, PE).
Yield: 9.5 g (56.6 % of theory)
C9H11BrSSi (M= 259.242)
Rf value: 0.77 (silica gel, PE)
CA 02504160 2005-04-28
Boehringer Ingelheim 271 Case 1-1406 if
11b 4-bromo-2-ethynyl-thiophene
4.6 g (14.58 mmol) TBAF are added to a solution, cooled to 0 C, of 6.3 g
(14.58 mmol) (4-bromo-thiophen-2-ylethynyl)-trimethyl-silane in 60 mL THF.
The cooling bath is removed and the mixture is stirred for a further 30 min.
The reaction mixture is combined with EtOAc, washed with water and the
organic phase is dried over MgSO4. After the desiccant and solvent have
been eliminated the residue is purified by chromatography (silica gel, PE).
Yield: 1.9 g (69.7 % of theory)
C6H3BrS (M= 187.059)
Calc.: molpeak (M+H)+: 186/188 Found: molpeak (M+H)+: 186/188
11c 1-{2-[4-(4-bromo-thiophen-2-ylethynyl)-phenoxy]-ethyl}-pyrrolidine
Under an argon atmosphere 0.3 mL (3.13 mmol) piperidine, 14.9 mg (0.08
mmol) Cul and 90.3 mg (0.08 mmol) tetrakis-triphenylphosphane-palladium
are added to a solution of 293 mg (1.56 mmol) 4-bromo-2-ethynyl-thiophene
and 620 mg (1.56 mmol) 1-[2-(4-iodo-phenoxy)-ethyl]-pyrrolidine in 10 mL
THE and the reaction mixture is stirred overnight at RT. To complete the
reaction another 150 mg (0.8 mmol) 4-bromo-2-ethynyl-thiophene are added
and the mixture is stirred for a further 24 h at RT. The mixture is evaporated
down i. vac., the residue is triturated with EtOAc and the insoluble
ingredients
are filtered off. After the solvent has been eliminated the residue is
purified by
chromatography (silica gel, EtOAc/MeOH/NH3 8:2:0.2).
Yield: 300 mg (51.0 % of theory)
C18H18BrNOS (M= 376.318)
Calc.: molpeak (M+H)+: 376/378 Found: molpeak (M+H)+: 376/378
Rf value: 0.52 (silica gel, EtOAc/MeOH/NH3 9:1:0.1)
11d 1-(2-{4-[4-(4-chloro-phenyl)-thiophen-2-ylethynyl]-phenoxy}-ethyl)-
pyrrolidine
Under an N2 atmosphere 5 mL 2 M Na2CO3 solution and 47 mg (0.41 mmol)
tetra kis-triphenylphosphane-palladium are added to a solution of 310 mg
(0.82 mmol) 1-{2-[4-(4-bromo-thiophen-2-ylethynyl)-phenoxy]-ethyl}-
pyrrolidine and 129 mg (0.82 mmol) 4-chlorophenyl-boric acid in 10 mL 1,4-
CA 02504160 2005-04-28
Boehringer Ingelheim 272 Case 1-1406 if
CA 02504160 2005-04-28
dioxane and the reaction mixture is refluxed for 1 h. The hot solution is
filtered
through a fibreglass filter, the filtrate is extracted with EtOAc , the
organic
phase is washed with water and dried over MgSO4. After the desiccant and
solvent have been eliminated the residue is purified by chromatography (silica
gel, EtOAc/MeOH/NH3 8:2:0.2).
Yield: 23 mg (6.8 % of theory)
C24H22CINOS (M= 407.966)
Calc.: molpeak (M+H)+: 408/410 Found: molpeak (M+H)+: 408/410
HPLC retention time: 5.35 min (method B)
Example 12
2-(4-chloro-phenyl)-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-pyrazine
12a 5-(4-chloro-phenyl)-pyrazin-2-ylamine
Under an argon atmosphere 50 mL 2 M Na2CO3 solution and 1.2 g (1.0 mmol)
tetrakis-triphenylphosphane-palladium are added to a solution of 8.7 g (50.0
mmol) 5-bromo-pyrazin-2-ylamine and 8.0 g (50.0 mmol) 4-chlorophenyl-boric
acid in 150 mL 1,4-dioxane and 50 mL MeOH and the reaction mixture is
heated to 110 C for 2.5 h. The mixture is evaporated down i. vac., the residue
is combined with water, extracted exhaustively with EtOAc and the organic
phase is dried over Na2SO4. After the desiccant and solvent have been
eliminated the residue is purified by chromatography (silica gel, gradient:
DCM to DCM/MeOH 20:1).
Yield: 8.3 g (80.7 % of theory)
C14H8CIN3 (M= 205.648)
Calc.: molpeak (M+H)+: 206/208 Found: molpeak (M+H)+: 206/208
HPLC retention time: 7.15 min (method A)
12b 2-(4-chloro-phenyl)-5-iodo-pyrazine
Boehringer Ingelheim 273 Case 1-1406 if
With the exclusion of light, 4.9 mL (40.0 mmol) tert-butylnitrite and 7.6 g
(30
mmol) iodine are added to a solution of 4.8 g (23.3 mmol) 5-(4-chloro-phenyl)-
pyrazin-2-ylamine in 100 mL CCI4 and 50 mL DCM and the reaction mixture is
stirred overnight at RT. It is combined with 100 mL water and 50 mL 10%
Na2S2O3 solution, the organic phase is separated off, washed again with 50
mL 10% Na2S2O3 solution and twice with 50 mL water and dried over MgSO4.
It is filtered through activated charcoal, evaporated down i.vac. and the
residue is purified by chromatography (silica gel, gradient: PE to PE/EtOAc
8:2).
Yield: 3.4 g (46.0 % of theory)
C10H6CIIN2 (M= 316.530)
Caic.: molpeak (M+H)+: 317/319 Found: molpeak (M+H)+: 317/319
Rf value: 0.55 (silica gel, PE/EtOAc 9:1)
12c 2-(4-chloro-phenyl)-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-
pyrazine
Under an N2 atmosphere 19 mg (0.1 mmol) Cul, 82 mg (0.1 mmol) [1,1'-bis-
(diphenylphosphine)-ferrocene]-paIladium(II)-chloride are added to a solution
of 316 mg (1.0 mmol) 2-(4-chloro-phenyl)-5-iodo-pyrazine and 215 mg (1.0
mmol) 1-[2-(4-ethynyl-phenoxy)-ethyl]-pyrrolidine in 50 mL THE and 0.4 mL (3
mmol) triethylamine and the reaction mixture is stirred overnight at RT. To
complete the reaction another 100 mg (0.32 mmol) 2-(4-chloro-phenyl)-5-
iodo-pyrazine are added and the mixture is again stirred overnight. It is
evaporated down i. vac., the residue is combined with 10% Na2CO3 solution,
extracted exhaustively with DCM, the combined organic phases are washed
three times with water and dried over MgSO4. This is filtered through
activated
charcoal, evaporated down i.vac. and the residue is purified by
chromatography (silica gel, gradient: EtOAc to EtOAc/MeOH/NH3 9:9:1).
Yield: 170 mg (42.1 % of theory)
C24H22CIN30 (M= 403.915)
Calc.: molpeak (M+H)+: 404/406 Found: molpeak (M+H)+: 404/406
Rf value: 0.58 (silica gel, DCM/MeOH/NH3 9:1:0.1)
CA 02504160 2005-04-28
Boehringer Ingelheim 274 Case 1-1406 if
CA 02504160 2005-04-28
Example 13
2-(4-chloro-phenyl)-5-[4-(2-pyrrolidin-1 -yl-ethoxy)-phenylethynyl]-pyridine
-N
13a 5-bromo-2-(4-chloro-phenyl)-pyridine
Under an N2 atmosphere 11 mL 2 M Na2CO3 solution and 240 mg (0.21
mmol) tetrakis-triphenylphosphane-palladium are added to a solution of 3.00 g
(10.6 mmol) 5-bromo-2-iodo-pyridine and 3.37 g (21.1 mmol) 4-chlorophenyl-
boric acid in 60 mL 1,4-dioxane and 15 mL MeOH and the reaction mixture is
heated to 110 C for 3 h. The mixture is evaporated down i. vac., the residue
is
combined with 50 mL water,10 mL 3% NH3 solution and 150 mL EtOAc, the
organic phase is separated off and dried over Na2SO4. After the desiccant and
solvent have been eliminated the residue is purified by chromatography (silica
gel, cyc).
Yield: 1.52 g (53.6 % of theory)
C11 H7BrCIN (M= 268.542)
Calc.: molpeak (M+H)+: 268/270/272 Found: molpeak (M+H)+:
268/270/272
Rf value: 0.1 (silica gel, cyc)
13b 2-(4-chloro-phenyl)-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-
pyridine
Under an N2 atmosphere 773 mg (2.25 mmol) Cs2CO3, 14 mg (0.08 mmol)
Cul and 87 mg (0.08 mmol) tetra kis-triphenylphosphane-palladium are added
to a solution of 403 mg (1.5 mmol) 5-bromo-2-(4-chloro-phenyl)-pyridine and
322 mg (1.5 mmol) 1-[2-(4-ethynyl-phenoxy)-ethyl]-pyrrolidine in 10 mL THE
and the reaction mixture is stirred for 4 h at RT. Then it is heated to 60 C
for
16 h. The mixture is evaporated down i. vac., the residue is combined with 30
mL water, 5 mL 3% NH3 solution and 60 mL EtOAc, the organic phase is
separated off and dried over Na2SO4. After the desiccant and solvent have
Boehringer Ingelheim 275 Case 1-1406 if
been eliminated the residue is purified first by chromatography (silica gel,
EtOAc/MeOH/NH3 19:1:0.1) and then by HPLC.
Yield: 9 mg (2.2 % of theory)
C25H23CIN20 (M= 402.928)
CaIc.: molpeak (M+H)+: 403/405 Found: molpeak (M+H)+: 403/405
HPLC retention time: 8.11 min (method A)
Example 14
ethyl 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-3-methyl-1-(2-pyrrolidin-1-
yl-
ethyl)-1 H-indole-2-carboxylate
N
0 N
r
14a ethyl 3-methyl-1-(2-pyrrolidin-1-yl-ethyl)-5-trimethylsilanylethynyl-1 H-
i n d o l e- 2-ca rbo xy l ate
Under an argon atmosphere 577 mg (0.5 mmol) tetrakis-triphenyiphosphane-
palladium and 95 mg (0.5 mmol) Cul are added to a solution of 2.82 g (10
mmol) ethyl 5-bromo-3-methyl-1 H-indole-2-carboxylate and 1.52 mL (11
mmol) ethynyl-trimethyl-silane in 3 mL (30 mmol) piperidine and 30 mL THE
and the reaction mixture is stirred for 14 h at 60 C. It is diluted with
water,
extracted exhaustively with EtOAc, the combined organic phases are washed
with saturated NaCl solution and dried over Na2SO4. After the desiccant and
solvent have been eliminated the residue is purified by chromatography (silica
gel, cyc/EtOAc 9:1).
Yield: 1.3 g (43.4 % of theory)
C1 71-121 NO2Si (M= 299.448)
Calc.: molpeak (M+H)+: 300 Found: molpeak (M+H)+: 300
Rf value: 0.61 (silica gel, cyc/EtOAc 7:3)
CA 02504160 2005-04-28
Boehringer Ingelheim 276 Case 1-1406 If
14b ethyl 5-ethynyl-3-methyl-1-(2-pyrrolidin-1-yl-ethyl)-1 H-indole-2-
carboxylate
Under an argon atmosphere 562 mg (3.3 mmol) 1-(2-chloro-ethyl)-pyrrolidine
(used as the hydrochloride) are added to a suspension of 900 mg (3.0 mmol)
ethyl 3-methyl-1-(2-pyrrolidin-1-yl-ethyl)-5-trimethylsilanylethynyl-1 H-
indole-2-
carboxylate and 457 mg (3.3 mmol) K2CO3 in 10 mL DMF and the reaction
mixture is stirred for 42 h at 60 C. It is diluted with water, extracted
exhaustively with EtOAc, the combined organic phases are washed with water
and dried over Na2SO4. After the desiccant and solvent have been eliminated
the residue is purified by chromatography (silica gel, EtOAc/MeOH/NH3
90:10:1).
Yield: 250 mg (25.6 % of theory)
C20H24N202 (M= 324.426)
Calc.: molpeak (M+H)+: 325 Found: molpeak (M+H)+: 325
HPLC retention time: 4.59 min (method B)
14c ethyl 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-3-methyl-1-(2-
pyrrol id i n-1-yl-eth yl)-1 H-indole-2-ca rboxyl ate
Under an argon atmosphere 11 mg (0.02 mmol) Pd(PPh3)2CI2 and 3 mg (0.02
mmol) Cul are added to a solution of 250 mg (0.77 mmol) ethyl 5-ethynyl-3-
methyl-1-(2-pyrrolidin-1-yl-ethyl)-1H-indole-2-carboxylate and 243 mg (0.77
mmol) 5-(4-chloro-phenyl)-2-iodo-pyridine in 1.52 mL (15.4 mmol) piperidine
and 25 mL THE and the reaction mixture is stirred for 4 h at RT. It is diluted
with water, extracted exhaustively with EtOAc, the combined organic phases
are washed with water and saturated NaCl solution and dried over Na2SO4.
After the desiccant and solvent have been eliminated the residue is purified
first by chromatography (silica gel, cyc/EtOAc 2:1) and then by HPLC.
Yield: 7 mg (1.8 % of theory)
C31 H30 CIN3O2 (M= 512.057)
Calc.: molpeak (M+H)+: 512/514 Found: molpeak (M+H)+: 512/514
Rf value: 0.67 (Alox, cyc/EtOAc 2:1)
HPLC retention time: 5.96 min (method B)
CA 02504160 2005-04-28
Boehringer Ingelheim 277 Case 1-1406 if
CA 02504160 2005-04-28
Example 15
N-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-3-methyl -pyridin-2-yl}-2-
pyrrolidin-1-yl-acetamide
N
0 ~
ONE
N N
I
H
15a N-(5-bromo-3-methyl-pyridin-2-yl)-2-chloro-acetamide
1.75 mL (22 mmol) chloroacetyl chloride are added to a solution, cooled to
0 C, of 3.74 g (20 mmol) 2-amino-5-bromo-3-methylpyridine in 50 mL DCM
and then 6.1 mL (44 mmol) triethylamine are slowly added dropwise. After the
addition has ended the ice bath is removed and the reaction mixture is stirred
for 4 h at RT. It is poured onto water, extracted exhaustively with DCM, the
combined organic phases are washed with water and saturated NaCl solution
and dried over Na2SO4. After the desiccant and solvent have been eliminated
the residue is purified by chromatography (silica gel, cyc/EtOAc 2:1).
Yield: 2.7 g (51.2 % of theory)
C8H8BrCIN2O (M= 263.523)
Calc.: molpeak (M+H)+: 263/265/267 Found: molpeak (M+H)+:
263/265/267
Rf value: 0.48 (silica gel, cyc/EtOAc 1:1)
15b N-(5-bromo-3-methyl-pyridin-2-yl)-2-pyrrolidin-1-yl-acetamide
0.81 mL (9.9 mmol) pyrrolidine are added to a suspension of 2.37 g (9.0
mmol) N-(5-bromo-3-methyl-pyridin-2-yl)-2-chloro-acetamide and 2.49 g (18
mmol) K2CO3 in 22.5 mL DMF and the reaction mixture is stirred for 20 h at
RT. It is diluted with water, extracted exhaustively with EtOAc, the combined
organic phases are washed with water and dried over Na2SO4. After the
desiccant and solvent have been eliminated the residue is taken up in a little
diisopropylether, cooled to 0 C , the crystals precipitated are suction
filtered
and dried in the air.
Yield: 1.4 g (52.2 % of theory)
C12H16BrN3O (M= 298.185)
Boehringer Ingelheim 278 Case 1-1406 if
Calc.: molpeak (M+H)+: 298/300 Found: molpeak (M+H)+: 298/300
Rf value: 0.48 (silica gel, EtOAc/MeOH/NH3 90:10:1)
15c N-(3-methyl-5-trimethylsilanylethynyl-pyridin-2-yl)-2-pyrrolidin-1-yl-
acetamide
Under an argon atmosphere 35 mg (0.03 mmol) tetrakis-triphenyiphosphane-
palladium and 5.7 mg (0.03 mmol) Cul are added to a solution of 447 mg (1.5
mmol) N-(5-bromo-3-methyl-pyridin-2-yl)-2-pyrrolidin-1-yl-acetamide and 0.23
mL (1.65 mmol) ethynyl-trimethyl-silane in 0.45 mL (4.5 mmol) piperidine and
mL THE and the reaction mixture is stirred for 14 h at RT. To complete the
reaction a further 35 mg tetrakis-triphenylphosphane-palladium are added and
the reaction mixture is heated to 50 C for 4 h. It is diluted with water,
extracted exhaustively with EtOAc, the combined organic phases are washed
with saturated NaCI solution and dried over Na2SO4. After the desiccant and
solvent have been eliminated the residue is purified by chromatography (silica
gel, EtOAc/MeOH/NH3 90:10:1).
Yield: 210 mg (44.4 % of theory)
C17H25N3OSi (M= 315.494)
Calc.: molpeak (M+H)+: 316 Found: molpeak (M+H)+: 316
Rf value: 0.65 (silica gel, EtOAc/MeOH/NH3 90:10:1)
15d N-(5-ethynyl-3-methyl-pyridin-2-yl)-2-pyrrolidin-1-yl-acetamide
Under an argon atmosphere 132 mg (0.48 mmol) TBAF are added to a
solution of 150 mg (0.48 mmol) N-(3-methyl-5-trimethylsilanylethynyl-pyridin-
2-yl)-2-pyrrolidin-1-yl-acetamide in 10 mL THE and the reaction mixture is
stirred overnight at RT. The mixture is evaporated down i. vac., the residue
is
taken up in EtOAc, the organic phase is washed with water and saturated
NaCI solution and dried over Na2SO4. After the desiccant and solvent have
been eliminated the desired product is obtained.
Yield: 110 mg (95.2 % of theory)
C14H17N30 (M= 243.311)
CaIc.: molpeak (M+H)+: 244 Found: molpeak (M+H)+: 244
Rf value: 0.48 (silica gel, EtOAc/MeOH/NH3 90:10:1)
CA 02504160 2005-04-28
Boehringer Ingelheim 279 Case 1-1406 ff
15e N-{5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-3-methyl-pyridin-2-yl}-2-
pyrrolidin-1-yl-acetamide
Under an argon atmosphere 4 mg (0.01 mmol) Pd(PPh3)2CI2 and 1 mg (0.01
mmol) Cul are added to a solution of 73 mg (0.3 mmol) N-(5-ethynyl-3-
methyl-pyridin-2-yl)-2-pyrrolidin-1-yl-acetamide and 95 mg (0.3 mmol) 5-(4-
chloro-phenyl)-2-iodo-pyridine in 59 pL (0.6 mmol) piperidine and 10 mL THE
and the reaction mixture is stirred for 30 min at RT. It is evaporated down
i.vac., the residue is taken up in EtOAc, the organic phase is washed with
water and saturated NaCI solution and dried over Na2SO4. After the desiccant
and solvent have been eliminated the residue is purified first by
chromatography (silica gel, EtOAc/MeOH/NH3 95:5:0.5) and then by HPLC.
Yield: 22 mg (17.0 % of theory)
C25H23CIN40 (M= 430.941)
Calc.: molpeak (M+H)+: 431/433 Found: molpeak (M+H)+: 431/433
Rf value: 0.39 (silica gel, EtOAc/MeOH/NH3 90:10:1)
Example 16
{5-[5-(4-ch loro-phenyl)-pyridin-2-ylethynyl]-3-methyl-pyrid in-2-yl}-(2-
pyrrol id in-
1-yl-ethyl)-amine
cI
CN\/-
N N
I
H
16a (5-bromo-3-methyl-pyridin-2-yl)-(2-pyrrolidin-1-yl-ethyl)-amine
Under an argon atmosphere 2 mL of a 1 M solution of LiAIH4 in THE are
slowly added dropwise to a solution, cooled to 0 C, of 800 mg (2.68 mmol) N-
(5-bromo-3-methyl-pyridin-2-yl)-2-pyrrolidin-1-yl-acetamide (Example 15b) in
mL THE and the reaction mixture is stirred for 3 h at this temperature. 20%
NaOH is slowly added dropwise, solid K2CO3 is added to the suspension and
this is stirred vigorously. The precipitate is filtered off, the filtrate is
evaporated
down and the residue is purified by chromatography (silica gel,
EtOAc/MeOH/NH3 80:20:2).
CA 02504160 2005-04-28
Boehringer Ingelheim 280 Case 1-1406 if
CA 02504160 2005-04-28
Yield: 500 mg (65.6 % of theory)
C12H18BrN3 (M= 284.201)
Calc.: molpeak (M+H)+: 284/286 Found: molpeak (M+H)+: 284/286
Rf value: 0.25 (silica gel, EtOAc/MeOH/NH3 80:20:2)
16b (3-methyl-5-trimethylsilanylethynyl-pyridin-2-yl)-(2-pyrrolidin-1-yl-
ethyl)-
amine
Prepared analogously to Example 15c from 500 mg (1.76 mmol) (5-bromo-3-
methyl-pyridin-2-yl)-(2-pyrrolidin-1-yl-ethyl)-amine and 0.29 mL (2.11 mmol)
ethynyl-trimethyl-silane, while the reaction mixture is heated to 50 C for 12
h.
Yield: 400 mg (75.4 % of theory)
C17H27N3Si (M= 301.511)
Calc.: molpeak (M+H)+: 302 Found: molpeak (M+H)+: 302
Rf value: 0.27 (silica gel, EtOAc/MeOH/NH3 90:10:1)
16c (5-ethynyl-3-methyl-pyridin-2-yl)-(2-pyrrolidin-1-yl-ethyl)-amine
Prepared analogously to Example 15d from 400 mg (1.33 mmol) (3-methyl-5-
trimethylsilanyl-ethynyl-pyridin-2-yl)-(2-pyrrolidin-1-yl-ethyl)-amine.
Yield: 250 mg (82.2 % of theory)
C14H19N3 (M= 229.328)
Rf value: 0.51 (silica gel, EtOAc/MeOH/NH3 80:20:2)
16d {5-[5-(4-chloro-phenyl)-pyridin-2-ylethynylj-3-methyl-pyridin-2-yl}-(2-
pyrrolidin-1-yl-ethyl)-amine
Prepared analogously to Example 15e from 69 mg (0.3 mmol) (5-ethynyl-3-
methyl-pyridin-2-yl)-(2-pyrrolidin-1-yl-ethyl)-amine and 95 mg (0.3 mmol) 5-(4-
chloro-phenyl)-2-iodo-pyridine, while after working up the crude product is
purified by chromatography on Alox (cyc/EtOAc 6:4).
Yield: 12 mg (9.6 % of theory)
C25H25CIN4 (M= 416.958)
Calc.: molpeak (M+H)+: 417/419 Found: molpeak (M+H)+: 417/419
Rf value: 0.42 (Alox, cyc/EtOAc 1:1)
Boehringer Ingelheim 28T---"`. Case 1-1406 if
CA 02504160 2005-04-28
Example 17:
6-(4-chloro-phenyl)-2-(4-pyrrolidin-1-ylmethyl-phenylethynyl)-quinoline
N
ON
17a (E)-3-ethoxy-acrylic acid chloride
20 g (0.172 mol) (E)-3-ethoxy-acrylic acid are added batchwise to a solution
of 14.99 mL (0.206 mol) thionyl chloride in 300 ml of toluene at RT and heated
to 90C for 2 h. The reaction mixture is evaporated to dryness and the yellow
oil remaining is further reacted without any more purification.
17b (E)-N-(4-bromo-phenyl)-3-ethoxy-acrylamide
26.63 g (0.155 mol) of 4-bromoaniline are dissolved in 120 ml of pyridine and
23.14 g (0.172 mol) (E)-3-ethoxy-acrylic acid chloride are added dropwise at a
temperature between 0 C and 5 C and the mixture is stirred for one hour at
0 C. Then the reaction mixture is allowed to warm up to RT and stirred for 14
h. The reaction mixture is combined with water, the precipitate formed is
filtered off and washed with water. The solid is dried at 65 C in the drying
cupboard.
Yield: 37.84 g (90.4 % of theory)
C11H12BrNO2 (M= 270.12)
Calc.: molpeak (M+H)+: 270/272 Found: molpeak (M+H)+:
270/272
Rr value: 0.7 (silica gel, cyc/EtOAc 1:1)
17c 6-bromo-1 H-quinolin-2-one
37.8 g (0.14 mol) (E)-N-(4-bromo-phenyl)-3-ethoxy-acrylamide are added
batchwise to 200 mL concentrated sulphuric acid and stirred for 2 h at RT.
Then the reaction mixture is poured into ice water, the precipitate is
filtered off
and washed with water. The solid is dried at 70C in the drying cupboard.
Yield: 28.6 g (91.2 % of theory)
C9H6BrNO (M= 224.05)
Boehringer Ingelheim 282 Case 1-1406 ff
Calc.: molpeak (M+H)+: 224/226 Found: molpeak (M+H)+:
224/226
Rf value: 0.6 (silica gel, EtOAc)
17d 6-(4-chloro-phenyl)-1 H-quinolin-2-one
A solution of 22.7 g (0.101 mol) 6-bromo-1H-quinolin-2-one in 380 mL 1,4-
dioxane and 380 mL MeOH is combined with 141.5 ml (0.283 ml) 2 M Na2CO3
solution and saturated with argon. Then 3.735 g (3.23 mmol) tetrakis-
triphenyl-phosphane-palladium and 4-chlorophenylboric acid are added
successively. The reaction mixture is heated to 110 C for four hours and then
evaporated down to a volume of 300 mL. 1.2 L water are added and the
precipitate is filtered off. The solid is dried at 55CC in the drying
cupboard,
washed with diisopropylether and dried again.
Yield: 25.4 (89.5 % of theory)
C15H10CINO (M= 255.70)
Calc.: molpeak (M+H)+: 256/258 Found: molpeak (M+H)+: 256/258
Rf value: 0.6 (silica gel, EtOAc/PE 3:1)
17e 2-bromo-6-(4-chloro-phenyl)-quinoline
50 g (0.174 mol) phosphorus oxybromide are heated to 65CC, combined with
g (0.039 mol) 6-(4-chloro-phenyl)-1 H-quinolin-2-one and heated to 110CC
for 3 h. The reaction mixture is then poured onto ice water and made alkaline
with ammonia solution. The precipitate is filtered off and dried in the drying
cupboard at 60 C.
Yield: 12.28 g (98.8 % of theory)
C15H9BrCIN (M= 318.60)
Calc.: molpeak (M+H)+: 318/320/322 Found: molpeak (M+H)+: 318/320/322
Rf value: 0.8 (silica gel, cyc/EtOAc 3:1)
17f 4-[6-(4-chloro-phenyl)-quinolin-2-ylethynyl]-benzaldehyde
Under a nitrogen atmosphere 0.6 mg Cul, 9.3 mg Pd(PPh3)2CI2 and 318 mg
(1 mmol) 2-bromo-6-(4-chloro-phenyl)-quinoline are added successively to a
solution of 85 mg (0.66 mmol) 4-ethynyl-benzaldehyde and 2.6 mL (18.67
CA 02504160 2005-04-28
Boehringer Ingelheim 283 Case 1-1406 ff
mmol) triethylamine in 5 mL absolute DMF and 10 mL acetonitrile. The
reaction mixture is stirred for 14 hours at RT and evaporated down. The
purification is carried out by column chromatography on silica gel (PE/EtOAc
1:1).
Yield: 290 mg (78.8 % of theory)
C24H14CINO (M= 367.83)
Calc.: molpeak (M+H)+: 368/370 Found: molpeak (M+H)+: 368/370
Rf value: 0.84 (silica gel, DCM/MeOH/NH3 90:10:1)
17g 6-(4-chloro-phenyl)-2-(4-pyrrolidin-1-ylmethyl-phenylethynyl)-quinoline,
3 mg p-toluenesulphonic acid and 100 pL glacial acetic acid are added to a
solution of 290 mg (0.78 mmol) 4-[6-(4-chloro-phenyl)-quinoline-2-ylethynyl]-
benzaldehyde and 56 mg (0.78 mmol) pyrrolidine in 10 mL THE at RT and
stirred for 30 minutes. Then 334 mg (1.57 mmol) NaBH(OAc)3 are added
batchwise and the reaction mixture is stirred for 14 h. A few drops of water
are
added dropwise to the reaction mixture and this is stirred for 15 minutes. The
reaction mixture is then combined with K2CO3 and filtered. The filtrate is
evaporated down. The purification is carried out by column chromatography
on silica gel (DCM/MeOH/NH3 90:10:1).
Yield: 150 mg (45 % of theory)
melting point: 170-193 C
C28H23CIN2 (M= 422.96)
Calc.: molpeak (M+H)+: 423/425 Found: molpeak (M+H)+: 423/425
Rf value: 0.49 (silica gel, DCM/MeOH/NH3 90:10:1)
The following compounds are prepared analogously to Example 17g with 17f
as educt:
CI
R \ I~
CA 02504160 2005-04-28
Boehringer Ingelheim 284 Case 1-1406 ff
Example R empirical formula mass mp [ C] Rf value
spectrum
17.1 C29H26CIN3 452/54 176- 0.33
N [M+H]+ 182
17.2 C28H23CIN20 439/41 170- 0.45
0") [M+H]+ 174
17.3 C30H27CIN20 467/69 159- 0.52
[M+H]+ 165
17.4 C32H30CIN3 492/94 140- 0.21
" [M+H]+ 148
N
17.5 00--
C30H27CIN20 467/69 139- 0.61
G" [M+H]+ 147
17.6 ,0 C30H27CIN20 467/69 143- 0.61
i
" [M+H]+ 173
17.7 C31H2SCIN30 494/96 142- 0.31
N
N [M+H]+ 145
17.8 C30H26CIN30 480/82 165- 0.30
"T N [M+H]+ 170
0
17.9 0 C29H24CIN30 466/68 152- 0.45
NJ [M+H]+ 157
17.10 C33H27CIN4 515/17 214- 0.47
NJ [M+H]+ 219
CA 02504160 2005-04-28
Boehringer Ingelheim 285 Case 1-1406 if
CA 02504160 2005-04-28
17.11 C28H25CIN20 441/43 153 0.38
/0 J [M+H]+
17.12 C30H27CIN20 467/69 130- 0.32
[M+H]+ 136
0
17.13 C31H24CIN3 474/476 140- 0.43
N [M+H]+ 149
N /
17.14 C30H27CIN20 467/69 190- 0.30
H, [M+H]+ 192
17.15 V C28H23CIN20S 471/73 170- 0.38
N
o,s J [M+H]+ 174
17.16 V C28H23CIN202S 487/89 216- 0.61
0.S [M+H]+ 220
0
17.17 C35H29CIN20 529/31 208- 0.34
H,o [M+H]+ 219
The Rf values specified are obtained on silica gel with DCM/MeOH/NH3
90:10:1 as the mobile phase.
Example 18:
6-(4-chloro-phenyl)-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-quinoline
CI
N~/~ \
O
18a 1-[2-(4-iodo-phenoxy)-ethyl]-pyrrolidine
Boehringer Ingelheim 286 Case 1-1406 if
A reaction mixture of 44 g (0.2 mol) 4-iodophenol, 34 g (0.2 mol) 1-(2-chloro-
ethyl)-pyrrolidine-hydrochloride, 110.56 g (0.8 mol) K2CO3 and 800 mL DMF is
stirred for 48 h at RT. The reaction mixture is filtered and the filtrate is
evaporated down. The residue is taken up in water and extracted with EtOAc.
The organic phase is extracted with saturated NaCI solution and dried over
Na2SO4. The purification is carried out by column chromatography on silica
gel (EtOAc/MeOH/NH3 85:15:1.5).
Yield: 34.8 g (54.9 % of theory)
C12H161NO (M= 317.17)
Rf value: 0.49 (silica gel, EtOAc/MeOH/NH3 90:10:1)
18b 1-[2-(4-trimethylsilanylethynyl-phenoxy)-ethyl]-pyrrolidine
Under a nitrogen atmosphere and while cooling with ice a reaction mixture of
1.5 g (4.72 mmol) 1-[2-(4-iodo-phenoxy)-ethyl]-pyrrolidine, 0.735 ml (5.2
mmol) ethynyl-trimethyl-silane, 15 mL piperidine, 115.5 mg (0.1 mmol)
tetrakis-triphenylphosphane-palladium and 19 mg (0.1 mmol) Cul is stirred for
1 h. Then the reaction mixture is evaporated down, the residue is taken up in
20 mL water and extracted with EtOAc. The organic phase is dried over
Na2SO4. The purification is carried out by column chromatography on silica
gel (EtOAc/MeOH/NH3 95:5:0.5).
Yield: 1.244 g (91.5 % of theory)
C17H25NOSi (M= 287.48)
Calc.: molpeak (M+H)+: 288 Found: molpeak (M+H)+: 288
Rf value: 0.45 (silica gel, EtOAc/MeOH/NH3 90:10:1)
18c 1-[2-(4-ethynyl-phenoxy)-ethyl]-pyrrolidine
A reaction mixture of 1.22 g (4.24 mmol) 1-[2-(4-trimethylsilanylethynyl-
phenoxy)-ethyl]-pyrrolidine, 1.47 g (4.67 mmol) TBAF and 25 mL THE is
stirred for 3 h at RT. Then the reaction mixture is evaporated down and the
residue is combined with 20 mL saturated NaCl solution and 50 mL EtOAc.
The organic phase is dried over Na2SO4. The purification is carried out by
column chromatography on silica gel (EtOAc/MeOH/NH3 90:10:1).
Yield: 0.91 g (100 % of theory)
CA 02504160 2005-04-28
Boehringer Ingelheim 287 Case 1-1406 if
C14H17NO (M= 215.29)
Calc.: molpeak (M+H)+: 216 Found: molpeak (M+H)+: 216
Rf value: 0.33 (silica gel, EtOAc/MeOH/NH3 90:10:1)
18d 6-(4-chloro-phenyl)-2-[4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-
quinoline
In a nitrogen atmosphere, 0.6 mg Cul, 9.3 mg Pd(PPh3)2CI2 and 318 mg (1
mmol) 2-bromo-6-(4-chloro-phenyl)-quinoline are added successively to a
solution of 142 mg (0.66 mmol) 1-[2-(4-ethynyl-phenoxy)-ethyl]-pyrrolidine and
2.6 mL (18.67 mmol) triethylamine in 5 mL absolute DMF and 10 mL
acetonitrile. The reaction mixture is stirred for 14 h at RT and evaporated
down. The purification is carried out by column chromatography on silica gel
(DCM/MeOH/NH3 90:10:1).
Yield: 148 mg (32.7 % of theory)
melting point: 176-185 C
C29H25CIN2O (M= 452.98)
Calc.: molpeak (M+H)+: 453/455 Found: molpeak (M+H)+: 453/455
Rf value: 0.71 (silica gel, DCM/MeOH/NH3 80:20:1)
Example 19:
6-(4-chloro-phenyl)-2-[3-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-quinoline
19a 1-[2-(3-ethynyl-phenoxy)-ethyl]-pyrrolidine
Prepared analogously to Example 18a from 1-(2-chloro-ethyl)-pyrrolidine-
hydrochloride and 3-ethynyl-phenol.
Yield: 1.44 g (79 % of theory)
C14H17NO (M= 215.29)
CaIc.: molpeak (M+H)+: 216 Found: molpeak (M+H)+: 216
Rf value: 0.37 (silica gel, DCM/MeOH/NH3 90:10:1)
CA 02504160 2005-04-28
Boehringer Ingelheim 2$8., 'r. Case 1-1406 if
CA 02504160 2005-04-28
19b 6-(4-chloro-phenyl)-2-[3-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-
quinoline
Prepared analogously to Example 18d from 1-[2-(3-ethynyl-phenoxy)-ethyl]-
pyrrolidine and 2-bromo-6-(4-chloro-phenyl)-quinoline.
Yield: 135 mg (29.8 % of theory)
melting point: 114-117 C
C29H25CIN20 (M= 452.98)
Calc.: molpeak (M+H)+: 453/455 Found: molpeak (M+H)+: 453/455
Rf value: 0.61 (silica gel, DCM/MeOH/NH3 80:20:1)
Example 20:
6-(4-chloro-phenyl)-2-(2-pyrrolidin-1-ylmethyl-benzoxazol-5-ylethynyl )-
quinoline
N N
N N
0
20a 5-bromo-2-chloromethyl-benzoxazole
1.79 mL (13.3 mmol) 2-chloro-1,1,1-trimethoxy-ethane are added dropwise at
RT to a solution of 2.5 g (13.29 mmol) 2-amino-4-bromophenol in 20 mL
ethanol and stirred for 48 h. Then 0.4 mL 2-chloro-1,1,1-trimethoxy-ethane
are added and stirred for 20 h. The reaction mixture is evaporated down. The
purification is carried out by column chromatography on silica gel
(DCM/ethanol 80:1).
Yield: 2 g (60.9 % of theory)
C8H5BrCINO (M= 246.49)
Calc.: molpeak (M+H)+: 246/248/250 Found: molpeak (M+H)+: 246/248/250
Rf value: 0.95 (silica gel, DCM/ethanol 20:1)
20b 5-bromo-2-pyrrolidin-1 -ylmethyl-benzoxazole
Boehringer Ingelheim 289 Case 1-1406 if
A solution of 2 g (8.11 mmol) 5-bromo-2-chloromethyl-benzoxazole in 30 mL
DMF is combined with 2.24 g (16.22 mmol) K2CO3 and 0.9 mL (10.78 mmol)
pyrrolidine and stirred for 24 hours at RT. The reaction mixture is diluted
with
water and extracted with EtOAc. The organic phase is dried over Na2SO4, the
desiccant is filtered off and the filtrate is evaporated down.
Yield: 2.2 g (96.4 % of theory)
C12H13BrN2O (M= 281.15)
Calc.: molpeak (M+H)+: 281/283 Found: molpeak (M+H)+: 281/283
Rf value: 0.15 (silica gel, DCM/ethanol 50:1)
20c 5-iodo-2-pyrrolidin-1-ylmethyl-benzoxazole
71 mg (0.36 mmol) Cul, 1 g (3.55 mmol) 5-bromo-2-pyrrolidin-1-ylmethyl-
benzoxazole and 1.07 g (7.15 mmol) Nal are successively placed in a flask in
an argon atmosphere. Then 0.08 mL (0.73 mmol) N,N'-
dimethylethylenediamine and 3.5 mL 1,4-dioxane are added and the reaction
mixture is refluxed for 14 h. The reaction mixture is then combined with 20 mL
concentrated ammonia solution at RT, diluted with 100 mL water and
extracted with DCM. The organic phase is extracted three times with water
and dried over Na2SO4.
Yield: 1 g (72.8 % of theory)
C12H13IN2O (M= 328.15)
Calc.: molpeak (M+H)+: 329 Found: molpeak (M+H)+: 329
Rf value: 0,35 (silica gel, cyc/EtOAc 1:1)
20d 2-pyrrolidin-1 -ylmethyl-5-trimethylsilanylethynyl-benzoxazole
Prepared analogously to Example 18b from 5-iodo-2-pyrrolidin-1-ylmethyl-
benzoxazole and ethynyl-trimethyl-silane.
Yield: 0.5 g (91.6 % of theory)
C17H22N2OSi (M= 298.46)
Calc.: molpeak (M+H)+: 299 Found: molpeak (M+H)+: 299
Rf value: 0.5 (silica gel, DCM/MeOH/NH3 90:10:1)
20e 5-ethynyl-2-pyrrolidin-1-ylmethyl-benzoxazole
CA 02504160 2005-04-28
Boehringer Ingelheim 290 Case 1-1406 if
Prepared analogously to Example 18c from 2-pyrrolidin-1-yimethyl-5-
trimethylsilanylethynyl-benzoxazole.
Yield: 0.265 g (69.9 % of theory)
C14H14N2O (M= 226.28)
Calc.: molpeak (M+H)+: 227 Found: molpeak (M+H)+: 227
Rf value: 0.79 (silica gel, DCM/MeOH/NH3 80:20:1)
20f 6-(4-chloro-phenyl)-2-(2-pyrrolidin-1 -yimethyl-benzoxazol-5-ylethynyl)-
quinoline
Prepared analogously to Example 18d from 5-ethynyl-2-pyrrolidin-1-ylmethyl-
benzoxazole and 2-bromo-6-(4-chloro-phenyl)-quinoline.
Yield: 90 mg (13.9 % of theory)
melting point: 151-153 C
C29H22CIN3O (M= 463.97)
Calc.: molpeak (M+H)+: 464/466 Found: molpeak (M+H)+:
464/466
Rf value: 0.53 (silica gel, DCM/MeOH/NH3 90:10:1)
Example 21:
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-pyrrolidin-1 -yimethyl-
benzoxazole
a
N
CN) N
o
A reaction mixture of 260 mg (0.792 mmol) 5-iodo-2-pyrrolidin-1-ylmethyl-
benzoxazole, 171 mg (0.8 mmol) 5-(4-chloro-phenyl)-2-ethynyi-pyridine, 23
mg (0.02 mmol) tetrakis-triphenylphosphane-palladium, 3.8 mg (0,02 mmol)
Cul and 350 mg (1.075 mmol) Cs2CO3 in 10 mL THE is stirred for 14 h in an
argon atmosphere at RT. Then the reaction mixture is evaporated down and
the residue is purified by column chromatography on silica gel (DCM/MeOH
80:1).
Yield: 140 mg (42.7 % of theory)
melting point: 145 C
CA 02504160 2005-04-28
Boehringer Ingelheim 291 Case 1-1406 if
C25H20CIN30 (M= 413.91)
Calc.: molpeak (M+H)+: 414/416 Found: molpeak (M+H)+:
4141416
Rf value: 0.1 (silica gel, DCM/MeOH 50:1)
Example 22
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-
benzoic
acid
0 I i
Hy
CN~~
1.6 mL aqueous 1 M NaOH are added to a solution of 369 mg (0.8 mmol)
methyl 5-[5-(4-chloro-phenyl )-pyridin-2-ylethynyl]-2-(2-pyrrolidin-l-yl-
ethoxy)-
benzoate (Example 3.4) in 20 mL MeOH and the reaction mixture is heated to
70 C for 3 h. It is combined with 1.6 mL 1 M HCI, evaporated down i.vac. and
the residue is coevaporated twice with in each case 20 mL MeOH. The
residue is triturated with EtOH with heating and suction filtered.
Yield: 340 mg (95.1 % of theory)
C26H23CIN203 (M= 446.938)
Calc.: molpeak (M+H)+: 447/449 Found: molpeak (M+H)+: 447/449
HPLC retention time: 7.0 min (method A)
Example 22.1
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-N-methyl-2-(2-pyrrolidin-l -yl-
ethoxy)-benzamide
c1
0
N
H
80 mg (0.25 mmol) TBTU and 69 pL triethylamine are added to a solution of
112 mg ( 0.25 mmol) 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-
CA 02504160 2005-04-28
Boehringer Ingelheim 292 Case 1-1406 ff
pyrrolidin-1-yl-ethoxy)-benzoic acid (Example 22) in 5 mL DMF and the
reaction mixture is stirred for 2 h at RT. Then 31 mg (1.0 mmol) methylamine
are added and stirring is continued for a further 2 h at RT. The mixture is
evaporated down i. vac., the residue is combined with dilute Na2CO3 solution,
extracted exhaustively with DCM and the organic phase is dried over Na2SO4.
After the desiccant and solvent have been eliminated the residue is purified
by
chromatography (silica gel, DCM to DCM/MeOH/NH3 7:3:0.3).
Yield: 45 mg (39.1 % of theory)
C27H26C1N302 (M= 459.980)
Calc.: molpeak (M+H)+: 460/462 Found: molpeak (M+H)+: 460/462
HPLC retention time: 6.8 min (method A)
The following compounds are prepared as described in Example 22.1, while
in Example 22.5 ammonium carbonate is used as the ammonia source:
I
0
R
O
Example R Yield (%) empirical mass HPLC retention time
formula spectrum in min
(method)
22.2 H,C,N 42.2 C28H28CIN302 474/476 6.95 (A)
CH, [M+H]+
22.3 ON "~N 9.3 C32H35CIN402 543/545 5.30 (A)
22.4 6.9 C29H28CIN302 486/488 7.07 (A)
[M+H]+
22.5 H, 4.0 C26H24CIN302 446/448 6.10 (A)
H [M+H]
CA 02504160 2005-04-28
Boehringer Ingelheim 293 Case 1-1406 if
Example 23
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-
phenylamine
cI
H
N
H
200 mg (2.5 mmol) NaHCO3 and 300 mg (1.1 mmol) tin-(II)-chloride dihydrate
are added to a solution of 100 mg (0.22 mmol) 5-(4-chloro-phenyl)-2-[3-nitro-
4-(2-pyrrolidin-1-yl-ethoxy)-phenylethynyl]-pyridine (Example 3.13) in 10 mL
EtOAc and the reaction mixture is refluxed for 2 h. To complete the reaction a
further 200 mg (2.5 mmol) NaHCO3, 300 mg (1.1 mmol) tin-(11)-chloride
dihydrate and 1 mL MeOH are added and the mixture is refluxed for a further
2 h. After cooling, 4 g of silica gel are added, the solvent is eliminated
i.vac.
and the residue is purified by chromatography (silica gel, DCM/MeOH/NH3
8:2:0.2).
Yield: 85 mg (39.1 % of theory)
C25H24CIN30 (M= 417.943)
Calc.: molpeak (M+H)+: 418/420 Found: molpeak (M+H)+: 418/420
HPLC retention time: 7.1 min (method A)
Example 23.1
N-[5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-
phenyl]-acetamide
N
H N
- I /
O
16 pL (170 pmol) acetic anhydride are added to a solution of 35 mg (84 pmol)
5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-
phenylamine in 2 mL DCM and the reaction mixture is stirred overnight at RT
and then purified by chromatography on silica gel (gradient: EtOAc to
EtOAc/MeOH/NH3 7:3:0.3) without any further working up
CA 02504160 2005-04-28
Boehringer Ingelheim 294 Case 1-1406 if
Yield: 10 mg (26.0 % of theory)
C27H26CIN302 (M= 459.980)
Calc.: molpeak (M+H)+: 460/462 Found: molpeak (M+H)+: 460/462
Rf value: 0.55 (silica gel, DCM/MeOH/NH3 90:10:1)
Example 23.2
N-[5-[5-(4-chloro-phenyl)-pyrid i n-2-ylethynyl]-2-(2-pyrrolid in-1-yl-ethoxy)-
phenyl]-methanesulphonamide
Cl
0
0
HEN
(DN
O
Under an N2 atmosphere 39 pL (0.5 mmol) methanesulphonic acid chloride
are added to a solution of 100 mg (0.24 mmol) 5-[5-(4-chloro-phenyl)-pyridin-
2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-phenylamine and 161 pL (2 mmol)
pyridine in 10 mL DCM and the reaction mixture is stirred for 2 h at RT. To
complete the reaction a further 160 pL pyridine and 39 pL methanesulphonic
acid chloride are added and the mixture is stirred overnight. It is combined
with 10% Na2CO3 solution, the organic phase is separated off and the solvent
is eliminated i.vac.. The residue is purified by HPLC.
Yield: 15 mg (13.0 % of theory)
C26H26CIN303S (M= 496.032)
Calc.: molpeak (M+H)+: 496/498 Found: molpeak (M+H)+: 496/498
HPLC retention time: 6.8 min (method A)
Example 23.3
[5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-
phenyl]-
dimethyl-amine
a
iJ
N
ON
CA 02504160 2005-04-28
Boehringer Ingelheim 295 Case 1-1406 if
CA 02504160 2005-04-28
180 pL (2.4 mmol) formalin solution (37% in water), 63 mg (1.0 mmol)
NaBH3CN and 57 pL (1.0 mmol) acetic acid are added to a solution of 100 mg
(0.24 mmol) 5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-
ethoxy)-phenyla mine in 5 mL acetonitrile and the reaction mixture is stirred
overnight at RT. It is acidified with 12% HCI, stirred vigorously for one
hour,
combined with saturated Na2CO3 solution until an alkaline reaction is obtained
and extracted exhaustively with DCM. After elimination of the solvent the
residue is purified by HPLC.
Yield: 9 mg (8.4 % of theory)
C27H28CIN30 (M= 445.997)
Calc.: molpeak (M+H)+: 446/448 Found: molpeak (M+H)+: 446/448
HPLC retention time: 6.7 min (method A)
Example 23.4
[5-[5-(4-chloro-phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-
phenyl]-
methyl-amine
0
HEN ~ ~
CAN
Under a nitrogen atmosphere 178 pL (1.35 mmol) N,N-dimethylformamide
dimethylacetal are added to a solution of 100 mg (0.24 mmol) 5-[5-(4-chloro-
phenyl)-pyridin-2-ylethynyl]-2-(2-pyrrolidin-1-yl-ethoxy)-phenylamine in 2 mL
DMF, the reaction mixture is stirred for 5 h at 60 C and cooled to RT
overnight. Then 32 mg (0.85 mmol) NaBH4 are added and the mixture is
again heated to 60 C for 1 h. To complete the reaction a further 32 mg NaBH4
are added and the mixture is heated to 60 C for a further 4 h. After cooling
it
is combined with saturated NaHCO3 solution, exhaustively extracted with
EtOAc and the organic phase is dried over MgSO4. After the desiccant and
solvent have been eliminated the residue is purified by HPLC.
Yield: 0.5 mg (0.5 % of theory)
C26H26CIN3O (M= 431.970)
CaIc.: molpeak (M+H)+: 432/434 Found: molpeak (M+H)+: 432/434
Boehringer Ingelheim 296 Case 1-1406 ff
CA 02504160 2005-04-28
HPLC retention time: 7.5 min (method A)
The following compounds may also be obtained by the processes described
in the foregoing experimental section:
R
,,~O
Example R
24.1
24.2 01"
N
24.3 01"
24.4
N
24.5
24.6
24.7 "
N
iN N
Boehringer Ingelheim 297 Case 1-1406 if
CA 02504160 2005-04-28
24.8
N N
24.9
24.10 CN
24.11
H
N.
24.12
H
N
24.13 "
\^
i`v1N
24.14
CAN
24.15 o
H
24.16
N
24.17
The following compounds may also be obtained by the processes described
in the foregoing experimental section:
Boehringer Ingelheim 298 Case 1-1406 if
CA 02504160 2005-04-28
CI
I \ \
N
Example R
25.1
25.2 1"
~N .
25.3 '"
25.4
25.5
N
25.6
25.7 "
N
N
iN C
25.8 4\.
N t~N
Boehringer Ingelheim 299 Case 1-1406 if
CA 02504160 2005-04-28
25.9 CNNT
25.10
CN
25.11
H
H
N
25.12
H
N
25.13 "
o`^
N
25.14
CAN
25.15 ~
N H
25.16
N
25.17
~N.
The following compounds may also be obtained by the processes described
in the foregoing experimental section:
Boehringer Ingelheim 300 Case 1-1406 if
CA 02504160 2005-04-28
Ci
F
N
R,~
Example R
26.1
ON
26.2 '"
26.3 I"
26.4
26.5
26.6
26.7 "
N
N N
26.8
iN N
Boehringer Ingelheim 301 Case 1-1406 ff
26.9 cJVNc
26.10 CN
26.11
`H
H
N
26.12
H
N
26.13 "
o\ON
26.14
(\~/ N
26.15 C-T'01
N H
26.16
N
26.17
N
The following compounds may also be obtained by the processes described
in the foregoing experimental section:
CA 02504160 2005-04-28
Boehringer Ingelheim 302 Case 1-1406 if
CA 02504160 2005-04-28
/ CI
NJ
Br
Example R
27.1
N
27.2 0'"
CN
27.3 01"
27.4
;:N"'
27.5
27.6
27.7 "
iN N
27.8 0
iiN c
N
Boehringer Ingelheim 303 Case 1-1406 if
27.9
CT N, ~
N ~/
27.10
C)N
27.11
H
H
N
27.12
H
N.
27.13 "
o\^
N
27.14
N
27.15 o
H
27.16
N
27.17
N
The following compounds may also be obtained by the processes described
in the foregoing experimental section:
CA 02504160 2005-04-28
Boehringer Ingelheim 304 Case 1-1406 if
cl
CI
Example R
28.1
N
28.2 0'"
28.3 01"
28.4
28.5
28.6
N
28.7 "
iN N
28.8 ~
iN N
CA 02504160 2005-04-28
Boehringer Ingelheim 305 Case 1-1406 if
CA 02504160 2005-04-28
28.9 CN~No
28.10
ON
28.11
H
H1
N.
28.12
H
N
28.13 "
N
O'
28.14 CCN
28.15 ~o
N H
28.16
28.17
N
The following compounds may also be obtained by the processes described
in the foregoing experimental section:
Boehringer Ingelheim 306 Case 1-1406 if
CA 02504160 2005-04-28
CI
I' \
Example R
29.1 0"
~N.
29.2 0"
29.3
29.4
29.5
29.6 "
iN N
29.7 ~ ~.
N N
29.8 N
CTN--
Boehringer Ingelheim 307 Case 1-1406 if
29.9
H
H
N
29.10
H
29.11 "
o\ON
28.12 ciixIiii
N
29.13 o
N H
29.14
N
29.15
N
The following compounds may also be obtained by the processes described
in the foregoing experimental section:
N IN
Example R
30.1
N
CA 02504160 2005-04-28
Boehringer Ingelheim 308 Case 1-1406 ff
CA 02504160 2005-04-28
30.2 o' H
30.3 o' H
30.4
30.5
30.6
N
30.7 "
iN N
30.8
iN N
30.9 CN~No
30.10
CN
30.11
H
H
N
30.12
H
H
Boehringer Ingelheim 309 Case 1-1406 if
CA 02504160 2005-04-28
30.13 "
0
N
30.14 C::DN
30.15 o
N Fi
30.16
N
30.17
N.
The following compounds may also be obtained by the processes described
in the foregoing experimental section:
~cl
Example R
31.1 IIN
31.2 0'H
N
Boehringer Ingelheim 310 Case 1-1406 ff
CA 02504160 2005-04-28
31.3 01H
31.4
N
31.5
31.6
31.7 "
iN N
31.8
iN N
31.9 CN,No
31.10
IIIL
31.11
H
H
N
31.12
H
H
N
31.13 "
0\^
N
Boehringer Ingelheim 311 Case 1-1406 if
CA 02504160 2005-04-28
31.14 cV
N
31.15 CIN"~0
Fi
31.16
N
31.17
N
The compounds of Examples 32 to 32.12 may also be obtained by the
processes described in the foregoing experimental section:
Example 32
ci
F
Example 32.1
j N
CN
Example 32.2
I,
CI
Boehringer Ingelheim 312 Case 1-1406 if
CA 02504160 2005-04-28
Example 32.3
cI
F
N
Example 32.4
F ICI
1 \
N~N
CN-/-- 0 I /
Example 32.5
,CI
N
,/N~0
Example 32.6
CI
Example 32.7
CI
/
N/
Example 32.8
CA 02504160 2005-04-28
Boehringer Ingelheim 313 Case 1-1406 if
ci
INJ
Example 32.9
N
Example 32.10
iI
Example 32.11
CI
N
I
Example 32.12
CI
N
N 0 /
The following compounds may also be obtained by the processes described
in the foregoing experimental section:
Boehringer Ingelheim 314 Case 1-1406 if
CA 02504160 2005-04-28
R
i
Example R
33.1
33.2
i F
33.3
33.4
,
33.5
33.6 F
33.7 F
F
33.8 F F
33.9 F a
33.10
Boehringer Ingelheim 315 Case 1-1406 if
CA 02504160 2005-04-28
33.11
33.12
33.13 O
33.14 0
Boehringer Ingelheim 316 Case 1-1406 if
Some test methods for determining an MCH-receptor antagonistic activity will
now be described. In addition, other test methods known to the skilled man
are used, e.g. by inhibiting the MCH-receptor-mediated inhibition of cAMP
production, as described by Hoogduijn M et al. in "Melanin-concentrating
hormone and its receptor are expressed and functional in human skin",
Biochem. Biophys. Res Commun. 296 (2002) 698-701 and by biosensory
measurement of the binding of MCH to the MCH receptor in the presence of
antagonistic substances by plasmon resonance, as described by Karlsson OP
and Lofas S. in "Flow-Mediated On-Surface Reconstitution of G-Protein
Coupled Receptors for Applications in Surface Plasmon Resonance
Biosensors", Anal. Biochem. 300 (2002), 132-138. Other methods of testing
antagonistic activity to MCH receptors are contained in the references and
patent documents mentioned hereinbefore, and the description of the test
methods used is hereby incorporated in this application.
MCH-1 receptor binding test
Method: MCH binding to hMCH-1 R transfected cells
Species: Human
Test cell: hMCH-1 R stably transfected into CHO/Galphal6 cells
Results: IC50 values
Membranes from CHO/Galphal6 cells stably transfected with human hMCH-
1 R are resuspended using a syringe (needle 0.6 x 25 mm) and diluted in test
buffer (50 mM HEPES, 10 mM MgCl2, 2 mM EGTA, pH 7.00; 0.1 % bovine
serum albumin (protease-free), 0.021 % bacitracin, 1 pg/ml aprotinin, 1 pg/ml
leupeptin and 1 pM phosphoramidone) to a concentration of 5 to 15 pg/ml.
200 microlitres of this membrane fraction (contains 1 to 3 pg of protein) are
incubated for 60 minutes at ambient temperature with 100 pM of 1251-tyrosyl
melanin concentrating hormone (1251-MCH commercially obtainable from
NEN) and increasing concentrations of the test compound in a final volume of
250 microlitres. After the incubation the reaction is filtered using a cell
harvester through 0.5% PEI treated glass fibre filters (GF/B, Unifilter
Packard). The membrane-bound radioactivity retained on the filter is then
determined after the addition of scintillator substance (Packard Microscint
20)
in a measuring device (TopCount of Packard).
CA 02504160 2005-04-28
Boehringer Ingeiheim 317 Case 1-1406 ff
CA 02504160 2005-04-28
The non-specific binding is defined as bound radioactivity in the presence of
1
micromolar MCH during the incubation period.
The analysis of the concentration binding curve is carried out on the
assumption of one receptor binding site.
Standard:
Non-labelled MCH competes with labelled 125l-MCH for the receptor binding
with an IC50 value of between 0.06 and 0.15 nM.
The KD value of the radioligand is 0.156 nM.
MCH-1 receptor-coupled Ca 2+ mobilisation test
Method: Calcium mobilisation test with human MCH (FLIPR3114)
Species: Human
Test cells: CHO/ Galpha 16 cells stably transfected with hMCH-R1
Results: 1st measurement: % stimulation of the reference (MCH 10"6M)
2nd measurement: pKB value
Reagents: HBSS (10x) (GIBCO)
HEPES buffer (1 M) (GIBCO)
Pluronic F-127 (Molecular Probes)
Fluo-4 (Molecular Probes)
Probenecid (Sigma)
MCH (Bachem)
bovine serum albumin (Serva)
(protease-free)
DMSO (Serva)
Ham's F12 (BioWhittaker)
FCS (BioWhittaker)
L-Glutamine (GIBCO)
Hygromycin B (GIBCO)
PENStrep (BioWhittaker)
Zeocin (Invitrogen)
Boehringer Ingelheim 318 Case 1-1406 if
CA 02504160 2005-04-28
Clonal CHO/Galpha16 hMCH-R1 cells are cultivated in Ham's F12 cell culture
medium (with L-glutamine; BioWhittaker; Cat.No.: BE12-615F). This contains
per 500 ml 10% FCS, I% PENStrep, 5 ml L-glutamine (200 mM stock
solution), 3 ml hygromycin B (50 mg/ml in PBS) and 1.25 ml zeocin (100
pg/mi stock solution). One day before the experiment the cells are plated on a
384-well microtitre plate (black-walled with a transparent base, made by
Costar) in a density of 2500 cells per cavity and cultivated in the above
medium overnight at 37 C, 5% CO2 and 95% relative humidity. On the day of
the experiment the cells are incubated with cell culture medium to which 2 mM
Fluo-4 and 4.6 mM Probenicid have been added, at 37 C for 45 minutes. After
charging with fluorescent dye the cells are washed four times with Hanks
buffer solution (1 x HBSS, 20 mM HEPES), which is combined with 0.07%
Probenicid. The test substances are diluted in Hanks buffer solution,
combined with 2.5% DMSO. The background fluorescence of non-stimulated
cells is measured in the presence of substance in the 384-well microtitre
plate
five minutes after the last washing step in the FLIPR384 apparatus (Molecular
Devices; excitation wavelength: 488 nm; emission wavelength: bandpass 510
to 570 nm). To stimulate the cells MCH is diluted in Hanks buffer with 0.1 %
BSA, pipetted into the 384-well cell culture plate 35 minutes after the last
washing step and the MCH-stimulated fluorescence is then measured in the
FLIPR384 apparatus.
Data analysis:
1 st measurement: The cellular Ca2+ mobilisation is measured as the peak of
the relative fluorescence minus the background and is expressed as the
percentage of the maximum signal of the reference (MCH 10"6M). This
measurement serves to identify any possible agonistic effect of a test
substance.
2nd measurement: The cellular Ca2+ mobilisation is measured as the peak of
the relative fluorescence minus the background and is expressed as the
percentage of the maximum signal of the reference (MCH 10"6M, signal is
standardised to 100%). The EC50 values of the MCH dosage activity curve
with and without test substance (defined concentration) are determined
Boehringer Ingelheim 319 Case 1-1406 ff
graphically by the GraphPad Prism 2.01 curve program. MCH antagonists
cause the MCH stimulation curve to shift to the right in the graph plotted.
The inhibition is expressed as a pKB value:
pKB=log(EC50(testsubstance+MCH) / EC50(MCH) -1) -log C(testsubstance)
The compounds according to the invention, including their salts, exhibit an
MCH-receptor antagonistic activity in the tests mentioned above. Using the
MCH-1 receptor binding test described above an antagonistic activity is
obtained in a dosage range from about 10.10 to 10"5 M, particularly from 10"9
to
10-6 M.
The following IC50 values were determined using the MCH-1 receptor binding
test described above:
Compound IC50 value
according to Name of substance
Example No.
1.8 5-(4-bromo-phenyl)-2-[4-(2-pyrrolidin-1-yl- 8 nM
ethoxy)-phenylethynyl]-pyridine
1.3 (2-{4-[5-(3,4-difluorophenyl)-pyridin-2- 74 nM
ylethynyl]-phenoxy}-ethyl)-diethyl-amine
Some examples of formulations will be described hereinafter, wherein the
term "active substance" denotes one or more compounds according to the
invention, including their salts. In the case of one of the combinations with
one
or more active substances described, the term "active substance" also
includes the additional active substances.
CA 02504160 2005-04-28
Boehringer Ingelheim 320 Case 1-1406 if
CA 02504160 2005-04-28
Example A
Capsules for powder inhalation containing 1 mg active substance
Composition:
1 capsule for powder inhalation contains:
active substance 1.0 mg
lactose 20.0 mg
hard gelatine capsules 50.0 mq
71.0 mg
Method of preparation:
The active substance is ground to the particle size required for inhalation.
The ground active substance is homogeneously mixed with the lactose. The
mixture is packed into hard gelatine capsules.
Example B
Inhalable solution for Respimat containing 1 mg active substance
Composition:
1 spray contains:
active substance 1.0 mg
benzalkonium chloride 0.002 mg
disodium edetate 0.0075 mg
purified water ad 15.0 pl
Method of preparation:
The active substance and benzalkonium chloride are dissolved in water and
packed into Respimat cartridges.
Boehringer Ingelheim 321 Case 1-1406 ff
CA 02504160 2005-04-28
Example C
Inhalable solution for nebulisers containing 1 mg active substance
Composition:
1 vial contains:
active substance 0.1 g
sodium chloride 0.18 g
benzalkonium chloride 0.002 g
purified water ad 20.0 ml
Method of preparation:
The active substance, sodium chloride and benzalkonium chloride are
dissolved in water.
Example D
Propellant type metered dose aerosol containing 1 mg active substance
Composition:
1 spray contains:
active substance 1.0 mg
lecithin 0.1 %
propellant gas ad 50.0 pl
Method of preparation:
The micronised active substance is homogeneously suspended in the mixture
of lecithin and propellant gas. The suspension is transferred into a
pressurised contained with a metering valve.
Boehringer Ingelheim 322 Case 1-1406 if
CA 02504160 2005-04-28
Example E
Nasal spray containing 1 mg active substance
Composition:
active substance 1.0 mg
sodium chloride 0.9 mg
benzalkonium chloride 0.025 mg
disodium edetate 0.05 mg
purified water ad 0.1 ml
Method of preparation:
The active substance and the excipients are dissolved in water and
transferred into a corresponding container.
Example F
Iniectable solution containing 5 mg of active substance per 5 ml
Composition:
active substance 5 mg
glucose 250 mg
human serum albumin 10 mg
glycofurol 250 mg
water for injections ad 5 ml
Preparation:
Glycofurol and glucose are dissolved in water for injections (Wfl); human
serum albumin is added; active ingredient is dissolved with heating; made up
to specified volume with Wfl; transferred into ampoules under nitrogen gas.
Boehringer Ingelheim 323 Case 1-1406 if
CA 02504160 2005-04-28
Example G
Injectable solution containing 100 mg of active substance per 20 ml
Composition:
active substance 100 mg
monopotassium dihydrogen phosphate
=KH2PO4 12 mg
disodium hydrogen phosphate
= Na2HPO4.2H2O 2 mg
sodium chloride 180 mg
human serum albumin 50 mg
Polysorbate 80 20 mg
water for injections ad 20 ml
Preparation:
Polysorbate 80, sodium chloride, monopotassium dihydrogen phosphate and
disodium hydrogen phosphate are dissolved in water for injections (Wfl);
human serum albumin is added; active ingredient is dissolved with heating;
made up to specified volume with Wfl; transferred into ampoules.
Example H
Lyophilisate containing 10 mg of active substance
Composition:
Active substance 10 mg
Mannitol 300 mg
human serum albumin 20 mg
Boehringer Ingelheim 324 Case 1-1406 if
CA 02504160 2005-04-28
Preparation:
Mannitol is dissolved in water for injections (Wfl); human serum albumin is
added; active ingredient is dissolved with heating; made up to specified
volume with Wfl; transferred into vials; freeze-dried.
Solvent for Iyophilisate:
Polysorbate 80 = Tween 80 20 mg
mannitol 200 mg
water for injections ad 10 MI
Preparation:
Polysorbate 80 and mannitol are dissolved in water for injections (Wfl);
transferred into ampoules.
Example I
Tablets containing 20 mg of active substance
Composition:
active substance 20 mg
lactose 120 mg
maize starch 40 mg
magnesium stearate 2 mg
Povidone K 25 18 mg
Preparation:
Active substance, lactose and maize starch are homogeneously mixed;
granulated with an aqueous solution of Povidone; mixed with magnesium
stearate; compressed in a tablet press; weight of tablet 200 mg.
Boehringer Ingelheim 325 Case 1-1406 ff
CA 02504160 2005-04-28
Example J
Capsules containing 20 mg active substance
Composition:
active substance 20 mg
maize starch 80 mg
highly dispersed silica 5 mg
magnesium stearate 2.5 mg
Preparation:
Active substance, maize starch and silica are homogeneously mixed; mixed
with magnesium stearate; the mixture is packed into size 3 hard gelatine
capsules in a capsule filling machine.
Example K
Suppositories containing 50 mg of active substance
Composition:
active substance 50 mg
hard fat (Adeps solidus) q.s. ad 1700 mg
Preparation:
Hard fat is melted at about 38 C; ground active substance is homogeneously
dispersed in the molten hard fat; after cooling to about 35 C it is poured
into
chilled moulds.
Boehringer Ingelheim 326 Case 1-1406 if
CA 02504160 2005-04-28
Example L
Injectable solution containing 10 mg of active substance per I ml
Composition:
active substance 10 mg
mannitol 50 mg
human serum albumin 10 mg
water for injections ad 1 ml
Preparation:
Mannitol is dissolved in water for injections (Wfl); human serum albumin is
added; active ingredient is dissolved with heating; made up to specified
volume with Wfl; transferred into ampoules under nitrogen gas.
